Loading...
Menu
Ebooks   ➡  Nonfiction  ➡  Medicine

ISHLT 2016 Final Program

TABLE OF CONTENTS

 

ABOUT ISHLT

2015-2016 BOARD OF DIRECTORS

ISHLT STAFF

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

ABSTRACT REVIEWERS

COMMITTEE ROSTERS

Education Committee

Grants and Awards Committee

International and Inter-Society Coordination Committee (I2C2)

ISHLT Mechanically Assisted Circulatory Support (IMACS®) Registry Steering Committee

International Pediatric Heart Failure Registry (IPHFR) Steering Committee

International Thoracic Transplant Registry Steering Committee

Journal of Heart and Lung Transplantation (JHLT) Editorial Board

Nominating Committee

Registries and Databases Committee

Standards and Guidelines Committee

Links Newsletter Editorial Staff

 

COUNCIL OPERATING BOARDS

Basic Science and Translational Research

Heart Failure and Transplantation

Infectious Diseases

Junior Faculty and Trainees

Mechanical Circulatory Support

Nursing, Health Sciences and Allied Health

Pathology

Pediatric Thoracic Transplantation and Heart Failure

Pharmacy and Pharmacology

Pulmonary Hypertension

Pulmonary Transplantation

 

PAST PRESIDENTS

PAST PROGRAM CHAIRS

[+JOURNAL AND LINKS NEWSLETTER EDITORS +]

[+REGISTRY MEDICAL DIRECTORS +
++]
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS

GRANTS AND SCHOLARSHIPS

ISHLT Norman E. Shumway Career Development Award

ISHLT Nursing Research Grant Award

ISHLT Research Fellowship Award

ISHLT Transplant Registry Early Career Award (Formerly Junior Faculty Award)

ISHLT/Bayer Pulmonary Hypertension Research Grant Award

ISHLT/HeartWare Award for Translational Research in MCS

ISHLT Branislav Radovancevic Memorial Fellowship Grant

ISHLT International Traveling Scholarship Award

ISHLT Leach-Abramson-Imhoff Links Travel Awards

 

ABSTRACT AWARDS

Philip K. Caves Award

Nursing, Health Sciences & Allied Health Excellence in Research Award

JFTC Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award

ISHLT Branislav Radovancevic Memorial Best MCS Abstract Award

 

ACCREDITATION INFORMATION

COMMERCIAL SUPPORT

HIGHLIGHTS OF THE MEETING

Basic Science

Heart Failure and Transplantation

Infectious Diseases

Lung Failure and Transplantation

Mechanical Circulatory Support

Nursing, Health Science, Allied Health

Pathology

Pediatrics

Pharmacy and Pharmacology

Pulmonary Hypertension

 

HOTEL FLOOR PLANS

Exhibition Level

Lobby Level

Mezzanine Level

 

ACRONYMS

DAILY SCHEDULE

Monday, April 25, 2016

Tuesday, April 26, 2016

Wednesday, April 27, 2016

Thursday, April 28, 2016

Friday, April 29, 2016

Saturday, April 30, 2016

[WEDNESDAY ANNUAL MEETING SCIENTIFIC PROGRAM +]APRIL 27, 2016[ ][ +]

Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better?

Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future

Pre-Meeting Symposium 3: Current Innovations and Future of EVLP

Pre-Meeting Symposium 4: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease

Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective

Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?

Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease

Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart – International Perspectives on MCS Issues

Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization

Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)

Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One?

Pre-Meeting Symposium 12: It’s All in the Translation: CMV from Bedside to Bench and Back Again

Pre-Meeting Symposium 13: Child’s Play: Infectious Risk After Transplant During Everyday Life

Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice?

Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS

Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle

Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation

Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH

Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates

Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation

Pre-Meeting Symposium 21: Unraveling “Chronic Rejection” in the Heart

Pre-Meeting Symposium 22: Great Debates in MCS

Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR

Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies

Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension

Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection

Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease

Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016

[+THURSDAY ANNUAL MEETING SCIENTIFIC PROGRAM +]APRIL 28, 2016

Opening Plenary Session: Transplantation: Where Does the Science End and the Art Begin?

Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support

Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support

Concurrent Session 3: Donor Organ Allocation and Management – What’s Hot and New?

Concurrent Session 4: Keep It Down: New Insights on Immunosuppression

Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex

Concurrent Session 6: Pediatric Heart Transplant Outcomes

Concurrent Session 7: It’s Tough to Make Predictions, Especially about the Future: Outcomes in MCS

Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS

Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation

Concurrent Session 10: The Frailty Construct and Body Composition – Impact on Lung Transplant Outcomes

Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft

Concurrent Session 12: Pediatric Lung Transplantation

Concurrent Session 13: Philip K. Caves Award Candidate Presentations

Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH

Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS

Concurrent Session 15: Let’s Be Specific: Donor Specific Antibodies – Challenges Ahead

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction

Concurrent Session 17: Pediatric Mechanical Circulatory Support

Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance

Concurrent Session 19: Improving Outcomes: Body and Soul

Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation

Mini Oral Session 1: Science, Surgery and Shock in MCS

Mini Oral Session 2: Donor Dilemmas in Heart Transplantation

Mini Oral Session 3: Candidate and Recipient Management in Heart Transplantation

Mini Oral Session 4: Donor and Recipient Management in Lung Transplantation

Mini Oral Session 5: Pediatrics: Organ Support and Transplantation

Mini Oral Session 6: Pharmacy & Pharmacology and Mechanical Circulatory Support

[+FRIDAY ANNUAL MEETING SCIENTIFIC PROGRAM +]APRIL 29, 2016

Sunrise Symposium 1: MCS Challenges and Engineering Solutions

Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward

Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy

Sunrise Symposium 4: Let’s Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease

Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology

Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections

Plenary Session: Where is the Future for Innovation?

Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management

Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS

Concurrent Session 23: Choosing a Gift: Donor Selection

Concurrent Session 24: What’s New in Primary Graft Dysfunction Post Lung Transplantation

Concurrent Session 25: Beyond Adherence: What’s New Out There?

Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The Anti-Body?

Symposium 30: JHLT at ISHLT: The Year in a Capsule

Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS

Concurrent Session 28: Pump Thrombosis: What’s Hot with the Clot

Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV

Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation

Concurrent Session 31: Pediatric Early Post Transplant Problems

Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment

Concurrent Session 33: “A Bipartisan Effort”: Antibodies and Complement in Heart and Lung Allografts

Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH

Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS

Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS

Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant

Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression

Concurrent Session 38: New Insights in Pulmonary Hypertension

Concurrent Session 39: Junior Faculty and Trainee Council’s Clinical Case Dilemmas: The Best of the Best

Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity

Mini Oral Session 7: Patient Management and Outcomes in MCS

Mini Oral Session 8: Technology, Physiology and Complications in MCS

Mini Oral Session 9: Risk Factors and Lung Transplant Outcomes

Mini Oral Session 10: Heart Transplantation and Heart Failure

Mini Oral Session 11: Models in Transplantation: From Mouse to Rat to Pig to Human

Mini Oral Session 12: Applied Health Research and Pulmonary Hypertension

[+SATURDAY ANNUAL MEETING SCIENTIFIC PROGRAM +]APRIL 30, 2016

Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle

Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure

Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival

Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It

Sunrise Symposium 11: Controversies in Pediatric Heart Failure

Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond

Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support

Concurrent Session 42: Difficult Decisions in Mechanical Support

Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant

Concurrent Session 44: Lung Transplantation – Advanced Diagnostics!

Concurrent Session 45: Pediatric Heart Failure

Concurrent Session 46: From ‘Jeans’ to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics

Plenary Session: Pushing New Scientific Frontiers: It’s In Our Heritage

Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS

Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient

Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems

Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation – Are We Getting It Right?

Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism

Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension

[+WEDNESDAY POSTER SESSION 1 +]APRIL 27, 2016

Basic Science

Heart Transplantation

Lung Transplantation

Mechanical Circulatory Support

Pathology

[+THURSDAY POSTER SESSION 2 +]APRIL 28, 2016

Economics, Ethics, Public Policy

Heart Failure

Heart Transplantation

Lung Transplantation

Mechanical Circulatory Support

Nursing, Health Sciences, Allied Health

Pediatrics

Pulmonary Hypertension

[+FRIDAY POSTER SESSION 3 +]APRIL 29, 2016

Infectious Diseases

Lung Transplantation

Mechanical Circulatory Support

Pediatrics

Pharmacy and Pharmacology

Junior Faculty Clinical Case Reports

ISHLT ACADEMY: CORE COMPETENCIES IN HEART FAILURE AND CARDIAC TRANSPLANT MEDICINE SCIENTIFIC PROGRAM

ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM

ISHLT ACADEMY: MASTER CLASS IN PULMONARY TRANSPLANTATION SCIENTIFIC PROGRAM

ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM

CORPORATE EVENT AND INDUSTRY THEATER LISTINGS

EXHIBIT HALL FLOOR PLAN

EXHIBITORS AND BOOTH NUMBER

EXHIBITOR DESCRIPTIONS

FUTURE ANNUAL MEETINGS

[
**]

* *

ABOUT ISHLT

 

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

 

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3,000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

 

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

 

The purposes of the Society are:

 

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.

 

 

*ABOUT WASHINGTON, DC *

Washington, DC is a living history book full of powerful moments and memorable experiences. It’s the only city in the world where you can visit with a 19-foot President Lincoln, read the real U.S. Constitution, see Dorothy’s ruby-red slippers, immerse yourself in internationally acclaimed art and explore space travel – all in one day.

 

When you’re not in sessions we hope that you will be able to explore America’s educational and entertaining venues, world-class museums and monuments, unique neighborhoods, top-rated restaurants, gorgeous parks and gardens, and endless performing arts choices.

 

To learn more about Washington, DC, please visit http://washington.org/

 

[* *]

2015-2016 BOARD OF DIRECTORS

 

R. Duane Davis, MD, MBA, President, Florida Hospital, Orlando, FL

Maryl R. Johnson, MD, President-Elect, University of Wisconsin, Madison, WI

Hermann Reichenspurner, MD, PhD, Past-President, University Heart Center Hamburg, Hamburg, Germany

Stuart C. Sweet, MD, PhD, Secretary-Treasurer, St. Louis Children’s Hospital, St. Louis, MO

Carla C. Baan, PhD, Director, Erasmus Medical Center, Rotterdam, The Netherlands

Christian Benden, MD, Director, University Hospital Zurich, Zurich, Switzerland

Lara Danziger-Isakov, MD, MPH, Director, Cincinnati Children’s Hospital, Cincinnati, OH

Tobias Deuse, MD, PhD, Director, University of California at San Francisco, San Francisco, CA

Andrew J. Fisher, FRCP, PhD, Director, Freeman Hospital, Newcastle, United Kingdom

Daniel J. Goldstein, MD, Director, Montefiore Medical Center, Bronx, NY

Daniel R. Goldstein, MD, Director, Yale New Haven Hospital, New Haven, CT

Peter M. Hopkins, FRACP, Director, The Prince Charles Hospital, Brisbane, Australia

Myung H. Park, MD, Director, Houston Methodist Hospital, Houston, TX

Michael G. Petty, PhD, RN, CNS, Director, University of Minnesota Medical Center, Minneapolis, MN

Jeffrey J. Teuteberg, MD, Director, University of Pittsburgh/Presbyterian, Pittsburgh, PA

 

Ex Officio Board Members

Mandeep R. Mehra, MD, Editor-in-Chief, Journal of Heart and Lung Transplantation

Josef Stehlik, MD, MPH, International Thoracic Transplant Registry Medical Director

Christopher H. Wigfield, MD, FRCS (C/Th), Medical Director of Educational Affairs

Amanda W. Rowe, ISHLT Executive Director

 

[* *]

ISHLT STAFF

 

Amanda W. Rowe

Executive Director

 

Phyllis Glenn

Director of Membership Services

 

Lisa Edwards

Director of Meetings

 

Lee Ann Mills

Director of Operations

 

Susie Newton

Communications Manager

 

Megan Barrett

Communications Assistant

 

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org

 

[* *]

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

 

[* • Symposium Planning Committee*]

[* Abstract Selection Committee]

 

Andrew J. Fisher, FRCP, PhD, Newcastle upon Tyne, UK, 2016 Program Chair[* • * *]

Duane Davis, MD, MBA, Orlando, FL, ISHLT President[* • * *]

Jeffrey J. Teuteberg, MD, Pittsburgh, PA, 2017 Program Chair[* • * *]

Andreas O. Zuckermann, MD, Vienna, Austria, 2015 Program Chair[* • * *]

David A. Baran, MD, Newark, NJ[* • * *]

Christian Benden, MD, Zurich, Switzerland[* * *]

Andrew J. Boyle, MD, Atlanta, GA[* * *]

Stephen C. Clark, FRCS, Newcastle upon Tyne, UK[* * *]

Hannah Copeland, MD, Carmel, IN • * 

Lara Danziger-Isakov, MD, MPH, Cincinnati, OH[* • * *]

Sabina M. De Geest, RN, PhD, Basel, Switzerland[* • * *]

Goran Dellgren, MD, PhD, Goteborg, Sweden[* * *]

Shashank S. Desai, MD, Falls Church, VA[* * *]

Kumud K. Dhital, MD, PhD, Sydney, Australia[* * *]

Stephan Ensminger, MD, DPhil, Bad Oeynhausen, Germany[* • * *]

Christopher R. Ensor, PharmD, BCPS-CV, Pittsburgh, PA[* * *]

Benjamin H. Freed, MD, Chicago, IL[* * *]

Andrew E. Gelman, PhD, St. Louis, MO[* • * *]

Patricia Ging, PharmD, Dublin, Ireland[* • * *]

Christopher S. Hayward, MD, Sydney, Australia[* * *]

Peter M. Hopkins, FRACP, Brisbane, Australia[* • * *]

Jonathan N. Johnson, MD, Rochester, MN[* • * *]

Annemarie Kaan, MCN, RN, Vancouver, BC, Canada[* • * *]

Mary E. Keebler, MD, Nashville, TN[* * *]

Kiran K. Khush, MD, Stanford, CA[* * *]

Richard Kirk, FRCP, FRCPCH, Newcastle upon Tyne, UK[* • * *]

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Melbourne, Australia[* * *]

Haifa Lyster, MSc, Harefield, UK[* • * *]

Tereza Martinu, MD, Toronto, ON, Canada[* • * *]

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Boston, MA[* • * *]

Hirsch S. Mehta, MD, San Diego, CA[* * *]

Anna L. Meyer, MD, Leipzig, Germany[* * *]

Carmelo A. Milano, MD, Durham, NC[* * *]

Dylan V. Miller, MD, Murray, UT[* • * *]

Martha L. Mooney, MD, FACP, Norfolk, VA[* * *]

Orla Morrissey, MD, Melbourne, Australia[* * *]

Desley Neil, FRCPath, Birmingham, UK[* • * *]

Joseph G. Rogers, MD, Durham, NC[* * *]

Eulalia Roig, MD, Barcelona, Spain[* • * *]

Antonio Roman, MD, PhD, Barcelona, Spain[* • * *]

Joanna M. Schaenman, MD, PhD, Los Angeles, CA[* • * *]

Jan Schmitto, MD, PhD, MBA, Hannover, Germany[* • * *]

Oksana A. Shlobin, MD, Falls Church, VA[* • * *]

Laurie D. Snyder, MD, Durham, NC[* * *]

Ryan J. Tedford, MD, Baltimore, MD[* • * *]

Mitesh V. Thakrar, MD, Calgary, AB, Canada[* * *]

Robin Vos, MD, PhD, Leuven, Belgium[* • * *]

Gregor Warnecke, MD, Hannover, Germany[* • * *]

Neil W. Wrightson, RN, Newcastle upon Tyne, UK[* • * *]

Vincent G. Valentine, MD, Galveston, TX[* * *]

Christopher H. Wigfield, MD FRCS, Chicago, IL[* • * *]

Tahir Yagdi, MD, PhD, Izmir, Turkey[* • * *]

 

[* *]

ABSTRACT REVIEWERS

Richa Agarwal, MD, W. Penn Allegheny Hospital, Pittsburgh, PA

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

Ruchan Akar, MD, Ankara University, Ankara, Turkey

Arezu Z. Aliabadi, MD, Medical University of Vienna, Vienna, Austria

Christopher Almond, MD, Stanford University, Stanford, CA

Annalisa Angelini, MD, University of Padua, Padua, Italy

Samantha J. Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

Martine Antoine, MD, Erasme University Hospital, Brussels, Belgium

Ani C. Anyanwu, MD, Mount Sinai Medical Center, New York, NY

Saima Aslam, MD, MS, University of California at San Diego, San Diego, CA

Robin K. Avery, MD, Johns Hopkins Hospital, Baltimore, MD

Estelle Azeka, MD, University of Sao Paulo, Sao Paulo, Brazil

Carla Baan, PhD, Erasmus Medical Center, Rotterdam, The Netherlands

Markus J. Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

Jay Baumwol, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia

Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany

Gerald J. Berry, MD, Stanford University, Stanford, CA

Reshma M. Biniwale, MD, UCLA, Los Angeles, CA

Nancy P. Blumenthal, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA

Hilde Bollen, RN, UZLeuven, Leuven, Belgium

Lee A. Borthwick, PhD, Newcastle University, Newcastle upon Tyne, UK

Patrick Bruneval, MD, Hospital European George Pompidou, Paris, France

Deborah Budge, MD, Intermountain Medical Center, Murray, UT

Caron L. Burch, MSN, Stanford Hospital & Clinics, Stanford, CA

Fay S. Burrows, PharmD, BCPS, St. Vincent’s Hospital, Sydney, Australia

Fiorella Calabrese, MD, University of Padova, Padova, Italy

Edward Cantu, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

Marilia Cascalho, MD, PhD, University of Michigan Hospital, Ann Arbor, MI

Chesney Castleberry, MD, Cincinnati Children’s Hospital MC, Cincinnati, OH

Alexandre S. Cauduro, MD, Heart Institute Sao Paulo University, Sao Paulo, Brazil

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada

Laveena Chhatwani, MD, Stanford University, Stanford, CA

Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

Jose M. Cifrian, MD, Hospital University Marques Valdecilla, Santander, Spain

Tamara E. Claridge, PharmD, Hospital of the University of Pennsylvania, Philadelphia, PA

Joseph C. Cleveland, Jr, MD, University of Colorado School of Medicine, Aurora, CO

Adam B. Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA

Erin Coglianese, MD, Loyola University Medical Center, Maywood, IL

Rebecca J. Cogswell, MD, University of Minnesota, Minneapolis, MN

Monica M. Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI

Pamela S. Combs, PhD, RN, Seton Medical Center, Austin, TX

Jennifer L. Cook, MD, University of Arizona Sarver Heart Center, Tucson, AZ

Jennifer Cowger, MD, St Vincent Heart Center, Indianapolis, IN

Rachel M. Crackett, MSc, Freeman Hospital, Newcastle upon Tyne, UK

Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain

Michiel Dalinghaus, MD, PhD, Erasmus Medical Center, Rotterdam, The Netherlands

Mani A. Daneshmand, MD, Duke University Medical Center, Durham, NC

Teresa De Marco, MD, FACC, University of California at San Francisco, San Francisco, CA

Fabio De Robertis, MD, Harefield Hospital, Harefield, UK

Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain

Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

Eugene C. DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA

Tobias Deuse, MD, PhD, University of California at San Francisco, San Francisco, CA

Gundeep S. Dhillon, MD, Stanford University, Stanford, CA

Joshua M. Diamond, MD, University of Pennsylvania, Philadelphia, PA

Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada

Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium

Debra A. Dodd, MD, Vanderbilt Children’s Hospital, Nashville, TN

Stavros G. Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

Debi H. Dumas-Hicks, RN, BS, CCTC, CCTN, Ochsner Medical Center, New Orleans, LA

Jean-Paul Duong-Van-Huyen, MD, PhD, Hospital Necker, Paris, France

Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

Jerry D. Estep, MD, The Methodist Hospital, Houston, TX

Roger W. Evans, PhD, UNRTP, Transplant Professionals.com, LLC, Rochester, MN

Katherine Y. Fan, MD, Grantham Hospital, Aberdeen, Hong Kong

Maryjane A. Farr, MD, Columbia University Medical Center, New York, NY

Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH

Brian Feingold, MD, MS, Children’s Hospital of Pittsburgh, Pittsburgh, PA

Mark E. Fenton, MD, FRCPC, Royal University Hospital, Saskatoon, SK, Canada

Katrina Ford, BPharm, Great Ormond Street Hospital, London, UK

Jennifer L. Franzwa, MSN, RN, CCTC, University of Iowa Hospitals and Clinics, Iowa City, IA

Darren H. Freed, MD, PhD, FRCSC, University of Alberta Hospital, Edmonton, AB, Canada

Jason S. Fritz, MD, FCCP, University of Pennsylvania, Philadelphia, PA

Laura K. Frye, MD, University of Pennsylvania, Philadelphia, PA

Louise M. Fuller, PT, Alfred Hospital, Melbourne, VIC, Australia

Rochelle M. Gellatly, PharmD, Alfred Hospital, Melbourne, VIC, Australia

Helen Gibbs, RN, Auckland City Hospital, Auckland, New Zealand

Claudia G. Gidea, MD, Barnabas Health, New York, NY

Allan R. Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, NSW, Australia

Martin J. Goddard, FRCS, MRCPa, Papworth Hospital, Cambridge, UK

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY

Mardi Gomberg-Maitland, MD, University of Chicago Medical Center, Chicago, IL

Jose Gonzalez-Costello, MD, Hospital Universitari de Bellvitge, Barcelona, Spain

Francisco Gonzalez-Vilchez, MD, PhD, Hospital Marques de Valdecilla, Santander, Spain

Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany

Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL

John R. Greenland, MD, PhD, University of California at San Francisco, San Francisco, CA

Aric L. Gregson, MD, UCLA School of Medicine, Los Angeles, CA

Cynthia J. Gries, MD, MSc, Florida Hospital, Orlando, FL

Jan F. Gummert, MD, PhD, Herz-und Diabeteszentrum NRW, Bad Oeynhausen, Germany

Richard Ha, MD, Stanford University, Stanford, CA

Kieran Halloran, MD, University of Alberta, Edmonton, AB, Canada

Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

Matthew G. Hartwig, MD, Duke University, Durham, NC

Reema Hasan, MD, University of Michigan, Ann Arbor, MI

Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

Edward Horn, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA

Douglas A. Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK

Howard J. Huang, MD, Baylor University Medical Center, Dallas, TX

Sharon A. Hunt, MD, Stanford University Medical Center, Stanford, CA

Shahid Husain, MD, MS, Toronto General Hospital, Toronto, ON, Canada

Michael Ison, MD, MS, Northwestern Memorial Hospital, Chicago, IL

Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

George Javorsky, MBBS, FRACP, The Prince Charles Hospital, Brisbane, Australia

Ulrich P. Jorde, MD, Columbia University, New York, NY

Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX

Stephen C. Juvet, MD, PhD, FRCPC, University Health Network, Toronto, ON, Canada

Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA

Cassie Kennedy, MD, Mayo Clinic, Rochester, MN

Anne Keogh, MBBS, MD, St. Vincent’s Hospital, Sydney, Australia

Feras Khaliel, MD, PhD, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia

Ivan Knezevic, MD, University Clinical Centre, Ljubljana, Slovenia

Thomas Krabatsch, MD, PhD, German Heart Center, Berlin, Germany

Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO

Christiane Kugler, PhD, University Witten, Witten, Germany

Jose Luis Lambert Rodriguez, FESC, FHFA, MD, PhD, Hospital University Central de Asturias, Oviedo, Spain

Brent C. Lampert, DO, The Ohio State University Wexner Medical Center, Columbus, OH

Jacob Lavee, MD, Sheba Medical Center, Tel Hashomer, Israel

Lorriana E. Leard, MD, University of California at San Francisco, San Francisco, CA

Erika D. Lease, MD, University of Washington, Seattle, WA

David J. Lederer, MD, Columbia University Medical Center, New York, NY

Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland

Choon Pin Lim, MBBS, National Heart Center, Singapore, Singapore

Ugolino Livi, MD, S. Maria della Misericordia General Hospital, Udine, Italy

Gabriel Loor, MD, University of Minnesota, Minneapolis, MN

Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH

Lars Lund, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

Peter Macdonald, MD, PhD, St. Vincent’s Hospital, Sydney, Australia

Claudius Mahr, DO, University of Washington, Seattle, WA

George

B. Mallory, MD, Texas Children’s Hospital, Houston, TX

Monique Malouf, FRACP, St. Vincent’s Hospital, Sydney, NSW, Australia

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN

Pradeep P. A. Mammen, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX

Charles C. Marboe, MD, Columbia University, New York, NY

Bradley A. Maron, MD, Brigham and Women’s Hospital, Boston, MA

Stanley I. Martin, MD, Geisinger Health System, Danville, PA

Oliver Mauthner, PhD, University of Basel, Basel, Switzerland

John McDyer, MD. University of Pittsburgh Medical Center, Pittsburgh, PA

Dana P. McGlothlin, MD, Kaiser San Francisco, San Francisco, CA

Tanya J. McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand

Tina Melicoff, MD, Baylor College of Medicine, Houston, TX

Sonia Mirabet, MD, Hospital Sant Pau, Barcelona, Spain

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH

Paul J. Mohacsi, MD, University Hospital, Bern, Switzerland

Thomas Moller, MD, PhD, Oslo University Hospital, Oslo, Norway

Joshua J. Mooney, Stanford University, Stanford, CA

Michiel Johan Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany

Michael S. Mulligan, MD, University of Washington School of Medicine, Seattle, WA

Jayan Nagendran, MD, University of Alberta, Edmonton, AB, Canada

Takeshi Nakatani, MD, PhD, National Cerebral & Cardiovascular Center, Osaka, JAPAN

Sanem

Nalbantgil, MD, Ege University, Izmir, Turkey

Tomohiro Nishinaka, MD, Tokyo Women’s Medical University, Tokyo, Japan

Robert F. Padera, MD, PhD, Brigham & Women’s Hospital, Boston, MA

Francis D. Pagani, MD, PhD, University of Michigan Health, Ann Arbor, MI

Maryse Palardy, MD, University of Michigan, Ann Arbor, MI

Kruti A. Pandya, MD, UCLA, Los Angeles, CA

Chetan B Patel, MD, Duke University Medical Center, Durham, NC

Caroline M. Patterson, MD, Papworth Hospital, Cambridge, UK

Simon Pecha, MD, University Heart Center Hamburg, Hamburg, Germany

Michael Pham, MD, MPH, Stanford University, Palo Alto, CA

Daniela Pini, MD, Istituto Clinico Humanitas, Milan, Italy

Sean P. Pinney, MD, Mt Sinai Medical Center, New York, NY

Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France

Evgenij V. Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

Ioana R. Preston, MD, Tufts Medical Center, Boston, MA

Yuriy Pya, MD, National Research Cardiac Surgery Center, Astana, Kazakhstan

Axel Rahmel, MD, German Procurement Organization DSO, Frankfurt, Germany

Keshava Rajagopal, MD, PhD, University of Texas Health Science Center at Houston, Houston, TX

J. Eduardo Rame, MD, Pennsylvania Heart & Vascular Center, Philadelphia, PA

Danny Ramzy, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA

Aaron M. Ranasinghe, MD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

Yazhini Ravi, MD, Baylor Scott & White Memorial Hospital, Temple, TX

Leigh C. Reardon, MD, UCLA, Los Angeles, CA

Anja C. Roden, MD, Mayo Clinic, Rochester, MN

Joseph W. Rossano, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA

Dmitry Rozenberg, MD, University of Toronto, Toronto, ON, Canada

Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD

John J. Ryan, MD, FACC, FAHA, University of Utah, Salt Lake City, UT

Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia

Christopher T. Salerno, MD, St. Vincent’s Heart Center, Indianapolis, IN

Murat Sargin, MD, Siyami Ersek Hospital, Istanbul, Turkey

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

Stephan Schubert, MD, German Heart Center, Berlin, Germany

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Martin Schweiger, MD, Children’s Hospital, Zurich, Switzerland

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

Ashish S. Shah, MD, Johns Hopkins Hospital, Baltimore, MD

Keyur B. Shah, MD, Virginia Commonwealth University, Richmond, VA

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA

Pali Shah, MD, Johns Hopkins University, Baltimore, MD

Esther Shao, MD, Maine Health Cardiology, Portland, ME

Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA

Scott C. Silvestry, MD, Washington University School of Medicine, St. Louis, MO

Andre R. Simon, MD, PhD, Harefield Hospital, London, UK

Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA

Kathleen Simpson, MD, Washington University St. Louis, St. Louis, MO

Tajinder P. Singh, MD, MSc, Boston Children’s Hospital, Boston, MA

Cumara C. Sivathasan, MBBS, FRCS, National Heart Centre, Singapore, Singapore

Mark S. Slaughter, MD, University CT Surgical Associates, Louisville, KY

George G. Sokos, DO, Allegheny General Hospital, Pittsburgh, PA

Amparo Sole, MD, PhD, Hospital Universitario la Fe Unidad de Trasplante Pulmonar, Valencia, Spain

Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada

Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany

Ajay V. Srivastava, MD, Stanford University, San Jose, CA

William E. Stansfield, MD, Toronto General Hospital, Toronto, ON, Canada

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT

Emily Stimpson, MSN, CCTC, Cedars-Sinai Medical Center, Los Angeles, CA

Valentina Stosor, MD, Northwestern University/Feinberg School of Medicine, Chicago, IL

Martin Strueber, MD, Spectrum Health Hospital, Grand Rapids, MI

Zsolt Szepfalusi, MD, Medical University of Vienna, Vienna, Austria

Carmela D. Tan, MD, Cleveland Clinic, Cleveland, Ohio

Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN

Adriana Torres, MD, Fundacion Cardioinfantil, Bogota, Colombia

Christopher Towe, MD, Cincinnati Children’s Hospital, Cincinnati, OH

Wayne M. Tsuang, MD, Cleveland Clinic, Cleveland, OH

Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC

Marian Urban, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Nir Uriel, MD, University of Chicago, Chicago, IL

Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

Jean-Luc Vachiery, MD, Erasme University Hospital ULB, Brussels, Belgium

Victor H. Van Berkel, MD, PhD, University of Louisville Physicians, Louisville, KY

Rebecca R. Vanderpool, PhD, University of Pittsburgh, Pittsburgh, PA

Rhea A. Varughese, MD, Alberta Health Services, Edmonton, AB, Canada

Rajamiyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, UK

Geert M. Verleden, MD, PhD, University Hospital Gathuisberg, Leuven, Belgium

Stijn Verleden, PhD, KU Leuven, Leuven, Belgium

Erik A. M. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

Gary A. Visner, DO, Boston Children’s Hospital, Boston, MA

C Dario Vizza, MD, University of Rome, Rome, Italy

I-Wen Wang, MD, PhD, Methodist Hospital, Indianapolis, IN

Katherine Watkins, PharmD, University of California, San Francisco, San Francisco, CA

Robert G. Weintraub, FRACP, FACC, Royal Children’s Hospital, Melbourne, Australia

Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, VIC, Australia

George M. Wieselthaler, MD, University of California at San Francisco, San Francisco, CA

Keith M. Wille, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL

Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

[* *]

ISHLT COMMITTEES

 

 

EDUCATION COMMITTEE

Christopher H. Wigfield, MD, FRCS, Director of Educational Affairs

Esme Dijke, PhD, Committee Vice Chair

Maryl R. Johnson, MD, Board of Directors Liaison

Andrew J. Fisher, FRCP, PhD, 2016 Scientific Program Chair

Jeffrey J. Teuteberg, MD, 2017 Scientific Program Chair

Kevin M. Chan, MD, 2016 Master Lung Academy Program Chair

Teresa De Marco, MD, FACC, 2016 Core Heart Academy Program Chair

Stavros G Drakos, MD, 2016 Master MCS Academy Program Co-Chair

Simon Maltais, MD, PhD, 2016 Master MCS Academy Program Co-Chair

Jennifer A. Beckman, MSN-FNP, RN, CHFN, 2016 Core MCS Academy Program Co-Chair

Jennifer Cowger, MD, MS, 2016 Core MCS Academy Program Co-Chair

Daniel Zimpfer, MD, 2016 Core MCS Academy Program Co-Chair

Marilia Cascalho, MD, PhD, Basic Science and Translational Research Council Workforce Leader

Bojan Vrtovec, MD, PhD, Heart Failure and Transplantation Council Workforce Leader

Me-Linh Luong, MD, Infectious Disease Council Workforce Leader

Martin Schweiger, MD, Junior Faculty and Trainee Council Workforce Leader

Salpy V. Pamboukian, MD, MSPH, Mechanical Circulatory Support Council Workforce Leader

Caron Burch, RN, MSN, FNP, CCTC, Nursing, Health Sciences and Allied Health Council Workforce Leader

Carol F. Farver, MD, Pathology Council Workforce Leader

Debra A. Dodd, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader

Kyle L. Dawson, PharmD, Pharmacy and Pharmacology Council Workforce Leader

Ioana R. Preston, MD, Pulmonary Hypertension Council Workforce Leader

Lorriana E. Leard, MD, Pulmonary Transplantation Council Workforce Leader

 

GRANTS AND AWARDS COMMITTEE

Daniel R. Goldstein, MD, Co-Chair

Stephan M. Ensminger, MD, DPhil, Co-Chair

Daniel Kreisel, MD, PhD, Co-Chair

Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Andrew E. Gelman, PhD, Lead Reviewer

Mark S. Slaughter, MD, Lead Reviewer

Laurie D. Snyder, MD, Lead Reviewer

Dirk Van Raemdonck, MD, PhD, Lead Reviewer

Oliver Mauthner, PhD, Lead Reviewer

Josef Stehlik, MD, MPH, Lead Reviewer

 

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)

Andreas Zuckermann, MD, Co-Chair (International)

Howard J. Eisen, MD, FAHA, FACC, FACP, Co-Chair (Inter-Societal)

Hermann Reichenspurner, MD, PhD, Board of Directors Liaison

David O. Taylor, MD, Standards & Guidelines Committee Vice-Chair

Christopher H. Wigfield, MD, FRCS, Director of Educational Affairs

Stuart C. Sweet, MD, PhD, Finance Committee Chair

Josef Stehlik, MD, MPH, Thoracic Registry Medical Director

Daniel H. Kim, MD, Heart Failure & Transplantation Council Workforce Leader

Martha L. Mooney, MD, Infectious Disease Council Workforce Leader

Reema Hasan, MD, Junior Faculty & Trainee Council Workforce Leader

Sean Pinney, MD, Mechanical Circulatory Support Council Workforce Leader

Pamela S. Combs, PhD, RN, Nursing, Health Sciences & Allied Health Council Workforce Leader

Annalisa Angelini, MD, Pathology Council Workforce Leader

James D. St. Louis, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader

Rochelle M. Gellatly, PharmD, Pharmacy & Pharmacology Council Workforce Leader

Oksana A. Shlobin, MD, Pulmonary Hypertension Council Workforce Leader

Lianne G. Singer, MD, FRCPC, Pulmonary Transplantation Council Workforce Leader

Jacob Lavee, MD, Ad Hoc Member

Lori J. West, MD, DPhil, Ad Hoc Member

Alejandro Bertolotti, MD (Argentina), Global Ambassador

Karine Nubret, MD (France), Global Ambassador

Denis Hadjiliadis, MD (Greece), Global Ambassador

Sandeep G. Attawar, MD (India, New Delhi), Global Ambassador

Yuriy Pya, MD (Kazakhstan), Global Ambassador

Ashari Yunus, MD (Malaysia), Global Ambassador

Amal A. Alotaibi, MD (Saudi Arabia), Global Ambassador

Cumara C. Sivathasan, MBBS, FRCS (Singapore), Global Ambassador

Ivan Knezevic, MD (Slovenia, Ljubljana), Global Ambassador

Martin Schweiger, MD (Switzerland), Global Ambassador

 

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®) REGISTRY STEERING COMMITTEE

James K. Kirklin, MD, Chair

Craig Collum, MPH, Administrator to Dr. Kirklin

Rongbing Xie, MPH, Statistician

Ryan Cantor, MSPH, Consulting Statistician

Josef Stehlik, MD, MPH, Board of Directors Liaison

Francisco Arabia, MD, USA

Theo DeBy, MBA, Germany

Anne I. Dipchand, MD, Canada

Daniel J. Goldstein, MD, USA

Margaret M. Hannan, MD, Ireland

Ulrich P. Jorde, MD, USA

Robert L. Kormos, MD, USA

Lars H. Lund, MD, PhD, Sweden

Mandeep Mehran, MD, MBBS, FACC, FACP, USA

Chris J. Merry, MD, Australia

Takeshi Nakatani, MD, PhD, Japan

Stephan Schueler, MD, PhD, FRCS, United Kingdom

Cumara C. Sivathasan, MBBS, FRCS, Singapore

Duane Davis, MD, MBA, ISHLT President, Ex-Officio

Amanda Rowe, Executive Director, Ex-Officio

 

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (IPHFR) STEERING COMMITTEE

Anne I. Dipchand, MD, Chair

Christopher Almond, MD

Scott Auerbach, MD

Estela Azeka, MD

Leah Edwards, PhD

Robert Gajarski, MD

Richard Kirk, FRCP, FRCPCH

Yuk Law, MD

Angela Lorts, MD

Elfriede Pahl, MD

Christina VanderPluym, MD

Warren Zuckerman, MD

 

INTERNATIONAL THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE

Josef Stehlik, MD, MPH, Medical Director & Chair

Stuart C. Sweet, MD, PhD, Board of Directors Liaison

Lars H. Lund, MD, PhD, Associate Medical Director (Adult Heart)

Roger D. Yusen, MD, MPH, Associate Medical Director (Adult Lung/Heart-Lung)

Anne I. Dipchand, MD, Associate Medical Director (Pediatric Heart)

Joseph W. Rossano, MD, Associate Medical Director (Pediatric Heart)

Samuel B. Goldfarb, MD, Associate Medical Director (Pediatric Lung/Heart-Lung)

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes

Bruno M. Meiser, MD, OEO Relations

Leah Edwards, PhD, Biostatistics

Jaime Williamson, SAS Analyst

Anna Kucheryavaya, MD, Assistant Biostatistician

 

JOURNAL OF HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Editor-in-Chief

Patricia A. Uber, PharmD, Executive Editor

Erica N. Bartmanis, Journal Office Coordinator

Maria Rosa Costanzo, MD, Consulting Editor (Editor Emeritus 1995-1999)

James K. Kirklin, MD, Consulting Editor (Editor Emeritus 2000-2009)

Claus B. Andersen, MD, DMSc (Denmark), Editorial Board Consultant

Annalisa Angelini, MD (Italy), Editorial Board Consultant

Robert Aris, MD (USA), Editorial Board Consultant

David A. Baran, MD (USA), Editorial Board Consultant

Christian Benden, MD (Switzerland), Editorial Board Consultant

Gerald Berry, MD (USA), Editorial Board Consultant

Marcelo Cantarovich, MD (Canada), Editorial Board Consultant

Charles E. Canter, MD (USA), Editorial Board Consultant

Pablo Castro, MD (Chile), Editorial Board Consultant

Cornelius J. Clancy, MD (USA), Editorial Board Consultant

Paul A. Corris, MB, FRCP (UK), Editorial Board Consultant

John Dark, MB, FRCS (UK), Editorial Board Consultant

Duane Davis, MD, MBA (USA), Editorial Board Consultant

Mary Amanda Dew, PhD (USA), Editorial Board Consultant

Fabienne Dobbels, MSc, PhD (Belgium), Editorial Board Consultant

Howard Eisen, MD (USA), Editorial Board Consultant

Roger W. Evans, PhD (USA), Editorial Board Consultant

Melanie Everitt, MD (USA), Editorial Board Consultant

Kimberly L. Gandy, MD, PhD (USA), Editorial Board Consultant

Edward R. Garrity, Jr, MD (USA), Editorial Board Consultant

James F. George, PhD (USA), Editorial Board Consultant

Allan R. Glanville, MBBS, MD, FRACP (Australia), Editorial Board Consultant

Marius M. Hoeper (Germany), Editorial Board Consultant

Valluvan Jeevanandam, MD (USA), Editorial Board Consultant

Maryl R. Johnson, MD (USA), Editorial Board Consultant

Shaf Keshavjee, MD, FRCSC (Canada), Editorial Board Consultant

Kiran Kaur Khush, MD (USA), Editorial Board Consultant

Richard Kirk, FRCP, FRCPCH (UK), Editorial Board Consultant

Jon Kobashigawa, MD (USA), Editorial Board Consultant

Neal K. Lakdawala, MD (USA), Editorial Board Consultant

JoAnn Lindenfeld, MD (USA), Editorial Board Consultant

Bruce McManus, MD, PhD (Canada), Editorial Board Consultant

Bruno Meiser, MD (Germany), Editorial Board Consultant

Thalachallour Mohanakumar, PhD (USA), Editorial Board Consultant

Martha Mooney, MD, FACP (USA), Editorial Board Consultant

David Morales, MD (USA), Editorial Board Consultant

Jeffery A. Morgan, MD (USA), Editorial Board Consultant

Jonah Odim, MD (USA), Editorial Board Consultant

Francis Pagani, MD, PhD (USA), Editorial Board Consultant

Jayan Parameshwar, FRCP (UK), Editorial Board Consultant

Myung H. Park, MD (USA), Editorial Board Consultant

Jeffery L. Platt, MD (USA), Editorial Board Consultant

Evgenij V. Potapov, MD, PhD (Germany), Editorial Board Consultant

Luciano Potena, MD, PhD (Italy), Editorial Board Consultant

Joseph G. Rogers, MD (USA), Editorial Board Consultant

Heather J. Ross, MD, MHSc, FRCPC (Canada), Editorial Board Consultant

Lewis Rubin, MD (USA), Editorial Board Consultant

Stephan Schueler, MD, PhD, FRCS (UK), Editorial Board Consultant

Keyur B. Shah, MD (USA), Editorial Board Consultant

Mark S. Slaughter, MD (USA), Editorial Board Consultant

Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultant

David O. Taylor, MD (USA), Editorial Board Consultant

Jean Luc Vachiery, MD (Belgium), Editorial Board Consultant

Hector O. Ventura, MD (USA), Editorial Board Consultant

Geert Verleden, MD, PhD (Belgium), Editorial Board Consultant

Aaron Waxman, MD, PhD (USA), Editorial Board Consultant

Lori J. West, MD, DPhil (Canada), Editorial Board Consultant

Roger D. Yusen, MD, MPH (USA), Editorial Board Consultant

Michael Zakliczynski, MD (Poland), Editorial Board Consultant

 

NOMINATING COMMITTEE

Hermann Reichenspurner, MD, PhD, Chair

Duane Davis, MD, MBA, President

Allan Glanville, MBBS, MD, FRACP, Past President

David O. Taylor, MD, Past President

Lori J. West, MD, DPhil, Past President

Christian Benden, MD, Ad-Hoc Member

Jeffrey J. Teuteberg, MD, Ad-Hoc Member

 

REGISTRIES AND DATABASES COMMITTEE

Josef Stehlik, MD, MPH, Chair

Stuart C. Sweet, MD, PhD, Board of Directors Liaison

Leah Edwards, PhD, Biostatistician

James K. Kirklin, MD, IMACS Registry Committee Chair

Anne I. Dipchand, MD, International Pediatric Heart Failure Registry Committee Chair

Dirk Van Raemdonck, MD, PhD, International Donation after Cardiac Death (DCD) Registry Committee Chair

 

STANDARDS AND GUIDELINES COMMITTEE

Maryl R. Johnson, MD, Chair

David O. Taylor, MD, Vice Chair

James K. Kirklin, MD, Past Chair

Duane Davis, MD, MBA, Board of Directors Liaison

David A. Baran, MD, Heart Failure & Transplantation Council Workforce Leader

Valentina Stosor, MD, Infectious Disease Council Workforce Leader

Steven Kindel, MD, Junior Faculty & Trainee Council Workforce Leader

Jose Nativi, MD, Junior Faculty & Trainee Council Workforce Leader (non-voting until April 2016)

Jennifer Cowger, MD, MS, Mechanical Circulatory Support Council Workforce Leader

Annemarie Kaan, MCN, RN, Nursing, Health Sciences & Allied Health Council Workforce Leader

Joseph J. Maleszewski, MD, Pathology Council Workforce Leader

Robert J. Boucek, Jr, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader

Kevin Daly, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader (Non-voting mentee through 2017)

Christopher R. Ensor, PharmD, BCPS-CV, Pharmacy & Pharmacology Council Workforce Leader

Teresa De Marco, MD, FACC, Pulmonary Hypertension Council Workforce Leader

Peter Hopkins, FRACP, Pulmonary Transplantation Council Workforce Leader

 

LINKS NEWSLETTER EDITORIAL STAFF

Vincent Valentine, MD, Editor

Megan Barrett, Managing Editor

Paul Corris, MB, FRCP, Senior Associate Editor

John Dark, MB, FRCS, Senior Associate Editor

Roger Evans, PhD, Senior Associate Editor

Allan Glanville, MBBS, MD, FRACP, Senior Associate Editor

Maryl Johnson, MD, Senior Associate Editor

Lori West, MD, DPhil, Senior Associate Editor

Emma Birks, MD, PhD, Associate Editor Cardiology

Stavros Drakos, MD, Associate Editor Cardiology

Daniel Dilling, MD, Associate Editor Junior Faculty & Trainee

Stanley I. Martin, MD, Associate Editor Infectious Disease

Tereza Martinu, MD, Associate Editor Pulmonary Transplantation & Pulmonary Transplantation Council Communications Liaison

Javier Carbone, MD, PhD, International Correspondents Board

Takeshi Nakatani, MD, PhD, International Correspondents Board

Luciano Potena, MD, PhD, International Correspondents Board

Andreas Zuckermann, MD, International Correspondents Board

Howard J. Eisen, MD, Basic Science & Translational Research Council Communications Liaison

David P. Nelson, MD, Heart Failure & Transplantation Council Communications Liaison

Stephanie Pouch, MD, Infectious Disease Council Communications Liaison

Jorge Silva Enciso, MD, Junior Faculty & Trainee Council Communications Liaison

Evgenij Potapov, MD, PhD, Mechanical Circulatory Support Council Communications Liaison

Emily Stimpson, MSN, RN, CCTC, Nursing, Health Sciences & Allied Health Council Communications Liaison

Brandon Larsen, MD, PhD, Pathology Council Communications Liaison

Martin Schweiger, MD, Pediatric Thoracic Transplantation & Heart Failure Council Communications Liaison

Ed Horn, PharmD, BCPS, Pharmacy & Pharmacology Council Communications Liaison

Amresh Raina, MD, Pulmonary Hypertension Council Communications Liaison

 

[* *]

ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

 

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Sonja Schrepfer, MD, PhD, Chair

Edward Cantu, III, MD, Vice Chair

Kimberly L. Gandy, MD, PhD, Past Chair

Carla C. Baan, PhD, Board of Directors Liaison

Doris A. Taylor, PhD, Senior Advisor

Jeffrey L. Platt, MD, Senior Advisor

Marilia Cascalho, MD, PhD, Education Committee Workforce Leader

Howard J. Eisen, MD, FAHA, FACC, FACP, ISHLT Links Newsletter Liaison

Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplantation Council Liaison

Orla Morrissey, MD, Infectious Diseases Council Liaison

J. Michael DiMaio, MD, Mechanical Circulatory Support Council Liaison

Monica Horn, RN, CCRN, CCTC, Nursing, Health Sciences & Allied Health Council Liaison

Annalisa Angelini, MD, Pathology Council Liaison

Carol K. Conrad, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

Tam Khuu, PharmD, BCPS, Pharmacy & Pharmacology Council Liaison

Aaron B. Waxman, MD, PhD, Pulmonary Hypertension Council Liaison

Joshua M. Diamond, MD, Pulmonary Transplantation Council Liaison

 

HEART FAILURE AND TRANSPLANTATION

Monica M. Colvin, MD, Chair

Michael Pham, MD, MPH, Vice Chair

Jignesh K. Patel, MD, PhD, Vice Chair Elect

Jose Tallaj, MD, Past Chair

Maryl R. Johnson, MD, Board of Directors Liaison

Bojan Vrtovec, MD, PhD, Education Committee Workforce Leader

Daniel H. Kim, MD, I2C2 Workforce Leader

David A. Baran, MD, Standards & Guidelines Committee Workforce Leader

David P. Nelson, MD, ISHLT Links Newsletter Liaison

Pradeep P.A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Liaison

Hannah Copeland, MD, Junior Faculty & Trainee Council Liaison

Quincy Young, PhD, RPsych, Nursing, Health Sciences & Allied Health Council Liaison

 

INFECTIOUS DISEASES

Paolo A. Grossi, MD, PhD, Chair

Stanley I. Martin, MD, Vice Chair

Fernanda Silveira, MD, Past Chair

Lara Danziger-Isakov, MD, MPH, Board of Directors Liaison

Me-Linh Luong, MD, Education Committee Workforce Leader

Martha Mooney, MD, I2C2 Workforce Leader

Valentina Stosor, MD, Standards & Guidelines Committee Workforce Leader

Stephanie M. Pouch, MD, ISHLT Links Newsletter Liaison

Catherine Orla Morrissey, MD, Basic Science & Translational Research Council Liaison

Saima Aslam, MD, MS, Junior Faculty & Trainee Council Liaison

 

JUNIOR FACULTY AND TRAINEES

Eugene C. DePasquale, MD, Chair

Keyur B. Shah, MD, Vice Chair

Evan P. Kransdorf, MD, PhD, Vice Chair Elect

Manreet Kanwar, MD, Past Chair

Hermann Reichenspurner, MD, PhD, Board of Directors Liaison

Martin Schweiger, MD, Education Committee Workforce Leader

Reema Hasan, MD, I2C2 Workforce Leader

Steven Kindel, MD, Standards & Guidelines Committee Workforce Leader

Jose Nativi, MD, Standards & Guidelines Committee Workforce Leader

Jorge Silva Enciso, MD, ISHLT Links Newsletter Liaison

Hannah Copeland, MD, Heart Failure & Transplantation Council Liaison

Saima Aslam, MD, MS, Infectious Diseases Council Liaison

Palak Shah, MD, MS, Mechanical Circulatory Support Council Liaison

Chesney Castleberry, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

Marco A. Caccamo, MD, Pulmonary Hypertension Council Liaison

Robin Vos, MD, PhD, Pulmonary Transplantation Council Liaison

 

MECHANICAL CIRCULATORY SUPPORT

Stephan Schueler, MD, PhD, FRCS, Chair

Nir Uriel, MD, Vice Chair

Ulrich P. Jorde, MD, Past Chair

Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Salpy V. Pamboukian, MD, MSPH, Education Committee Workforce Leader

Sean P. Pinney, MD, I2C2 Workforce Leader

Jennifer Cowger, MD, MS, Standards & Guidelines Committee Workforce Leader

Evgenij V. Potapov, MD, ISHLT Links Newsletter Liaison

Dawn M. Christensen, MS, CRNP, VAD Coordinator Liaison

J. Michael DiMaio, MD, Basic Science & Translational Research Council Liaison

Palak Shah, MD, MS, Junior Faculty & Trainee Council Liaison

Jennifer A. Beckman, MSN-FNP, RN, CHFN, Nursing, Health Sciences & Allied Health Council Liaison

 

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Samantha J. Anthony, PhD, MSW, Chair

Kevin Carney, MSN, CRNP, CCTC, Vice Chair

Pamela S. Combs, PhD, RN, Vice Chair Elect

Masina Scavuzzo, RN, Past Chair

Michael G. Petty, PhD, RN, CCNS, CNS, Board of Directors Liaison

Caron Burch, RN, MSN, FNP, CCTC, Education Committee Workforce Leader

Pamela S. Combs, PhD, RN, I2C2 Workforce Leader

Annemarie Kaan, MCN, RN, Standards & Guidelines Committee Workforce Leader

Oliver Mauthner, PhD, Grants & Award Committee Workforce Leader

Emily Stimpson, MSN, RN, CCTC, ISHLT Links Newsletter Liaison

Monica Horn, RN, CCRN, CCTC, Basic Science & Translational Research Council Liaison

Quincy Young, PhD, RPsych, Heart Failure & Transplantation Council Liaison

Jennifer A. Beckman, MSN-FNP, RN, CHFN, Mechanical Circulatory Support Council Liaison

Erin Wells, RN, Pediatric Thoracic Transplantation and Heart Failure Council Liaison

Rachel M. Crackett, MSc, Pulmonary Hypertension Council Liaison

Tara R. Fuller, Pulmonary Transplantation Council Liaison

 

PATHOLOGY

Martin J. Goddard, FRCS, MRCPa, Chair

Robert F. Padera, MD, PhD, Vice Chair

Carmela D. Tan, MD, Past Chair

Daniel R. Goldstein, MD, Board of Directors Liaison

Carol F. Farver, MD, Education Committee Workforce Leader

Annalisa Angelini, MD, I2C2 Workforce Leader & Basic Science & Translational Research Council Liaison

Joseph J. Maleszewski, MD, Standards & Guidelines Committee Workforce Leader

Brandon T. Larsen, MD, PhD, ISHLT Links Newsletter Liaison

 

PEDIATRIC THORACIC TRANSPLANTATION AND HEART FAILURE

Tajinder P. Singh, MD, MSc, Chair

Brian Feingold, MD, MS, Vice Chair

Janet N. Scheel, MD, Past Chair

Christian Benden, MD, Board of Directors Liaison

Debra A. Dodd, MD, Education Committee Workforce Leader

James D. St. Louis, MD, I2C2 Workforce Leader

Robert J. Boucek, Jr, MD, Standards & Guidelines Committee Workforce Leader

Kevin Daly, MD, Standards & Guidelines Committee Workforce Leader

Ryan Butts, MD, Pediatric Heart Failure Workforce Leader

Martin Schweiger, MD, ISHLT Links Newsletter Liaison

Carol K. Conrad, MD, Basic Science & Translational Research Council Liaison

Chesney Castleberry, MD, Junior Faculty & Trainee Council Liaison

Erin Wells, RN, Nursing, Health Sciences & Allied Health Council Liaison

 

PHARMACY AND PHARMACOLOGY

Walter Uber, PharmD, Chair

Adam B. Cochrane, PharmD, Vice Chair

Tamara E. Claridge, PharmD, Past Chair

Tobias Deuse, MD, PhD, Board of Directors Liaison

Kyle L. Dawson, PharmD, Education Committee Workforce Leader

Rochelle M. Gellatly, PharmD, I2C2 Workforce Leader

Christopher R. Ensor, PharmD, BCPS-CV, Standards & Guidelines Committee Workforce Leader

Edward Horn, PharmD, BCPS, ISHLT Links Newsletter Liaison

Tam Khuu, PharmD, BCPS, Basic Science & Translational Research Council Liaison

 

PULMONARY HYPERTENSION

Mardi Gomberg-Maitland, MD, MSc, Chair

Dana P. McGlothlin, MD, Vice Chair

Jean-Luc Vachiery, MD, Vice Chair Elect

Robert P. Frantz, MD, Past Chair

Myung H. Park, MD, Board of Directors Liaison

Ioana R. Preston, MD, Education Committee Workforce Leader

Oksana A. Shlobin, MD, I2C2 Workforce Leader

Teresa De Marco, MD, FACC, Standards & Guidelines Committee Workforce Leader

Amresh Raina, MD, ISHLT Links Newsletter Liaison

Aaron B. Waxman, MD, PhD, Basic Science & Translational Research Council Liaison

Marco A. Caccamo, MD, Junior Faculty & Trainee Council Liaison

Rachel M. Crackett, MSc, Nursing, Health Sciences & Allied Health Council Liaison

 

PULMONARY TRANSPLANTATION

Michael Mulligan, MD, Chair

Cynthia J. Gries, MD, MSc, Vice Chair

Ramsey R. Hachem, MD, Vice Chair Elect

David Weill, MD, Past Chair

Peter M. Hopkins, FRACP, Board of Directors Liaison & Standards & Guidelines Committee Workforce Leader

Lorriana E. Leard, MD, Education Committee Workforce Leader

Lianne G. Singer, MD, FRCPC, I2C2 Workforce Leader

Jonathan P. Singer, MD, MS, Quality of Life Workforce Leader

Tereza Martinu, MD, ISHLT Links Newsletter Liaison

Joshua Diamond, MD, Basic Science & Translational Research Council Liaison

Robin Vos, MD, PhD, Junior Faculty & Trainee Council Liaison

Tara R. Fuller, Nursing, Health Sciences & Allied Health Council Liaison

 

[* *]

PAST PRESIDENTS

 

^.
p. Michael Hess, MD
^.
p. Jack Copeland, MD
^.
p. Terence English, FRCS
^.
p. Stuart Jamieson, MD
^.
p. Bruno Reichart, MD
^.
p. Margaret Billingham, MD
^.
p. Christian Cabrol, MD
^.
p. John O’Connell, MD
^.
p. Eric Rose, MD
^.
p. John Wallwork, FRCS
^.
p. Sharon Hunt, MD
^.
p. William Baumgartner, MD
^.
p. Leslie Miller, MD
^.
p. Alan Menkis, MD, FRCS
^.
p. Robert L. Kormos, MD
^.
p. Anne Keogh, MBBS, MD
^.
p. James B. Young, MD
^.
p. Stephan Schueler, MD
^.
p. Jon Kobashigawa, MD
^.
p. Alec Patterson, MD
^.
p. Mark L. Barr, MD
^.
p. Robert C. Robbins, MD
^.
p. Paul A. Corris, MB FRCP
^.
p. Mandeep R. Mehra, MD
^.
p. James K. Kirklin, MD
^.
p. John Dark, MB, FRCS
^.
p. Lori J. West, MD, DPhil
^.
p. David O. Taylor, MD
^.
p. Allan R. Glanville, MBBS, MD, FRACP
^.
p. Hermann Reichenspurner, MD, PhD

 

 

[* *]

PAST PROGRAM CHAIRS

 

^.
p. San Francisco, CA
^.
p. Edward B. Stinson, MD and Michael L. Hess, MD
^.
p. Phoenix, AZ
^.
p. Michael Kaye and Bernard Gersh
^.
p. New Orleans, LA
^.
p. Stuart W. Jamieson, MD and Mark E. Thompson, MD
^.
p. New York, NY
^.
p. Randall B. Griepp, MD
^.
p. Anaheim, CA
^.
p. Terence A. H. English and Hillel Laks
^.
p. New York, NY
^.
p.  
^.
p. New Orleans, LA
^.
p.  
^.
p. Los Angeles, CA
^.
p. John C. Baldwin, MD
^.
p. Munich, Germany
^.
p. Bruno Reichart, MD
^.
p. San Diego, CA
^.
p. D. Glenn Pennington, MD
^.
p. Paris, France
^.
p. John B. O’Connell, MD
^.
p. San Diego, CA
^.
p. Eric A. Rose, MD
^.
p. Boca Raton, FL
^.
p. Maria Rosa Costanzo, MD
^.
p. Venice, Italy
^.
p. John Wallwork, MBChB, FRCS
^.
p. San Francisco, CA
^.
p. Leslie W. Miller, MD
^.
p. New York, NY
^.
p. William A. Baumgartner, MD
^.
p. London, England
^.
p. Stephan Schueler, MD
^.
p. Chicago, IL
^.
p. James B. Young, MD
^.
p. San Francisco, CA
^.
p. Mark L. Barr, MD
^.
p. Osaka, Japan
^.
p. Jon Kobashigawa, MD
^.
p. Vancouver, Canada
^.
p. David O. Taylor, MD
^.
p. Washington, DC
^.
p. Robert C. Robbins, MD
^.
p. Vienna, Austria
^.
p. Bruce R. Rosengard, MD
^.
p. San Francisco, CA
^.
p. Mandeep R. Mehra, MD
^.
p. Philadelphia, PA
^.
p. Shaf Keshavjee, MD
^.
p. Madrid, Spain
^.
p. John Dark, MB, FRCS
^.
p. San Francisco, CA
^.
p. Duane Davis, MD
^.
p. Boston, MA
^.
p. Lori J. West, MD, DPhil
^.
p. Paris, France
^.
p. Randall C. Starling, MD, MPH
^.
p. Chicago, IL
^.
p. Hermann Reichenspurner, MD, PhD
^.
p. San Diego, CA
^.
p. Richard N. Pierson, III, MD
^.
p. Prague, Czech Republic
^.
p. Stuart C. Sweet, MD, PhD
^.
p. Montreal, Canada
^.
p. Allan R. Glanville, MBBS, MD, FRACP
^.
p. San Diego, CA
^.
p. Jason D. Christie, MD
^.
p. Nice, France
^.
p. Andreas Zuckermann, MD

 

[* *]

EDITORS

 

 

JOURNAL OF HEART AND LUNG TRANSPLANTATION

^.
p. Jacques G. Losman, MD
^.
p. Michael P. Kaye, MD
^.
p. Maria Rosa Costanzo, MD
^.
p. James K. Kirklin, MD
^.
p. Mandeep R. Mehra, MD

 

 

LINKS NEWSLETTER

^.
p. David S. Feldman, MD, PhD
^.
p. Vincent G. Valentine, MD

 

 

[* *]

REGISTRY MEDICAL DIRECTORS

 

 

INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION

^.
p. Michael P. Kaye, MD
^.
p. Jeffrey D. Hosenpud, MD
^.
p. Marshall I. Hertz, MD
^.
p. Josef Stehlik, MD, PhD

 

 

ISHLT REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®)

2012-Present

James K. Kirklin, MD

 

 

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (iPHFR)

2015-Present

Anne I. Dipchand, MD

 

 

[* *]

ISHLT AWARD RECIPIENTS

 

OUTSTANDING ACHIEVEMENT AWARDS

 

ISHLT PIONEER AWARD

^.
p. Christiaan Barnard, MD
^.
p. Joel D. Cooper, MD
^.
p. Norman E. Shumway, MD
^.
p. Michael DeBakey, MD
^.
p. Bruce A. Reitz, MD
^.
p. Leonard L. Bailey, MD
^.
p. Richard E. Lower, MD
^.
p. Christian E. A. Cabrol, MD
^.
p. Elizabeth Hammond, MD
^.
p. Jack G. Copeland, MD
^.
p. Bruno Reichart, MD

 

ISHLT LIFETIME ACHIEVEMENT AWARD

^.
p. Norman Shumway, MD
^.
p. Keith Reemtsma, MD
^.
p. Sir Magdi Yacoub, MD
^.
p. Margaret Billingham, MD
^.
p. Sharon Hunt, MD
^.
p. Sir Terence English, KBE, FRCS

 

ISHLT LIFETIME SERVICE AWARD

^.
p. Michael P. Kaye, MD
^.
p. Jacques G. Losman, MD

 

EMERITUS MEMBERSHIP

Margaret D. Allen, MD

Christian Cabrol, MD

Sir Terence English, KBE, FRCS

Albert J. Guerraty, MD

Sharon A. Hunt, MD

Carl V. Leier, MD

Bruno Reichart, MD

Marlene Rose, PhD

John Wallwork, FRCS

Elaine M. Winkel, MD

Prof. Magdi Yacoub, MD

 

[* *]

GRANTS AND SCHOLARSHIPS

 

ISHLT NORMAN E. SHUMWAY CAREER DEVELOPMENT AWARD

^.
p. Gordon D. Wu, MD (supported by Roche)
^.
p. Anthony Azakie, MD (supported by Roche)
^.
p. Allan M. Ramirez, MD (supported by Novartis Pharma)
^.
p. Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
^.
p. Glen Westall, MD, PhD (supported by Roche)
^.
p. Sonja Schrepfer, MD, PhD (supported by Astellas)
^.
p. Tereza Martinu, MD, PhD
^.
p. Keshava Rajagopal, MD, PhD
^.
p. Xingan Wang, MD, PhD

 

ISHLT NURSING RESEARCH GRANT AWARD

^.
p. Eileen Collins, RN, PhD
^.
p. Katherine St. Clair, RN, MSN
^.
p. Jeanne Salyer, PhD
^.
p. Nancy M. Albert, MSN, RN
^.
p. Lynn Doering, RN, DNSc
^.
p. Annette J. De Vito Dabbs, RN, MN, PhD
^.
p. Diane H. Leloudis, RN, MSN
^.
p. Janet E. Madill, PhD
^.
p. Deidre E. Logan, PhD
^.
p. Annemarie F. Kaan, MCN
^.
p. Thierry Troosters, PhD
^.
p. Mi-Kyung Song, PhD
^.
p. Stacey M. Pollock-BarZiv, PhD
^.
p. Jane MacIver, RN, MSc
^.
p. Heike Spaderna, PhD
^.
p. Gerdi Weidner, PhD
^.
p. Christiane Kugler, PhD (supported by CSL Behring)
^.
p. Hilde Bollen, RN
^.
p. Lut Berben, PhD, RN (supported by CSL Behring)
^.
p. Connie White-Williams, PhD, RN, FAAN
^.
p. Jo Wray, PhD
^.
p. Jane Haines, DNP, RN, CMSRN
^.
p. Lea Ann Matura, PhD, RN
^.
p. JiYeon Choi, PhD, RN

 

ISHLT RESEARCH FELLOWSHIP AWARD

^.
p. Frances L. Johnson, MD (supported by Ortho-Biotech)
^.
p. Tuija S. Ikonen, MD (supported by Roche)
^.
p. Andrew F. Pierre, MD (supported by Ortho-Biotech)
^.
p. Jonathan Chen, MD (supported by Roche)
^.
p. Alyssa M. Krasinskas, MD (supported by Astellas)
^.
p. Owen T. Lawrence, MD (supported by Ortho-Biotech)
^.
p. Anne K. Raisanen-Sokolowski, MD (supported by Roche)
^.
p. Kelly S.A. Blair, MD (supported by Roche)
^.
p. A.M. El Gamel, MD (supported by Roche)
^.
p. Christine L. Lau, MD (supported by Wyeth-Ayerst)
^.
p. Scott D. Ross, MD
^.
p. Margaret L. Schwarze, MD (supported by Novartis)
^.
p. George Juang, MD (supported by Novartis)
^.
p. Sivasai Krovvidi, PhD (supported by Roche)
^.
p. Satoshi Saito, MD (supported by Novartis)
^.
p. Donald Wong, PhD (supported by Roche)
^.
p. Richard S. Lee, MD (supported by Novartis)
^.
p. Christopher H. Wigfield, FRCS (supported by Roche)
^.
p. Arnar Geirsson, MD (supported by Roche)
^.
p. Matteo Vatta, PhD (supported by Roche)
^.
p. Ruediger Hoebelt, MD (supported by Roche)
^.
p. Ewout J. van den Bos, MD (supported by Astellas)
^.
p. Felix Fernandez, MD (supported by Roche)
^.
p. Christian A. Gleissner, MD (supported by Astellas)
^.
p. Tsuyoshi Shoji, MD, PhD (supported by Actelion)
^.
p. Kendra N. Taylor, PhD (supported by Roche)
^.
p. Monica Zwierzchonieuska, MD (supported by XDx)
^.
p. Ryan C. Fields, MD (supported by Chiron)
^.
p. Arne Neyrinck, MD (supported by Astellas)
^.
p. Ahmad Saad, MD (supported by Roche)
^.
p. Rachel L. Anderson, MBBS (supported by Roche)
^.
p. Zhaohui Li, PhD (supported by Transmedics)
^.
p. Heather E. Merry, MD (supported by Encysive)
^.
p. Edward N. Seung, PhD (supported by XDx)
^.
p. Matthew J. Weiss, MD (supported by Novartis)
^.
p. J. Raymond Fitzpatrick, III, MD (supported by Encysive)
^.
p. Howard J. Huang, MD (supported by Transmedics)
^.
p. Mylvganam Jeyakanthan, MD (supported by XDx)
^.
p. Timothy M. Millington, MD (supported by Novartis)
^.
p. Satish N. Nadig, MD (supported by Roche)
^.
p. Takeshi Oyaizu, MD, PhD (supported by Actelion)
^.
p. Sonja Schrepfer, MD (supported by Astellas)
^.
p. Jonathan Choy, PhD (supported by XDx)
^.
p. Satoshi Itoh, MD (supported by Transmedics)
^.
p. Tereza Martinu, MD (supported by Novartis)
^.
p. Deepti Saini, PhD (supported by Gilead)
^.
p. Atsushi Shiozaki, MD, PhD (supported by Astellas)
^.
p. Seiichiro Sugimoto, MD, PhD (supported by Roche)
^.
p. Hua Shen, MD, PhD (supported by Astellas)
^.
p. Tobias Deuse, MD, PhD (supported by Novartis)
^.
p. Masahiro Miyajima, MD, PhD (supported by XDx)
^.
p. Shin Hirayama, MD, PhD (supported by Gilead)
^.
p. Esme Dijke, PhD (supported by Novartis)
^.
p. Smita Sihag, MD (supported by Genentech)
^.
p. Sumiharu Yamamoto, MD (supported by Gilead)
^.
p. Khurram Shahzad, MD (supported by United Therapeutics)
^.
p. Nina Pilat, MSc, PhD (supported by XDx)
^.
p. Alejandro Bribriesco, MD (supported by Astellas)
^.
p. Alexey Dashkevich, MD (supported by XDx)
^.
p. Patricia E. de Almeida, DVM, MS, PhD
^.
p. Tiago Machuca, MD, PhD
^.
p. Stephen C. Juvet, MD, FRCPC
^.
p. Maria Lucia L. Madariga, MD
^.
p. Jessica H. Spahn, PhD
^.
p. Konstantinos Malliaras, PhD
^.
p. Nikolaos Diakos, MD
^.
p. Raymond Givens, MD, PhD
^.
p. Pablo Sanchez, MD, PhD
^.
p. Charles Evans, MD
^.
p. Christine Lin, MD
^.
p. Stijn Verleden, PhD
^.
p. Jonathan Merola, MD

 

*ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD *

(formerly Junior Faculty Award)

^.
p. Beth D. Kaufman, MD
^.
p. Cynthia Gries, MD, MSc
^.
p. Scott Halpern, MD, PhD
^.
p. Josef Stehlik, MD, MPH
^.
p. Jennifer Conway, MD, FRCPC
^.
p. Kiran K. Khush, MD, MAS
^.
p. Jose Nativi, MD
^.
p. Erin M. Lowery, MD
^.
p. Omar E. Wever-Pinzon, MD
^.
p. Chesney Castleberry, MD
^.
p. Eugene DePasquale, MD
^.
p. Aaron Healy, MD
^.
p. Marian Urban, MD
^.
p. Miranda Paraskeva, MBBS
^.
p. Hrishikesh Kulkarni, MD
^.
p. Agnieszka Ciarka, MD, PhD
^.
p. Livia Goldraich, MD, MSc
^.
p. Deipanjan Nandi, MD, MSc
^.
p. Evan Kransdorf, MD, PhD
^.
p. Manreet Kanwar, MD
^.
p. Natasha Loghmanpour, PhD
^.
p. Alexander Bernhardt, MD
^.
p. Jong-Chan Youn, MD, PhD

 

[* *]

ISHLT/BAYER PULMONARY HYPERTENSION RESEARCH GRANT AWARD

^.
p. Benjamin Freed, MD

 

ISHLT/HEARTWARE AWARD FOR TRANSLATIONAL RESEARCH IN MCS

^.
p. Leigh Reardon, MD
^.
p. Alexander Bernhard, MD

 

*ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT *

(supported by Thoratec)

^.
p. Sasa D. Borovic, MD
^.
p. Iki Adachi, MD
^.
p. Antigone Koliopoulou, MD
^.
p. Masahiro Ono, MD, PhD

 

ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP AWARD

^.
p. Stephanie T. Yerkovich, PhD
^.
p. Sarah E. Gilpin, PhD
^.
p. Kimberly M. Derkatz, BNSc
^.
p. Jennifer Conway, MD, FRCPC
^.
p. Ramin E. Beygui, MD
^.
p. Kevin C. Carney, MSN
^.
p. Alexandre Souza Cauduro, MD
^.
p. Esme Dijke, PhD
^.
p. Ana Belen Mendez, MD
^.
p. David Schibilsky, MD
^.
p. Aleem Siddique, MBBS
^.
p. Amparo Solé, MD, PhD
^.
p. Manon Huibers, MSc
^.
p. Daniel R. Goldstein, MD
^.
p. Laveena Munshi, MD, FRCPC
^.
p. Marco Masetti, MD
^.
p. Rochelle M. Gellatly, PScPharm, ACPR, PharmD
^.
p. Alison Gareau, MSc
^.
p. Erin Schumer, MD, MS
^.
p. Bojan Vrtovec, MD, PhD
^.
p. Marsha Renikunta, PhD (student)
^.
p. Katie Morley, BA(Hons), RCN, MA
^.
p. Ali Yeginsu, MD
^.
p. Fabrizio Gandolfo, MD
^.
p. Marian Urban, MD
^.
p. Alexander Bernhardt, MD
^.
p. Victor Rossel, MD
^.
p. Mohammed Quader, MD
^.
p. Marny Fedrigo, MD, PhD
^.
p. Zachary Kon, MD
^.
p. Evgenios Neofytou, MD
^.
p. Dong, Wang, MD
^.
p. Stephen Clark, DM, FRCS
^.
p. Caroline Patterson, BMBS, BMedSci, MRCP
^.
p. Tahaunty Pena, MD
^.
p. Oisin O’Connell, MD, MRCPI
^.
p. Lucas Van Aelst, MD, PhD
^.
p. Arezu Aliabadi, MD
^.
p. Timothy Sladden, MBBS, BVSc
^.
p. Bao Tran, MD
^.
p. L G Saptharishi, MD, DM
^.
p. Allison Carroll, MD
^.
p. Akshay Pendyal, MD
^.
p. Stefania Paolillo, MD, PhD
^.
p. Soumitra Sinha Roy, MD

 

ISHLT LEACH-ABRAMSON-IMHOFF LINKS TRAVEL AWARDS

^.
p. Tereza Martinu, MD, Writer of the Year
^.
p. Stanley I. Martin, MD, First Runner-Up
^.
p. Luciano Potena, MD, PhD, First Runner-Up
^.
p. Nancy P. Blumenthal, CRNP, Honorable Mention
^.
p. Bronwyn J. Levvey, RN, Honorable Mention
^.
p. Javier Carbone, MD, PhD, Honorable Mention
^.
p. Stavros G. Drakos, MD, Honorable Mention
^.
p. Daniel F. Dilling, MD, Honorable Mention
^.
p. Michele Estabrook, MD, Writer of the Year
^.
p. Melanie Everitt, MD, First Runner-Up
^.
p. Christina Migliore, MD, First Runner-Up
^.
p. Veronica Franco, MD, Honorable Mention
^.
p. Manreet Kanwar, MD, Honorable Mention
^.
p. Luciano Potena, MD, PhD, Honorable Mention
^.
p. Macé Schuurmans, MD, Honorable Mention
^.
p. Jeffrey J. Teuteberg, MD, Honorable Mention
^.
p. Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year
^.
p. Amanda Ingemi, PharmD, First Runner-Up
^.
p. Simon Urschel, MD, Honorable Mention
^.
p. Pamela S. Combs, PhD, RN, Writer of the Year
^.
p. Manreet Kanwar, MD, First Runner-Up
^.
p. Oveimar De la Cruz, MD, Honorable Mention
^.
p. Heather T. Henderson, MD, Honorable Mention
^.
p. Simon Urschel, MD, Honorable Mention
^.
p. Erin Wells, RN, BSN, CPN, Honorable Mention

 

[* *]

ABSTRACT AWARDS

 

PHILIP K. CAVES AWARD

^.
p. Robbin G. Cohen, MD
^.
p. Hermann Reichenspurner, MD
^.
p. Michael A. Breda, MD
^.
p. Stuart J. Knechtle, MD
^.
p. Wim Van Der Bij, MD
^.
p. Charles D. Fraser, Jr., MD
^.
p. A.M. Wood, MD
^.
p. Andres J. Duncan, MD
^.
p. A. Jiminez, MD
^.
p. David P. Kapelanski, MD
^.
p. David Marshman, MD
^.
p. Jobst Winter, MD
^.
p. Alain Chapelier, MD
^.
p. Elizabeth A. Davis, MD
^.
p. Moninder S. Bhabra, MD
^.
p. Simon D. Eiref, MD
^.
p. Carla C. Baan, MD
^.
p. Joerg Koglin, MD
^.
p. Michael P. Fischbein, MD
^.
p. Alexander S. Krupnick, MD
^.
p. Peter Blaha, MD
^.
p. Sigrid Sandner, MD
^.
p. M.D. Peterson, MD
^.
p. Sigrid Sandner, MD
^.
p. Frank D’Ovidio, MD
^.
p. Gregor Warnecke, MD
^.
p. Heather E. Merry, MD
^.
p. Satish N. Nadig, MD
^.
p. Howard Huang, MD
^.
p. Tobias Deuse, MD, PhD
^.
p. Ankit Bharat, MD
^.
p. Simo Syrjälä, MD
^.
p. Alexey Dashkevich, MD
^.
p. Jessica Spahn
^.
p. Simon Pecha, MD

 

NURSING, HEALTH SCIENCES & ALLIED HEALTH EXCELLENCE IN RESEARCH AWARD

^.
p. Mary Amanda Dew, PhD
^.
p. Kathleen L. Grady, PhD, RN
^.
p. Christiane Kugler, PhD
^.
p. Annette DeVito Dabbs, RN, PhD
^.
p. Connie White-Williams, MSN
^.
p. Bronwyn Levvey, RN
^.
p. Samantha J. Anthony, PhD, MSW
^.
p. Kate Hayes, MPhysio (Cardio)
^.
p. Jane Haines, DNP, RN, CMSRN
^.
p. Louise Fuller, PT
^.
p. Catherine Murks, PhD, APN

 

JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION AWARD

^.
p. Michelle M. Kittleson, MD, PhD
^.
p. Erin Albers, MD
^.
p. Mustafa Ahmed, MD
^.
p. Lauren Sacha
^.
p. Ankit Bharat, MD

 

[*ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS ABSTRACT AWARD *](supported by Thoratec)

^.
p. Nishant Shah, MD
^.
p. Jose N. Nativi, MD
^.
p. Arun Raghav Mahankali Sridhar, MD, MPH
^.
p. Claire Watkins, MD
^.
p. Jason O. Robertson, MD

 

[* *]

ACCREDITATION INFORMATION

 

Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

 

Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

 

Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

 

Target Audience

The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

 

Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end stage heart and lung disease

 

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with end stage heart and lung failure.

 

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end stage heart and lung disease management and prevention.

 

ACCREDITATION INFORMATION (Continued)

 

ACCME Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement

ISHLT designates this live activity for a maximum of 30 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

 

ACPE Accreditation

Pharmacists

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Successful completion of this program qualifies for up to 13.0 contact hours.  Full attendance is required.  No partial contact hours will be awarded for partial attendance. Unique Activity Numbers: 0453-9999-16-029-L04-P through 0453-9999-16-047-L04-P

 

ABTC Accreditation
The ABTC Board of Governors has granted a total of 30 Category 1 Continuing Education Points for Transplant Certification (CEPTC) to the International Society for Heart & Lung Transplantation’s ISHLT 36th Annual Meeting and Scientific Sessions.

 

*ANCC Accreditation *

ANCC credits for this activity have been applied for.

 

[* *]

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the 36th Annual Meeting and Scientific Sessions:

 

Actelion Pharmaceuticals

United Therapeutics

Gilead Sciences

Bayer Healthcare

 

 

 

 

*******************************************************

 

 

 

 

The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2016:

 

Tier 1

Actelion Pharmaceuticals

 

Tier 2

Bayer Healthcare
Gilead Sciences
HeartWare
St. Jude
United Therapeutics

Tier 3

CareDx

Lung Bioengineering

Transmedics

 

HIGHLIGHTS OF THE MEETING

 

*Basic Science and Translational Research *

The 2016 ISHLT Annual Meeting will include a range of sessions covering basic science and translational research topics in heart and lung failure and transplantation. These carefully crafted symposia will feature internationally recognized leaders in the field. The aim of each session will be to bring together in one room basic scientists as well as clinicians and clinical researchers who wish to explore the given topics. The pre-meeting symposium entitled, Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation, will include talks given by experts in biobanking, omics data analysis, big data modeling, and multi-center study design. Speakers will also explore the potential clinical applications of the resulting datasets. Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant? will be an exciting state-of-the-art set of lectures by world-renowned pioneers in tissue engineering, cell therapy, and tolerance induction presented in the context of heart and lung failure and transplantation. A sunrise symposium will offer a more basic coverage of transplant immunology and biology: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology. This will be an opportunity for all ISHLT members to brush up on their basic science knowledge and also review the clinical relevance of underlying mechanisms of allograft rejection and injury. In addition to these three core symposia, other talks focused on basic and translational research have been incorporated into other sessions in order to create a well-rounded high-quality program for the ISHLT conference attendees.

 

Heart Failure and Transplantation

The ISHLT 2016 in Washington DC will bring dynamic and thought provoking symposia in heart failure and transplantation for clinicians, surgeons and allied health professionals. Timing Support in Cardiogenic Shock: When to Move Forward will confront us with the difficult question of when is the best time to intervene in an emergent situation? Then we will challenge our current paradigm with Rethinking Valvular Heart Disease in Heart Failure from percutaneous intervention to surgical interventions. We will also explore how to select the best donor and optimize the current donor shortage with the session, Donor Heart Selection: Strategies to Improve Organ Utilization. A comprehensive discussion on how to diagnose and manage right heart failure will be included in When Right Is Wrong: Management of the Dying Right Ventricle. We will look at post-transplant surgical challenges with a session on Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective that will discuss topics such as technical considerations in adult congenital heart transplantation, surgical management of primary graft dysfunction and surgical options for late graft failure. We will tackle post heart transplant immunology with a Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR from the most update diagnoses to the best treatments. We will continue with immunology to immunosuppression with Controversies in Heart Transplantation: Past, Present and Future.

 

Infectious Diseases

ISHLT 2016 will offer wide-ranging insight into topics of vital importance to infection in thoracic organ transplantation and MCSD, with symposia of interest both to the diehard Transplant Infectious Diseases provider as well as to other clinicians and scientists with interest in Infectious Diseases. We lead off with The Future is Here: Emerging Issues in Infectious Disease, a whirlwind tour of challenging topics including Mycobacterium abscessus, RSV, Scedosporium and other emerging fungi, Clostridium difficile, and those troublesome resistant Gram-negative organisms. Next up is a comprehensive look at CMV in It’s All in the Translation: CMV from Bedside to Bench and Back, which will examine the impact of CMV on the heart and lung allograft, the anti-CMV immune response, and review our current antiviral armamentarium and preview new tools on the horizon. We end the day with a not-to-be-missed session entitled Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infections with an update on UNOS data on donor derived infections and a review of the European perspective, a look at the donor with possible encephalitis, nucleic acid based testing for HIV, hepatitis C, and hepatitis B, and new opportunities ahead for HIV-positive organs. Grab some coffee for our Sunrise Symposium on The Fly in the Ointment: Nosocomial Infections, a novel look at antimicrobial stewardship, infection prevention, and outbreaks in the transplant center, with a special look at patients with open chest or ECMO. But that’s not all—our colleagues in MCS are presenting Achilles Heel: Infectious Complications in MCS, our friends in Pharmacy will review the lifecycle of Hepatitis C patient with heart failure, specialists from the Pediatrics community will discuss Child’s Play: Infectious Risk After Transplant During Everyday Life, and from Lung Transplantation, a session on infection in the elderly lung transplant recipient.

 

Lung Failure and Transplantation

This year there will be numerous stimulating sessions with 4 Pre-meeting Symposia and 2 Sunrise Symposia dedicated to lung transplantation. Current Innovations and Future of EVLP will explore the future of EVLP with respect to lung repair using cell or gene based therapies and drug or molecular interventions. Advanced techniques of ex-vivo perfusion using portable systems and dual artery cannulation techniques will be discussed. EVLP as a platform to reduce infection and possible allo responsiveness will be summarized. Multiorgan Transplantation for Lung Recipients: When is Two Better than One? will summarize key recommendations pertaining to heart-lung, lung-liver and lung-kidney transplantation. Furthermore, the ethics and equity debate of multi organ transplantation shall be outlined as well as issues of possible immunological allograft protection. The Biology of Aging and Lung Transplantation will cover issues of immunosenescence, impact of telomerase mutations, measures of frailty and other challenges in the elderly recipient including infection and immunosuppressive regimens. Our persistent nemesis CLAD will be reviewed in Endotypes of CLAD and Novel Treatment Strategies. The symposium will include a presentation on the historical basis for CLAD phenotypes and review of current clinical, radiological and pathological criteria. Contemporary medical and surgical treatment practices for patients as directed by phenotype will be outlined, along with future perspectives with regards to CLAD prevention. Thoracic Organ Transplantation and Malignancy, will review key issues including relevance to lung transplant candidate selection and overview of current cancer screening guidelines. Lung Transplant Benefit is More Than Just Survival will question the outcome of survival as the only relevant measure of success with lung transplantation. The session will assess contemporary assessment tools of health related quality of life, functioning and disability and their relevance to measuring important patient outcomes, as well as the impact of neuro cognitive changes post lung transplant.

 

Mechanical Circulatory Support

We are looking forward to the 2016 Annual Meeting and expect the MCS content will stimulate the broad interests of the MCS community and actively represent the variety of subspecialties which contribute to the advancement of the field. The challenges of managing anticoagulation and antiplatelet therapy, the use of platelet functional assays, and the approach to high-risk patients will be addressed in Anticoagulation and MCS: Can We Do Better? _]The ISHLT is very pleased to introduce the first joint ISHLT/ICCAC symposium, [_Joined at the Heart – International Perspectives on MCS Issues, which has leaders from both societies exploring the factors which allow multidisciplinary teams to achieve excellent results across a wide array of practice environments. Achilles Heel: Infectious Complications in MCS will have representatives from both MCS and infectious disease review the diagnosis, therapy, prevention and long-term consequences of infections in patients with MCS. We will tackle several controversial issues such as transplantation versus DT in the elderly, mechanical support in less sick patients, and the use of minimally invasive implant techniques in Great Debates in MCS. The debates will be case-based and will provide both an informative and entertaining review of these contentious topics. The MCS community recognizes the importance of patient selection and management on outcomes and the incidence of adverse events, but device engineering also plays a critical role. In MCS Challenges and Engineering Solutions, we will review the role of shear stress, the impact of pump miniaturization, the use of physiologic controls and available engineering options to improve outcomes and reduce adverse events. These engineering principles will be presented in the context of their clinical applications and in a manner that is accessible to the practicing MCS care provider. [_Clear as Mud: Assessing the Right Ventricle _]will address the always challenging issues of preoperative assessment of RV function, intraoperative treatment strategies and the approach to treatment of chronic RV failure.

 

*Nursing, Health Science, Allied Health *

This year, we are showcasing how art and evidence can inspire innovation in several areas of clinical care. An attractive program has been created through the collaboration of several different specialties including three diverse symposia in the areas of genomics, selection of marginal donors and ECMO. Genomics: What do I Have to Know and How Will It Affect My Practice? will provide all attendees with the basics of this new field and provides examples of how genomics will impact clinical transplant care in the future. The ethical reflection on this field and a discussion of nursing competencies will complete this session. In Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates, treatment decisions for marginal transplant and mechanical support candidates will be tackled in three debates developed around difficult issues that clinicians face every day. Should we, or should we not list this patient? What is the evidence base? Which ethical reflections influence our decisions? An interactive response system and a panel discussion will maximize the involvement of the audience. Ambulatory ECMO in Adults: We Like to Move It, Move It addresses the issue at the forefront of critical care practice: ambulation in adult ECMO patients. What are the risks and benefits? What is required to implement such a practice in your program? Which team members should be involved? In addition, there will be nursing, health sciences, and allied health content being presented in other symposia. This “cross-pollination” will serve to make this year’s ISHLT conference richer and more relevant.

 

Pathology

This year’s pathology satellite symposium takes aim at “chronic rejection” in the heart. Controversy and confusion surrounding this topic stem from varying definitions of what “chronic” means as well as whether the observed changes in the allograft are truly rejection. Speakers in this session will address the myocardial alterations (beyond CAV) seen after years of repetitive rejection episodes, novel mechanisms of CAV development, the role of complement and other mechanisms in potentiating late graft damage, a morphologic comparison to analogues of chronic rejection in other organs, and a review of animal models of late graft loss.

 

Pediatrics

We all recognize that there are major variations in pediatric heart failure and transplant management, and so this year’s pediatric symposia will spotlight major controversies in these fields. VADs in Patients with Congenital Heart Disease will focus on the big questions in this difficult group of patients, both pediatric and adult. [Child’s Play: Infectious Risk After Transplant During Everyday Life _]will examine the prevailing dogma after heart and lung transplantation in children, addressing whether isolation is necessary, which pets are allowed, what limits can be placed on travel, which water and food sources are safe, and current vaccination practices for endemic diseases. _Controversies in Pediatric Heart Failure will focus squarely on the heart failure community, engaging the audience with discussions of novel pharmaceutical agents in pediatric heart failure, and how to prevent sudden death in the pediatric heart failure patient. We will continue the important discussion from last year’s meeting on making palliative care part of the plan for every patient, and conclude with a presentation on the new ISHLT pediatric heart failure registry – will it result in useable data, or just make more work?

 

Pharmacy and Pharmacology

The 2016 ISHLT Annual Meeting will showcase clinical care and research initiatives through a diverse program of informative sessions. Two Pharmacy and Pharmacology sessions, which focus on drug therapy, lend applicability across all disciplines represented by the ISHLT membership. Join us in the return of the ever-popular lifecycle journey series, with a look at a Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016. An enduring case will be presented, interspersed with a best practice based discussion at pre-defined, key “journey intervals”. In this session, we focus on how the new hepatitis treatments have altered management at all stages of this lifecycle; pay particular consideration to the controversial areas of listing these patients for transplant; evaluate the tricky issue of immunosuppression; malignancy post-transplantation; and finally when to consider palliation? This is certain to be a lively session giving challenging insights into this developing area of practice, definitely not to be missed! The sunrise symposium on Saturday, Precision Medicine in Transplantation: Drug Levels and Beyond, involve a bench-to-bedside exploration of pharmacogenetics and the impact on drug metabolism and predicting adverse effects. We then approach the problem from the other angle as we consider therapeutic gene modulation, learning from the field of cystic fibrosis.

 

Pulmonary Hypertension

Pulmonary hypertension is truly at the forefront of the 2016 ISHLT Scientific Sessions with a total of seven provocative symposia! Areas covered will include pulmonary hypertension related to chronic thromboembolic disease, parenchymal lung disease, left heart disease and congenital heart disease. Sessions will also detail important issues in lung transplantation related to pulmonary hypertension, the use of combination therapy in pulmonary artery hypertension, and a translational symposium on emerging biology of pulmonary hypertension and the right heart. The two joint sessions with the European Society of Cardiology (ESC) and the Pulmonary Vascular Research Institute (PVRI) in particular are not to be missed.

 

 

[* *]

HOTEL FLOOR PLANSEXHIBITION LEVEL

 

[
**]

  • *

HOTEL FLOOR PLANSLOBBY LEVEL

 

[
**]

  • *

HOTEL FLOOR PLANSMEZZANINE LEVEL

 

[
**]

  • *

ACRONYMS

 

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

 

 

^.
p. BASIC SCIENCE
^.
p. JUNIOR FACULTY CLINICAL CASE REPORTS
^.
p. ECONOMICS, ETHICS, PUBLIC POLICY
^.
p. HEART FAILURE –ADULT
^.
p. HEART TRANSPLANTATIONADULT
^.
p. INFECTIOUS DISEASES
^.
p. LATE BREAKING CLINICAL SCIENCE
^.
p. LUNG FAILUREADULT
^.
p. LUNG TRANSPLANTATIONADULT
^.
p. MECHANICAL CIRCULATORY SUPPORTADULT
^.
p. NURSING, HEALTH SCIENCES, ALLIED HEALTH
^.
p. PATHOLOGY
^.
p. PEDIATRICS
^.
p. PHARMACY AND PHARMACOLOGY
^.
p. PULMONARY HYPERTENSION

 

 

*DAILY SCHEDULE *

 

All meetings and activities will take place at the Marriott Wardman Park Hotel in Washington, DC, USA, unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.ishlt.org) for updates. This Final Program reflects the latest session schedule and room assignments.

 

 

Monday, April 25, 2016

 

8:00 AM – 11:00 PM

Exhibit Hall Build (Exhibit Hall A)

 

9:00 AM – 5:00 PM

ISHLT Strategic Planning Meeting (Delaware Suite)

 

6:00 PM – 9:00 PM

Academy Registration Open (Thurgood Marshall Foyer)

Speaker Ready Room Open (Madison)

 

 

Tuesday, April 26, 2016

 

6:00 AM – 7:00 PM

Speaker Ready Room Open (Madison)

 

7:00 AM – 3:00 PM

Academy Registration Open (Thurgood Marshall Foyer)

 

8:00 AM – 2:00 PM

ISHLT Board of Directors Meeting (Harding)

 

8:00 AM – 6:00 PM

[*ISHLT Academy: Core Competencies in Heart Failure and Cardiac Transplant Medicine *](Thurgood Marshall North)

[*ISHLT Academy: Core Competencies in Mechanical Circulatory Support *](Thurgood Marshall East)

[*ISHLT Academy: Master Class in Pulmonary Transplantation *](Thurgood Marshall South & West)

 

9:00 AM – 11:00 AM

Airway Complications after Lung Transplantation Writing Committee (Balcony B)

 

12:00 PM – 1:00 PM

I2C2 Asia Meeting (Balcony A)

 

2:00 PM – 6:00 PM

ISHLT Board/Committee/Council Leadership Orientation (Hoover)

 

2:00 PM – 7:00 PM

Registration Open (Convention Registration)

 

5:00 PM – 7:00 PM

Press Office Open (Park Tower 8219)

 

6:00 PM – 8:00 PM

I2C2 Committee Meeting (Balcony A)

Education Committee Meeting (Balcony B)

Grants & Awards Committee Meeting (Park Tower 8212)

International Transplant Registry Committee Meeting (Park Tower 8217)

Standards and Guidelines Committee Meeting (Park Tower 8216)

 

 

Wednesday, April 27, 2016

 

6:00 AM – 7:00 PM

Speaker Ready Room Open (Madison)

 

7:00 AM – 7:00 PM

Registration Open (Convention Registration)

 

7:00 AM – 10:00 AM

Exhibitor Set-Up (Exhibit Hall A)

Poster Session 1 Mount (Exhibit Hall B & C)

 

[*8:00 AM – 10:00 AM *]

Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better? (Salons 2-3)[* *](MCS, HF, PHARM)

Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future (Thurgood Marshall)[* *](HTX, HF, ID, NHSAH, PATH, PEDS, PHARM)

Pre-Meeting Symposium 3: Current Innovations and Future of EVLP (Salon 1)[* *](LTX, LF, MCS)

Pre-Meeting Symposium 4: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease (Maryland Suite)[* *](PH, HF, LF, LTX)

Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective (Virginia Suite)[* *](HTX, HF, MCS, NHSAH, PEDS)

Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant? (Delaware Suite)[* *](ALL)

[Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease *](Washington Ballroom 2)[ *](ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM)

 

9:00 AM – 7:00 PM

Press Office Open (Park Tower 8219)

 

9:00 AM – 10:30 AM

Smithsonian Curators Meeting (Cap BoD)

 

10:00 AM – 7:00 PM

Exhibit Hall Open (Exhibit Hall A)

Poster Hall Open (Exhibit Hall B & C)

 

10:00 AM – 10:15 AM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

10:15 AM – 12:15 PM

Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart – International Perspectives on MCS Issues (Salons 2-3)[* *](MCS, HF, HTX, NHSAH)

Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization (Thurgood Marshall)[* *](HTX, LTX, MCS, NHSAH, PEDS)

Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group) (Salon 1)[* *](PH, ALL)

Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One? (Maryland Suite)[* *](LTX, HTX)

Pre-Meeting Symposium 12: It’s All in the Translation: CMV from Bedside to Bench and Back Again (Virginia Suite)[* *](ALL)

Pre-Meeting Symposium 13: Child’s Play: Infectious Risk After Transplant During Everyday Life (Delaware Suite)[* *](PEDS, HTX, ID, LTX, NHSAH, PHARM)

Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice? (Washington Ballroom 2)[* *](NHSAH, BSI, HF, HTX, LTX)

 

12:15 PM – 1:45 PM

Lunch Break

Junior Faculty and Mentor Lunch Meeting (Wilson)

IMACS Registry Committee Meeting (Taft)

Basic Science and Translational Research Scientific Council Meeting (Hoover)

Nursing, Health Sciences & Allied Health Scientific Council Meeting (Washington Ballroom 2)

Pharmacy and Pharmacology Scientific Council Meeting (Harding)

DCD Registry Committee Meeting (Taylor)

 

1:45 PM – 3:45 PM

[Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS *](Salons 2-3)[ *](MCS, HTX, ID, NHSAH, PHARM)

Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle (Thurgood Marshall)[* *](ALL)

Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation (Salon 1)[* *](LTX, ID, LF, MCS, NHSAH, PH)

Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH (Maryland Suite)[* *](PH, HF, LF, PEDS)

Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates (Virginia Suite)[* *](NHSAH, HF, HTX, LTX, MCS)

Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation (Delaware Suite)[* *](ALL)

Pre-Meeting Symposium 21: Unraveling “Chronic Rejection” in the Heart (Washington Ballroom 2)[* *](PATH, BSI, HF, HTX, LTX, PEDS)

 

3:45 PM – 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

4:00 PM – 6:00 PM

Pre-Meeting Symposium 22: Great Debates in MCS (Salons 2-3)[* *](MCS, HF, HTX, NHSAH)

Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR (Thurgood Marshall)[* *](HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM)

Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies (Salon 1)[* *](LTX, BSI, PATH, PEDS)

Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension (Maryland Suite)[* *](PH, ALL)

Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection (Virginia Suite)[* *](ALL)

Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease (Delaware Suite)[* *](PEDS, HF, HTX, MCS, NHSAH, PH)

Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016 (Washington Ballroom 2)[* *](PHARM, HF, HTX, ID, MCS, NHSAH)

 

6:00 PM – 7:00 PM

Exhibit Hall Grand Opening Reception (Exhibit Hall A)

Poster Session 1 (Exhibit Hall B & C) (ALL)

EUROMACS Meeting (Room 8205)

 

6:00 PM – 9:00 PM

Pulmonary AMR Workforce Meeting (Park Tower 8216)

 

7:00 PM – 7:30 PM

Poster Session 1 Removal (Exhibit Hall B & C)

 

7:00 PM – 10:00 PM

ICCAC Annual Meeting (Virginia Suite)

 

 

Thursday, April 28, 2016

 

7:00 AM – 7:00 PM

Registration Open (Convention Registration)

Speaker Ready Room Open (Madison)

 

7:00 AM – 10:00 AM

Poster Session 2 Mount (Exhibit Hall B & C)

 

7:00 AM – 8:00 AM

Junior Faculty and Trainees Council Meeting (Harding)

 

8:00 AM – 10:00 AM

Opening Plenary Session – Transplantation: Where Does the Science End and the Art Begin? (Salons 1-3) (ALL)

 

9:00 AM – 7:00 PM

Press Office Open (Park Tower 8219)

 

10:00 AM – 7:00 PM

Exhibit Hall Open (Exhibit Hall A)

Poster Hall Open (Exhibit Hall B & C)

 

10:00 AM – 10:30 AM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

10:30 AM – 12:00 PM

Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support (Salons 1-3) (MCS, HF, ID, NHSAH)

Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support (Thurgood Marshall) (MCS, BSI, HF)

Concurrent Session 3: Donor Organ Allocation and Management – What’s Hot and New? (Maryland Suite) (LTX, BSI, EEP, ID, NHSAH, PEDS, PHARM)

Concurrent Session 4: Keep It Down: New Insights on Immunosuppression (Virginia Suite) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex (Delaware Suite) (HF, MCS, NHSAH, PHARM)

Concurrent Session 6: Pediatric Heart Transplant Outcomes (Washington Ballroom 2) (PEDS, HTX, NHSAH)

 

12:00 PM – 2:00 PM

Lunch Break

JHLT Editorial Board Lunch Meeting (Wilson)

ID Symposium Planning Workgroup Meeting (Park Tower 8205)

IPLTC Meeting (Park Tower 8212)

Mechanical Circulatory Support Scientific Council Meeting (Delaware Suite)

Pathology Scientific Council Meeting (Harding)

Pulmonary Hypertension Scientific Council Meeting (Washington Ballroom 1)

Pulmonary Transplantation Scientific Council Meeting (Washington Ballroom 2)

 

1:00 PM – 2:00 PM

I2C2 Latin American Meeting (Balcony A)

 

2:00 PM – 3:30 PM

Concurrent Session 7: It’s Tough to Make Predictions, Especially about the Future: Outcomes in MCS (Salons 2-3) (MCS, HTX, NHSAH)

Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS (Thurgood Marshall) (MCS, EEP, NHSAH)

Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation (Salon 1) (HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

Concurrent Session 10: The Frailty Construct and Body Composition – Impact on Lung Transplant Outcomes (Maryland Suite) (LTX, NHSAH, PEDS, PHARM)

Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft (Virginia Suite) (HTX, BSI, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 12: Pediatric Lung Transplantation (Delaware Suite) (PEDS, LTX)

Concurrent Session 13: Philip K. Caves Award Candidate Presentations (Washington Ballroom 2) (ALL)

Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH (Washington Ballroom 1) (PH, BSI, LF, LTX, NHSAH, PHARM)

 

3:30 PM – 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

2017 Symposium Planning Committee Meeting (Harding)

 

4:00 PM – 5:30 PM

Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS (Salons 2-3) (MCS, HF)

Concurrent Session 15: Let’s Be Specific: Donor Specific Antibodies – Challenges Ahead (Thurgood Marshall) (HTX, BSI, ID, MCS, PATH, PEDS, PHARM)

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction (Salon 1) (LTX, BSI, PEDS, PHARM)

Concurrent Session 17: Pediatric Mechanical Circulatory Support (Maryland Suite) (PEDS, MCS)

Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance (Virginia Suite) (BSI, HTX, LTX)

Concurrent Session 19: Improving Outcomes: Body and Soul (Delaware Suite) (NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH)

Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation (Washington Ballroom 2) (EEP, HF, HTX, LTX, MCS, NHSAH)

 

5:30 PM – 6:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

6:00 PM – 7:00 PM

Mini Oral 1: Science, Surgery and Shock in MCS (Thurgood Marshall) (MCS, BSI, HTX, NHSAH)

Mini Oral 2: Donor Dilemmas in Heart Transplantation (Salon 1) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

Mini Oral 3: Candidate and Recipient Management in Heart Transplantation (Maryland Suite) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

Mini Oral 4: Donor and Recipient Management in Lung Transplantation (Virginia Suite) (LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM)

Mini Oral 5: Pediatrics: Organ Support and Transplantation (Delaware Suite) (PEDS, HTX)

Mini Oral 6: Pharmacy & Pharmacology and Mechanical Circulatory Support (Washington Ballroom 1 & 2) (PHARM, HTX, ID, LTX, MCS)

Wine & Cheese Reception (Exhibit Hall A)

Poster Session 2 (Exhibit Hall B & C) (ALL)

Past Presidents Committee Meeting (Harding)

 

7:00 PM – 7:30 PM

Poster Session 2 Removal (Exhibit Hall B & C)

 

 

Friday, April 29, 2016

 

6:00 AM – 7:00 PM

Speaker Ready Room Open (Madison)

 

7:00 AM – 7:00 PM

Registration Open (Convention Registration)

 

7:00 AM – 10:00 AM

Poster Session 3 Mount (Exhibit Hall B & C)

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 1: MCS Challenges and Engineering Solutions *](Thurgood Marshall) (MCS, HF, HTX, NHSAH)

[*Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward *](Salon 1) (ALL)

Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy (Maryland Suite) (LTX, HF, HTX, LF, NHSAH, PEDS, PHARM)

Sunrise Symposium 4: Let’s Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease (Virginia Suite) (PH, LTX, NHSAH, PEDS)

Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology (Delaware Suite) (ALL)

Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections (Washington Ballroom 2) (ID, ALL)

 

8:00 AM – 10:00 AM

Plenary Session: Where is the Future for Innovation? (Salons 2-3) (ALL)

 

9:00 AM – 7:00 PM

Press Office Open (Park Tower 8219)

 

10:00 AM – 4:00 PM

Exhibit Hall Open (Exhibit Hall A)

 

10:00 AM – 7:00 PM

Poster Hall Open (Exhibit Hall B & C)

 

10:00 AM – 10:30 AM

Annual Business Meeting (Salons 2-3)

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

10:30 AM – 12:00 PM

Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management (Salons 2-3) (MCS, HF, NHSAH)

Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS (Thurgood Marshall) (MCS, HF, NHSAH, PHARM)

Concurrent Session 23: Choosing a Gift: Donor Selection (Salon 1) (HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 24: What’s New in Primary Graft Dysfunction Post Lung Transplantation (Virginia Suite) (LTX, BSI, ID, NHSAH, PEDS, PHARM)

Concurrent Session 25: Beyond Adherence: What’s New Out There? (Delaware Suite) (NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

[*Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The Anti-Body? *](Washington Ballroom 2) (BSI, HTX, LTX, MCS, PEDS)

Symposium 30: JHLT at ISHLT: The Year in a Capsule (Maryland Suite) (ALL)

 

12:00 PM – 2:00 PM

Lunch Break

Heart Failure and Transplantation Scientific Council Meeting (Delaware Suite)

Infectious Diseases Scientific Council Meeting (Hoover)

Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting (Washington Ballroom 2)

IMACS Users Group Meeting (Harding)

ISHLT/AST Lung Transplant Benefit Meeting (Wilson)

Registries and Databases Committee Meeting (Taft)

 

12:00 PM – 1:00 PM

Lung Quality of Life Workforce Meeting (Jefferson)

ID Symposium Planning Workgroup Meeting (Park Tower 8205)

 

12:15 PM – 1:30 PM

Women in Transplantation Meeting (Salon 1)

 

1:00 PM – 2:00 PM

Pulmonary AMR Workgroup Meeting (McKinley)

 

2:00 PM – 3:30 PM

Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS (Salons 2-3) (MCS, HF, NHSAH, PH)

Concurrent Session 28: Pump Thrombosis: What’s Hot with the Clot (Thurgood Marshall) (MCS, HF, NHSAH)

Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV (Salon 1) (HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation (Maryland Suite) (LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 31: Pediatric Early Post Transplant Problems (Virginia Suite) (PEDS, HTX, MCS)

Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment (Delaware Suite) (ID, HTX, LTX, MCS, NHSAH)

Concurrent Session 33: “A Bipartisan Effort”: Antibodies and Complement in Heart and Lung Allografts (Washington Ballroom 2) (PATH, BSI, HF, HTX, LTX, PEDS)

Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH (Washington Ballroom 1) (PH, ALL)

 

3:30 PM – 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

4:00 PM – 5:30 PM

Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS (Salons 2-3) (MCS, HTX, NHSAH)

Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS (Thurgood Marshall) (MCS, HF, NHSAH, PHARM)

Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant (Salon 1) (HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression (Maryland Suite) (LTX, BSI, ID, NHSAH, PEDS, PHARM)

[*Concurrent Session 38: New Insights in Pulmonary Hypertension *](Virginia Suite) (PH, BSI, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

Concurrent Session 39: Junior Faculty and Trainee Council’s Clinical Case Dilemmas: The Best of the Best (Delaware Suite) (CASE, ALL)

Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity (Washington Ballroom 2) (PHARM, HTX, ID, LTX, MCS, NHSAH)

 

5:30 PM – 6:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

 

5:30 PM – 6:30 PM

Psychosocial Guidelines Writing Group Meeting (Park Tower 8216)

 

6:00 PM – 7:00 PM

Mini Oral 7: Patient Management and Outcomes in MCS (Thurgood Marshall) (MCS, HF, NHSAH)

Mini Oral 8: Technology, Physiology and Complications in MCS (Salon 1) (MCS, HTX, NHSAH)

Mini Oral 9: Risk Factors and Lung Transplant Outcomes (Maryland Suite) (LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM)

Mini Oral 10: Heart Transplantation and Heart Failure (Virginia Suite) (HTX, BSI, LTX, NHSAH, PATH, PEDS, PHARM)

Mini Oral 11: Models in Transplantation: From Mouse to Rat to Pig to Human (Delaware Suite) (BSI, HTX, LTX, MCS)

Mini Oral 12: Applied Health Research and Pulmonary Hypertension (Washington Ballroom 2) (NHSAH, EEP, HTX, LTX, MCS, PEDS)

Wine & Cheese Reception (Exhibit Hall A)

Poster Session 3 (Exhibit Hall B & C) (ALL)

 

7:00 PM – 7:30 PM

Poster Session 3 Removal (Exhibit Hall B & C)

 

8:00 PM – 9:30 PM

PRESIDENT’S COCKTAIL RECEPTION (Smithsonian National Museum of Natural History)

 

 

Saturday, April 30, 2016

 

6:00 AM – 5:00 PM

Speaker Ready Room Open (Madison)

 

7:00 AM – 12:00 PM

Registration Open (Convention Registration)

 

7:00 AM – 8:00 AM

Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle (Thurgood Marshall) (MCS, ALL)

Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure (Maryland Suite) (HF, HTX, MCS, NHSAH, PEDS, PH)

Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival (Virginia Suite) (LTX, ALL)

Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It (Delaware Suite) (NHSAH, HF, HTX, LTX, MCS)

Sunrise Symposium 11: Controversies in Pediatric Heart Failure (Washington Ballroom 2) (PEDS, HF, HTX, NHSAH, PHARM)

Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond (Washington Ballroom 1) (ALL)

 

7:45 AM – 9:45 PM

Committee/Council Reports to Board (Harding)

 

8:00 AM – 9:30 AM

Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support (Thurgood Marshall) (MCS, HTX, NHSAH)

Concurrent Session 42: Difficult Decisions in Mechanical Support (Maryland Suite) (MCS, HTX, NHSAH)

Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant (Virginia Suite) (HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

Concurrent Session 44: Lung Transplantation – Advanced Diagnostics! (Delaware Suite) (LTX, BSI, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 45: Pediatric Heart Failure (Washington Ballroom 2) (PEDS, HF, HTX)

Concurrent Session 46: From ‘Jeans’ to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics (Washington Ballroom 1) (BSI, HF, HTX, LTX, MCS)

 

9:30 AM – 9:45 AM

Coffee Break (Convention Registration)

 

9:45 AM – 11:45 AM

Plenary Session – Pushing New Scientific Frontiers: It’s In Our Heritage (Thurgood Marshall) (ALL)

 

11:45 AM – 12:00 PM

Coffee Break (Convention Registration)

 

12:00 PM – 1:30 PM

Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS (Thurgood Marshall) (MCS, HF, NHSAH, PH)

Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient (Maryland Suite) (MCS, HTX, NHSAH)

Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems (Virginia Suite) (HTX, BSI, ID, MCS, NHSAH, PATH, PEDS, PHARM)

Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation – Are We Getting It Right? (Delaware Suite) (LTX, BSI, ID, NHSAH, PATH, PHARM)

Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism (Washington Ballroom 2) (HF, BSI, HTX, NHSAH)

Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension (Washington Ballroom 1) (PH, BSI, HF, LTX, PEDS, PH, PHARM)

 

12:00 PM – 6:00 PM

ISHLT Board of Directors Meeting (Harding)

 

12:00 PM – 3:00 PM

Academy Registration Open (Convention Registration)

 

1:45 PM – 6:30 PM

[*ISHLT Academy: Master Class in Mechanical Circulatory Support *](Washington Ballroom 1 & 2)

 

[* *]

*ANNUAL MEETING SCIENTIFIC PROGRAM *

WEDNESDAY APRIL 27, 2016

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better? *]

 

[*Location: *]

Salons 2-3

 

[*Target Audience: *]

MCS, HF, PHARM

 

[*Chairs: *]

Michael A Shullo, PharmD, and Sanem Nalbantgil, MD

 

Session Summary: The goal of this symposium is to familiarize clinicians with current, widely available tests of blood coagulability and pitfalls in their interpretation in the MCS population. Additional topics will include comorbid states, such as acquired von Willebrand’s disease and genetic variations like Factor V mutations, and how they impact patients after device implantation.

 

8:00 AM

Too Thick or Too Thin? Bleeding and Thrombosis in MCS

Ulrich Jorde, MD, Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, USA

 

8:15 AM

Q & A

 

8:20 AM

Pre-operative Genetic Screening for Coagulation Abnormalities and Impact on Post-operative Management

Douglas L. Jennings, PharmD, New York – Presbyterian, New York, NY, USA

 

8:35 AM

Q & A

 

8:40 AM

Who Should Be Monitoring INR and How?

Anna L Meyer, MD, Leipzig Heart Center, Leipzig, Germany

 

8:55 AM

Q & A

 

9:00 AM

Heparin Monitoring: Xa vs. aPTT

Christopher S. Hayward, MD, St. Vincent’s Hospital, Sydney, Australia

 

9:15 AM

Q & A

 

9:20 AM

Is There a Role for Antiplatelet Monitoring in MCS?

Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

 

9:35 AM

Q & A

 

9:40 AM

Alternative Approaches to Recurrent Bleeding – Octreotide, Hormonal Therapy, Etc.

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

 

9:55 AM

Q & A

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future *]

 

[*Location: *]

Thurgood Marshall

 

[*Target Audience: *]

HTX, HF, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Savitri E Fedson, MD, and Eulalia Roig, MD

 

Session Summary: This session will review current immunosuppressant pharmacology as well as the current status of rejection surveillance. The utility of endomyocardial biopsy will be debated and then a report on future of heart transplant immunosuppression will be presented including perspectives on where the next advances will come from.

 

8:00 AM

Back to Basics: Pharmacology & Pharmacodynamics of Immunosuppressants

Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

 

8:20 AM

Putting it Together: Approaches to Immune Monitoring

Michael Pham, MD, Stanford University, Palo Alto, CA, USA

 

8:40 AM

DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (PRO)

Stuart D Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

 

8:55 AM

DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (CON)

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

 

9:10 AM

DEBATE REBUTTAL (PRO)

 

9:15 AM

DEBATE REBUTTAL (CON)

 

9:20 AM

The Future of Heart Transplant Immunosuppression: Something’s Old, Something’s New, Something’s Borrowed, Somebody’s Blue

David A Baran, MD, Newark Beth Israel, Newark, NJ, USA

 

9:40 AM

PANEL DISCUSSION

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 3: Current Innovations and Future of EVLP *]

 

[*Location: *]

Salon 1

 

[*Target Audience: *]

LTX, LF, MCS

 

[*Chairs: *]

Christopher H. Wigfield, MD, FRCS, and Jasleen Kukreja, MD, MPH

 

Session Summary: This symposia will explore the prospect of gene, cell, drug and molecular interventions during EVLP to improve outcomes for lung transplant recipients. How essential EVLP is to the running of a modern day program will be debated.

 

8:00 AM

The Future of Lung Repair – Drug and Molecular Interventions during EVLP

Christine L Lau, MD, University of Virginia, Charlottesville, VA, USA

 

8:15 AM

Q & A

 

8:20 AM

The Future of Lung Repair – Cell and Gene Interventions during EVLP

Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

 

8:35 AM

Q & A

 

8:40 AM

The Future of Lung Preservation Techniques

Gregor Warnecke, MD, FRCSC, Hannover Medical School, Hannover, Germany

 

8:55 AM

Q & A

 

9:00 AM

EVLP as a Platform to Reduce Infection

John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

9:15 AM

Q & A

 

9:20 AM

Is Reduced Allo Responsiveness after EVLP a Reality? – Long Term Follow Up

Goran Dellgren, MD, PhD, Salgrenska University Hospital, Goteborg, Sweden

 

9:35 AM

Q & A

 

9:40 AM

DEBATE: My Clinical Program Needs an EVLP Service (PRO)

Frank d’Ovidio, MD, FRCS, Columbia University, New York, NY, USA

 

9:50 AM

DEBATE: My Clinical Program Needs an EVLP Service (CON)

David C McGiffin, MB, BS, FRACS, Alfred Hospital, Melbourne, Australia

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 4: Under Pressure: PH in Parenchymal Lung Disease *]

 

[*Location: *]

Maryland Suite

 

[*Target Audience: *]

PH, HF, LF, LTX

 

[*Chairs: *]

Oksana A. Shlobin, MD, and Trevor J Williams, MD

 

Session Summary: Pulmonary hypertension (PH) is a common and serious complication of interstitial lung diseases (ILD). Its occurrence and severity are highly variable. This session will summarize the clinical features of this challenging condition and review its impact on gas exchange and cardiac function. Challenges related to lung transplantation for ILD with PH will be reviewed. A pro-con debate will discuss the controversies regarding the use of PAH targeted therapies for this indication.

 

8:00 AM

PH in ILD: Pathophysiology and Epidemiology

John Granton, MD, University of Toronto, Toronto, ON, Canada

 

8:15 AM

Q & A

 

8:20 AM

Shrinking with Age: The Role of Telomerases in ILD and PH-ILD

Leann Silhan, MD, Johns Hopkins School of Medicine, Baltimore, MD, USA

 

8:35 AM

Q & A

 

8:40 AM

Connective Tissue Disease PH-ILD: Which One Matters?

Jerome Le Pavec, MD, Hôpital Marie Lannelongue, Le Plessis Robinson, France

 

8:55 AM

Q & A

 

9:00 AM

Sarcoid-associated Pulmonary Hypertension: An Enigma or a Run of the Mill Complication?

Robert P Baughman, MD, University of Cincinnati, Cincinnati, OH, USA

 

9:15 AM

Q & A

 

9:20 AM

Impact of PH on Transplant Outcomes in ILD

Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany

 

9:35 AM

Q & A

 

9:40 AM

Are PAH Specific Therapies Beneficial in PH-ILD?

Steven Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

 

9:55 AM

Q & A

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon’s Perspective *]

Location:

Virginia Suite

 

[*Target Audience: *]

HTX, HF, MCS, NHSAH, PEDS

 

[*Chairs: *]

Hannah Copeland, MD, and Tahir Yagdi, MD

 

Session Summary: To discuss the controversies, advances, and new directions in heart transplant surgery.

 

8:00 AM

Out of Time: Surgical Options for Late Graft Failure

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

 

8:20 AM

Surgical Management of Cardiac Primary Graft Dysfunction

Yoshifumi Naka, MD, Columbia University, New York, NY, USA

 

8:40 AM

When Great Vessels Go Bad Following Transplantation

Gregorio Rabago, MD, Clinica Universitaria Apartado, Pamplona, Spain

 

9:00 AM

Valvular Heart Disease after Heart Transplant

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

 

9:20 AM

Advanced Plumbing: How to Manage Complex Connections in Adult Congenital Heart Transplant Recipients

Jonathan M Chen, MD, Seattle Children’s Hospital, Seattle, WA, USA

 

9:40 AM

PANEL DISCUSSION

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant? *]

Location:

Delaware Suite

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Daniel Chambers, MBBS, MRCP, FRACP, MD, and Lori J. West, MD, DPhil

 

Session Summary: This session will focus on cutting edge therapies that involve cells. There will be a focus on using cells to repair or fully regenerate a failing organ, for transplant tolerance induction or treatment of chronic rejection.

 

8:00 AM

Tissue Engineering for Dummies: How to Build a Heart or Lung

Doris Taylor, PhD, Texas Heart Institute, Houston, TX, USA

 

8:15 AM

Q & A

 

8:20 AM

Cell Therapy for the Failing Organ: Patch Up the Heart

Eduardo Marban, MD, PhD, Cedars-Sinai, Los Angeles, CA, USA

 

8:35 AM

Q & A

 

8:40 AM

Cell Manipulation for Transplant Tolerance

Joren C. Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

 

8:55 AM

Q & A

 

9:00 AM

Myeloid Cells to Induce Transplant Tolerance

Angus Thomson, PhD, DSc, University of Pittsburgh, Pittsburgh, PA, USA

 

9:15 AM

Q & A

 

9:20 AM

Stem Cells to Cure the Incurable: Treatment for Chronic Lung and Heart Allograft Dysfunction

Sonja Schrepfer, MD, PhD, Stanford University Transplant and Stem Cell Immunobiology Lab (TSI), Stanford, CA, USA

 

9:35 AM

Q & A

 

9:40 AM

Case Presentation: Back to the Future – Real Life Example of Cell Therapy and Tolerance in Lung Transplantation

Alice L Gray, MD, Duke University Medical Center, Durham, NC, USA

 

9:45 AM

Case-Based Discussion: Back to the Future – Real Life Example of Cell Therapy and Tolerance in Lung Transplantation

Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA

 

 

8:00 AM – 10:00 AM

[*Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease *]

Location:

Washington Ballroom 2

 

[*Target Audience: *]

ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Me-Linh Luong, MD, and Denis Hadjiliadis, MD

 

Session Summary: This symposium will explore the emergence and resurgence of difficult to treat pathogens in thoracic transplant and MCSD patients that challenge practitioners worldwide.

 

8:00 AM

Mycobacterium Abscessus and Friends

Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

 

8:15 AM

Q & A

 

8:20 AM

RSV and the Paramyxoviruses: Should We Treat?

Peter M Hopkins, FRACP, Prince Charles Hosp, Brisbane, Australia

 

8:35 AM

Q & A

 

8:40 AM

The Unwelcome Guests: Strongyloides and Chagas Disease

Fernando Bacal, MD, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil

 

8:55 AM

Q & A

 

9:00 AM

The Fungus Among Us: Scedosporium and Other Emerging Fungi

Orla Morrissey, MD, Alfred Hospital, Melbourne, Australia

 

9:15 AM

Q & A

 

9:20 AM

Running Away With It: C. difficile and Norovirus

Ignacio Echenique, MD, Cleveland Clinic Florida, Weston, FL, USA

 

9:35 AM

Q & A

 

9:40 AM

The Coming Apocalypse: Resistant Gram negatives, B cepaciae, Achromobacter, Stenotrophomonas

Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

 

9:55 AM

Q & A

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart – International Perspectives on MCS Issues *]

Location:

Salons 2-3

 

[*Target Audience: *]

MCS, HF, HTX, NHSAH

 

[*Chairs: *]

Jennifer Beckman, MSN-FNP, RN, CHFN, and Stephan Schueler, MD, PhD

 

Session Summary: This session will discuss questions frequently asked by MCS Teams around the world regarding program structure, practice guidelines, international variations in care delivery from a program perspective, and challenges faced by patients, families and staff caring for them.

 

10:15 AM

Coordinator Perspective: Characteristics of a Successful MCS Program

Tonya I Elliott, MSN, RN, CCTC, CHFN, MedStar Washington Hospital Center, Washington, DC, USA

 

10:30 AM

Q & A

 

10:35 AM

Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away – The International Perspective

Desiree Robson, RN, BSc (Hons), St Vincent’s Hospital, Sydney, Australia

 

10:50 AM

Q & A

 

10:55 AM

Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away – The North American Perspective

Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, BC, Canada

 

11:10 AM

Q & A

 

11:15 AM

Collaborative Care in the ICU

Aly El Banayosy, MD, Nazih Zuhdi Transplant Institute, Oklahoma City, OK, USA

 

11:30 AM

Q & A

 

11:35 AM

Delivering Optimal Care While Reaching For Exceptional Outcomes – The North American Perspective

Carole Ballew, MSN, University of Virginia Health System, Charlottesville, VA, USA

 

11:50 AM

Q & A

 

11:55 AM

Delivering Optimal Care While Reaching For Exceptional Outcomes – The International Perspective

Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria

 

12:10 PM

Q & A

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization *]

Location:

Thurgood Marshall

 

[_Target Audience: _]

HTX, LTX, MCS, NHSAH, PEDS

 

[*Chairs: *]

Jon A. Kobashigawa, MD, and Maria G Crespo-Leiro, MD

 

Session Summary: This symposium will focus on strategies to improve organ utilization in heart transplantation. Since lack of donor organs and appropriate donor management guidelines is a pressing problem worldwide, it will be of great importance to have a symposium dedicated to delivering the outcomes of two recent consensus conferences in this area.

 

10:15 AM

US and European Donor Management Consensus Conferences: Key Messages to Improve Heart and Lung Utilization

Kiran K Khush, MD, MAS, Stanford University, Stanford, CA, USA

 

10:35 AM

Q & A

 

10:39 AM

Donor Management vs Organ Reconditioning: Lessons From Lung Transplantation

Arne Neyrinck, MD, PhD, University Hospital Leuven, Leuven, Belgium

 

10:59 AM

Q & A

 

11:03 AM

Heart Allocation Score: Insights from Eurotransplant

Jacqueline M Smits, MD, PhD, Eurotransplant International, Leiden, Netherlands

 

11:23 AM

Q & A

 

11:27 AM

DCD Hearts: An Additional Resource or the Answer to the Donor Crisis?

Kumud Dhital, MD, St Vincent’s Hospital, Sydney, Australia

 

11:47 AM

Q & A

 

11:51 AM

Donor Risk Scores and Allocation Algorithms: Will Numbers Do Better than the Surgeon’s Basic Instinct?

Abbas Ardehali, MD, University of California Los Angeles, Los Angeles, CA, USA

 

12:11 PM

Q & A

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group) *]

Location:

Salon 1

 

[_Target Audience: _]

PH, ALL

 

[*Chairs: *]

Stavros Konstantinides, MD, PhD, FESC, and Mardi Gomberg-Maitland, MD

 

Session Summary: This session will explore the role of the pulmonary circulation in heart failure from left heart disease. It will discuss the interdependence of the right and left heart as well as diagnostic strategies and treatments. It is a joint session with the European Society of Cardiology Working Group of the Right Ventricle and the Pulmonary Circulation.

 

10:15 AM

Pulmonary Hypertension-Left Heart Disease: Defining Group 2 PH

Irene Lang, MD, Medical University of Vienna, Vienna, Austria

 

10:35 AM

Is All Heart Failure the Same on the Pulmonary Circulation, and How Does It Impact Survival?

Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy

 

10:55 AM

Monitoring and Therapeutic Options for Pulmonary Hypertension in Left Heart Disease

Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

 

11:15 AM

Provocative Testing in Pulmonary Hypertension in Left Heart Disease

Robert Naeije, MD, Free University of Brussels, Brussels, Belgium

 

11:35 AM

DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary _][_Hypertension in Left Heart Disease (PRO)

Jean-Luc Vachiery, MD, Erasme University Hospital – ULB, Brussels, Belgium

 

11:43 AM

DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease (CON)

Stephan Rosenkranz, MD, Herzzentrum der Universität zu Köln, Koln, Germany

 

11:51 AM

DEBATE REBUTTAL (PRO)

 

11:53 AM

DEBATE REBUTTAL (CON)

 

11:55 AM

A Challenging Case of Pulmonary Hypertension

Myung H. Park, MD, Houston Methodist, Houston, TX, USA

 

12:00 PM

PANEL DISCUSSION

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One? *]

Location:

Maryland Suite

 

[_Target Audience: _]

LTX, HTX

 

[*Chairs: *]

Peter M Hopkins, FRACP, and Lianne G. Singer, MD, FRCPC

 

Session Summary: Referrals for multi-organ transplantation have increased as patients accumulate more complex comorbidities and those considered for re-transplantation have acquired renal disease. This session will evaluate the indications, benefits, disadvantages and challenges of performing multi-organ transplantation in patients with advanced lung disease. This will include how organ allocation policies differ in this group of potential recipients.

 

10:15 AM

Heart-Lung Transplantation is Dead – The Right Ventricle Will Remodel

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

 

10:30 AM

Q & A

 

10:35 AM

Combined Lung-Liver Transplantation – How Bad Does the Liver Have to Be?

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

 

10:50 AM

Q & A

 

10:55 AM

Combined Lung-Liver Transplantation – Surgical Approach and Post-operative Management

John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

 

11:10 AM

Q & A

 

11:15 AM

Combined Lung-Kidney Transplantation – What to Do with Vulnerable Kidneys Pre-lung Transplant?

Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

 

11:30 AM

Q & A

 

11:35 AM

Ethics and Equity in Multi-Organ Transplantation

Edward J. Garrity, MD, MSc, The University of Chicago, Chicago, IL, USA

 

11:50 AM

Q & A

 

11:55 AM

Is There an Allograft Combi Effect in Multi-Organ Transplantation?

Mark Greer, MB BCh, Hanover Medical School, Hannover, Germany

 

12:10 PM

Q & A

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 12: It’s All in the Translation: CMV from Bedside to Bench and Back Again *]

Location:

Virginia Suite

 

[_Target Audience: _]

ALL

 

[*Chairs: *]

Jutta K Preiksaitis, MD, and Martin Zamora, MD

 

Session Summary: This session seeks to evaluate the latest epidemiologic studies in CMV, new antiviral agents, and understanding the effective immune response to CMV. These effects range from direct organ-specific disease, to the burden of potentially toxic drug use, to indirect effects on the graft including CLAD and cardiac allograft vasculopathy.

 

10:15 AM

Be Still My Heart: CMV and CAV

Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain

 

10:35 AM

Q & A

 

10:39 AM

Breathless: CMV and CLAD

Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

 

10:59 AM

Q & A

 

11:03 AM

Measuring the Immune Response to CMV: Expanding Our Options

Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

 

11:23 AM

Q & A

 

11:27 AM

The CMV Toolkit: What do we have now?

Kyle L Dawson, PharmD, Houston Methodist, Houston, TX, USA

 

11:47 AM

Q & A

 

11:51 AM

The CMV Toolkit: What is on the horizon?

Robin K. Avery, MD, Johns Hopkins, Baltimore, MD, USA

 

12:11 PM

Q & A

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 13: Child’s Play: Infectious Risk After Transplant During Everyday Life *]

Location:

Delaware Suite

 

[_Target Audience: _]

PEDS, HTX, ID, LTX, NHSAH, PHARM

 

[*Chairs: *]

Debra A. Dodd, MD, and Richard Kirk, FRCP, FRCPCH

 

Session Summary: This session addresses commonly encountered situations in the care of thoracic transplant recipients that place them at increased risk of infection. Audience will be invited to participate using an electronic response system.

 

10:15 AM

Isolation – So Old Hat!

Michele Estabrook, MD, St. Louis Children’s Hospital, St Louis, MO, USA

 

10:30 AM

The Cystic Fibrosis Child – a Risk to their Transplanted Twin or Not?

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

 

10:45 AM

Outbreak – Measles, Varicella and Mumps

Marian G. Michaels, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

 

11:00 AM

Food and Water – Dangerous Stuff!

Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

 

11:15 AM

You Ain’t Nothing but a Hound Dog!

Nancy P Blumenthal, DNP, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

 

11:30 AM

Can We Visit Grandma?

Lara Danziger-Isakov, MD, MPH, Children’s Hospital Medical Center, Cincinnati, OH, USA

 

11:45 AM

PANEL DISCUSSION

 

 

10:15 AM – 12:15 PM

[*Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice? *]

Location:

Washington Ballroom 2

 

[_Target Audience: _]

NHSAH, BSI, HF, HTX, LTX

 

[*Chairs: *]

Evan P Kransdorf, MD, PhD, and Bernice L. Coleman, PhD, NP

 

Session Summary: This session will provide an introduction to genomics and will discuss it’s application in the care of thoracic transplant patients. The session will highlight the need for development of nursing competencies related to genomics.

 

10:15 AM

Genomics: A Crash Course

Edward Cantu, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

 

10:45 AM

Proteomic and Genomic Biomarkers of Allograft Injury: Coming Soon to a Lab Near You

Bruce McManus, MD, PhD, St. Paul’s Hospital, Vancouver, BC, Canada

 

11:00 AM

Differences in Minority Tacrolimus Levels: Would Genotyping Shed Light on Dosing?

Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

 

11:15 AM

Behavioral Genetics: Is there a Future for Personalized Medicine to Support Patient Self-Management in Transplantation?

Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

 

11:30 AM

It’s Not All Smooth Sailing: Ethical Implications of Genomic Applications in Transplantation

Neal K Lakdawala, MD, Brigham & Women’s Hospital, Boston, MA, USA

 

11:45 AM

Emerging Age of Personal Medicine: Need for Genetic Nursing Competencies in Transplantation

Kathleen Calzone, PhD, APGN, FAAN, National Cancer Institute, Bethesda, MD, USA

 

12:00 PM

PANEL DISCUSSION

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS *]

Location:

Salons 2-3

 

[_Target Audience: _]

MCS, HTX, ID, NHSAH, PHARM

 

[*Chairs: *]

Neil W. Wrightson, RN, and Orla Morrissey, MD

 

Session Summary: Infections account for clinically significant morbidity/mortality, increased cost of care, and reduced quality of life in MCS patients. This session will discuss strategies to reduce complications and identify and treat them effectively.

 

1:45 PM

MCS Infection – What is the Scope of the Problem?

Shashank S. Desai, MD, Inova Fairfax Hosp, Falls Church, VA, USA

 

2:00 PM

Q & A

 

2:05 PM

Preventing DLI: Role of a Dressing Change Protocol

Barbara Cagliostro, MSN, New York-Presbyterian / Columbia University, New York, NY, USA

 

2:20 PM

Q & A

 

2:25 PM

If We Can’t See It, Does It Not Exist? Imaging Modalities for Diagnosis of MCSD Infections

Stanley I. Martin, MD, Geisinger Health System, Danville, PA, USA

 

2:40 PM

Q & A

 

2:45 PM

Approach to the MCSD Recipient with Bloodstream Infection

Saima Aslam, MD, MS, University of California, San Diego, CA, USA

 

3:00 PM

Q & A

 

3:05 PM

PANEL DISCUSSION

 

3:25 PM

DEBATE: Device Infection, Thrombosis, and CVA – It Is All Linked (PRO)

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

 

3:35 PM

DEBATE: Device Infection, Thrombosis, and CVA – It Is All Linked (CON)

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle *]

Location:

Thurgood Marshall

 

[_Target Audience: _]

HF, ALL

 

[*Chairs: *]

Teresa De Marco, MD, and Daniel H. Kim, MD

 

Session Summary: This session will show how evaluation of right heart function plays an important role in the assessment of patients undergoing placement of left ventricular assist devices or heart transplantation.

 

1:45 PM

Deconstructing the Right Ventricle: An Overview of RV Structure and Function, Mechanical, Electrical, and Chemical Signaling

Eduardo Rame, MD, University of Pennsylvania, Philadelphia, PA, USA

 

2:02 PM

Q & A

 

2:05 PM

Peering Through the Looking Glass: Imaging the Right Ventricle

Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

 

2:22 PM

Q & A

 

2:25 PM

Finger on the Pulse: Hemodynamic Considerations in RV Failure

Ryan J Tedford, MD, Johns Hopkins University, Baltimore, MD, USA

 

2:42 PM

Q & A

 

2:45 PM

RV-PA Coupling in PAH: Can Medical Management Restore the Balance?

Rogerio Souza, MD, University of Sao Paulo, Sao Paulo, Brazil

 

3:02 PM

Q & A

 

3:05 PM

OR in the Morning: “Buffing” the Bad Right Ventricle

Vigneshwar Kasirajan, MD, Virginia Commonwealth University, Richmond, VA, USA

 

3:22 PM

Q & A

 

3:25 PM

Heterotopic Heart Transplant – What’s Old is What’s New Again!

Hannah Copeland, MD, Indiana University, Indianapolis, IN, USA

 

3:42 PM

Q & A

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation *]

Location:

Salon 1

 

[_Target Audience: _]

LTX, ID, LF, MCS, NHSAH, PH

 

[*Chairs: *]

John McDyer, MD, and Tanya J. McWilliams, MD, PhD

 

Session Summary: This session will provide the latest clinical and translational science on aging and lung transplant. By the end of this session, attendees will recognize basic science concepts such as genetic telomeropathies and immunosenescence that may impede post transplant outcomes. These insights will enhance our approach to elderly lung transplant candidates/recipients.

 

1:45 PM

Immunobiology of Aging in Lung Transplantation

Daniel R Goldstein, MD, Yale University, New Haven, CT, USA

 

2:00 PM

Q & A

 

2:05 PM

The Long and Short Of It: Telomerase Mutations and Implications for Lung Transplantation

Mary Armanios, MD, Johns Hopkins University, Baltimore, MD, USA

 

2:20 PM

Q & A

 

2:25 PM

Frailty is a Superior Measure of Age than Date of Birth

Jonathan Singer, MD, University of California, San Francisco, CA, USA

 

2:40 PM

Q & A

 

2:45 PM

Immunosuppressive Regimens Including CNI Sparing Protocols in the Elderly Lung Transplant Patient

Steve Ivulich, PharmD, Alfred Hospital, Melbourne, Australia

 

3:00 PM

Q & A

 

3:05 PM

Infectious Challenges in the Older Lung Transplant Recipient

Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

 

3:20 PM

Q & A

 

3:25 PM

DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (PRO)

Erik A. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

 

3:35 PM

DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (CON)

Steven Hays, MD, FRCPC, University of California, San Francisco, CA, USA

 

 

1:45 PM – 3:45 PM

Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH

Location:

Maryland Suite

 

[_Target Audience: _]

PH, HF, LF, PEDS

 

[*Chairs: *]

William Auger, MD, and Olaf Mercier, MD, PhD

 

Session Summary: This session will focus on indications for pulmonary endarterectomy (PEA), updated definitions, medical therapy both pre and post PEA, as well as the use of balloon pulmonary angioplasty in CTEPH.

 

1:45 PM

Epidemiology and Diagnosis of CTEPH: From Initial Insult to Elusive V/Q Scan

Carmine Dario Vizza, MD, University of Rome, Rome, Italy

 

2:05 PM

Q & A

 

2:09 PM

The Surgeon’s Paradise: Pre-operative Risk Stratification and Intra-operative Grading System of CTEPH

Michael M. Madani, MD, UCSD Medical Center, San Diego, CA, USA

 

2:29 PM

Q & A

 

2:33 PM

BPA vs PEA: Selection Criteria for the Appropriate Use of Balloon Pulmonary Angioplasty

Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France

 

2:53 PM

Q & A

 

2:57 PM

Distal Disease: Who is a Surgical Candidate and Not?

Marc De Perrot, MD, University of Toronto, Toronto, ON, Canada

 

3:17 PM

Q & A

 

3:21 PM

CTEPH Thereafter: How to Define Residual PH After PEA?

Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

 

3:41 PM

Q & A

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates *]

Location:

Virginia Suite

 

[_Target Audience: _]

NHSAH, HF, HTX, LTX, MCS

 

[*Chairs: *]

Michael G. Petty, PhD, RN, CNS, and Michael A. McDonald, MD

 

Session Summary: This session will include three debates, each one presenting a marginal psychosocial candidate for transplant (TX) listing and/or mechanical circulatory support (MCS) implantation. Speakers will use best available evidence and current clinical practice in different healthcare systems to guide the arguments.

 

1:45 PM

Case Presentation for DEBATE 1: You Can Go Your Own Way

Michael A. McDonald, MD, Toronto General Hospital, Toronto, ON, Canada

 

1:50 PM

DEBATE 1: You Can Go Your Own Way (PRO)

Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium

 

2:00 PM

DEBATE 1: You Can Go Your Own Way (CON)

Luke J Burchill, MD, Oregon Health Sciences University, Portland, OR, USA

 

2:10 PM

PANEL DISCUSSION

 

2:25 PM

Case Presentation for DEBATE 2: MCS: I Don’t Need Anyone’s Help!

Finn Gustafsson, MD, PhD, ViCare Medical Rigshospitalet, Copenhagen, Denmark

 

2:30 PM

DEBATE 2: MCS: I Don’t Need Anyone’s Help! (PRO[*)*]

Quincy Young, PhD, RPsych, St. Paul’s Hospital, Vancouver, BC, Canada

 

2:40 PM

DEBATE 2: MCS: I Don’t Need Anyone’s Help! (CON)

Jeremy Kobulnik, MD, University of Toronto, Toronto, ON, Canada

 

2:50 PM

PANEL DISCUSSION

 

3:05 PM

Case Presentation for DEBATE 3: Substance Use: It’s OK To Dabble

Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA

 

3:10 PM

DEBATE 3: Substance Use: It’s OK To Dabble (PRO)

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

 

3:20 PM

DEBATE 3: Substance Use: It’s OK To Dabble (CON)

Jay Baumwol, MBBS, FRACP, Royal Perth Hospital, Perth, Australia

 

3:30 PM

PANEL DISCUSSION

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to “Omics” to Personalized Medicine in Thoracic Organ Transplantation *]

Location:

Delaware Suite

 

[_Target Audience: _]

ALL

 

[*Chairs: *]

Howard Eisen, MD, and Glen P Westall, FRACP, PhD

 

Session Summary: As organ transplant research programs continue to develop worldwide, there will be an urgent need to externally validate individual findings before clinical application. This session will review how and why we collect each biospecimen and ensure proper use of those specimens. The aim is to personalize modern medicine by integrating multilevel clinical and omic data into clinical management tools.

 

1:45 PM

Why to Biobank? How It Has Advanced Our Understanding of Transplant Immunobiology?

Peter Heeger, MD, Mount Sinai Medical Center, New York, NY, USA

 

2:00 PM

Q & A

 

2:05 PM

How to Biobank? Lessons Learned (The Hard Way)

Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

 

2:20 PM

Q & A

 

2:25 PM

Big Data and Modeling: Turning Diversity Into Patient Care Benefit

Octavio Pajaro, MD, Mayo Clinic, Phoenix, AZ, USA

 

2:40 PM

Q & A

 

2:45 PM

OMICS in Heart Transplant: Pumping Out the Answers?

Hendrik Milting, PhD, Heart & Diabetes Center, Bad Oeynhausen, Germany

 

3:00 PM

Q & A

 

3:05 PM

OMICS in Lung Transplant: Airing Out the Data

Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France

 

3:20 PM

Q & A

 

3:25 PM

Turning Dream Into Reality: How Will Omics and Big Data Deliver Personalized Medicine?

Mario C. Deng, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

 

3:40 PM

Q & A

 

 

1:45 PM – 3:45 PM

[*Pre-Meeting Symposium 21: Unraveling “Chronic Rejection” in the Heart *]

Location:

Washington Ballroom 2

 

[_Target Audience: _]

PATH, BSI, HF, HTX, LTX, PEDS

 

[*Chairs: *]

Carmela D. Tan, MD, and Martin J. Goddard, FRCS MRCPa

 

Session Summary: This session will evaluath=e “chronic rejection”; a controversial and somewhat ambiguous term. Despite major advances in HLA matching, rejection surveillance, and immunosuppression in cardiac transplantation, allograft vasculopathy (CAV) and other “chronic rejection” changes at the microvascular and myocardial levels continue to contribute to premature demise of transplanted hearts.

 

1:45 PM

Beyond CAV: Immunopathology, Histopathology, and Ultrastructural Pathology in “Chronic Rejection” of the Cardiac Allograft

M. Elizabeth H. Hammond, MD, LDS Hospital, Salt Lake City, UT, USA

 

2:05 PM

Q & A

 

2:09 PM

Evidence for Local Antibody Production in Cardiac Allograft Vasculopathy

Manon Huibers, PhD, University Medical Center, Utrecht, Netherlands

 

2:29 PM

Q & A

 

2:33 PM

Complement and Non-complement Mediated Mechanisms of Graft Injury and Their Role in “Chronic Rejection”

William M Baldwin III, MD PhD, Cleveland Clinic, Cleveland, OH, USA

 

2:53 PM

Q & A

 

2:57 PM

“Chronic Rejection” Elsewhere: Analogs and Lessons from the Transplanted Lung, Kidney, and Liver

Martin J. Goddard, FRCS MRCPa, Papworth Hospital, Cambridge, United Kingdom

 

3:17 PM

Q & A

 

3:21 PM

Animal Models of Graft Vasculopathy – Evidence for Antibodies and Potential Therapeutic Targets

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

 

3:41 PM

Q & A

 

 

4:00 PM – 6:00 PM

[*Pre-Meeting Symposium 22: Great Debates in Mechanical Circulatory Support *]

Location:

Salons 2-3

 

[_Target Audience: _]

MCS, HF, HTX, NHSAH

 

[*Chairs: *]

Eugene C DePasquale, MD, and Steven SL Tsui, MD, FRCS

 

Session Summary: The role of MCS worldwide is steadily increasing, however, certain challenges remain in management of LVAD patients. This session focuses on controversial treatment strategies for patients at the boundaries of accepted MCS management.

 

4:00 PM

Case Presentation for DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant

Sebastian V Rojas, MD, Hannover Medical School, Hannover, Germany

 

4:05 PM

DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant (PRO)

Andrew J. Boyle, MD, Piedmont Heart Institute, Atlanta, GA, USA

 

4:15 PM

DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant (CON)

Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

 

4:25 PM

[*DEBATE REBUTTAL (PRO) *]

 

4:30 PM

DEBATE REBUTTAL (CON)

 

4:35 PM

Case Presentation for DEBATE 2: INTERMACS 4-7: The Time is Now

Brent C Lampert, DO, Ohio State University Wexner Medical Center, Columbus, OH, USA

 

4:40 PM

DEBATE 2: INTERMACS 4-7: The Time is Now (PRO)

Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA

 

4:50 PM

DEBATE 2: INTERMACS 4-7: The Time is Now (CON)

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

 

5:00 PM

DEBATE REBUTTAL (PRO)

 

5:05 PM

DEBATE REBUTTAL (CON)

 

5:10 PM

Case Presentation for DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice

Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

 

5:15 PM

DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (PRO)

Jan D. Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

 

5:30 PM

DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (CON)

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

 

5:45 PM

DEBATE REBUTTAL (PRO)

 

5:50 PM

DEBATE REBUTTAL (CON)

 

 

4:00 PM – 6:00 PM

[*Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR *]

Location:

Thurgood Marshall

 

[_Target Audience: _]

HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Palak Shah, MD, MS, and A. G. Kfoury, MD, FACC

 

Session Summary: This symposium will provide a state-of-the-art evaluation of diagnosing and managing antibody-mediated rejection (AMR) of the cardiac allograft with a focus on immunologic, pathologic and genomic diagnostics as well as the pharmacologic and non-pharmacologic treatment of more refractory AMR.

 

4:00 PM

It is Time to Move to Molecular Technologies for Detection of AMR

Elaine F Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

 

4:20 PM

Q & A

 

4:24 PM

Do We Need Both Histologic and Immunologic Features on Biopsy to Accurately Diagnose Antibody-Mediated Rejection?

Annalisa Angelini, MD, University of Padua, Padua, Italy

 

4:44 PM

Q & A

 

4:48 PM

What Drug Therapies, What Data for Refractory AMR?

Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

 

5:08 PM

Q & A

 

5:12 PM

What Immunologic Testing Features Suggest Clinically Significant Antibodies vs an Innocent Bystander?

Kathryn J Tinckam, MD, University Health Network, Toronto, ON, Canada

 

5:32 PM

Q & A

 

5:36 PM

Management of Antibodies in Heart Transplantation: Insights from 2016 Consensus Conference

Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

 

5:56 PM

Q & A

 

 

4:00 PM – 6:00 PM

[*Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies *]

Location:

Salon 1

 

[_Target Audience: _]

LTX, BSI, PATH, PEDS

 

[*Chairs: *]

Tereza Martinu, MD, and Stijn E Verleden, PhD

 

Session Summary: The aim of this symposium is to provide both basic and clinical data regarding different CLAD phenotypes, their differing prognoses and treatment algorithms. Novel treatments will be reviewed including the role of cell based therapies and extracorporeal photopheresis.

 

4:00 PM

Current and Historical Evidence for Phenotyping of CLAD

Miranda Paraskeva, MBBS, Alfred Hospital, Melbourne, Australia

 

4:15 PM

Q & A

 

4:20 PM

CLAD Endotypes – Diagnosis, Radiology and Pathology

Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

 

4:35 PM

Q & A

 

4:40 PM

Contemporary Medical and Surgical Treatment Options for CLAD Phenotypes – Are All CLAD Patients Created Equal?

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

 

4:55 PM

Q & A

 

5:00 PM

Extracorporeal Photopheresis and Regulatory T cells – Role in CLAD?

Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

 

5:15 PM

Q & A

 

5:20 PM

Cell-Based Therapy for CLAD – Current Evidence and Future Prospects

Cesar Keller, MD, The Mayo Clinic, Jacksonville, FL, USA

 

5:35 PM

Q & A

 

5:40 PM

Future Perspectives: Prevention of CLAD – Why are We Failing and How to Improve?

Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA

 

5:55 PM

Q & A

 

 

4:00 PM – 6:00 PM

Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension

Location:

Maryland Suite

 

[_Target Audience: _]

PH, ALL

 

[*Chairs: *]

Thenappan Thenappan, MD, and John Granton, MD

 

Session Summary: This session will combine basic and translational research focusing on alteration in metabolism and inflammation in pulmonary vascular disease.

 

4:00 PM

The Pathobiology of Inflammation in Pulmonary Hypertension

Marc Humbert, MD, Université Paris-Sud, Clamart, France

 

4:15 PM

Q & A

 

4:20 PM

The Impact of Insulin Resistance in Pulmonary Hypertension

Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

 

4:35 PM

Q & A

 

4:40 PM

Inflammatory Cytokines And Their Role In Pulmonary Hypertension

Mark Nicolls, MD, Stanford University, Palo Alto, CA, USA

 

4:55 PM

Q & A

 

5:00 PM

Alterations in Lipid Metabolism in Pulmonary Hypertension

Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA

 

5:15 PM

Q & A

 

5:20 PM

MicroRNAs in Pulmonary Hypertension: Insights in Signaling Pathways

Lars Huber, MD, University Hospital of Zurich, Zurich, Switzerland

 

5:35 PM

Q & A

 

5:40 PM

Neurohormonal and Metabolic Modulations for Improving Right Ventricular-Pulmonary Artery Coupling in PAH

Lisa M Mielniczuk, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

 

5:55 PM

Q & A

 

 

4:00 PM – 6:00 PM

[*Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection *]

Location:

Virginia Suite

 

[_Target Audience: _]

ALL

 

[*Chairs: *]

Martha L. Mooney, MD, FACP, and Kate Gould, FRCPath

 

Session Summary: Maintaining the balance between the shortage of donor organs and avoiding transmission of infection is an ongoing challenge in thoracic transplantation. Attendees at this session will receive a complete update of the current state of donor-derived infections to be prepared for that next complex donor call.

 

4:00 PM

Donor Derived Infections: The European Perspective

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

 

4:17 PM

Q & A

 

4:20 PM

Donor Derived Infections: The North American Perspective

Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

 

4:37 PM

Q & A

 

4:40 PM

The Infected Donor: Pre-transplant & Post-transplant Management

Phillip Zakowski, MD, Tower ID Medical Associates, Inc., Los Angeles, CA, USA

 

4:57 PM

Q & A

 

5:00 PM

The Encephalitic Donor: A Cautionary Tale

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

 

5:17 PM

Q & A

 

5:20 PM

Playing the Odds: The ABCs of NAT for HIV, HCV and HBV in Increased Risk Donors

Michael G Ison, MD MS, Northwestern Memorial Hospital, Chicago, IL, USA

 

5:37 PM

Q & A

 

5:40 PM

The HIV-positive Donor: “Hope” or Havoc?

Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

 

5:57 PM

Q & A

 

 

4:00 PM – 6:00 PM

[*Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease *]

Location:

Delaware Suite

 

[_Target Audience: _]

PEDS, HF, HTX, MCS, NHSAH

 

[*Chairs: *]

Angela Lorts, MD, and Martin Schweiger, MD

 

Session Summary: This session will focus on VAD therapy for heart failure in congenital heart disease and will debate current organ allocation policies for ACHD patients.

 

4:00 PM

VADs for Univentricular Circulation – Fact or Fiction?

Pirooz Eghtesady, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO, USA

 

4:15 PM

Q & A

 

4:20 PM

Can We Get VAD Patients Home?

Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada

 

4:35 PM

Q & A

 

4:40 PM

Collateral Damage From VADs – What Will Compromise Transplant Outcomes?

Kathleen Simpson, MD, Washington University and St. Louis Children’s Hospital, St. Louis, MO, USA

 

4:55 PM

Q & A

 

5:00 PM

ACHD Patients – Why Are They Different?

Leigh C Reardon, MD, UCLA, Los Angeles, CA, USA

5:15 PM

Q & A

 

5:20 PM

DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (PRO)

David Crossland, MRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

5:30 PM

DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (CON)

Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

 

5:40 PM

PANEL DISCUSSION

 

 

4:00 PM – 6:00 PM

Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016

Location:

Washington Ballroom 2

 

[*Target Audience: *]

PHARM, HF, ID, MCS, NHSAH

 

[*Chairs: *]

Jerrica E Shuster, PharmD, and Andreas Zuckermann, MD

 

Session Summary: The lifecycle journey of a heart failure patient with hepatitis C will be used to evaluate issues including candidate selection, balancing the risk of immunosuppression and malignancy post transplant and finally, when to palliate.

 

4:00 PM

Case Presentation: Lifecycle Journey

Jerrica E Shuster, PharmD, Barnes-Jewish Hospital, St. Louis, MO, USA

 

4:04 PM

Hepatitis C Medications – New Armamentarium Has Arrived!

Adam B Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

 

4:21 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

 

4:25 PM

Chronic Hepatitis C Candidate – Timing of Intervention

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

 

4:37 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

 

4:41 PM

Immunosuppression – A Tricky Balance?

Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

 

4:58 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

 

5:02 PM

Malignancies in Heart Transplant

Donna M. Mancini, MD, New York Presbyterian Hospital, New York, NY, USA

 

5:19 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

 

5:23 PM

Heavy is the Heart….

Deborah E. Meyers, MD. FRACP, FACC, Texas Heart Institute, Houston, TX, USA

 

5:45 PM

PANEL DISCUSSION

 

 

*ANNUAL MEETING SCIENTIFIC PROGRAM *

THURSDAY, APRIL 28, 2016

 

8:00 AM – 10:00 AM

[*Opening Plenary Session – Transplantation: Where Does the Science End and the Art Begin? *]

 

Location:

Salon 1-3

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Duane Davis, MD, MBA, and Andrew J. Fisher, FRCP, PhD

 

8:00 AM

Welcome/Program Chair Report

 

Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK

 

8:05 AM

Thoracic Registry Report

 

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

 

8:25 AM

IMACS Registry Report

 

James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

 

8:35 AM

[(1) FEATURED ABSTRACT: *][ HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure -1 Year Results from the CE Mark Trial *]; T. Krabatsch^1^, J. D. Schmitto2, Y. Pya3, D. Zimpfer4, J. Garbade5, V. Rao6, M. Morshuis7, S. Marasco8, F. Beyersdorf9, P. Sood10, L. Damme10, I. Netuka11. 1Deutsches Herzzentrum Berlin, Berlin, Germany, 2Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 3National Research Cardiac Surgery Center, Astana, Kazakhstan, 4University of Vienna, Vienna, Austria, 5Heart Center Leipzig, Leipzig, Germany, 6Toronto General Hospital, Toronto, ON, Canada, 7Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany, 8The Alfred Hospital, Melbourne, Australia, 9University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany, 10Thoratec Corporation, Burlington, MA, 11Institute for Clinical and Experimental Medicine, Prague, Czech Republic

 

8:45 AM

Expert Discussant Q & A

 

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

 

8:50 AM

Introduction to Speaker

 

Reda E. Girgis, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

 

8:52 AM

From Lung Transplant to Lincoln Center

 

Charity Tilleman-Dick, Washington, DC, USA

 

9:15 AM

President’s Report

 

Duane Davis, MD, Florida Hospital, Orlando, FL, USA

 

9:30 AM

Pioneer Award Recipient Lecture: The Quest for Effective Immunosuppression

 

Sir Roy Calne, FRCP, FRCS, FRS, Cambridge University, London, UK

 

10:30 AM – 12:00 PM

[*Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support *]

Location:

Salons 1-3

[*Target Audience: *]

MCS, HF, ID, NHSAH

[*Chairs: *]

Michel Morshuis, MD, and Chetan B Patel, MD

 

[*10:30 AM (2) *]Temporal Changes in Adverse Events in the ENDURANCE Trial; _]C. A. Milano^1^, F. D. Pagani2, A. J. Tatooles3, N. A. Mokadam4, J. Miller5, T. C. Wozniak6, C. H. Selzman7, K. Leadley8, K. D. Aaronson2, J. G. Rogers9. [^1^]_]Department of Surgery, Duke University School of Medicine, Durham, NC, 2University of Michigan, Ann Arbor, MI, 3Advocate Christ Medical Center, Oak Lawn, IL, 4University of Washington, Seattle, WA, 5Emory Healthcare, Atlanta, GA, 6Indiana University Health, Indianapolis, IN, 7University of Utah, Salt Lake City, UT, 8HeartWare, Framingham, MA, 9Duke University School of Medicine, Durham, NC

 

[*10:45 AM (3) *]Stroke with Continuous-Flow LVADs; _]D. Acharya^1^, C. Morgan2, S. Pamboukian1, R. Loyaga-Rendon1, J. Kirklin1, W. Holman1, J. Tallaj1. [^1^]_]University of Alabama at Birmingham, Birmingham, AL, 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL

 

[*11:00 AM (4) *][Hemorrhagic Transformation of Ischemic Strokes in Patients with Continuous Flow Left Ventricular Assist Devices; _]J. K. Wong, A. L. Melvin, A. K. Lidder, W. J. Archibald, J. Lehoux, P. A. Knight. _Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY

 

[*11:15 AM (5) *]Clinical Outcomes Reveal a Spectrum of Early Right Heart Failure after Left Ventricular Assist Device; _]E. W. Grandin^1^, G. S. Troutman1, A. A. Gulati2, P. Zamani1, J. A. Mazurek1, E. Y. Birati1, J. W. Wald1, K. B. Margulies1, P. Atluri3, J. E. Rame1. [^1^]_]Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 3Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

 

11:30 AM (6) Incidence and Impact of Sustained Ventricular Arrhythmias after Continuous-Flow Left Ventricular Assist Device Implantation; S. Yap1, R. Muslem1, F. Ramjankhan2, N. De Jonge3, A. A. Constantinescu1, O. C. Manintveld^1^, T. Szili-Torok1, K. Caliskan1. 1Cardiology, Erasmus MC, Rotterdam, Netherlands, 2Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands, 3Cardiology, University Medical Center Utrecht, Utrecht, Netherlands

 

[*11:45 AM (7) *]Device-Related Infection Rates of Continuous-Flow Ventricular Assist Devices Using a Thoracic Driveline Exit Site; _]M. A. Psotka^1^, D. Lowe2, J. C. Cox2, R. G. Kiel1, M. Janmohamed1, V. N. Selby1, T. De Marco1, L. Klein1, G. M. Wieselthaler2. [^1^]_]Cardiology, University of California San Francisco, San Francisco, CA, 2Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA

 

10:30 AM – 12:00 PM

[*Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, BSI, HF, LBCS

[*Chairs: *]

Martin Strueber, MD, and Stavros G Drakos, MD

 

[*10:30 AM (8) *]LVAD Explantation for Cardiac Recovery: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support; _]O. Wever-Pinzon^1^, S. G. Drakos1, S. H. McKellar2, A. Koliopoulou2, J. Stehlik1, C. H. Selzman2. [^1^]_]Cardiology, University of Utah, Salt Lake City, UT, 2Cardiothoracic Surgery, University of Utah, Salt Lake City, UT

 

[*10:45 AM (9) *][Association of Pre-Implant Inflammatory Profile and Functional Recovery with Chronic LVAD Unloading; _]L. McCreath, S. G. Drakos, P. Ferrin, N. Diakos, S. Navankasattusas, H. Javan, D. Budge, S. H. McKellar, W. T. Caine, O. Wever-Pinzon, M. Bonios, K. Skedros, A. Ragnhildstveit, K. Afshar, D. Y. Li, J. Stehlik, A. G. Kfoury, C. H. Selzman. _UTAH Cardiac Transplant Program, Salt Lake City, UT

 

[*11:00 AM (10) *]LVAD Support Is Associated with Reduced Serum VEGF-D Levels; _]B. A. Houston^1^, J. Vaishnav2, D. P. Judge1, R. J. Tedford1, S. D. Russell1, R. Rouf1. [^1^]_]Cardiology, Johns Hopkins Hospital, Baltimore, MD, 2Medicine, Johns Hopkins Hospital, Baltimore, MD

 

[*11:15 AM (11) *]Relationship of Myocardial Fibrosis with the Potential of Mechanical Unloading to Induce Favorable Cardiac Structural and Functional Response; _]P. Ferrin^1^, L. McCreath1, N. Diakos1, S. Navankasattusas1, A. G. Kfoury1, O. Wever-Pinzon1, M. Al-Sarie1, A. Catino1, M. Bonios1, R. Alharethi1, G. Russell2, A. Ragnhildstveit1, K. Skedros1, E. H. Hammond1, D. Y. Li1, C. H. Selzman1, W. Caine1, J. Stehlik1, S. G. Drakos1. [^1^]_]UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT, 2Intermountain Donor Services, Salt Lake City, UT

 

[*11:30 AM (12) *]Soluble ST2 Levels in End-Stage Heart Failure and during LVAD Support; _]C. C. Tseng^1^, M. M. Huibers2, L. Gaykema2, S. A. Chamuleau1, N. de Jonge1. [^1^]_]Cardiology, University Medical Center Utrecht, Utrecht, Netherlands, 2Pathology, University Medical Center Utrecht, Utrecht, Netherlands

 

[*11:45 AM (13) *]Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients with Left Ventricular Assist Devices; _]A. H. Healy^1^, M. E. Bowen1, B. S. Brooke1, S. H. McKellar1, S. G. Drakos2, C. H. Selzman1. [^1^]_]Surgery, University of Utah, Salt Lake City, UT, 2Medicine, University of Utah, Salt Lake City, UT

 

10:30 AM – 12:00 PM

Concurrent Session 3: Donor Organ Allocation and Management – What’s Hot and New?

 

Location:

Maryland Suite

[*Target Audience: *]

LTX, BSI, EEP, ID, LBCS, NHSAH, PEDS, PHARM

[*Chairs: *]

Michael S Mulligan, MD, and Marc De Perrot, MD

 

[*10:30 AM (14) *][Lung Allocation Score Does Not Reflect Post-Lung Transplant Outcome in a Use of Low Risk Donor; _]T. Kurosaki, K. Miyoshi, K. Imanishi, T. Okawa, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. _Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

 

[*10:45 AM (15) *]Low Correlation in Longevity between Lung Grafts from the Same Donor; _]M. Zemtsovski^1^, M. Perch2, C. H. Møller3, P. Bredahl1, M. Iversen2. [^1^]_]Cardiothoracic Anaesthesia, Rigshospitalet, Copenhagen, Denmark, 2Department of Cardiology, Division of Lung Transplantation, Rigshospitalet, Copenhagen, Denmark, 3Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark

 

[*11:00 AM (16) *]‘Unacceptable’ Human Leukocyte Antigens in Lung Re-Transplantation; _]W. Sommer^1^, M. Hallensleben2, F. Ius1, C. Kuehn1, I. Tudorache1, M. Avsar1, J. Salman1, T. Siemeni1, M. Greer3, J. Gottlieb3, D. Boethig4, R. Blasczyk2, A. Haverich1, G. Warnecke1. [^1^]_]Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Pneumology, Hannover Medical School, Hannover, Germany, 4Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany

 

[*11:15 AM (17) *]Lung First vs. Liver First Sequence for Combined Lung and Liver Transplantation; _]J. Salman^1^, F. Ius1, W. Sommer1, T. Siemeni1, I. Tudorache1, M. Avsar1, C. Kuehn1, G. Grannas2, J. Gottlieb3, T. Welte3, F. Lehner1, N. Richter2, J. Klempnauer2, A. Haverich1, G. Warnecke1. [^1^]_]Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department for General, Abdominal and Transplant Surgery, Hannover Medical School, Hannover, Germany, 3Department of Pneumology, Hannover Medical School, Hannover, Germany

 

[*11:30 AM (18) *][Single Center Results with Normothermic Ex Vivo Lung Perfusion: A Propensity Matched Analysis; _]J. C. Yeung, P. Reck dos Santos, J. Reeb, K. Yasufuku, M. de Perrot, A. F. Pierre, T. K. Waddell, L. G. Singer, S. Keshavjee, M. Cypel. _University of Toronto, Toronto, ON, Canada

 

[*11:45 AM (19) *]Mid and Long-Term Clinical Results of OCS Lung INSPIRE International Trial; _]G. Warnecke^1^, D. Van Raemdonck2, J. Kukreja3, M. Smith4, G. Loor5, F. Rea6, G. Massard7, F. De Robertis8, J. Nagendran9, J. Moradiellos10, K. Dhital11, C. Knosalla12, C. Bermudez13, S. Tsui14, J. Madsen15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, W. Sommer1, B. Weigmann1, C. Khun1, I. Tudorache1, M. Avsar1, M. Schiavon6, N. Santelmo20, A. Olland20, P. Falcoz20, A. Varela10, M. Hertz21, A. Simon8, H. Resichenspurner22, A. Haverich1, A. Ardehali23. [^1^]_]Thoracic Surgery, Hannover Medical School, Hannover, Germany, 2Thoracic Surgery, Leuven University Hospital, Leuven, Belgium, 3Thoracic Surgery, University of California San Francisco Medical, San Francisco, CA, 4Thoracic Surgery, St. Joseph’s Medical Center, Phoenix, AZ, 5Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN, 6Thoracic Surgery, University of Padua Hospital, Padua, Italy, 7Thoracic Surgery, 7Strasbourg University Hospital, Strasbourg, France, 8Thoracic Surgery, Harefield Hospital, London, United Kingdom, 9Thoracic Surgery, 9University of Alberta Medical Center, Edmonton, ON, Canada, 10Thoracic Surgery, University Puerta de Hierro Hospital, Madrid, Spain, 11Thoracic Surgery, 11St. Vincent’s Hospital, Sydney, Australia, 12Thoracic Surgery, German Heart Institute, Berlin, Germany, 13Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 14Cardiothoracic Surgery, Papworth Hospital, Papworth, United Kingdom, 15Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, 16Cardiothoracic Surgery, Indiana University Medical Center, Indianapolis, IN, 17Thoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH, 18Thoracic Surgery, Hamburg University Hospital, Hamburg, Germany, 19Thoracic Surgery, University Hospitals of Marseille, Marseille, France, 20Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France, 21Transplant Pulmonary Medicine, University of Minnesota Medical Center, Minneapolis, MN, 22Cardiothoracic Surgery, Hamburg University Hospital, Hamburg, Germany, 23Cardiothoracic Surgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA

 

10:30 AM – 12:00 PM

[*Concurrent Session 4: Keep It Down: New Insights on Immunosuppression *]

 

Location:

Virginia Suite

[*Target Audience: *]

HTX, ID, LBCS, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Mario C Deng, MD, and Anique Ducharme, MD, MSC

 

[*10:30 AM (20) *]Urine Cell-Free Donor-Derived DNA (ucfdDNA) after Heart Transplantation; _]S. Agbor-Enoh^1^, J. Doveikis1, J. Zhu1, i. Tunc1, X. Wang1, A. Jackson2, M. Solomon1, H. Valantine1. [^1^]_]Nat’l Inst. of Health, Bethesda, MD, 2Johns Hopkins Hospital, Baltimore, MD

 

[*10:45 AM (21) *]Outcomes with Gene Expression Profiling for Cardiac Transplant Recipients within North America; _]P. Shah^1^, D. Hiller2, M. Maydosz1, E. Deljkich2, J. Yee2, A. Cochrane1. [^1^]_]Heart Failure & Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2CareDx, Inc., Brisbane, CA

 

[*11:00 AM (22) *]The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy Assessed by Virtual Histology: Results of the SCHEDULE Trial; _]S. Arora^1^, O. Solberg1, F. Gustafsson2, K. Karason3, H. Eiskjær4, H. E. Bøtker4, G. Rådegran5, G. Dellgren3, D. Ioanes3, E. Gude1, D. Solbu6, A. K. Andreassen1, L. Gullestad1. [^1^]_]Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, 3Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Cardiology, Skejby University Hospital, Aarhus, Denmark, 5Cardiology, Skåne University Hospital and Lund University, Lund, Sweden, 6Novartis Norge AS, Oslo, Norway

 

[*11:15 AM (23) *]Duration of Corticosteroid (CS) Use as Maintenance Immunosuppression and Long-Term Outcomes after Adult Heart Transplantation: A Contemporary Analysis of the International Society for Heart and Lung Transplantation (ISHLT) Registry; _]L. A. Goldraich^1^, J. Stehlik2, L. B. Edwards3, A. Dipchand4, H. J. Ross5. [^1^]_]Cardiac Transplant Program, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2University of Utah School of Medicine, Salt Lake City, UT, 3International Society for Heart and Lung Transplantation, Richmond, VA, 4Cardiac Transplant Program, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 5Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada

 

[*11:30 AM (24) *]Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks; _]A. Z. Aliabadi^1^, J. Goekler1, O. Salameh1, T. Haberl1, B. Steinlechner2, P. Opfermann2, A. Kaider1, K. Uyanik-Ünal1, G. Laufer1, A. O. Zuckermann1. [^1^]_]Cardiac Surgery, Med Univ of Vienna, Vienna, Austria, 2Cardiothoracic and Vascular Anaesthisiology, Med Univ of Vienna, Vienna, Austria

 

[*11:45 AM (25) *]Molecular Correlates of Endothelial mTOR Activation in Heart Transplant Recipients; _]M. Racapé^1^, A. Loupy1, J. Reeve2, J. Venner2, R. Guillemain3, L. Hidalgo2, C. Lefaucheur1, X. Jouven1, P. Bruneval3, J. Duong Van Huyen1, P. Halloran2. [^1^]_]PARCC INSERM U970, Paris, France, 2ATAGC, University of Alberta, Edmonton, AB, Canada, 3Hôpital Européen Georges Pompidou, Paris, France

 

10:30 AM – 12:00 PM

[*Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex *]

Location:

Delaware Suite

[*Target Audience: *]

HF, MCS, NHSAH, PHARM

 

[*Chairs: *]

Christopher S Hayward, MD, and Jose Gonzalez-Costello, MD

 

[*10:30 AM (26) *]Assessing Renal Blood Flow Hemodynamics and Autoregulation in Humans Using Intrarenal Doppler Flow Velocity Measurement: A Novel Pilot Study; _]D. H. Kim^1^, A. Kiepas2, E. Nath2, N. Mitrou3, W. A. Cupples4, B. Braam5. [^1^]_]Cardiology, University of Alberta, Edmonton, AB, Canada, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Medicine, University of Western Ontario, London, ON, Canada, 4Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada, 5Nephrology, University of Alberta, Edmonton, AB, Canada

 

[*10:45 AM (27) *]Renal Response to Levosimendan in Patients Listed for Heart Transplantation Predicts Postoperative Renal Function Course; _]G. Zemljic1, G. Poglajen1, I. Knezevic1, F. Haddad2, B. Vrtovec^1^. [^1^]_]Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA

 

[*11:00 AM (28) *]Bilateral Sympathetic Denervation Improves Left Ventricular Function and Prevents Post-Infarction Chamber Remodeling in Rats; _]F. L. Zanoni, L. F. Moreira, R. Simas, R. G. da Silva, F. B. Jatene. [_Department of Cardiovascular Surgery, Heart Institute (Incor), University of Sao Paulo Medical School, Sao Paulo, Brazil

 

[*11:15 AM (29) *]Long-Term Adaptive Servo-Ventilator Treatment Prevents Cardiac Death and Improves Clinical Outcome in Patients with Advanced Heart Failure; _]T. Imamura^1^, K. Kinugawa1, D. Nitta2, M. Hatano2, I. Komuro2. [^1^]_]Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

 

[*11:30 AM (30) *][Laparoscopic Sleeve Gastrectomy: Safe and Effective in Heart Failure and LVAD Patients; _]S. C. George, A. A. Phancao, D. H. Karia, M. J. Sasevich, H. C. Wright, H. S. Le, S. M. Kitchen, J. W. Long, D. A. Horstmanshof. _INTEGRIS Advanced Cardiac Care, Integris Baptist Med Center, Oklahoma City, OK

 

[*11:45 AM (31) *]Bringing Sexy Back: Sexuality and Intimacy Concerns in an Advanced Heart Failure Population Receiving Palliative Care Consultation; _]A. Kelemen^1^, J. Groninger1, J. Cagle2, K. Walker3. [^1^]_]Section of Palliative Care, Department of Medicine, MedStar Washington Hospital Center, Washington, DC, 2University of Maryland School of Social Work, Baltimore, MD, 3Section of Palliative Care, Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD

 

10:30 AM – 12:00 PM

[*Concurrent Session 6: Pediatric Heart Transplant Outcomes *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

PEDS, HTX, NHSAH

 

[*Chairs: *]

Richard E Chinnock, MD, and Rakesh K. Singh, MD, MS

 

[*10:30 AM (32) *][Health Related Quality of Life after Pediatric Heart Transplantation in Young Children; _]G. Garcia Guerra, A. R. Joffe, G. Y. Alton, C. Sheppard, J. Pugh, J. Conway, C. M. Robertson, S. Urschel. _Pediatrics, University of Alberta, Edmonton, AB, Canada

 

[*10:45 AM (33) *]Congenital Heart Disease and Severe Peri-Transplant Course Are Associated with Worse Neurocognitive Outcomes in Children Post-Heart Transplant; _]S. Urschel^1^, G. Alton1, F. Moradi1, I. Dinu1, J. Conway1, G. Guerra1, B. Acton2, A. Joffe1, M. AlAklabi3, I. M. Rebeyka3, C. Robertson1. [^1^]_]Pediatrics, University of Alberta, Edmonton, AB, Canada, 2Pediatrics, University of Saskatoon, Saskatoon, SK, Canada, 3Cardiac Surgery, University of Alberta, Edmonton, AB, Canada

 

[*11:00 AM (34) *]Cancer Recurrence and Mortality After Pediatric Heart Transplantation for Anthracycline Cardiomyopathy; _]M. J. Bock^1^, E. Pahl2, P. G. Rusconi3, G. J. Boyle4, J. J. Parent5, C. J. Twist6, J. K. Kirklin7, E. Pruitt7, D. Bernstein8. [^1^]_]Pediatric Cardiology, Loma Linda University Children’s Hospital, Loma Linda, CA, 2Cardiology, Ann & Robert H. Lurie Children’s Hospital of Northwestern University, Chicago, IL, 3Pediatric Cardiology, University of Miami, Jackson Memorial Hospital, Miami, FL, 4Pediatric Cardiology, Cleveland Clinic Foundation, Cleveland, OH, 5Pediatric Cardiology, Riley Hospital for Children, Indianapolis, IN, 6Pediatric Hematology and Oncology, Lucile Packard Children’s Hospital at Stanford, Palo Alto, CA, 7Cardiovascular and Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 8Pediatric Cardiology, Lucile Packard Children’s Hospital at Stanford, Palo Alto, CA

 

[*11:15 AM (35) *]Bacterial Infections in Pediatric Heart Transplant Recipients: Epidemiology, Risk Factors, and Outcomes; _]C. A. Rostad^1^, K. Wehrheim2, K. Berkowitz3, T. M. Hoffman4, T. L’Ecuyer5, W. T. Mahle6, E. Pruitt7, J. K. Kirklin8, J. Scheel9. [^1^]_]Pediatric Infectious Diseases, Emory University, Atlanta, GA, 2Pediatric Cardiology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Pediatric Cardiology, Children’s Healthcare of Atlanta, Atlanta, GA, 4Pediatric Cardiology, UNC Children’s, Chapel Hill, NC, 5Pediatric Cardiology, University of Virginia, Charlottesville, VA, 6Pediatric Cardiology, Emory University, Atlanta, GA, 7School of Public Health, University of Alabama, Birmingham, AL, 8Cardiothoracic Surgery, University of Alabama, Birmingham, AL, 9Pediatric Cardiology, Children’s National Medical Center, Washington, DC

 

[*11:30 AM (36) *]Number of Refusals for Donor Quality Does Not Impact Post-Transplant Outcomes in Pediatric Heart Transplantation; _]D. L. Morales^1^, R. Rizwan1, R. Bryant 3rd1, J. S. Tweddell1, C. Chin2, F. Zafar1. [^1^]_]Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*11:45 AM (37) *]Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: Coronary Stenting as a Prognostic Indicator; _]T. Samad^1^, A. Razzouk2, M. Bock3, R. Chinnock1, L. Bailey2, N. Hasaniya2, M. Kuhn3, H. Anthony1, L. Stoletniy1. [^1^]_]Pediatrics, Loma Linda University Children’s Hospital, Loma Linda, CA, 2Cardiothoracic Surgery, Loma Linda University Children’s Hospital, Loma Linda, CA, 3Pediatrics, Division of Cardiology, Loma Linda University Children’s Hospital, Loma Linda, CA

 

2:00 PM – 3:30 PM

[*Concurrent Session 7: It’s Tough to Make Predictions, Especially about the Future: Outcomes in MCS *]

 

Location:

Salons 2-3

[*Target Audience: *]

MCS, HTX, NHSAH

Chairs:

James L Kirklin, MD, and Jeffrey J Teuteberg, MD

 

[*2:00 PM (38) *]Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP) – 2 Year Results; _]R. C. Starling^1^, J. D. Estep2, D. A. Horstmanshof3, C. A. Milano4, C. H. Selzman5, K. B. Shah6, B. A. Bruckner2, S. Lee7, J. W. Long3, J. Stehlik5, V. Kasirajan6, D. C. Haas8, A. J. Boyle9, J. Chuang10, D. J. Farrar10, J. G. Rogers4, .. for the ROADMAP Study Investigators11. [^1^]_]Cleveland Clinic, Cleveland, OH, 2Houston Methodist Hospital, Houston, TX, 3INTEGRIS Baptist Medical Center, Oklahoma City, OK, 4Duke University, Durham, NC, 5University of Utah School of Medicine, Salt Lake City, UT, 6Virginia Commonwealth University, Richmond, VA, 7Spectrum Health, Grand Rapids, MI, 8Abington Memorial Hospital, Abington, PA, 9Piedmont Hospital, Atlanta, GA, 10St. Jude Medical, Pleasanton, CA, 11., ., OH

 

[*2:15 PM (39) *]Insights from INTERMACS into Patient Characteristics Leading to Futility in LVAD Therapy; _]R. L. Kormos^1^, F. D. Pagani2, A. D. Althouse3, L. Warner Stevenson4, J. J. Teuteberg5, J. B. Young6, J. K. Kirklin7. [^1^]_]Cardiothoracic Surgery, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Cardiothoracic Surgery, Univ of Michigan Hlth, Ann Arbor, MI, 3Heart and Vascular Institute, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4Cardiology, Brigham & Women ‘s Hosp, Boston, MA, 5Cardiology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 6Cardiology, Cleveland Clinic Foundation, Cleveland, OH, 7Cardiothoracic Surgery, Univ of Alabama, Birmingham, AL

 

[*2:30 PM (40) *]An Updated Bayesian Model for Predicting Mortality in Continuous Flow-Left Ventricular Assist Device Patients; _]L. E. Lohmueller^1^, M. K. Kanwar2, N. L. Loghmanpour1, S. Murali2, J. F. Antaki1. [^1^]_]Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 2Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

 

[*2:45 PM (41) *]Muscular Strength Predicts Functional Capacity in Left Ventricular Assist Device Supported Patients; _]R. Y. Loyaga-Rendon^1^, S. V. Pamboukian1, D. Acharya1, J. Tallaj1, F. Siric2, C. Hoopes2, W. Holman1, J. Kirklin1, E. P. Plaisance3. [^1^]_]Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, 2Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, 3Department of Human Studies and Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL

 

[*3:00 PM (42) *]Long-Term Outcomes in Continous-Flow Left Ventricular Assist Device Patients with and without ICD; _]X. Mai1, V. K. Topkara1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, K. Ross3, A. Uryevick1, J. Eadie3, J. Murphy3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, P. C. Colombo1, A. R. Garan^1^. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*3:15 PM (43) *]Impact of Morbid Obesity on Left Ventricular Assist Device Support and Heart Transplantation; _]S. Cohen^1^, L. Wolfe1, D. Tang1, G. Katlaps1, V. Kasirajan1, K. Shah2, R. Cooke3, M. Smallfield3, I. Tchoukina3, K. Rao3, M. Quader1. [^1^]_]Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, 2Cardioloy, Virginia Commonwealth University, Richmond, VA, 3Cardiology, Virginia Commonwealth University, Richmond, VA

 

2:00 PM – 3:30 PM

[*Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, EEP, NHSAH

 

[*Chairs: *]

Mary Amanda Dew, PhD, and Brent C Lampert, DO

 

[*2:00 PM (44) *]Impact of Baseline Measures and Adverse Events on Functional Assessments in the ENDURANCE Destination Therapy Trial; _]J. G. Rogers^1^, C. A. Milano1, S. V. Pamboukian2, G. Bhat3, E. J. Birks4, S. S. Najjar5, B. B. Reid6, D. Meyer7, K. Leadley8, F. D. Pagani9. [^1^]_]Duke University School of Medicine, Durham, NC, 2University of Alabama at Birmingham, Birmingham, AL, 3Advocate Heart Institute, Oak Lawn, IL, 4University of Louisville, Louisville, KY, 5MedStar Washington Hospital Center, Washington, DC, 6University of Utah School of Medicine, Salt Lake City, UT, 7University of Texas Southwestern Medical Center, Dallas, TX, 8HeartWare, Framingham, MA, 9University of Michigan, Ann Arbor, IL

 

[*2:15 PM (45) *]HRQOL Improves from Before to 2 Years After MCS, Regardless of Implant Strategy: Analyses from INTERMACS; _]C. White-Williams^1^, P. Fazeli-Wheeler1, S. Myers1, J. Kirklin1, S. Pamboukian1, D. Naftel1, K. Grady2. [^1^]_]University of Alabama, Birmingham, AL, 2Northwestern University, Chicago, IL

 

[*2:30 PM (46) *]Reduced Anxiety and Depression in Patients with Advanced Heart Failure after Left Ventricular Assist Device Implantation; _]G. Yost1, G. Bhat^2^, E. Mahoney1, A. Tatooles2. [^1^]_]Heart Transplant, Advocate Christ Medical Center, Oak Lawn, IL, 2Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL

 

[*2:45 PM (47) *]Patient Reported Quality of Life with Mechanical Circulatory Support vs Continued Medical Therapy in Ambulatory Heart Failure Patients; _]J. Stehlik^1^, J. D. Estep2, C. H. Selzman1, J. G. Rogers3, K. B. Shah4, J. Chuang5, D. J. Farrar5, R. C. Starling6, .. for the ROADMAP Study Investigators7. [^1^]_]University of Utah School of Medicine, Salt Lake City, UT, 2Houston Methodist Hospital, Houston, TX, 3Duke University, Durham, NC, 4Virginia Commonwealth University, Richmond, VA, 5St Jude Medical, Pleasanton, CA, 6Cleveland Clinic, Cleveland, OH, 7., ., UT

 

[*3:00 PM (48) *][Caregiver Burden in Post-Ventricular Assist Device Patients; _]R. Ghashghaei, A. Sabet, D. Nagle, H. Tran, E. D. Adler. _Cardiology, University of California, San Diego, San Diego, CA

 

[*3:15 PM (49) *]Hospital Readmission during Left Ventricular Assist Device Support: Causes, Temporal Trends, and Terminal Readmissions; _]M. L. Inra^1^, S. M. Dunlay2, D. L. Joyce3, L. D. Joyce3, R. C. Daly3, S. Maltais3, J. M. Stulak3. [^1^]_]Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Disease, Mayo Clinic, Rochester, MN, 3Cardiovascular Surgery, Mayo Clinic, Rochester, MN

2:00 PM – 3:30 PM

[*Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation *]

 

Location:

Salon 1

[*Target Audience: *]

HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Donna M. Mancini, MD, and Gregorio Rabago, MD

 

[*2:00 PM (50) *]Frailty Measures in Advanced Heart Failure Patients Listed for Transplantation; _]S. R. Jha^1^, M. K. Hannu1, K. Wilhelm2, P. J. Newton3, S. Chang3, S. Chang3, E. Montgomery1, M. Harkess1, P. Tunnicliff1, A. Smith1, C. Hayward1, A. Jabbour1, A. Keogh1, E. Kotlyar1, K. Dhital1, E. Granger1, P. Jansz1, P. Spratt1, P. S. Macdonald1. [^1^]_]Heart and Lung Clinic, St. Vincent’s Hospital, Darlinghurst, Sydney, Australia, 2Psychiatry, St. Vincent’s Hospital, Darlinghurst, Sydney, Australia, 3Health Science, University of Technology, Sydney, Australia

 

[*2:15 PM (51) *][Risk Stratification to Improve Transplant Benefit in Older Candidates: Are All Comorbidities Created Equal?; _]M. Masetti, M. Sabatino, V. Manfredini, L. Borgese, A. Loforte, G. Marinelli, G. Magnani, F. Grigioni, C. Rapezzi, L. Potena. _University of Bologna, Bologna, Italy

 

[*2:30 PM (52) *][Evaluating Hepatorenal Factors for Perioperative Transplant Mortality in Adult Congenital Heart Disease; _]E. Adams, L. Reardon. _David Geffen School of Medicine, UCLA, Los Angeles, CA

 

[*2:45 PM (53) *]Influence of the MELD-XI (Model of End-Stage Liver Disease Excluding INR) on Heart Transplant Outcomes; _]A. Iyengar, C. Eisenring, L. Reardon, A. Nsair, M. Deng, A. Ardehali, E. DePasquale. [_University of California – Los Angeles, Los Angeles, CA

 

[*3:00 PM (54) *]Reversibility of Frailty in Advanced Heart Failure Patients Listed for Transplantation; _]S. R. Jha^1^, M. K. Hannu1, K. Wilhelm2, P. J. Newton3, S. Chang3, E. Montgomery1, M. Harkess1, P. Tunnicliff1, A. Smith1, C. Hayward1, A. Jabbour1, A. Keogh1, E. Kotlyar1, K. Dhital1, E. Granger1, P. Jansz1, P. Spratt1, P. Macdonald1. [^1^]_]Heart and Lung Clinic, St. Vincent’s Hospital, Darlinghurst, Sydney, Australia, 2Psychiatry, St. Vincent’s Hospital, Darlinghurst, Sydney, Australia, 3Health Science, University of Technology, Sydney, Australia

 

[*3:15 PM (55) *]Donor-Recipient Matching Using Cardiac Donor Risk Score Allows Optimization of Graft Survival; _]C. Jasseron^1^, C. Legeai1, C. Cantrelle1, P. Leprince2, C. Dambrin3, A. Vincentelli4, R. Bronchard1, O. Huot1, O. Bastien1, R. Dorent1. [^1^]_]Medical & Scientific, Agence de la Biomedecine, La Plaine Saint Denis, France, 2Cardiovascular Surgery, Hopital la Pitié-Salpétrière, Paris, France, 3Cardiovascular Surgery, Hopital Rangueil, Toulouse, France, 4Cardiovascular Surgery, Hopital Calmette, Lille, France

 

2:00 PM – 3:30 PM

[*Concurrent Session 10: The Frailty Construct and Body Composition – Impact on Lung Transplant Outcomes *]

 

Location:

Maryland Suite

[*Target Audience: *]

LTX, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Joshua J Mooney, MD, and Jonathan P Singer, MD, MS

 

[*2:00 PM (56) *]Frailty Score Predicts Death on the Waiting List, but Not Early Outcome Post Lung Transplantation (LTx); _]H. M. Whitford^1^, L. Fuller2, R. Stewart2, Y. Cristiano1, B. Levvey1, M. Paraskeva1, G. P. Westall1, T. J. Williams1, G. I. Snell1. [^1^]_]Respiratory Medicine, Alfred Hospital, Melbourne, Australia, 2Physiotherapy, Alfred Hospital, Melbourne, Australia

 

[*2:15 PM (57) *]Frailty and Clinical Benefits with Lung Transplantation; _]D. Rozenberg^1^, S. Mathur2, L. Wickerson3, N. A. Chowdhury4, L. G. Singer1. [^1^]_]Medicine, Respirology, Lung Transplant Program, University of Toronto, University Health Network, Toronto, ON, Canada, 2Physical Therapy, University of Toronto, Toronto, ON, Canada, 3Physical Therapy, Lung Transplant Program, University of Toronto, University Health Network, Toronto, ON, Canada, 4Lung Transplant Program, University Health Network, Toronto, ON, Canada

 

[*2:30 PM (58) *]Improvement in Frailty Is Associated with Improved Disability in Lung Transplantation; _]J. P. Singer^1^, P. Shrestha1, A. Soong1, D. Huang1, M. Mindo1, L. Leard1, J. Golden1, S. Hays1, K. Jasleen1, R. Shah1, D. Lederer2, P. Katz1, P. D. Blanc1. [^1^]_]Medicine, UCSF Medical Center, San Francisco, CA, 2Medicine, Columbia University, New York, NY

 

[*2:45 PM (59) *]Change in Body Mass Index at Listing from Primary Transplant to Re-Transplantation Predicts Re-Transplant Survival; _]J. Kim^1^, E. Barr2, M. Terrin2, I. Timofte1, P. Sanchez3, Z. Kon3, R. Pierson3, M. Wijesinha1, S. Pham3, A. Iacono1. [^1^]_]Pulmonary Critical Care, University of Maryland, Baltimore, MD, 2Epidemiology, University of Maryland, Baltimore, MD, 3Cardiothoracic Surgery, University of Maryland, Baltimore, MD

 

[*3:00 PM (60) *]Pectoralis Muscle Area Change Following Lung Transplantation Is Related to Underlying Disease; _]V. Hoang1, G. Li1, G. Dronovalli1, N. Capuano2, C. Kao1, A. Parulekar^1^. [^1^]_]Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, 2Lung Transplant Program, Cooley Transplant Center, CHI St. Luke’s Health – Baylor St. Luke’s Medical Center, Houston, TX

 

[*3:15 PM (61) *]Outcome in Age-Mismatched Lung Transplant Recipients; _]H. Auråen^1^, A. Fiane2, O. Geiran2, V. Lyngstadaas1, U. Christen3, I. Leuckfeld1, S. Hans Henrik4, M. Iversen4, E. Andreas5, A. M. Holm1. [^1^]_]Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway, 2Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway, 3Department of Transplantation, Oslo University Hospital, Oslo, Norway, 4Department of Cardiology, Division of Lung Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 5Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway

 

2:00 PM – 3:30 PM

[*Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft *]

 

Location:

Virginia Suite

[*Target Audience: *]

HTX, BSI, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Maryjane A Farr, MD, and Kumud K Dhital, MD,PhD

 

[*2:00 PM (62) *]Capillary Damage and Fibrin in Heart Transplantation: Significant Impact on Survival with or without Rejection; _]D. Budge^1^, D. V. Miller2, G. L. Snow3, M. P. Revelo4, J. Stehlik5, K. Molina6, R. Alharethi1, C. Selzman5, B. Reid1, S. Drakos5, E. M. Gilbert5, J. Nativi-Nicolau5, E. H. Hammond2, A. G. Kfoury1. [^1^]_]U.T.A.H. Cardiac Transplant Program, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT, 2Pathology, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT, 3Statistical Data Center, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT, 4Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, 5U.T.A.H. Cardiac Transplant Program, University of Utah Health Sciences Center, Salt Lake City, UT, 6U.T.A.H. Cardiac Transplant Program, Primary Childrens Medical Center, Salt Lake City, UT

 

[*2:15 PM (63) *]Role of Novel Cardiovascular Magnetic Resonance Based Tissue Characterization in the Detection of Cardiac Transplant Rejection; _]M. Imran^1^, L. Wang1, J. McCrohon1, C. Yu1, J. Huang1, C. Holloway1, O. James2, C. Stehning3, K. Moffat4, J. Ross4, E. Kotlyar1, C. Hayward1, A. Keogh1, P. Macdonald1, A. Jabbour1. [^1^]_]Cardiology, St. Vincent`s Hospital, Sydney, Australia, 2Cardiology, Liverpool Hospital, Sydney, Australia, 3Philips GmbH Innovative Technologies, Philips, Hamburg, Germany, 4Medical Imaging, St. Vincent`s Hospital, Sydney, Australia

 

[*2:30 PM (64) *][Heart Transplantation without Routine Endomyocardial Biopsies Is Feasible: Experience with a Clinical-Echocardiographic Strategy; _]J. A. Vazquez de Prada, F. J. Gonzalez Vilchez, F. Rodriguez Entem, J. Ruano, M. del Olmo, R. Martin Duran. _Cardiology Department, Hospital Valdecilla, Santander, Spain

 

[*2:45 PM (65) *]Biomarkers Monitoring for Absence of Acute Allograft Rejection; _]Z. Hollander^1^, D. L. Dai1, C. Shannon1, V. Chen1, K. K. Lam1, J. E. McManus1, S. Assadian1, M. Toma2, S. J. Tebbutt1, R. Balshaw3, C. H. Borchers4, R. A. Davies5, D. Delgado6, H. Haddad5, A. Ignaszewski2, D. L. Isaac7, D. Kim8, A. Mui2, M. Rajda9, H. Ross10, L. J. West11, M. White12, S. Zieroth13, W. McMaster2, P. A. Keown2, R. T. Ng2, B. M. McManus14. [^1^]_]The PROOF Centre of Excellence, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3BC Centre for Disease Control, Vancouver, BC, Canada, 4University of Victoria, Victoria, BC, Canada, 5University of Ottawa Heart Institute, Ottawa, ON, Canada, 6Toronto General Hospital, Toronto, ON, Canada, 7University of Calgary, Calgary, AB, Canada, 8University of Alberta & Mazankowski Alberta Heart Institute, Edmonton, AL, Canada, 9Dalhousie University, Halifax, NS, Canada, 10MultiOrgan Transplant Program, Toronto General Hospital, Toronto, ON, Canada, 11University of Alberta, Edmonton, AB, Canada, 12Montreal Heart Institute, Montreal, QC, Canada, 13University of Manitoba, Winnipeg, MB, Canada, 14Universitiy of BC & PROOF Centre of Excellence, Vancouver, BC, Canada

 

[*3:00 PM (66) *]Initial Analysis of the Donor-Derived Cell-Free DNA – Outcomes AlloMap Registry (D-OAR) Study in Heart Transplant Recipients Undergoing Surveillance for Rejection; _]J. A. Kobashigawa^1^, K. Khush2, J. Teuteberg3, M. Song4, M. Grskovic4, D. Hiller4, R. Woodward4, E. Deljkich4, J. Yee4, F. Latif5, N. Sulemanjee6, S. Murali7. [^1^]_]Cedars-Sinai Heart Institute, Los Angeles, CA, 2Stanford University, Palo Alto, CA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4CareDx, Brisbane, CA, 5Columbia University Medical Center, New York, NY, 6Aurora St. Luke’s Medical Center, Milwaukee, WI, 7Allegheny General Hospital, Pittsburgh, PA

 

[*3:15 PM (67) *]Utility of Gene Expression (Allomap Score) in Antibody Mediated Rejection Detection; _]S. Adatya^1^, E. Delijkich2, D. Hiller2, G. Sayer1, J. Yee2, N. Uriel1. [^1^]_]University of Chicago, Chicago, IL, 2CareDx, San Francisco, CA

 

2:00 PM – 3:30 PM

[*Concurrent Session 12: Pediatric Lung Transplantation *]

Location:

Delaware Suite

[*Target Audience: *]

PEDS, LTX

 

[*Chairs: *]

Carol K Conrad, MD, and Stuart C Sweet, MD, PhD

 

[*2:00 PM (68) *]Are We Refusing Good Organs? Outcomes of Ventilator Management of Sub-Optimal Lung Donors; _]B. B. Scully^1^, D. Horne2, J. S. Heinle2, E. D. McKenzie2, K. E. Hosek3, W. Zhang3, G. B. Mallory4, E. Melicoff4. [^1^]_]Surgery, Baylor College of Medicine, Houston, TX, 2Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, 3Outcomes and Impact Services, Texas Children’s Hospital, Houston, TX, 4Pulmonology, Texas Children’s Hospital, Houston, TX

 

[*2:15 PM (69) *][Controlled Donation after Circulatory Death (DCD) Donors and Pediatric Lung Transplant (pLTx): Enhanced Opportunities and Excellent Outcomes; _]G. I. Snell, B. J. Levvey, M. Paraskeva, H. Whitford, T. Williams, J. Hobson, A. Henriksen, D. McGiffin, G. Westall. _Alfred Hospital, Melbourne, Australia

 

[*2:30 PM (70) *]Improved Waitlist and Transplant Outcomes for Pediatric Lung Transplantation After Implementation of the Lung Allocation Score; _]T. S. Lancaster^1^, J. R. Miller1, D. J. Epstein1, N. C. DuPont1, S. C. Sweet2, P. Eghtesady1. [^1^]_]Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO, 2Pediatrics, Washington University School of Medicine, St. Louis, MO

 

[*2:45 PM (71) *]Respiratory Viral Infections Are Common in the First Year After Pediatric Lung Transplantation: A Multi-Center Prospective Study; _]L. Danziger-Isakov^1^, R. Buller2, N. Williams3, S. Mason2, M. Fenchel1, T. Astor4, C. Conrad5, A. Faro2, S. Goldfarb6, D. Hayes7, E. Melicoff-Portillo8, M. Schecter1, G. Visner9, D. Ikle10, G. Storch2, S. Sweet2. [^1^]_]Cincinnati Children’s Hosp Med Ctr, Cincinnati, OH, 2Washington University, St. Louis, MO, 3National Institutes of Health, Bethesda, MD, 4Massachusetts General Hospital, Boston, MA, 5Lucille Packard Children’s Hospital, Palo Alto, CA, 6Children’s Hopsital of Philadelphia, Philadelphia, PA, 7Nationwide Children’s Hospital, Columbus, OH, 8Texas Children’s Hospital, Houston, TX, 9Boston Children’s Hospital, Boston, MA, 10Rho, Inc., Chapel Hill, NC

 

[*3:00 PM (72) *]Pediatric Lung Transplantation – 25 Years of Experience; _]R. Waseda^1^, P. Jaksch1, G. Muraközy1, S. Gruber2, C. Lambers1, A. Benazzo1, Z. Szepfalusi2, E. Nachbaur2, W. Klepetko1. [^1^]_]Thoracic Surgery, Medical University Vienna, Vienna, Austria, 2Department of Pediatrics, Medical University Vienna, Vienna, Austria

 

[*3:15 PM (73) *]The Hard Truth: Outcomes of Adolescent Recipients Following Lung Transplantation; _]M. Paraskeva^1^, L. B. Edwards2, B. Levvey1, J. Stehlik2, S. Goldfarb2, R. D. Yusen2, G. P. Westall1, G. I. Snell1. [^1^]_]Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2ISHLT Transplant Registry, Dallas, TX

 

2:00 PM – 3:30 PM

[*Concurrent Session 13: Philip K. Caves Award Candidate Presentations *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

ALL

 

[*Chairs: *]

John A. Belperio, MD, and Sonja Schrepfer, MD, PhD

 

[*2:00 PM (74) *]Increased Angiogenesis and Non-Surgical Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices Are Mediated by Thrombin-Induced Angiopoietin-2; _]C. E. Tabit^1^, G. H. Kim1, S. E. Fedson2, G. Sayer1, M. J. Coplan1, V. Jeevanandam3, N. Uriel1, J. K. Liao1. [^1^]_]Cardiology, The University of Chicago Medical Center, Chicago, IL, 2Baylor Center for Medical Ethics and Health Policy, Baylor University, Houston, TX, 3Cardiac and Thoracic Surgery, The University of Chicago Medical Center, Chicago, IL

 

[*2:15 PM (75) *]Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy; _]D. Chatterjee^1^, C. Moore2, B. Gao3, K. J. Clerkin1, S. B. See1, D. Shaked1, K. J. Rogers1, S. Nunez1, Y. Veras1, L. Addonizio1, M. M. Givertz4, Y. Naka1, D. Mancini1, R. Vasilescu5, C. Marboe5, S. Restaino1, J. C. Madsen2, E. Zorn1. [^1^]_]Dept. of Medicine, Columbia University, New York, NY, 2Massachusetts General Hospital Transplant Center, Boston, MA, 3First Hospital of Jilin University, Changchun, China, 4Brigham and Women’s Hospital, Boston, MA, 5Dept. of Pathology & Cell Biology, Columbia University, New York, NY

 

[*2:30 PM (76) *]Feasibility of Detecting Fungal DNA in Exhaled Breath Condensate by the Luminex Multiplex xTAG Fungal PCR Assay in Lung transplant Recipients: A Pilot Study; _]A. Bhimji^1^, L. G. Singer2, D. Kumar2, A. Humar2, R. Pavan2, H. Zhang3, C. Rotstein2, S. Keshavjee2, T. Mazzulli2, S. Husain2. [^1^]_]Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada, 2Medicine, University Health Network, Toronto, ON, Canada, 3Luminex Molecular Diagnostics, Toronto, ON, Canada

 

[*2:45 PM (77) *][Graft-Infiltrating Neutrophils Cannibalize Dying Neutrophils to Produce IL-10 and to Protect Lung Transplants from Ischemia-Reperfusion Injury; _]M. Zhu, X. Wang, D. Scozzi, K. A. Toth, J. Zhu, X. Lin, A. S. Krupnick, D. Kreisel, A. E. Gelman. _Department of Surgery, Washington University in Saint Louis, Saint Louis, MO

 

[*3:00 PM (78) *]Clara Cell Secretory Protein Limits Small Airway Inflammation and Fibrosis Induced by De Novo Donor Specific Antibodies; _]D. Nayak^1^, F. Zhou2, T. Mohanakumar3. [^1^]_]Washington University School of Medicine, St. Louis, MO, 2Surgery, Washington University School of Medicine, St. Louis, MO, 3Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

[*3:15 PM (79) *][_ Early CD20+ B Cell Depletion Attenuates Cardiac Allograft Vasculopathy in Anti-CD154 Treated Non-Human Primate Model; ]N. A. O’Neill, A. M. Azimzadeh, X. Cheng, T. Zhang, A. Hershfeld, G. Wu, S. S. Kelishadi, T. Stoddard, A. Kronfli, E. Rybak, L. Burdorf, R. N. Pierson. _Surgery, University of Maryland School of Medicine, Baltimore, MD

 

2:00 PM – 3:30 PM

Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH

 

Location:

Washington Ballroom 1

 

[*Target Audience: *]

PH, BSI, LF, LTX, NHSAH, PHARM

 

[*Chairs: *]

Paul A. Corris, MB BS FRCP, and Myung H. Park, MD

 

Session Summary: This joint symposium between ISHLT and the Pulmonary Vascular Research Institute (PVRI), will explore the clinical data regarding combination therapy in PAH and identify differences suggesting that not all combinations are the same. The potential for drug interactions and differences in pharmacology of drugs in the same broad class will be discussed. Finally the strategy of when to introduce combination therapy including triple therapy will be discussed.

 

2:00 PM

Combination Therapy in PAH: What Do The Clinical Trials Tell Us?

 

Paul A Corris, MBBS FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

2:20 PM

The Differing Pharmacology Between Drugs in PDE5i and ERA Class and their Interactions

 

Martin Wilkins, MD, Imperial College, London, United Kingdom

 

2:40 PM

The Pharmacology of sGC Stimulators from Bench to Bedside, Single Therapy and In Combination

 

Ardeschir Ghofrani, MD, University of Giessen, Giessen, Germany

 

3:00 PM

Which Combinations, and Upfront or Sequential When Treating PAH?

 

Mardi Gomberg-Maitland, MD, University of Chicago, Chicago, IL, USA

 

3:20 PM

PANEL DISCUSSION

 

4:00 PM – 5:30 PM

[*Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS *]

 

Location:

Salons 2-3

[*Target Audience: *]

MCS, HF

 

[*Chairs: *]

Mark Slaughter, MD, and Francis D. Pagani, MD, PhD

 

[*4:00 PM (80) *]The Jarvik 2000: Results of the United States Bridge to Transplant Trial; _]C. H. Selzman^1^, E. Felker2, B. C. Sheridan3, S. Silvestry4, R. C. Daly5, A. Anyanwu6, D. Madigan7, O. Frazier8, B. P. Griffith2. [^1^]_]Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 2University of Maryland, Baltimore, MD, 3University of North Carolina, Chapel Hill, NC, 4Florida Hospital, Orlando, FL, 5Mayo Clinic, Rochester, MN, 6Mt. Sinai, New York City, NY, 7Columbia University, New York City, NY, 8Texas Heart Institute, Houston, TX

 

[*4:15 PM (81) *][_ HeartMate 3 Left Ventricular Assist Device Pre- and Post-Approval Experience Through 1 Year at a Single Center; ]Y. Pya^1^, S. Bekbossynov2, M. Bekbossynova3, S. Andossova4, S. Dzhetybayeva5, A. Medressova6, M. Murzagaliyev7, S. Novikova7, R. Salov8, R. Abildayeva9, L. Damme10. [1_]CEO, National Research Cardiac Surgery Center, Astana, Kazakhstan, 2Head of Cardiac Surgery Department No2, National Research Cardiac Surgery Center, Astana, Kazakhstan, 3First Vice of the CEO, National Research Cardiac Surgery Center, Astana, Kazakhstan, 4Head of the LVAD Department, National Research Cardiac Surgery Center, Astana, Kazakhstan, 5Head of Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan, 6Cardiac Surgery No2, National Research Cardiac Surgery Center, Astana, Kazakhstan, 7Cardiac Department No2, National Research Cardiac Surgery Center, Astana, Kazakhstan, 8LVAD Department, National Research Cardiac Surgery Center, Astana, Kazakhstan, 9Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan, 10Thoratec Corporation, Burlington, MA

 

[*4:30 PM (82) *]Open Chest Epicardial Voltage Mapping during Left Ventricular Assist Device Implant in Patients with End-Stage Heart Failure; _]J. D. Moss^1^, M. J. Raiman2, E. E. Flatley1, T. Ota1, V. Jeevanandam1, N. Uriel1. [^1^]_]University of Chicago, Chicago, IL, 2St. Jude Medical, St. Paul, MN

 

[*4:45 PM (83) *]Lessons Learned from over 250 Continuous-Flow Centrifugal Left Ventricular Assist Device Implantation: Growing Experience and Outcomes in Alternative Approaches Era; _]S. Maltais^1^, N. Haglund2, P. Shah3, J. Cowger4, K. A. Aaronson5, F. Pagani5, S. Dunlay1, J. M. Stulak1. [^1^]_]Mayo Clinic, Rochester, MN, 2Vanderbilt, Nahsville, TN, 3Inova Fairfax, Virginia, VA, 4St-Vincent, Indianapolis, IN, 5Michigan, Michigan, MI

 

[*5:00 PM (84) *]Less-Invasive Left Ventricular Assist Device Implantations: Experience after More Than 100 Treated Patients; _]J. D. Schmitto^1^, S. V. Rojas1, M. Avsar1, J. S. Hanke1, A. Uribarri1, D. Burkhoff2, K. Tümler1, P. Ahrens1, U. Molitoris1, A. Martens1, D. Berliner3, J. Bauersachs3, M. Shrestha1, S. Cebotari1, M. Strueber1, A. Haverich1. [^1^]_][_ Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2_]Department of Cardiology, Columbia University, New York, NY, 3Department of Cardiology, Hannover Medical School, Hannover, Germany

 

[*5:15 PM (85) *]An Examination of Bleeding and Thromboembolic Complications during the First Year of Support with the HeartMate 3 Fully Magnetically-Levitated Left Ventricular Assist Device; _]V. Rao^1^, I. Netuka2, J. Schmitto3, Y. Pya4, J. Heatley5, L. Damme6. [^1^]_]Toronto General Hospital, Toronto, ON, Canada, 2Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 3Hannover Medical School, Hanover, Germany, 4National Research Cardiac Surgery Center, Astana, Kazakhstan, 5Thoratec Corp, Pleasanton, CA, 6Thoratec, Pleasanton, CA

 

4:00 PM – 5:30 PM

Concurrent Session 15: Let’s Be Specific: Donor Specific Antibodies – Challenges Ahead

 

Location:

Thurgood Marshall

[*Target Audience: *]

HTX, BSI, ID, MCS, PATH, PEDS, PHARM

 

[*Chairs: *]

Deborah Budge, MD, and Jayan Parameshwar, FRCP

 

[*4:00 PM (86) *]Discordance between C4d Staining by Immunohistochemistry and Immunofluorescence and Clinical Outcomes; _]S. Kalantari Tannenbaum^1^, I. Uraizee2, J. Grinstein1, B. Smith1, K. Marinescu1, G. Sayer1, N. Sarswat1, G. H. Kim1, S. Adatya1, V. Jeevanandam3, T. Ota3, A. Husain2, N. Uriel1. [^1^]_]Cardiology, University of Chicago, Chicago, IL, 2Pathology, University of Chicago, Chicago, IL, 3Cardiac Surgery, University of Chicago, Chicago, IL

 

[*4:15 PM (87) *][_ Donor Specific Antibodies Associated with Micro- and Macrovascular Coronary Disease and Restrictive Myocardial Damage in Heart Transplanted Patients; ]T. S. Clemmensen^1^, P. Koefoed-Nielsen2, S. H. Poulsen1, N. R. Holm1, B. B. Løgstrup1, E. H. Christiansen1, L. P. Tolbod3, H. J. Harms3, H. Eiskjær1. [1_]Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark, 2Department of Immunology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark, 3Department of Nuclear Medicine & PET Center, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark

 

[*4:30 PM (88) *]The Timeline of DSA after Cardiac Transplantation; _]A. Vu^1^, J. J. Teuteberg1, A. Zeevi2, M. A. Shullo1. [^1^]_]University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

 

[*4:45 PM (89) *]Human Leukocyte Antigen-G Polymorphisms Association with Post Heart Transplant Donor Specific Antibodies; _]J. Lazarte^1^, L. Goldraich2, C. Manlhiot2, H. Kawajiri3, A. Ghashghai1, L. Grosman-Rimon3, V. Rao3, D. Delgado2. [^1^]_]Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada, 3Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

 

[*5:00 PM (90) *]Pre-Transplant Donor Specific Antibody Levels Using Single Antigen Bead Assay and Long-Term Survival Post Heart Transplant; _]R. Dhingra, M. D. Yu, M. Johnson, L. Lozonschi, T. Kohmoto, S. A. Akhter, T. Ellis. [_University of Wisconsin-Madison, Madison, WI

 

[*5:15 PM (91) *][De Novo DQ Donor-Specific Antibodies Are Associated with Worse Outcomes Compared to Non-DQ DSA Following Heart Transplantation; _]R. T. Cole, J. Gandhi, A. Morris, C. Lambert, A. McCue, M. Yin, S. Laskar, A. Smith, J. D. Vega, D. Gupta. _Cardiology, Emory Univ Sch of Med, Atlanta, GA

 

4:00 PM – 5:30 PM

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction

 

Location:

Salon 1

[*Target Audience: *]

LTX, BSI, LBCS, PEDS, PHARM

 

[*Chairs: *]

Michael T Musk, MBBS, and Sangeeta M Bhorade, MD

 

[*4:00 PM (92) *]Results of a First-in-Man Study of Mesenchymal Stem Cell Therapy for Bronchiolitis Obliterans Syndrome; _]D. Chambers^1^, D. Enever1, S. Lawrence2, N. Lawson2, S. T. Yerkovich1, L. Sparkes3, R. Herrmann4, M. Sturm4, M. Musk2, P. Hopkins1. [^1^]_]Qld Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, 2WA Lung Transplant Service, Royal Perth Hospital, Perth, Australia, 3Qld Heart Valve Bank, The Prince Charles Hospital, Brisbane, Australia, 4Cell & Tissue Therapies WA, Royal Perth Hospital, Perth, Australia

 

[*4:15 PM (93) *]Preliminary Report on the Effect of Mesenchymal Stem Cell (MSC) Infusion in Lung Function on Patients with Chronic Allograft Dysfunction (CLAD); _]C. A. Keller^1^, D. B. Erasmus1, F. G. Alvarez1, J. M. Mallea1, K. E. Hurst1, H. A. David-Robinson1, A. C. Zubair2. [^1^]_]Transplant, Mayo Clinic, Jacksonville, FL, 2Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL

 

[*4:30 PM (94) *][Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation: A Randomized Controlled Trial; _]D. Ruttens, S. Verleden, E. Vandermeulen, H. Bellon, D. Van Raemdonck, J. Yserbyt, L. Dupont, B. Vanaudenaerde, R. Vos, G. Verleden. _KULeuven, Leuven, Belgium

 

[*4:45 PM (95) *]Comparison of Extracorporeal Photophoresis (ECP) or Alemtuzumab (AL) Treatment Efficacy for Chronic Lung Allograft Dysfunction (CLAD); _]K. Townsend1, A. Moniodis^2^, A. Rabin3, O. Aloum4, J. Stempel4, P. Burkett5, P. Camp6, M. Divo7, S. El-Chemaly5, H. Mallidi6, I. Rosas5, A. Fuhlbrigge5, H. J. Goldberg5, S. Koo4. [^1^]_]Lung Transplant Program, Dept. of Pharmacy, Brigham & Women’s Hospital, Boston, MA, 2Division of Pulmonary & Critical Care Medicine, Brigham & Women’s Hospital, Boston, MA, 3Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, MA, 4Transplant Infectious Disease, Infectious Disease Division, Brigham & Women’s Hospital, Boston, MA, 5Lung Transplant Program, Division of Pulmonary Critical Care Medicine, Brigham & Women’s Hospital, Boston, MA, 6Lung Transplant Program, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA, 7Lung Transplant Program, Pharmacy Department, Brigham & Women’s Hospital, Boston, MA

 

[*5:00 PM (96) *][High Doses of Vitamin D to Reduce Chronic Lung Allograft Dysfunction After Lung Transplantation: A Randomized Trial; _]R. Vos, D. Ruttens, E. Vandermeulen, H. Bellon, S. E. Verleden, D. Van Raemdonck, L. Dupont, J. Yserbyt, B. Vanaudenaerde, G. Verleden. _KU Leuven, Leuven, Belgium

 

[*5:15 PM (97) *]A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation; _]A. Iacono^1^, M. Terrin2, K. Rajakopal3, J. McGrain1, E. Barr2, J. Rinaldi1, A. Patel1, I. Timofte4, J. Kim4, Z. Kon3, P. G. Sanchez3, R. Pierson3, B. Griffith3, S. Pham3. [^1^]_]Shock Trauma and Transplantation, University of Maryland, Baltimore, MD, 2Epidemiology, University of Maryland, Baltimore, MD, 3Cardiothoracic Surgery, University of Maryland, Baltimore, MD, 4Pulmonary Critical Care, University of Maryland, Baltimore, MD

 

4:00 PM – 5:30 PM

[*Concurrent Session 17: Pediatric Mechanical Circulatory Support *]

 

Location:

Maryland Suite

[*Target Audience: *]

PEDS, MCS

 

[*Chairs: *]

Tajinder P Singh, MD, MSc, and Christina J VanderPluym, MD

 

[*4:00 PM (98) *]Global Experience with the Heartware HVAD® in Pediatric Patients: A Preliminary Analysis; _]J. Conway^1^, O. Miera2, H. T. Henderson3, C. VanderPluym4, H. Buchholz1, M. Fenton5, R. A. Niebler6, M. Padalino7, M. Slaughter8, A. Lorts9, M. Schweiger10, M. Hassan11, J. D. Schmitto12, J. N. Scheel13, B. Martin1, Y. Li14, P. E. Parrino15, D. L. Morales9, R. Kirk16. [^1^]_]Stollery Children ‘s Hospital, Edmonton, AB, Canada, 2Deutsches Herzzentrum Berlin, Berlin, Germany, 3Duke University Medical Center, Durham, NC, 4Boston Children’s Hospital, Boston, MA, Canada, 5Great Ormond Street Hospital, London, United Kingdom, 6Medical College of Wisconsin, Children’s Hospital of Wisconsin, Milwaukee, WI, Canada, 7University of Padova Medical School, Padova, Italy, 8University of Louisville, Louisville, KY, 9Cincinnati Children’s Hospital, Cincinnati, OH, 10University Children’s Hospital Zurich, Zurich, Switzerland, 11Aswan Heart Centre, Cairo University, Aswan, Egypt, 12Medizinische Hochschule Hannover, Hannover, Germany, 13Children’s National Health System, Washington, DC, 14University Heart Center Freiburg, Freiburg, Germany, 15Ochsner Clinic Foundation, New Orleans, LA, 16Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

[*4:15 PM (99) *]Utilization and Outcomes of Temporary Ventricular Assist Devices in Children: A Report from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs); _]A. Lorts^1^, R. R. Davies2, J. C. Alejos3, K. R. Kanter4, J. G. Gossett5, R. S. Cantor6, I. Adachi7. [^1^]_]Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Nemours Cardiac Center, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, 3Pediatrics, Mattel Children’s Hospital-UCLA, Los Angeles, CA, 4Pediatric Cardiac Surgery, Emory University School of Medicine, Atlanta, GA, 5Pediatric Cardiology, Ann and Robert H Lurie Children’s Hospital of Chicago, Chicago, IL, 6Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, 7Congenital Heart Surgery, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX

 

[*4:30 PM (100) *]In Vitro Examination of the HeartWare Circulite VAD in the Fontan Circulation; _]M. Tree^1^, P. Trusty2, B. Munz3, M. Samuel4, T. Slesnick5, K. O. Maher5, A. P. Yoganathan6, S. R. Deshpande5. [^1^]_]School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, 2Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 3School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 4School of Chemical & Biomolecular Engineering,, Georgia Institute of Technology, Atlanta, GA, 5Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA, 6Wallace H. Coulter School of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA

 

[*4:45 PM (101) *]Mechanical Circulatory Support as a Bridge to Transplantation in Children with Single Ventricle Physiology: A Multicenter Study; _]B. B. Das^1^, J. Kirklin2, E. Pruitt2, M. Chrisant3, K. Lin4, B. Hong5, S. Daneman6, C. Canter7. [^1^]_]UT Southwestern Med Ctr, Dallas, TX, 2University of Alabama at Brimingham, Brimingham, AL, 3Joe DiMaggio Children’s Hospital, Hollywood, FL, 4Children’s Hospital of Philadelphia, Philadelphia, PA, 5Seattle Children’s Hopsital, Seattle, WA, 6Children’s Medical Center, Dallas, TX, 7St Louis Children’s Hospital, St Louis, MO

 

[*5:00 PM (102) *]Infectious Complications of Ventricular Assist Device Use in Children in the US: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs); _]S. R. Auerbach^1^, M. E. Richmond2, K. R. Schumacher3, D. Lopez-Colon4, M. B. Mitchell5, M. W. Turrentine6, R. S. Cantor7, R. A. Niebler8, P. Eghtesady9. [^1^]_]Pediatrics, Division of Cardiology, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, CO, 2Division of Pediatric Cardiology, Columbia University, New York, NY, 3Pediatrics, Cardiology, University of Michigan, Ann Arbor, MI, 4Pediatrics, Congenital Heart Center, University of Florida, Gainesville, FL, 5Surgery, Children’s Hospital Colorado, Aurora, CO, 6Dept of Surgery, Division of Thoracic & Cardiovascular Surgery, Indiana University School of Medicine, Indianapolis, IN, 7Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, 8Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 9Surgery – Cardiothoracic, Washington University School of Medicine, St. Louis, MO

 

[*5:15 PM (103) *]Measuring the Effect of Dipyridamole and Clopidogrel Using Thromboelastography/Platelet Mapping®: Is There Evidence of a Meaningful Dose-Response Relationship in Children Supported with the Berlin Heart EXCOR Ventricular Assist Device?; _]L. J. May^1^, C. Lo2, T. M. Tesoro2, J. L. Zehnder3, L. Yang2, S. Chen3, J. Lee2, D. B. McElhinney2, D. N. Rosenthal3, K. Maeda2, C. S. Almond3. [^1^]_]Pediatric Cardiology, University of Utah, Salt Lake City, UT, 2Stanford University, Palo Alto, CA, 3Pediatric Cardiology, Stanford University, Palo Alto, CA

 

 

4:00 PM – 5:30 PM

Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance

 

Location:

Virginia Suite

[*Target Audience: *]

BSI, HTX, LTX

 

[*Chairs: *]

Stephen C Juvet, MD, PhD, FRCPC, and Andrew Gelman, PhD

 

[*4:00 PM (104) *]Multi-Transgenic Expression for Improved Xenograft Survival in Pig-to-Baboon Heart Xenotransplantation Model; _]J. L. Chan^1^, A. K. Singh1, M. L. Thomas2, D. L. Ayares3, K. A. Horvath1, M. M. Mohiuddin1. [^1^]_]Cardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 2Division of Veterinary Resources/Office of Research Services, National Institutes of Health, Bethesda, MD, 3Revivicor Inc., Blacksburg, VA

 

[*4:15 PM (105) *]The Real Time Visualization of Neutrophil Extracellular Trap Formation in Lung Transplants Reveals a Critical Role in Tolerance; _]X. Wang^1^, D. Scozzi1, D. Kreisel1, A. Krupnick1, M. J. Miller2, A. E. Gelman1. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Medicine, Washington University School of Medicine, St. Louis, MO

 

[*(106) *]WITHDRAWN

 

[*4:30 PM (374) *]Tissue Injury and Loss of Regulatory T Cells Leads to Lung-Specific Autoantibodies Following Lung Transplantation; _]S. Chiu^1^, V. Subramanian2, D. Kreisel2, G. S. Budinger3, H. Perlman4, M. M. DeCamp1, T. Mohanakumar2, A. Bharat1. [^1^]_]Thoracic Surgery, Northwestern University, Chicago, IL, 2Surgery, Washington University, St. Louis, MO, 3Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL, 4Rheumatology, Northwestern University, Chicago, IL

 

[*4:45 PM (107) *][Leukocytes Transfer More Severe Rejection from Lung Transplant Recipients with Severe PGD into Humanized Mice and Are Sensitive to T Cell Regulation; _]T. Siemeni, A. Knöfel, N. Madrahimov, W. Sommer, D. Bobylev, M. Avsar, F. Ius, K. Jansson, J. Salman, I. Tudorache, C. Kühn, A. Haverich, G. Warnecke. _Hannover HTTG, Hannover, Germany

 

[*5:00 PM (108) *]Thalidomide Treatment Prevents Chronic Graft Rejection after Transplantation in Rats; _]K. K. Miller^1^, X. Hua1, T. Deuse1, X. Hu1, E. Neofytou1, T. Renne2, H. Reichenspurner3, S. Schrepfer1, D. Bernstein4. [^1^]_]TSI Lab, University Heart Center Hamburg, Hamburg, Germany, 2Clinical Chemistry, University Medical Center Hamburg, Hamburg, Germany, 3CT Surgery, University Heart Center Hamburg, Hamburg, Germany, 4Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA

 

[*5:15 PM (109) *][BOS Is Associated with Increased Cytotoxic Pro-Inflammatory CD8 T and NKT-Like and NK Cells in the Distal Airways; _]G. Hodge, S. Hodge, A. Yeo, P. Nguyen, E. Hopkins, C. Holmes-Liew, P. N. Reynolds, M. Holmes. _Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia

 

4:00 PM – 5:30 PM

[*Concurrent Session 19: Improving Outcomes: Body and Soul *]

Location:

Delaware Suite

[*Target Audience: *]

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH

 

[*Chairs: *]

Louise M Fuller, PT, and Erin Wells, RN

 

[*4:00 PM (110) *]Change in Body Mass Index over Time after Continuous Flow Left Ventricular Assist Device Implantation; _]J. M. Tatum^1^, S. Abdoli1, F. S. Schenkel1, T. Possemato1, M. L. Barr1, P. Crookes2, M. E. Bowdish1. [^1^]_]Cardiothoracic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 2Upper GI and Bariatric Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA

 

[*4:15 PM (111) *]Pre-Lung Transplant Body Composition and Associations with Post Transplant Outcomes; _]E. M. Capel^1^, M. O’Driscoll1, A. Tierney1, G. Snell2. [^1^]_]Nutrition Services, The Alfred Hospital, Melbourne, Australia, 2Lung Transplantation Services, The Alfred Hospital, Melbourne, Australia

 

[*4:30 PM (112) *][Single Centre Observational Study on Adequacy and Tolerance of Nutrition Support on the First 7 Days of ECMO as Bridge to Lung Transplant; _]R. Patel, P. Mohite, S. Soresi, M. Carby, A. Simon, A. Reed. _Royal Brompton and Harefield Hospital, Middlesex, United Kingdom

 

[*4:45 PM (113) *]Lung Transplantation Does Not Impact on Daily Physical Activity Despite Substantial Improvements in Respiratory Function and Exercise Capacity; _]J. R. Walsh^1^, D. C. Chambers1, S. T. Yerkovich1, P. M. Hopkins1, N. R. Morris2. [^1^]_]Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, 2School of Rehabilitation Sciences and Griffith Health Institute, Griffith University, Gold Coast, Australia

 

[*5:00 PM (114) *]Incidence of Vocal Cord Palsy and Aspiration Status in the Lung Transplant Population; _]Z. Meszarich1, N. Patel^1^, A. Reed2, A. Simon3. [^1^]_]Speech and Language Therapy, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, 2Transplant Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, 3Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

 

[*5:15 PM (115) *]A Multi-Centre Study on the Effects of Iyengar Yoga on Health Related Quality of Life in Patients with Pulmonary Arterial Hypertension; _]M. V. Thakrar^1^, D. S. Helmersen1, N. Hirani1, K. Jackson2, D. C. Lien2, M. J. Santana3. [^1^]_]Department of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada, 2Alberta Lung Transplant Program, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, W21C, University of Calgary, Calgary, AB, Canada

 

4:00 PM – 5:30 PM

Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation

 

Location:

Washington Ballroom 2

[*Target Audience: *]

EEP, HF, HTX, LTX, MCS, NHSAH

 

[*Chairs: *]

Helen Gibbs, RN, and Soma S Jyothula, MD

 

[*4:00 PM (116) *]Single Versus Double Lung Transplantation in the Setting of Constrained Donor Availability; _]P. Samson^1^, S. Chang2, R. Hachem3, D. Byers3, E. Trulock3, C. Witt3, R. D. Yusen3, D. Kreisel1, A. Krupnick1, G. Patterson1, B. Meyers1, V. Puri1. [^1^]_]Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO, 2Department of Surgery, Washington University in St. Louis, St. Louis, MO, 3Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, MO

 

[*4:15 PM (117) *][Changes in Smoking Habits in Potential Lung Transplant (LTx) Candidates; _]J. Nuttall, H. Newton, C. Culshaw, L. Pate, C. Leonard, M. Al-Aloul. _Cardiothoracic Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom

 

[*4:30 PM (118) *][Implementation of the 7-Day National Health Service (NHS) Working Week in UK will be Detrimental to Heart and Lung Transplantation; Fact or Fiction?; _]L. Ong, G. Parry, S. C. Clark. _Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

[*4:45 PM (119) *]Impact of Socioeconomic Status on Bridging with Contemporary Left Ventricular Assist Device (LVAD): Analysis of the UNOS Registry; _]V. K. Topkara^1^, B. J. Wayda1, S. D. Rao2, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, F. Castagna1, A. M. Clemons1, K. Wong1, P. N. Trinh4, S. Restaino1, F. Latif1, J. Haythe1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka3, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Medicine, New York University, New York, NY, 3Surgery, Columbia University, New York, NY, 4Epidemiology, Columbia University, New York, NY

 

[*5:00 PM (120) *]Socioeconomic Deprivation Is Associated with Worse Survival After Heart Transplantation in England; _]J. D. Evans^1^, S. Kaptoge2, E. Di Angelantonio2, C. Lewis1, J. Parameshwar1, S. J. Pettit1. [^1^]_]Transplant Unit, Papworth Hospital, Cambridge, United Kingdom, 2Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

 

[*5:15 PM (121) *]Cost-Effectiveness of a Blood-Based Biomarker Compared to Endomyocardial Biopsy for the Diagnosis of Acute Allograft Rejection; _]Z. Hollander^1^, T. H. Mohammadi2, S. Assadian1, J. E. Wilson-McManus1, K. K. Lam1, R. T. Ng3, W. McMaster4, P. A. Keown4, B. M. McManus3, C. Marra5. [^1^]_]PROOF Centre of Excellence, Vancouver, BC, Canada, 2Centre for Health Evaluation & Outcome Sciences, Vancouver, BC, Canada, 3University of BC & PROOF Centre of Excellence, Vancouver, BC, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5School of Pharmacy, Memorial University, St. John’s, NL, Canada

 

6:00 PM – 7:00 PM

[*Mini Oral 1: Science, Surgery and Shock in Mechanical Circulatory Support *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, BSI, HTX, NHSAH

 

[*Chairs: *]

Scott Silvestry, MD, and Theodoros Kofidis, MD, PhD, FRCS

 

[*6:00 PM (122) *]Access Matters: Survival Advantage with Minimally Invasive Implantation of LVAD as Destination Therapy; _]V. Tarzia^1^, M. Di Mauro2, G. Bortolussi1, J. Bejko1, D. Marinelli2, M. Foschi2, M. Maccherini3, S. Bernazzali3, M. Maiani4, V. Tursi4, P. Agostoni5, A. Apostolo5, F. Alamanni5, U. Livi4, G. Sani3, T. Bottio1, G. Di Giammarco2, G. Gerosa1. [^1^]_]Cardiac Surgery, University of Padova, Padova, Italy, 2Cardiac Surgery, University of Chieti, Chieti, Italy, 3Cardiac Surgery, University of Siena, Siena, Italy, 4Cardiac Surgery, University of Udine, Udine, Italy, 5Cardiac Surgery, University of Milano, Milano, Italy

 

[*6:05 PM (123) *][Heparin-Free Off-Pump LVAD Implantation Reduces Early Adverse Events Compared with On-Pump Implantation; _]S. K. Balasubramanian, E. Pavlushkov, S. Pettit, C. Lewis, Y. Abu-Omar, M. Berman, J. K. Parameshwar, S. Tsui. _Transplantation, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

 

[*6:10 PM (124) *][_ Short-, Mid- and Long-Term Efficacy of Aortic Valve Repair in Patients Supported with Continuous Flow-Left Ventricular Assist Device; ]S. Fukuhara, H. Takayama, K. Takeda, J. Han, P. Kurlansky, A. R. Garan, M. Yuzefpolskaya, P. C. Colombo, V. K. Topkara, Y. Naka. _Columbia University Medical Center, New York, NY

 

[*6:15 PM (125) *]Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation – Comparison of Systematic Mitral Valve Repair vs Surgical Abstention; _]A. Pawale^1^, S. Itagaki1, N. Moss2, S. Pinney2, D. H. Adams1, A. C. Anyanwu1. [^1^]_]Cardiovascular Surgery, Mount Sinai Medical Center, New York, NY, 2Cardiology, Mount Sinai Medical Center, New York, NY

 

[*6:20 PM (126) *]Use of Impella 5.0 Ventricular Assist Device as a Bridge to Decision during Acute Decompensation of End-Stage Chronic Heart Failure; _]S. A. Hall^1^, S. Carey1, M. Edens1, G. Gong1, M. Esposito2, R. O’Kelly2, S. Annamalai2, N. Aghili2, S. Adatya3, A. Medjami4, M. Hout4, N. Josephy4, N. Kapur2, N. Uriel3. [^1^]_]Baylor University Medical Center, Dallas, TX, 2Tufts Medical Center, Boston, MA, 3University of Chicago, Chicago, IL, 4Abiomed, Danvers, MA

 

[*6:25 PM (127) *][A Shock Team Improves Survival in Cardiogenic Shock by Decreasing Time to Intervention; _]C. Dillane, A. Bove, H. Cohen, R. Bashir, B. O’Murchu, B. O’Neill, J. Gomez-Abraham, A. Shiose, D. Schwartz, D. Dries, L. Punnoose, Y. Toyoda, R. Alvarez, E. Hamad. _Internal Medicine, Temple University Hospital, Philadelphia, PA

 

[*6:30 PM (128) *]Contemporary Outcome of Unplanned Right Ventricular Assist Device for Severe Right Heart Failure After Continuous Flow Left Ventricular Assist Device Insertion; _]K. Takeda^1^, H. Takayama1, R. A. Garan2, V. K. Topkara2, J. Han1, S. Fukuhara1, P. A. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1. [^1^]_]Cardiac Surgery, Columbia University, NY, NY, 2Cardiology, Columbia University, NY, NY

 

[*6:35 PM (129) *]Extracorporeal Membrane Oxygenator Therapy after Heart Transplantation; _]P. Vallabhajosyula^1^, A. Habertheuer1, S. Miller1, P. Atluri1, C. Bermudez1, M. Acker1, L. Goldberg2, M. Williams1. [^1^]_]Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA

 

[*6:40 PM (130) *][_ Increase in Frequency of Terminally Differentiated and Exhausted CD8+ T Cells Is Associated with Worse Clinical Outcomes after Mechanical Circulatory Support Device Implantation; ]J. M. Schaenman^1^, Y. Korin2, T. Sidwell2, E. Chang3, M. Bakir3, N. Wisniewski4, G. Bondar3, M. Cadeiras3, M. Kwon5, E. Reed2, M. Deng3. [1_]Medicine/Infectious Diseases, UCLA School of Medicine, Los Angeles, CA, 2Pathology, UCLA School of Medicine, Los Angeles, CA, 3Medicine/Cardiology, UCLA School of Medicine, Los Angeles, CA, 4Department of Integrative Biology and Physiology, UCLA School of Medicine, Los Angeles, CA, 5Cardiovascular Surgery, UCLA School of Medicine, Los Angeles, CA

 

[*6:45 PM (131) *]Increased Aortic Stiffness Index Among Patients Bridged to Transplant with Non-Pulsatile Left Ventricular Assist Devices; _]A. C. Patel1, R. B. Dodson1, K. S. Hunter1, A. Brieke1, J. Lindenfeld2, A. V. Ambardekar^1^. [^1^]_]University of Colorado, Aurora, CO, 2Vanderbilt Heart and Vascular Institute, Nashville, TN

 

[*6:50 PM (132) *]Changes in Metabolic Substrate Utilization and Pyruvate Mitochondrial Oxidation Mismatch during Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning; _]N. Diakos1, S. Navankasattusas1, S. H. McKellar1, A. G. Kfoury1, P. Ferrin1, L. McCreath1, D. Miller1, S. Wright1, K. Skedros1, M. Al-Sari1, A. Ragnhildstveit1, O. Wever-Pinzon1, G. Russel2, A. Koliopoulou1, B. Reid1, J. Stehlik1, C. H. Selzman1, S. G. Drakos^1^. [^1^]_]UTAH Cardiac Transplant Program, Salt Lake City, UT, 2Intermountain Donor Services, Salt Lake City, UT

 

[*6:55 PM (133) *]A Gene Expression Biomarker Panel for Predicting Mechanical Circulatory Support Outcomes; _]N. Wisniewski^1^, G. Bondar1, C. Rau2, J. Chittoor1, E. Chang1, A. Esmaeili1, M. Deng1. [^1^]_]Department of Medicine (Cardiology), University of California, Los Angeles, Los Angeles, CA, 2Department of Anesthesiology, University of California, Los Angeles, Los Angeles, CA

 

6:00 PM – 7:00 PM

[*Mini Oral 2: Donor Dilemmas in Heart Transplantation *]

 

Location:

Salon 1

[*Target Audience: *]

HTX, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Daniel Zimpfer, MD, and Carmelo A Milano, MD

 

[*6:00 PM (134) *]Impact of a New Urgency-Based Cardiac Allocation System on Candidate Outcomes: Results from a Simulated Allocation Study; _]C. Jacquelinet, B. Audry, C. Jasseron, C. Canterelle, C. Legeai, O. Bastien, R. Dorent. [_Direction Médicale et Scientifique, Agence de la Biomedecine, Saint Denis la Plaine, France

 

[*6:05 PM (135) *]Prolonged Cardiac Allograft Donor Distance Does Not Impact Long-Term Survival; _]A. C. Gaffey^1^, C. W. Chen1, J. J. Chung1, J. Wald2, M. A. Acker1, P. Atluri1. [^1^]_]Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Department of Cardiology, University of Pennsylvania, Philadelphia, PA

 

[*6:10 PM (136) *]Low Ejection Fraction in Young Donor Hearts Is Not Associated with Increased Recipient Mortality; _]C. W. Chen^1^, A. C. Gaffey1, M. H. Sprys1, J. J. Chung1, K. B. Margulies2, M. A. Acker1, P. Atluri1. [^1^]_]Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Department of Medicine, University of Pennsylvania, Philadelphia, PA

 

[*6:15 PM (137) *]Predicting One-Year Cardiac Transplant Survival Using a Donor/Recipient Risk Assessment Tool; _]D. L. Joyce^1^, Z. Li1, L. B. Edwards2, J. A. Kobashigawa3, R. C. Daly1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Assistant Director of Research, UNOS, Richmond, VA, 3Cardiology, Cedars-Sinai Heart Institute, Beverly Hills, CA

 

[*6:20 PM (138) *]Are Pediatric Donor Hearts Viable in Adult Recipients?; _]M. Kittleson, J. Patel, L. Czer, T. Aintablian, J. Rush, M. Johnson, D. Chang, D. Ramzy, D. Geft, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*6:25 PM (139) *]The Overall Concept of Bridging to Transplantation by an Ventricular Assist Device in Comparison to Bridging by Conservative Treatment – Results Using the United Network for Organ Sharing Database; _]A. M. Bernhardt^1^, A. P. Levin2, A. Schaefer1, F. M. Wagner1, H. Reichenspurner1. [^1^]_]Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Columbia University Medical Center, New York City, NY

 

[*6:30 PM (140) *]Prolonged Corrected QT Interval in the Donor Heart: Is There a Risk?; _]J. Patel, M. Kittleson, L. Czer, T. Aintablian, D. Phan, D. Leong, J. Rush, E. Stimpson, D. Chang, A. Hage, A. Trento, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*6:35 PM (141) *][Impact of Cytomegalovirus on Survival after Heart Transplant: Analysis of 20,000 Patients from the UNOS Registry Data; _]G. Ashrith, A. Daoud, L. D. Teeter, J. Amione-Guerra, A. M. Cordero-Reyes, E. Graviss, B. H. Trachtenberg, A. Bhimaraj, A. Gaber, S. Scheinin, G. Torre-Amione, J. D. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX

 

[*6:40 PM (142) *]Stress Cardiomyopathy in Donor Hearts Does Not Affect the Outcome after Heart Transplantation; _]T. Pintar^1^, G. Poglajen2, R. Okrajšek2, J. Kšela3, I. Kneževič^3^, B. Vrtovec2. [^1^]_]Dept. of Anesthesiology and Intensive Therapy, UMC Ljubljana, Ljubljana, Slovenia, 2Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, 3Dept. of Cardiovascular Surgery, UMC Ljubljana, Ljubljana, Slovenia

 

[*6:45 PM (143) *]Similar Post-Heart Transplant Outcomes with Undersized or Oversized Donors When Left Ventricular End Diastolic Dimension (LVEDD) Is within Range; _]N. Bassi^1^, C. Murks2, S. Adatya2, G. Kim2, N. Sarswat2, G. Sayer2, D. Rodgers2, T. Ota3, N. Uriel2, V. Jeevanandam3. [^1^]_]Medicine, University of Chicago, Chicago, IL, 2Medicine (Section of Cardiology), University of Chicago, Chicago, IL, 3Surgery (Section of Cardiac and Thoracic Surgery), University of Chicago, Chicago, IL

 

[*6:50 PM (144) *][Heart Transplantation Following Donor Circulatory Death in Patients Bridged to Transplant with Implantable Left Ventricular Assist Devices; _]D. García Sáez, P. Mohite, C. T. Bowles, O. Maunz, B. Zych, M. Zeriouh, A. F. Popov, S. Rahman-Haley, N. Banner, A. R. Simon. _Heart Lung Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom

 

[*6:55 PM (145) *]Early and Late Outcomes of Cardiac Transplanted Patients with Marginal Donors: A Single Centre 10 Years Experience; _]A. Galeone^1^, G. Lebreton1, S. Ouldamar1, G. Coutance1, M. Schimdt2, J. Amour3, P. Leprince1. [^1^]_]Department of Thoracic and Cardiovascular Surgery, La Pitiè-Salpêtrière Hospital, Paris, France, 2Department of Medical Reanimation, La Pitiè-Salpêtrière Hospital, Paris, France, 3Department of Anesthesiology, La Pitiè-Salpêtrière Hospital, Paris, France

 

6:00 PM – 7:00 PM

[*Mini Oral 3: Candidate and Recipient Management in Heart Transplantation *]

 

Location:

Maryland Suite

[*Target Audience: *]

HTX, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Simon Maltais, MD, PhD, and Daniela Pini, MD

 

[*6:00 PM (146) *][Treating the Failing Heart: An Evaluation of the Past Decade; _]M. C. Black, J. R. Trivedi, E. M. Schumer, A. Cheng, H. T. Massey, M. S. Slaughter. _Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

 

[*6:05 PM (147) *]Induction Immunosuppression Strategies and Long-Term Outcomes after Heart Transplantation; _]D. Ansari^1^, J. Stehlik2, L. H. Lund3, B. Andersson4, L. B. Edwards5, J. Nilsson1. [^1^]_]Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 2Cardiovascular Medicine, University of Utah School of Medicine, Utah, UT, 3Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 4Surgery, Lund University and Skane University Hospital, Lund, Sweden, 5The ISHLT Transplant Registry, Dallas, TX

 

[*6:10 PM (148) *]Implications of Amiodarone Use Before Heart Transplantation; _]L. B. Cooper^1^, R. J. Mentz1, L. B. Edwards2, A. Wilk2, J. G. Rogers1, C. B. Patel1, C. A. Milano1, A. F. Hernandez1, J. Stehlik3, L. H. Lund4. [^1^]_]Duke University, Durham, NC, 2United Network for Organ Sharing, Richmond, VA, 3University of Utah School of Medicine, Salt Lake City, UT, 4Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

 

6:15 PM (149) *]Impact of Cytomegalovirus Infection on Longitudinal Gene-Expression Profiling Score: Results from the Outcomes AlloMap[*® Registry; _]M. Kanwar^1^, S. Murali1, D. Hiller2, E. Deljkich2. [^1^]_]Allegheny General Hospital, Pittsburgh, PA, 2CareDx, San Fransisco, CA

 

[*6:20 PM (150) *][Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy; _]M. Sabatino, L. Potena, S. Longhi, M. Masetti, C. Gagliardi, A. Milandri, V. Manfredini, M. Cinelli, G. Marinelli, A. D. Pinna, C. Rapezzi, F. Grigioni. _University of Bologna, Bologna, Italy

 

[*6:25 PM (151) *]Outcomes of Heart Transplantation in Adults with Hypertrophic Cardiomyopathy (HCM): UNOS Registry Analysis; _]E. C. DePasquale^1^, M. Deng1, A. Ardehali1, D. Jacoby2. [^1^]_]David Geffen Sch Med, Los Angeles, CA, 2Yale, New Haven, CT

 

[*6:30 PM (152) *][_ Assessment of Molecular Mechanisms of Non-Transplant Cardiac Hypertrophy in Cardiac Allograft Hypertrophy- An Exploratory Gene Array Study of Myocardial Biopsy Samples; ]R. Araujo-Gutierrez^1^, M. Park2, J. D. Estep2, G. Ashrith2, B. H. Trachtenberg2, G. Torre-Amione2, A. Bhimaraj2. [1_]DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, TX, 2Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

 

[*6:35 PM (153) *]Temporal Trends of Incidence and Types of De Novo Malignancy after Heart Transplantation; _]J. Youn^1^, L. B. Edwards2, L. H. Lund3, J. Stehlik4, S. Kang1, J. A. Kobashigawa5. [^1^]_]Division of Cardiolgoy, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2United Network for Organ Sharing, Richmond, VA, 3Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, 4Division of Cardiology, University of Utah Health Sciences Center, Salt Lake City, UT, 5Division of Cardiolgoy, Cedars-Sinai Medical Center, Los Angeles, CA

 

[*6:40 PM (154) *]Heart Transplantation Versus Ventricular Assist Device: Which Therapy for Patient with Refractory Cardiogenic Shock?; _]C. Vidal, G. Lebreton, N. Djavidi, S. Varnous, A. Bouglé, A. Genton, E. Barreda, P. Leprince, J. Amour. [_Institut de Cardiologie, Hôpital Pitié Salpétrière, Paris, France

 

[*6:45 PM (155) *]Immune Mediators IL-10 and TNF-alpha as a Potential Diagnostic Tool for Detection of Developed Cardiac Allograft Vasculopathy; _]C. L. Bara1, B. Przybylek^2^, A. Neumann1, A. Haverich1, C. S. Falk3. [^1^]_]Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School (MHH), Hannover, Germany, 2Hannover Medical School (MHH), Hannover, Germany, 3Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany

 

[*6:50 PM (156) *]Differences in the Impact of Donor-Related Variables on Post-Heart Transplantation Outcomes in Mechanically Bridged Recipients and Recipients without Prior Mechanical Support – An Analysis from the ISHLT Registry; _]M. Urban^1^, L. Edwards2, J. Stehlik3, K. Booth4, J. Pirk1, I. Netuka1. [^1^]_]Cardiac Surgery, IKEM, Prague, Czech Republic, 2Biostatistics, United Network for Organ Sharing, Richmond, VA, 3University of Utah, Salt Lake City, UT, 4Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

[*6:55 PM (157) *][Competing Outcomes of Heart Transplantation in Adults Bridged with Total Artificial Heart (TAH): UNOS Registry Analysis; _]E. C. DePasquale, A. Salimbangon, A. Chang, E. Howell, E. Howell, A. Nsair, M. Deng, A. Ardehali. _David Geffen Sch Med, Los Angeles, CA

 

6:00 PM – 7:00 PM

[*Mini Oral 4: Donor and Recipient Management in Lung Transplantation *]

 

Location:

Virginia Suite

[*Target Audience: *]

LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM

 

[*Chairs: *]

Mark Benzimra, MD, MRCP and Christophe Pison, MD, PhD

 

[*6:00 PM (158) *]Obstacles to Lung Transplant from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs); _]T. M. Egan^1^, J. J. Requard2, P. Stewart3, C. Thys4. [^1^]_]Surgery, U. North Carolina Sch Med, Chapel Hill, NC, 2Lung Banks of America, Chapel Hill, NC, 3Biostatistics, U. North Carolina Gillings School of Public Health, Chapel Hill, NC, 4Carolina Donor Services, Durham, NC

 

[*6:05 PM (159) *]Lung Function: How Good Does It Get?; _]M. Paraskeva^1^, B. Borg2, E. Paul3, J. Fuller4, G. Westall5, G. I. Snell5. [^1^]_]Alfred Hospital, Melbourne, Australia, 2Lung Function Service, Alfred Hospital, Melbourne, Australia, 3Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia, 4Monash University, Melbourne, Australia, 5Lung Transplant Service, Alfred Hospital, Melbourne, Australia

 

[*6:10 PM (160) *]Long-Term Impact of Coronary Artery Disease in Lung Transplantation; _]W. S. Ragalie^1^, J. D. Maloney2, K. C. Meyer3, R. D. Cornwell3, N. C. De Oliveira2. [^1^]_]Surgery, Medical College of Wisconsin, Milwaukee, WI, 2Cardiothoracic Surgery, University of Wisconsin, Madison, WI, 3Pulmonary Medicine, University of Wisconsin, Madison, WI

 

[*6:15 PM (161) *][Does Single Lung Transplantation Change Perfusion in Relation to Native Lung in Pulmonary Fibrosis? Implications in Choosing Laterality; _]L. S. Reddy, M. Daneshmand, J. C. Haney, L. Snyder, A. L. Gray, J. M. Reynolds, M. G. Hartwig. _Transplant Division, Duke University Medical Center, Durham, NC

 

[*6:20 PM (162) *]Simulated Regionalization of Lung Transplantation in the United States; _]J. Magruder^1^, T. C. Crawford2, J. C. Grimm2, A. S. Shah3, B. Kim4, E. L. Bush2, R. S. Higgins2, C. A. Merlo4. [^1^]_]Johns Hopkins, Baltimore, MD, 2Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD, 3Department of Cardiac Surgery, Vanderbilt, Nashville, TN, 4Division of Pulmonary and Critical Care Medicine, Johns Hopkins, Baltimore, MD

 

[*6:25 PM (163) *]The OCS Lung EXPAND International Trial Interim Results; _]G. Loor^1^, G. Warnecke2, M. Smith3, J. Kukreja4, A. Ardehali5, J. Moradiellos6, A. Varela6, J. Madsen7, M. Hertz1, D. Van Raemdonck8. [^1^]_]University of Minnesota Medical Center, Mineapolis, MN, 2Hannover Medical School, Hannover, Germany, 3St. Joseph’s Medical Center, Phoenix, AZ, 4University of California San Francisco Medical Center, San Francisco, CA, 5Ronald Reagan UCLA Medical Center, Los Angeles, CA, 6University Puerta de Hierro Hospital, Madrid, Spain, 7Massachusetts General Hospital, Boston, MA, 8Leuven University Hospital, Leuven, Belgium

 

[*6:30 PM (164) *]Impact of OCS Lung Portable EVLP on Pulmonary Function and Bronchiolitis Obliterans in Standard Lung Transplant Recipients – Prospective Evidence from the OCS Lung INSPIRE Trial Patients; _]A. Ardehali^1^, G. Warnecke2, D. Van Raemdonck3, G. Loor4, J. Kukreja5, M. Smith6, F. Rea7, G. Massard8, F. De Robertis9, J. Nagendran10, J. Moradiellos11, K. Dhital12, C. Knosalla13, C. Bermudez14, S. Tsui15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, W. Sommer2, B. Wiegmann2, I. Tudorache2, C. Khun2, M. Avsar2, M. Schiavon7, N. Santelmo8, A. Olland8, P. Falcoz8, A. Varela11, A. Simon9, H. Reichenspurner18, A. Haverich2, J. Madsen20, M. Hertz21. [^1^]_]Ronald Reagan UCLA Medical Center, Los Angeles, CA, 2Hannover Medical School, Hannover, Germany, 3Leuven University Hospital, Leuven, Belgium, 4University of Minnesota Medical Center, Mineapolis, MN, 5University of California San Francisco Medical Center, San Francisco, CA, 6St. Joseph’s Medical Center, Phoenix, AZ, 7University of Padua Hospital, Padua, Italy, 8Strasbourg University Hospital, Strasbourg, France, 9Harefield Hospital, London, United Kingdom, 10University of Alberta Medical Center,, Edmonton, ON, Canada, 11University Puerta de Hierro Hospital, Madrid, Spain, 12St. Vincent’s Hospital, Sydney, Australia, 13German Heart Institute, Berlin, Germany, 14University of Pittsburgh Medical Center, Pittsburgh, PA, 15Papworth Hospital, Papworth, Cambridge, United Kingdom, 16Indiana University Medical Center, Indianapolis, IN, 17Cleveland Clinic Foundation, Cleveland, OH, 18Hamburg University Hospital, Hamburg, Germany, 19University Hospitals of Marseille, Marseille, France, 20Massachusetts General Hospital, Boston, MA, 21University of Minnesota Medical Center, Minneapolis, MN

 

[*6:35 PM (165) *][On-Demand Immunoglobulin-G Replacement Is Not Associated with Benefits in Lung Transplant Recipients with Hypogammaglobulinemia; _]A. B. Lichvar, C. R. Ensor, M. R. Morrell, J. M. Pilewski, J. Hayanga, J. D’Cunha, A. Zeevi, J. F. McDyer, A. A. Petrov. _University of Pittsburgh, Pittsburgh, PA

 

[*6:40 PM (166) *][Carfilzomib-Based Therapy Produces Favorable Outcomes for Antibody Mediated Rejection of the Lung Allograft; _]C. R. Ensor, A. Zeevi, M. Marrari, M. R. Morrell, S. A. Yousem, J. M. Pilewski, J. D’Cunha, J. F. McDyer. _University of Pittsburgh, Pittsburgh, PA

 

[*6:45 PM (167) *]Total Lymphoid Irradiation (TLI) for the Management of Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplant: A Single Centre Experience; _]R. Miller1, B. Hartog2, J. Frew1, G. Parry1, A. Fisher^1^, P. Corris1, G. Meachery1, J. Lordan1. [^1^]_]Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

 

[*6:50 PM (168) *]Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplantation: Identifying Predictors of Mortality; _]J. A. Hayanga^1^, N. Shigemura1, E. Chan1, T. Richards1, M. Morrell2, J. D. Luketich1, J. D’Cunha1. [^1^]_]Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Pulmonary Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:55 PM (169) *]Age Trends for Cystic Fibrosis Patients Undergoing Lung Transplantation: An Analysis of the ISHLT Thoracic Transplant Registry; _]C. Benden^1^, L. B. Edwards2, S. B. Goldfarb3, R. D. Yusen4, J. Stehlik5. [^1^]_]University Hospital Zurich, Zurich, Switzerland, 2ISHLT Thoracic Transplant Registry, Dallas, TX, 3Children’s Hospital of Philadelphia, Philadelphia, PA, 4Washington University School of Medicine, St. Louis, MO, 5University of Utah Health Care, Salt Lake City, UT

 

6:00 PM – 7:00 PM

[*Mini Oral 5: Pediatrics: Organ Support and Transplantation *]

Location:

Delaware Suite

[*Target Audience: *]

PEDS, HTX, LBCS

 

[*Chairs: *]

Estela Azeka, MD, and Chesney Castleberry, MD

 

[*6:00 PM (170) *]Pancreas: The Forgotten Organ in Children Undergoing Implantable Continuous-Flow VAD Support; _]S. Burki^1^, D. Horne1, S. C. Tume2, A. Jeewa3, A. G. Cabrera3, E. McKenzie1, C. D. Fraser, Jr.1, I. Adachi1. [^1^]_]Congenital Heart Surgery, Texas Children’s Hospital, Houston, TX, 2Pediatric Critical Care, Texas Children’s Hospital, Houston, TX, 3Pediatric Cardiology, Texas Children’s Hospital, Houston, TX

 

[*6:05 PM (171) *]Pre-Transplantation Mechanical Circulatory Support Duration Effects Candidacy and Graft Longevity; _]F. Zafar^1^, D. L. Morales1, A. Lorts2, C. Villa2, N. Kimura1, R. Rizwan1, C. Chin2, R. Bryant 3rd1. [^1^]_]Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*6:10 PM (172) *][Steroid Therapy as a Strategy to Treat Hyperfibrinogenemia in Pediatric Ventricular Assist Device Patients: Does It Actually Hasten the Decline?; _]J. Murray, J. Lee, N. Do, S. Chen, C. Almond, S. A. Hollander, K. Maeda, V. Yarlagadda, D. Rosenthal, M. Gowen, P. Shuttleworth. _Lucile Packard Children’s Hospital, Palo Alto, CA

 

[*6:15 PM (173) *]Impact of Donor Cause of Death on Graft Utilization in Pediatric Heart Transplantation; _]A. M. Khan^1^, S. Malerba1, M. Bock2, I. Lytrivi1. [^1^]_]Icahn School of Medicine at Mount Sinai, New York, NY, 2Loma Linda University Children’s Hospital, Loma Linda, CA

 

[*6:20 PM (174) *]Impact of Induction Therapy Type in High and Low Risk Pediatric Patients After Heart Transplant: Analysis of the PHTS Database; _]C. Castleberry^1^, R. Amenduri2, K. Schowengerdt3, E. Edens4, N. Hagin1, E. Pruitt5, J. Kirklin6, S. Urschel7. [^1^]_]Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO, 2Pediatric Cardiology, University of Minnesota, Amplatz Children’s Hospital, Minneapolis, MN, 3Pediatric Cardiology, Cardinal Glennon Children’s Medical Center, St. Louis, MO, 4Pediatric Cardiology, University of Iowa Children’s Hospital, Iowa City, IA, 5Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, 6Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 7Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada

 

[*6:25 PM (175) *]Increased Frequency of Surveillance Biopsy Does Not Improve Pediatric Heart Transplant Outcomes: Time for a Change in Practice?; _]J. Godown^1^, M. McKane1, B. A. Mettler2, A. C. Westrick3, C. N. Shannon3, H. Chen4, S. Zhao4, D. A. Dodd1. [^1^]_]Pediatric Cardiology, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 2Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 3Surgical Outcomes Center for Kids, Monroe Carell Jr. Children’s Hospital, Nashville, TN, 4Biostatistics, Vanderbilt University, Nashville, TN

 

[*6:30 PM (176) *]Donor-Specific Anti-HLA Antibodies of Immunoglobulin G3 Subclass Correlate with Cellular Rejection after Cardiac Transplantation; _]S. Khan^1^, C. Chin1, E. Portwood2, P. A. Brailey2, A. Tica3, A. L. Girnita4. [^1^]_]Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Transplant Immunology Division, Hoxworth Blood Center, Cincinnati, OH, 3Department of Pharmacology, University of Medicine and Pharmacy, Craiova, Romania, 4Department of Surgery, COM, Transplant Immunology Division, University of Cincinnati, Cincinnati, OH

 

[*6:35 PM (177) *]Application of New Antibody-Mediated Rejection Classification (pAMR) on Pediatric Heart Transplant: A Retrospective Study  * ; _]M. Fedrigo^1^, A. Angelini1, G. J. Berry2. [^1^]_]Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy, 2Pathology Department, Stanford University, Stanford, CA

 

[*6:40 PM (178) *][Pediatric Heart Transplant Waitlist Time Is Increased and Survival Is Decreased in Overweight-Obese (BMI>85%) Individuals; _]T. D. Ryan, F. Zafar, R. M. Siegel, C. R. Villa, R. Bryant, C. Chin. _The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*6:45 PM (179) *]Heart Transplantation in Adolescents: Does Pediatric Experience Improve Outcomes?; _]R. R. Davies^1^, S. J. Kindel2, M. A. McCulloch1, C. Pizarro1, W. T. Mahle3, D. L. Morales4. [^1^]_]Nemours/A.I. duPont Hospital for Children, Wilmington, DE, 2Children’s Hospital of Wisconsin, Milwaukee, WI, 3Children’s Healthcare of Atlanta, Atlanta, GA, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*6:50 PM (180) *]The Quilty Effect in Pediatric Heart Transplant Recipients; _]A. Joong^1^, M. E. Richmond1, K. O. Stack2, R. J. Rodriguez1, J. M. McAllister2, W. A. Zuckerman1, T. M. Lee1, S. Law1, L. J. Addonizio1. [^1^]_]Pediatric Cardiology, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*6:55 PM (181) *]Circulating Cell-Free DNA as a Non-Invasive Marker of Pediatric Heart Transplant Rejection and Immunosuppressive Treatment; _]K. K. Khush^1^, M. Grskovic2, H. Luikart1, G. Cohen1, C. Strehl1, J. Wylie1, K. Thompson2, B. Christie2, J. Collins2, D. Hiller2, J. Yee2, D. Bernstein3. [^1^]_]Medicine/Cardiology, Stanford University, Stanford, CA, 2CareDx, Inc, Brisbane, CA, 3Pediatrics/Cardiology, Stanford University, Stanford, CA

 

6:00 PM – 7:00 PM

[*Mini Oral 6: Pharmacy & Pharmacology and Mechanical Circulatory Support *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

PHARM, HTX, ID, LTX, MCS

 

[*Chairs: *]

Peter J Bergin, MBBS, FRACP, and Walter Uber, PharmD

 

[*6:00 PM (182) *]Genotype-Guided Warfarin Dosing in Continuous-Flow Left-Ventricular Assist Device (CF-LVAD) Patients; _]D. L. Jennings^1^, R. C. Li1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda1, H. Takayama1, B. Cagliostro2, M. A. Flannery1, B. Toennes1, M. A. Farr1, D. M. Mancini1, Y. Naka1, P. C. Colombo1, V. K. Topkara1. [^1^]_]Columbia University Medical Center, New York, NY, 2New York Presbyterian Hospital, New York, NY

 

[*6:05 PM (183) *][Suppressive Antibiotics for LVAD-Associated Infections: Are They Helpful or Harmful?; _]S. Strout, T. Veasey, K. Rieger, C. Floroff, D. Wray, M. Brisco, J. Cook, M. Craig, J. Toole, A. Van Bakel, D. Heyward, W. Uber, H. Meadows. _Medical University of South Carolina, Charleston, SC

 

[*6:10 PM (184) *]CYP3A5 Pharmacogenetic Testing Predicts High Tacrolimus Dose Requirements Early after Cardiac Transplantation; _]K. M. Deininger^1^, A. Vu2, R. L. Page II3, A. V. Ambardekar4, J. Lindenfeld5, C. L. Aquilante1. [^1^]_]Pharmaceutical Sciences, University of Colorado, Aurora, CO, 2University of Pittsburgh, Pittsburgh, PA, 3Clinical Pharmacy, University of Colorado, Aurora, CO, 4Division of Cardiology, University of Colorado, Aurora, CO, 5Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN

 

[*6:15 PM (185) *]Carfilzomib-Rituximab Desensitization in Sensitized Heart Transplant Candidates: A Single Center Experience; _]P. Weeks^1^, A. Sieg1, M. Ling2, Y. Bai3, S. Nathan4, I. Rajapreyar4. [^1^]_]Pharmacy, Memorial Hermann – Texas Medical Center, Houston, TX, 2Transplant Immunology, University of Texas Health Science Center, Houston, TX, 3Pathology, University of Texas Health Science Center, Houston, TX, 4Center for Advanced Heart Failure, University of Texas Health Science Center, Houston, TX

 

[*6:20 PM (186) *][Early Experience with Carfilzomib as an Adjunct to Current Therapies for Donor Specific Antibodies After Lung Transplantation; _]T. L. Molina, K. L. Dawson, A. Fuentes, A. Goodarzi, J. Youssef, N. Sinha, T. Kaleekal. _Houston Methodist Hospital, Houston, TX

 

[*6:25 PM (187) *][Hepatitis B Immunity Prior to Lung Transplantation: Three Shots and You’re Out?; _]A. B. Cochrane, M. LoRusso, M. Fregoso, M. Bowen, S. Nathan, A. W. Brown. _Inova Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA

 

[*6:30 PM (188) *][Single Center Experience with Medical Therapy for Management of LVAD Pump Thrombosis; _]D. T. Majure, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, A. Pratt, E. J. Molina, L. M. Peters, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC

 

[*6:35 PM (189) *]Prospective Evaluation of Urine Dipstick for Detection of Significant Hemolysis in Outpatients on CF-LVAD Support; _]M. Gavalas^1^, A. Breskin2, A. B. Eisenberger1, M. Yuzefpolskaya1, A. R. Garan1, F. Castagna1, K. Wong1, M. Tiburcio3, R. Te-Frey3, J. Haythe1, D. M. Mancini1, H. Takayama3, K. Takeda3, Y. Naka3, V. K. Topkara1, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*6:40 PM (190) *]Fibrin Density and Platelet Location Varies Based on HeartMate II Thrombus Site; _]L. Baumann Kreuziger^1^, M. Slaughter2, K. Sundareswaran3, A. Mast1. [^1^]_]BloodCenter of Wisconsin, Milwaukee, WI, 2University of Louisville, Louisville, KY, 3Thoratec Corporation, Pleasanton, CA

 

[*6:45 PM (191) *]Clinical Predictors and Outcomes of Patients with Left Ventricular Assist Device Related Gastrointestinal Bleeding in the ROADMAP Study; _]K. B. Shah^1^, P. A. Uber1, J. G. Rogers2, V. Kasirajan1, J. S. Chuang3, D. J. Farrar3, J. D. Estep4. [^1^]_]Virginia Commonwealth Univ, Richmond, VA, 2Duke University, Durham, NC, 3St. Jude Medical, Pleasanton, CA, 4Houston Methodist Hospital, Houston, TX

 

[*6:50 PM (192) *][Increased Risk of Gastrointestinal Bleeding in HeartMate II Compared to HeartWare Left Ventricular Assist Devices – A Single Center Retrospective Cohort; _]W. T. Love, G. M. Zawadowski, J. Noelting, J. L. Horsley-Silva, L. L. Staley, M. E. Amity, L. Schroedl, M. D. Crowell, B. W. Hardaway, F. C. Ramirez, O. E. Pajaro. _Mayo Clinic Arizona, Scottsdale, AZ

 

[*6:55 PM (193) *]Early Heparin Bridging after Left Ventricular Assist Device Implantation Is Associated with Increased Length of Stay and a High Rate of Hospital Readmission; _]S. S. Roy^1^, J. Larson2, S. Phanco2, D. Ramu1, M. Bearns2, R. John3, R. Cogswell1. [^1^]_]Cardiology, University of Minnesota, Minneapolis, MN, 2University of Minnesota, Minneapolis, MN, 3Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

 

 

*ANNUAL MEETING SCIENTIFIC PROGRAM *

FRIDAY, APRIL 29, 2016

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 1: MCS Challenges and Engineering Solutions *]

 

Location:

Thurgood Marshall

 

[*Target Audience: *]

MCS, HF, HTX, MCS

 

[*Chairs: *]

Jan D. Schmitto, MD, PhD, MBA, and George M. Wieselthaler, MD

 

Session Summary: In this session the latest technologies and trends in MCS will be presented, with particular focus on challenges such as bleeding and thrombosis, new pump concepts and pump miniaturization, physiologic pump control or usability of peripherals.

 

7:00 AM

Flow, Shear and MCS Coagulopathies: Mechanisms, Design Implications, Next Steps

 

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

 

7:12 AM

Q & A

 

7:15 AM

Size Matters: Limitations and Drawbacks of Pump Miniaturization

 

Ulrich Steinseifer, PhD, University Hospital Aachen, Aachen, Germany

 

7:27 AM

Q & A

 

7:30 AM

What Technologies Will Be the Most Impactful to Reduce Adverse Events?

 

Scott C Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

 

7:42 AM

Q & A

 

7:45 AM

Smarter Pumps: Hemodynamic Monitoring and Physiological Control

 

Francesco Moscato, PhD, Medical Univ of Vienna, Vienna, Austria

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward *]

 

Location:

Salon 1

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Francisco Arabia, MD, and Susan M. Joseph, MD

 

Session Summary: Cardiogenic shock remains a clinical challenge with a high mortality despite advances in medical and surgical therapies. This session will describe techniques to evaluate and manage to promote improved outcomes.

 

7:00 AM

INTERMACS 0: Making A Case for Severe Refractory Cardiogenic Shock

 

Jaime A Hernandez-Montfort, MD MPH, Newark Beth Israel Medical Center, Newark, NJ, USA

 

7:12 AM

Q & A

 

7:15 AM

Choice of Support: Evidence Based or Expertise Driven?

 

Pranav Loyalka, MD, Memorial Hermann, Houston, TX, USA

 

7:27 AM

Q & A

 

7:30 AM

Friday Night Disaster: Considerations Before, During and After the OR

 

Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

 

7:42 AM

Q & A

 

7:45 AM

Transition from Acute Support to Durable Ventricular Support or Transplant: Challenges and Limitations

 

Bart Meyns, MD, PhD, KU Leuven, Leuven, Belgium

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy *]

 

Location:

Maryland Suite

 

[*Target Audience: *]

LTX, HF, HTX, LF, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Robin Vos, MD, PhD, and Cassie C. Kennedy, MD

 

Session Summary: This session will discuss the controversies in managing thoracic organ transplant candidates who have previously had cancer and in recipients who develop a malignancy after transplant.

 

7:00 AM

When is Malignancy a Contraindication To or Indication For Lung Transplantation?

 

David Weill, MD, Stanford University Medical Center, Stanford, CA, USA

 

7:12 AM

Q & A

 

7:15 AM

Cancer Screening Guidelines – Are They Good Enough for Thoracic Organ Transplant Recipients?

 

Monique Malouf, FRACP, St. Vincent’s Hospital, Sydney, Australia

 

7:27 AM

Q & A

 

7:30 AM

Lung Transplantation for Patients with Chronic GVHD Following Allogeneic Stem Cell Transplant

 

Sam Goldfarb, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

 

7:42 AM

Q & A

 

7:45 AM

Management of Patients with Unexpected Cancer in Explanted Lung or in the Pulmonary Allograft

 

Thomas K. Waddell, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 4: Let’s Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease *]

 

Location:

Virginia Suite

 

[*Target Audience: *]

PH, LTX, NHSAH, PEDS

 

[*Chairs: *]

Jacqueline R. Szmuszkovicz, MD, and Maurice Beghetti, MD

 

Session Summary: The aims of this session are to explain the classification and physiology of different congenital shunt lesions and to discuss indications and risks for shunt closure. Furthermore use of PAH therapies and timing of referral for transplantation for Eisenmenger’s syndrome and Fontan circulation will be discussed.

 

7:00 AM

Not Every Hole is Created Equal: Congenital Shunt Physiology, Classification, and the Association with Pulmonary Hypertension

 

Warren A. Zuckerman, MD, Columbia University Medical Center, New York, NY, USA

 

7:12 AM

Q & A

 

7:15 AM

ASD with PAH: To Close or Not to Close, That is the Question…

 

Dana P McGlothlin, MD, Kaiser San Francisco, San Francisco, CA, USA

 

7:27 AM

Q & A

 

7:30 AM

Feelin’ Blue: Advanced PAH Therapies for Eisenmenger’s Syndrome and Timing of Referral for Transplantation

 

Maurice Beghetti, MD, HUG Children’s University Hospital, Geneva, Switzerland

 

7:42 AM

Q & A

 

7:45 AM

The Fontan Under Pressure: a Role for PAH Therapies?

 

Alexander R Opotowsky, MD, Boston Children’s and Brigham & Women’s Hospital, Boston, MA, USA

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology *]

Location:

Delaware Suite

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Monica Colvin, MD, and Andrew E. Gelman, PhD

 

Session Summary: The goal of this symposium is to provide the clinical thoracic transplant professional with a basic yet clinically oriented overview of the immunobiology responsible for thoracic allograft injury after transplantation.

 

7:00 AM

Where Do We Start? Link Between Innate and Adaptive Immunity in Early Events After Transplantation

 

Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

 

7:15 AM

Q & A

 

7:20 AM

The Bat CAV: Mechanisms of the Vanishing Coronaries

 

Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany

 

7:35 AM

Q & A

 

7:40 AM

So CLAD You Came! Mechanisms of Chronic Lung Allograft Rejection

 

Lee Borthwick, RN, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

7:55 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections *]

 

Location:

Washington Ballroom 2

 

[*Target Audience: *]

ID, ALL

 

[*Chairs: *]

Kathleen L. Grady, PhD, APN, FAAN, and Margaret M. Hannan, MD

 

Session Summary: Nosocomial infections are a dreaded reality in critically ill patients either awaiting or following organ transplantation. This sessions will review antimicrobial stewardship practices, preventative clinical care strategies, and management options that decrease the rate of infections and improve outcomes in the hospital setting.

 

7:00 AM

Educate Before You Medicate: Antimicrobial Stewardship

 

Mary Bradbury, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

 

7:12 AM

Q & A

 

7:15 AM

An Ounce of Prevention is Worth a Pound of Cure: Infection Prevention

 

Valentina Stosor, MD, Northwestern University, Chicago, IL, USA

 

7:27 AM

Q & A

 

7:30 AM

Devices, SIRS and Open Chest – The Role of Antibiotics?

 

Angela Lorts, MD, Cincinnati Children’s Hosp, Cincinnati, OH

 

7:42 AM

Q & A

 

7:45 AM

Outbreak! Infection Clusters and the Transplant Center

 

Barbara D Alexander, MD, Duke University, Durham, NC, USA

 

7:57 AM

Q & A

 

 

8:00 AM – 10:00 AM

[*Plenary Session: Where is the Future for Innovation? *]

 

Location:

Salons 2-3

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

John Dark, MB, FRCS, and Lori J. West, MD, DPhil

 

8:00 AM

Innovation in an Age of Risk Adversity and Regulation

 

Robert M Califf, MD, US Food and Drug Administration, Washington, DC, USA

 

8:25 AM

[(194) FEATURED ABSTRACT: *]*Functional Assessment of the Donor Heart Following Circulatory Death and Clinical Transplantation;[* *]S. Messer^1^, R. Axell2, S. Colah1, P. White2, A. Page1, B. Parizkova1, K. Valchanov1, J. Dunning1, J. Parameshwar1, A. Ali1, S. Tsui1, S. Large1. 1Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, 2Medical Physics, Addenbrookes Hospital, Cambridge, United Kingdom

 

8:35 AM

Expert Discussant Q & A

 

Kumud K Dhital, MD, PhD, St Vincent’s Hospital, Sydney, Australia

 

8:40 AM

Cell Therapy for Advanced Lung Disease: Pathway to the Clinic

 

Dennis Wigle, MD, Mayo Clinic, Rochester, MN, USA

 

9:00 AM

(195) FEATURED ABSTRACT: *][*A Study of Donor Ex-Vivo Lung Perfusion in UK Lung Transplantation (DEVELOP-UK);

A. J. Fisher^1^, N. Yonan2, J. Mascaro3, N. Marczin4, S. Tsui5, A. Simon6, J. Dark1, & on behalf of the DEVELOP-UK Investigators7. 1Institute of Transplantation, Newcastle University, Newcastle Upon Tyne, United Kingdom, 2Wythenshawe Hospital, Manchester, United Kingdom, 3Queen Elizabeth Hospital, Birmingham, United Kingdom, 4Imperial College, London, United Kingdom, 5Papworth Hospital, Cambridge, United Kingdom, 6Harefield Hospital, London, United Kingdom, 7All Adult, Lung Transplant Centres,* *United Kingdom

 

9:10 AM

Expert Discussant Q & A

 

Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

 

9:15 AM

Research and Innovation by Crowdfunding

 

Denny Luan, Experiment, San Francisco, CA, USA

 

9:35 AM

Minimizing the Risk of Preventable Patient Deaths

 

Michael Shabot, MD, Memorial Hermann Health System, Houston, TX, USA

 

 

10:30 AM – 12:00 PM

[*Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management *]

 

Location:

Salons 2-3

[*Target Audience: *]

MCS, HF, NHSAH

 

[*Chairs: *]

Ugolino Livi, MD, and George Javorsky, MBBS, FRACP

 

[*10:30 AM (196) *][Invasive Hemodynamic Ramp Test: A Comparison of Ventricular Unloading between Current Generation Continuous-Flow LVADs; _]K. Abdullah, N. Badoe, S. Phillips, J. Nabut, R. Singh, S. S. Desai, P. Shah. _Inova Heart and Vascular Institute, Falls Church, VA

 

[*10:45 AM (197) *]HVAD Waveform as a Surrogate Marker of Cardiac Index and Pulmonary Capillary Wedge Pressure; _]J. Grinstein^1^, D. E. Rodgers1, S. Kalantari Tannenbaum1, S. Adatya1, N. Sarswat1, G. H. Kim1, G. Sayer1, T. Ota1, V. Jeevanandam1, V. Mor-Avi1, D. Burkhoff2, N. Uriel1. [^1^]_]University of Chicago, Chicago, IL, 2Columbia University, New York, NY

 

[*11:00 AM (198) *]LVAD Device Design Features and Operational Settings Minimize von Willebrand Factor Degradation; _]J. Kang1, D. Zhang1, T. Motomura2, M. Acker1, P. Atluri1, C. R. Bartoli^1^. [^1^]_]University of Pennsylvania, Philadelphia, PA, PA, 2EVAHEART, Houston, TX, TX

 

[*11:15 AM (199) *]Impact of Aortic Valve Closure on Adverse Events and Outcomes with the HeartWare HVAD; _]D. Dobarro^1^, M. Urban2, K. Booth2, N. Wrightson2, J. Castrodeza1, J. Jungschleger2, N. Robinson-Smith2, A. Woods2, G. Parry3, S. Schueler2, G. MacGowan3. [^1^]_]Cardiology, Hospital Clinico Universitario de Valladolid and Newcastle Freeman Hospital, Valladolid, Spain, 2Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

[*11:30 AM (200) *]Competing Flow Between Partial Circulatory Support and Native Cardiac Output: A Computational Fluid Dynamics-Study; _]J. Engelke^1^, A. Popov2, A. R. Simon3, S. Partovi4, M. Karck1, F. Rengier5, A. Weymann1, P. W. Raake6, A. Doesch6, J. Lotz7, C. Karmonik8, A. Ruhparwar1. [^1^]_]Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, 2Royal Brompton & Harefield NHS Foundation Trust, Harefield, United Kingdom, 3Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield, United Kingdom, 4Department of Radiology, University Hospitals Case Medical Center, Cleveland, OH, 5Department of Radiology, University Hospital Heidelberg, Heidelberg, Germany, 6Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany, 7Department of Radiology, University Hospital Goettingen, Goettingen, Germany, 8Translational Imaging MRI Core, Houston Methodist Research Institute, Houston, TX

 

[*11:45 AM (201) *][Minimally Invasive Exchange of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD) to the Intrapericardial HeartWare Ventricular Assist Device (HVAD); _]B. Soleimani, B. Burk, E. Stephenson, W. Pae. _Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA

 

 

10:30 AM – 12:00 PM

[*Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, HF, NHSAH, PHARM

 

[*Chairs: *]

Anna L Meyer, MD, and Ulrich Jorde, MD

 

[*10:30 AM (202) *][Use of Long Acting Octreotide in an Outpatient Clinic Reduces the Rate of Gastro-Intestinal Bleeding in Continuous Flow LVAD Patients; _]C. Juricek, V. Kagan, H. Ruedlinger, W. Lee. _Cardiac Surgery, University of Chicago, Chicago, IL

 

[*10:45 AM (203) *]Serial Evaluation of Von Willebrand Factor Performance with a Fully Magnetically Levitated Centrifugal Continuous Flow Left Ventricular Assist Device; _]I. Netuka^1^, J. Kvasnička2, T. Kvasnička2, I. Hrachovinová^3^, P. Ivák1, J. Bílková^2^, I. Malíková^2^, M. Jančová^4^, F. Mareček3, J. Malý^1^, J. M. Connors5, M. R. Mehra6. [^1^]_]Cardiac Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, 2Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of The General University Hospital and of The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic, 3NRL for Hemostasis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic, 4Laboratory Methods, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, 5Hematology, Brigham Womens Hospital, Boston, MA, 6Heart and Vascular Center, Brigham and Women’s Hospital, Boston, MA

 

[*11:00 AM (204) *]Danazol for the Treatment of Gastrointestinal Bleeding in Left Ventricular Assist Device (LVAD) Patients: A Multicenter Experience; _]S. Schettle^1^, B. Al Bawardy2, S. Sherazi3, C. Cheyne3, S. Kushwaha4, E. Rajan2, N. Pereira4. [^1^]_]Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN, 2Gastroenterology, Mayo Clinic Rochester, Rochester, MN, 3Cardiovascular Surgery, University of Rochester Medical Center, Rochester, NY, 4Cardiology, Mayo Clinic Rochester, Rochester, MN

 

[*11:15 AM (205) *][Vascular Abnormalities of the Nasal Mucosa Are Associated with Gastrointestinal Bleeding During Continuous Flow LVAD Support; _]S. R. Patel, O. Saeed, S. Madan, M. Algodi, A. Luke, M. Gibber, D. J. Goldstein, U. P. Jorde. _Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

 

[*11:30 AM (206) *]Warfarin Sensitive Patients Have Higher Risk of Gastrointestinal Bleeding and Device Thrombosis on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support; _]V. K. Topkara^1^, A. B. Eisenberger1, R. Knotts1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Li1, J. A. Fried1, F. Castagna1, B. Cagliostro1, M. Tiburcio2, D. M. Mancini1, Y. Naka2, P. C. Colombo1, U. P. Jorde3. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY, 3Medicine, Montefiore Medical Center, New York, NY

 

[*11:45 AM (207) *][Predictors of Out-of-Therapeutic-Range INR during Support with Continuous-Flow Left Ventricular Assist Device; _]M. Yin, W. Schultz, Y. Ko, R. T. Cole, D. Gupta, S. Laskar, A. Smith, D. Vega, D. Nguyen, A. Pekarek, K. Wittersheim, A. Morris. _Emory University School of Medicine, Atlanta, GA

 

 

10:30 AM – 12:00 PM

[*Concurrent Session 23: Choosing a Gift: Donor Selection *]

 

Location:

Salon 1

[*Target Audience: *]

HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Luciano Potena, MD, PhD, and David A Baran, MD

 

[*10:30 AM (208) *][Early Results of Heart Transplantation Using Donation after Circulatory Death Donors; _]M. B. Connellan, H. Chew, A. Iyer, A. Watson, C. Soto, A. Dinale, P. Nair, E. Granger, P. Jansz, A. Jabbour, E. Kotlyar, A. Keogh, C. Hayward, P. Spratt, P. MacDonald, K. Dhital. _Heart and Lung Transplant Unit, St. Vincent ‘s Hospital, Sydney, Australia

 

[*10:45 AM (209) *][Heart Transplantation from Donors Outside Standard Acceptability Criteria Using Ex-Vivo Normothermic Preservation; _]D. García Sáez, B. Zych, P. Mohite, A. Sabashnikov, F. De Robertis, A. F. Popov, T. Bahrami, N. R. Banner, A. R. Simon. _Heart Lung Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom

 

[*11:00 AM (210) *][Utility of Heart Transplant by Waitlist Mortality and Donor/Recipient Match; _]V. Nguyen, J. Beckman, R. Cheng, W. Levy, C. Mahr, N. Mokadam, J. Pal, T. Dardas. _University of Washington, Seattle, WA

 

[*11:15 AM (211) *]High Donor Sequence Number Grafts Can Be Safely Transplanted into Select Patients; _]J. J. Squiers^1^, G. Saracino2, T. Chamogeorgakis3, J. C. MacHannaford3, A. E. Rafael3, G. V. Gonzalez-Stawinski3, S. A. Hall4, J. M. DiMaio1, B. Lima3. [^1^]_]Baylor Research Institute, Baylor Scott & White Health, Dallas, TX, 2Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, 3Cardiac and Thoracic Surgery, Baylor University Medical Center, Dallas, TX, 4Cardiology, Baylor University Medical Center, Dallas, TX

 

[*11:30 AM (212) *][Too Much Information: Interaction of Donor Sequence and Acceptance in the UNOS Database; _]D. A. Baran, K. Liaquat, J. Pieretti, C. Gidea, M. Munagala, M. Camacho, C. Patel, M. Divita, M. J. Zucker. _Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ

 

[*11:45 AM (213) *]Intermediate Outcomes with Ex-Vivo Allograft Perfusion for Heart Transplantation; _]F. Esmailian^1^, J. L. Chan2, H. Reich2, D. Ramzy2, M. Thottam3, Z. Xu3, T. Aintablian3, F. Liou3, J. Patel3, M. Kittelson3, L. S. Czer3, A. Trento2, J. Kobashigawa3. [^1^]_]Cedars-Sinai Heart Institute, Los Angeles, CA, 2Surgery, Cedars-Sinai Heart Institute, Los Angeles, CA, 3Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA

 

 

10:30 AM – 12:00 PM

Concurrent Session 24: What’s New in Primary Graft Dysfunction Post Lung Transplantation

 

Location:

Virginia Suite

[*Target Audience: *]

LTX, BSI, ID, LBCS, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Jason D Christie, MD, and Helen M Whitford, MBBS, FRACP

 

[*10:30 AM (214) *]Plasma RIP3 Is Decreased in PGD after Lung Transplantation; _]C. D’Errico^1^, M. Hotz1, E. Cantu1, M. Porteous1, M. Oyster1, R. Shah2, S. Arcasoy3, L. Snyder4, K. M. Wille5, M. Hartwig4, L. B. Ware6, P. Shah7, M. Crespo8, C. Hage9, A. Weinacker10, V. Lama11, Y. Suzuki1, J. Orens7, S. Kawut1, S. Palmer4, D. J. Lederer3, J. D. Christie1, N. Mangalmurti1, J. M. Diamond1. [^1^]_]University of Pennsylvania, Philadelphia, PA, 2University of California San Francisco, San Francisco, CA, 3Columbia University, New York, NY, 4Duke University, Durham, NC, 5University of Alabama Birmingham, Birmingham, AL, 6Vanderbilt University, Nashville, TN, 7Johns Hopkins University, Baltimore, MD, 8University of Pittsburgh, Pittsburgh, PA, 9Indiana University, Indianapolis, IN, 10Stanford University, Stanford, CA, 11University of Michigan, Ann Arbor, MI

 

[*10:45 AM (215) *]Role of Donor Microbiota in the Development of Primary Graft Dysfunction Following Human Lung Transplantation; _]Z. Xu^1^, R. Schuessler1, D. Nayak1, W. Yang2, E. Trulock3, A. Patterson1, D. Kreisel1, R. Hachem3, T. Mohanakumar4. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Genetics, Washington University School of Medicine, St. Louis, MO, 3Medicine, Washington University School of Medicine, St. Louis, MO, 4Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

[*11:00 AM (216) *]Profiling Biomarkers of Inflammation and Tissue Injury during Human Ex Vivo Lung Perfusion in the DEVELOP-UK Study; _]A. Andreasson^1^, N. Yonan2, J. E. Fildes3, J. Mascaro4, N. Marczin5, S. Tsui6, A. Simon7, J. H. Dark1, A. J. Fisher1 , &. on behalf of the DEVELOP-UK Investigators 8. [^1^]_]Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2University Hospital of South Manchester, Manchester, United Kingdom, 3Machester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, United Kingdom, 4Queen Elizabeth Hospital, Birmingham, United Kingdom, 5Imperial College, London, United Kingdom, 6Papworth Hospital, Cambridge, United Kingdom, 7Harefield Hospital, London, United Kingdom, 8All Adult Lung Transplant Centers, United Kingdom

 

[*11:15 AM (217) *]Warm Ischemic Time (WIT) Measurements Do Not Correlate with Early Lung Allograft Function: Analysis from the Australian Donation after Circulatory Death (DCD) Lung Transplant (LTx) Collaborative; _]B. Levvey^1^, M. Harkess2, D. Chambers3, S. Lawrence4, M. Musk4, P. Hopkins3, A. Glanville2, G. Snell1. [^1^]_]Alfred Hospital, Melbourne, Australia, 2St Vincent’s Hospital, Sydney, Australia, 3Prince Charles Hospital, Brisbane, Australia, 4Royal Perth /Fiona Stanley Hospital, Perth, Australia

 

[*11:30 AM (218) *]Down Regulation of microRNA-21 Is Significantly Associated with Signaling and Activation of the Toll-Like Receptor in Human Lung Transplant Recipients with Primary Graft Dysfunction; _]Z. Xu^1^, A. Gelman1, R. Hachem2, T. Mohanakumar3. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Medicine, Washington University School of Medicine, St. Louis, MO, 3Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

[*11:45 AM (219) *]Redefining Primary Graft Dysfunction after Lung Transplantation; _]E. Cantu^1^, J. Diamond1, J. Nellen1, B. Beduhn1, Y. Suzuki1, C. Borders1, J. Lasky1, C. Schaufler1, R. Shah1, M. Porteous1, D. J. Lederer2, S. M. Kawut1, S. Arcasoy2, S. M. Palmer3, L. Snyder3, M. G. Hartwig3, V. N. Lama4, M. Crespo5, K. Wille6, J. Orens7, P. D. Shah7, A. Weinacker8, L. B. Ware9, S. L. Bellamy1, J. D. Christie1. [^1^]_]University of Pennsylvania, Philadelphia, PA, 2Columbia University College of Physicians and Surgeons, New York, NY, 3Duke University Medical Center, Durham, NC, 4University of Michigan, Ann Arbor, MI, 5University of Pittsburgh, Pittsburgh, PA, 6University of Alabama at Birmingham, Birmingham, AL, 7Johns Hopkins University Hospital, Baltimore, MD, 8Stanford University, Palo Alto, CA, 9Vanderbilt University, Nashville, TN

 

  • *

10:30 AM – 12:00 PM

[*Concurrent Session 25: Beyond Adherence: What’s New Out There? *]

Location:

Delaware Suite

[*Target Audience: *]

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM

 

[*Chairs: *]

Connie White-Williams, RN, PhD, and Christiane Kugler, PhD

 

[*10:30 AM (220) *][Impact of Early Adoption of Affordable Care Act Medicaid Expansion on Heart Transplant Listings in the United States; _]S. G. Al-Kindi, M. Farhoud, M. Sabeh, M. Ginwalla, C. ElAmm, M. Zacharias, R. D. Benatti, M. Kattea, S. Deo, B. Sareyyupoglu, B. Medalion, S. Park, G. H. Oliveira. _Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH

 

[*10:45 AM (221) *]Medical Adherence in the Late-Term after Lung Transplant; _]K. R. Fox1, A. J. DeVito Dabbs2, A. F. DiMartini3, D. M. Posluszny4, E. M. Rosenberger5, J. M. Pilewski4, M. A. Dew^3^. [^1^]_]Psychology, Ohio University, Athens, OH, 2Acute and Tertiary Care Nursing, Univ of Pittsburgh Sch Nursing, Pittsburgh, PA, 3Psychiatry, Univ of Pittsburgh Sch Med, Pittsburgh, PA, 4Medicine, Univ of Pittsburgh Sch Med, Pittsburgh, PA, 5Clinical and Translational Science Institute, Univ of Pittsburgh Sch Med, Pittsburgh, PA

 

[*11:00 AM (222) *]Adequate Health Literacy Is Associated with Sufficient Physical Activity: Findings from the BRIGHT Study; _]M. I. Cajita^1^, K. Denhaerynck2, F. Dobbels3, L. Berben2, C. L. Russell4, S. De Geest2. [^1^]_]School of Nursing, Johns Hopkins University, Baltimore, MD, 2Institute of Nursing Science, Universität Basel, Basel, Switzerland, 3Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium, 4School of Nursing and Health Studies, University of Missouri, Kansas City, MO

 

[*11:15 AM (223) *]Testing the Efficacy of a Multicomponent Theory-Based Tailored Behavioral Medication Adherence Intervention in Transplantation: The MAESTRO-TX RCT; _]F. Dobbels^1^, L. De Bleser1, L. Berben2, P. Kristanto3, L. Dupont4, F. Nevens5, J. Vanhaecke6, G. Verleden7, S. De Geest2. [^1^]_]Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium, 2Institute of Nursing Science, University of Basel, Basel, Switzerland, 3Aardex Group, Meadwestveco Healthcare Company, Visé, Belgium, 4Lung Transplantation Program, University Hospitals of Leuven, Leuven, Belgium, 5Liver Transplant Program, University Hospitals of Leuven, Leuven, Belgium, 6Heart Transplantation Program, University Hospitals of Leuven, Leuven, Belgium, 7Lung Transplant Program, University Hospitals of Leuven, Leuven, Belgium

 

[*11:30 AM (224) *]Self-Efficacy and Adherence Are Predictors of Quality of Life in Patients with Left Ventricular Assist Devices; _]J. Casida^1^, H. Wu2, V. Senkiv1, J. Yang1. [^1^]_]School of Nursing, University of Michigan, Ann Arbor, MI, 2Office of Nursing Research, Barnes-Jewish College School of Nursing, St. Louis, MO

 

[*11:45 AM (225) *]A Multicenter Quality of Life (QoL) Survey Regarding LVAD Drivelines: A Look Beyond the Medical Aspects; _]L. J. Bogar^1^, S. Phillips2, F. D. Pagani3, N. A. Haglund4, J. A. Cowger5, S. Maltais6, A. Ravichandran7, J. M. Stulak6, M. Binetti8, M. Lefebvre9, S. E. Womak4, P. Shah2. [^1^]_]Cardiac Surgery, Inova Fairfax Heart and Vascular Institute, Falls Church, VA, 2Heart Failure and Transplantation, Inova Fairfax Heart and Vascular Institute, Falls Church, VA, 3Cardiac Surgery, University of Michigan Hospital, Ann Arbor, MI, 4Cardiolgy, Vanderbilt, Nashville, TN, 5Cardiology, St. Vincent Heart Center of Indiana, Indianapolis, IN, 6Cardiac Surgery, Mayo Clinic, Rochester, MN, 7Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN, 8Advanced Heart Failure and Transplant, Inova Fairfax Heart and Vascular Institute, Falls Church, VA, 9Cardiolgy, University of Michigan Hospital, Ann Arbor, MI

 

 

10:30 AM – 12:00 PM

[*Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The *]

[*Anti-Body? *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

BSI, HTX, LTX, MCS, PEDS

 

[*Chairs: *]

Marilia Cascalho, MD, PhD, and John R Greenland, MD, PhD

 

[*10:30 AM (226) *]Left-Ventricular Assist Device Is Associated with Elevated Serum Levels of Natural IgG Reactive to Apoptotic Cells and Oxidized Epitopes; _]S. B. See^1^, P. J. Kennel2, M. Weber2, K. Rogers1, D. Chatterjee1, Y. Gu1, G. Vlad3, K. J. Clerkin2, V. K. Topkara2, P. C. Colombo2, D. M. Mancini2, Y. Naka4, M. A. Farr2, E. R. Vasilescu3, S. W. Restaino2, P. C. Schulze2, E. Zorn1. [^1^]_]Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY, 2Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, 3Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 4Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY

 

[*10:45 AM (227) *]T-Cell Dependence of Antibody Response to Blood Group A-Antigen; _]I. Adam^1^, B. Motyka2, K. Tao2, J. Pearcey2, L. West3. [^1^]_]Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada, 2Pediatrics, University of Alberta, Edmonton, AB, Canada, 3Depts. of Pediatics, Surgery, and Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada

 

[*11:00 AM (228) *][Exosomes from Rejected Syngeneic Cardiac Grafts Express Myosin and Vimentin and Immunoregulatory miRNA and Induce Graft Rejection; _]M. Sharma, M. Gunasekaran, Z. Xu, W. Liu, N. Benshoff, T. Mohanakumar. _Surgery, Washington University, St. Louis, MO

 

[*11:15 AM (229) *]NK Cells Require the Secretion of Interferon- to Mediate Allograft Vasculopathy in a Model of Antibody-Mediated Chronic Rejection; _]C. M. Lin^1^, R. J. Plenter1, R. G. Gill2. [^1^]_]Medicine, University of Colorado, Denver – Anschutz Medical Campus, Aurora, CO, 2Surgery, University of Colorado, Denver – Anschutz Medical Campus, Aurora, CO

 

[*11:30 AM (230) *]Bortezomib and ONX0914 in Experimental Heart Transplantation; _]M. Waechter1, J. Abicht2, B. Reichart3, J. Kindermann1, M. C. Langenmayer4, T. Mayr5, P. Brenner1, C. Hagl1, P. Beck6, M. Groll6, R. Wanke7, S. Guethoff^8^. [^1^]_]Department of Cardiac Surgery, Ludwig-Maximilians-Universität München, Munich, Germany, 2Department of Anaesthesiology,, Ludwig-Maximilians-Universität München, Munich, Germany, 3Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-Universität München, Munich, Germany, 4Institute of Veterinary Pathology and Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, Munich, Germany, 5Department of Anaesthesiology, Ludwig-Maximilians-Universität München, Munich, Germany, 6Munich Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Munich, Germany, 7Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany, 8Department of Cardiac Surgery and Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-Universität München, Munich, Germany

 

[*11:45 AM (231) *]Ibrutinib Suppresses De Novo Alloantibodies and Recall Antibody Responses in a Mouse Model of Allosensitization: A Preliminary Report; _]G. D. Wu, I. Kim, N. Chai, A. S. Klein, S. Jordan. [_Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

 

 

10:30 AM – 12:00 PM

[*Symposium 30: JHLT at ISHLT: The Year in a Capsule *]

 

Location:

Maryland Suite

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Jonathan N Johnson, MD, and Maryl R. Johnson, MD

 

Session Summary: This session will highlight the most exciting publications in JHLT over the past year, followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

 

10:30 AM

Introduction and Recognition of Top Papers of the Year

 

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women’s Hospital, Boston, MA, USA

 

10:40 AM

Highlights of Heart Transplantation and Mechanical Circulatory Support

 

Eugene C DePasquale, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

 

10:55 AM

EXPERT DISCUSSANT: Highlights of Heart Transplantation and Mechanical Circulatory Support

 

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

 

11:00 AM

Highlights of Lung Transplantation

 

Howard J. Huang, MD, Baylor University Medical Center, Dallas, TX, USA

 

11:15 AM

EXPERT DISCUSSANT: Highlights of Lung Transplantation

 

John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

11:20 AM

Highlights of Pediatric Heart and Lung Transplantation

 

Ranny Goldwasser, MD, University Hospital Heidelberg, Heidelberg, Germany

 

11:35 AM

EXPERT DISCUSSANT: Highlights of Pediatric Heart and Lung Transplantation

 

David Morales, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

 

11:40 AM

Highlights of Pulmonary Hypertension

 

Bradley Maron, MD, Brigham and Women’s, Boston, MA, USA

 

11:55 AM

EXPERT DISCUSSANT: Highlights of Pulmonary Hypertension

 

Myung H. Park, MD, Houston Methodist, Houston, TX, USA

2:00 PM – 3:30 PM

[*Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS *]

 

Location:

Salons 2-3

[*Target Audience: *]

MCS, HF, NHSAH, PH

 

[*Chairs: *]

Ivan Netuka, MD, PhD, and Daniel J. Goldstein, MD

 

[*2:00 PM (232) *]Risk Factors Associated with Right Ventricular Assist Device Implantation: Insights from INTERMACS; _]M. S. Kiernan^1^, D. DeNofrio1, D. T. Pham2, N. K. Kapur1, R. Ruthazer3, E. W4, J. E. Rame4, P. Alturi4, E. Y. Birati4, S. L. Myers5, G. H. Oliveira6, J. K. Kirklin5, R. L. Kormos7, F. D. Pagani8, J. Teuteberg7. [^1^]_]Cardiology, Tufts Medical Center, Boston, MA, 2Cardiology, Northwestern University Medical Center, Chicago, IL, 3Tufts Clinical and Translational Science Institute, Boston, MA, 4University of Pennsylvania, Philedelphia, PA, 5University of Alabama, Birmingham, Birmingham, AL, 6Case Western Reserve University, Cleveland, OH, 7University of Pittsburg Medical Center, Pittsburg, PA, 8University of Michigan, Ann Arbor, MI

 

[*2:15 PM (233) *]A Novel, Highly Discriminatory Risk Model Predicting Acute Severe Right Ventricular Failure in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implant; _]V. Tchantchaleishvili^1^, S. Maltais2, N. A. Haglund3, M. E. Davis3, J. Cowger4, P. Shah5, K. D. Aaronson6, F. D. Pagani6, S. M. Dunlay2, J. M. Stulak2. [^1^]_]University of Rochester, Rochester, NY, 2Mayo Clinic, Rochester, MN, 3Vanderbilt University, Nashville, TN, 4St.Vincent Medical Group, Indianapolis, IN, 5Inova Fairfax Hospital, Falls Church, VA, 6University of Michigan, Ann Arbor, MI

 

[*2:30 PM (234) *]Chemokine Receptor Down Regulation in Mechanical Circulatory Support Patients with Right Ventricular Failure; _]A. Nayak^1^, T. N. Bachman2, K. Hanley-Yanez3, C. McTiernan2, D. McNamara3, R. L. Kormos3, O. Hunter4, A. Inashvili1, L. Lagazzi3, J. Teuteberg3, M. A. Simon3. [^1^]_]Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 3Heart and Vascular Institute at UPMC Presbyterian, University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh Medical School, University of Pittsburgh, Pittsburgh, PA

 

[*2:45 PM (235) *][Biventricular Bridge to Transplant: Total Artificial Heart (TAH) vs Thoratec Paracorporeal VADs (PVADs) Outcomes Post Heart Transplant (HT); _]E. C. DePasquale, A. Salimbangon, E. Howell, A. Chang, A. Nsair, A. Ardehali. _David Geffen Sch Med, Los Angeles, CA

 

[*3:00 PM (236) *]Early Results of Biventricular Support with Durable, Intracorporeal Continuous Flow Centrifugal Ventricular Assist Devices: Analysis from INTERMACS; _]F. Arabia^1^, C. A. Milano2, C. Mahr3, E. C. McGee Jr.4, S. Maltais5, S. W. Boyce6, V. Pretorius7, A. B. Civitello8, H. R. Mallidi9, N. A. Mokadam10, J. E. Rame11, D. C. Naftel12, S. L. Myers12, J. K. Kirklin12. [^1^]_]Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, 2Duke University Medical Center, Durham, NC, 3University of Washington, Seattle, WA, 4Loyola University Medical Center, Maywood, IL, 5Mayo Clinic, Rochester, MN, 6Washington Hospital Center, Washington, DC, 7University of California at San Diego Medical Center, La Jolla, CA, 8Baylor St. Luke’s Medical Center, Houston, TX, 9Brigham and Women’s Hospital, Boston, MA, 10University of Washington Medical Center, Seattle, WA, 11Penn Heart and Vascular Center, Philadelphia, PA, 12University of Alabama at Birmingham, Birmingham, AL

 

[*3:15 PM (237) *]Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events in Intermacs; _]F. Arabia^1^, I. Gregoric2, V. Kasirajan3, J. D. Moriguchi4, D. C. Naftel5, S. L. Myers5, J. K. Kirklin5. [^1^]_]Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, 2University of Texas Health Science Center Houston, Houston, TX, 3Virginia Commonwealth University Medical Center, Richmond, VA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 28: Pump Thrombosis: What’s Hot with the Clot *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, HF, NHSAH

 

[*Chairs: *]

Andrew J Boyle, MD, and Andre R Simon, MD, PhD

 

[*2:00 PM (238) *][Outcomes of Medical and Surgical Therapy for Patients with Left Ventricular Assist Device Pump Thrombosis; _]D. T. Majure, F. H. Sheikh, S. I. Ahmed, M. E. Rodrigo, R. K. Young, T. I. Elliott, E. J. Molina, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC

 

[*2:15 PM (239) *]Diagnosis and Treatments of Three Different Types of Blood Flow Abnormalities in Patients Supported with HeartWare HVAD: Analysis of More Than 600 Cases; _]A. Scandroglio^1^, F. Kaufmann2, M. Pieri1, A. Kretzschmar2, M. Muller2, P. Pergantis2, S. Dreysse3, V. Falk2, T. Krabatsch2, E. Potapov2. [^1^]_]Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy, 2Department for Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 3Department of Internal Medicine-Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

 

[*2:30 PM (240) *][Does High Blood Pressure Early Post LVAD Implant Increase the Risk of Pump Thrombosis?; _]A. K. Johnson, R. McCubrey, N. C. Ridge, A. Rauf, H. H. Choi, A. C. Millers, S. Stoker, R. Alharethi, W. T. Caine, D. Budge, B. Y. Rasmusson, K. Afshar, B. B. Reid, A. G. Kfoury. _Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT

 

[*2:45 PM (241) *][Utility of Echocardiography in Defining Inflow Cannula Malposition in Left Ventricular Assist Device and the Association with Adverse Outcome; _]M. Kassi, C. Eshelbrenner, J. Amione-Guerra, J. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX

 

[*3:00 PM (242) *]Micro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices; _]K. Dimitrov^1^, J. Riebandt1, T. Haberl1, D. Wiedemann1, P. Simon1, R. Moayedifar1, T. Schlöglhofer1, G. Necid1, C. Gross2, M. Maw2, H. Schima2, G. Laufer1, D. Zimpfer1. [^1^]_]Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria

 

[*3:15 PM (243) *]Hemolysis Does Not Lead to Increased Discordance between Measured APTT and ANTI-XA Levels in Patients with Continuous-Flow Left Ventricular Assist Devices; _]V. K. Topkara^1^, A. B. Eisenberger1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, D. Jennings1, R. Givens1, J. Fried1, K. Wong1, M. Torres2, K. Ross2, G. Parkis1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV *]

 

Location:

Salon 1

[*Target Audience: *]

HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Sonia Mirabet, MD, and Vivek Rao, MD, PhD

 

[*2:00 PM (244) *]Myocardial Capillary Loss in Cardiac Allograft Vasculopathy: A Longitudinal Case-Control Study; _]D. Budge^1^, M. Revelo2, K. D. Brunisholz3, E. H. Hammond2, A. G. Kfoury1, R. Alharethi1, K. Afshar1, J. R. Doty4, T. A. Jensen5, J. C. Fang1, J. Stehlik1, E. Gilbert1, C. H. Selzman4, K. M. Molina6, D. V. Miller2. [^1^]_]Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 2Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 3Biostatistics, UTAH Cardiac Transplant Program, Salt Lake City, UT, 4Cardiac Surgery, UTAH Cardiac Transplant Program, Salt Lake City, UT, 5Intermountain Biorepository, UTAH Cardiac Transplant Program, Salt Lake City, UT, 6Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT

 

[*2:15 PM (245) *]Development of a Clinical Prediction Model for Cardiac Allograft Vasculopathy: Comparison of Three Mutlivariate Methods; _]E. P. Kransdorf^1^, N. A. Loghmanpour2, M. K. Kanwar3, M. H. Temkit4, J. Stehlik5. [^1^]_]Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, 2Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 3Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 4Division of Health Sciences Research, Mayo Clinic Arizona, Scottsdale, AZ, 5Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT

 

[*2:30 PM (246) *]Incremental Value to Coronary Angiography by Optical Coherence Tomography for Detection and Interpretation of Cardiac Allograft Vasculopathy; _]T. S. Clemmensen^1^, H. Eiskjær1, N. R. Holm1, B. B. Løgstrup1, E. H. Christiansen1, C. J. Terkelsen1, M. Maeng1, J. Dijkstra2, S. H. Poulsen1. [^1^]_]Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark, 2Division of Image Processing, Leiden University Medical Center, Leiden, Netherlands

 

[*2:45 PM (247) *]Circulating Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and miRNA Are Induced in Cardiac Transplant Recipients with Cardiac Allograft Vasculopathy; _]M. Sharma^1^, Z. Xu1, N. Steward1, T. Mohanakumar2. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

[*3:00 PM (248) *]Early Use of Antiplatelet Therapy and Development of Cardiac Allograft Vasculopathy: A 5 Year Outcomes Analysis; _]M. Kim, M. R. Mehra, G. C. Stewart, G. S. Couper, D. S. Page, E. L. Woodcome, J. A. Smallwood, S. Gabardi, M. M. Givertz. [_Brigham & Women’s Hospital, Boston, MA

 

[*3:15 PM (249) *]Utility of sAXL, hs-cTnT , Lp-PLA2, GDF-15 Biomarkers and Th1/Treg Ratio in the Detection of Cardiac Allograft Vasculopathy; _]S. Mirabet^1^, P. Gacia de Frutos2, J. Ordóñez3, V. Brossa1, L. Lopez1, C. Gelpi4, A. Ferrero1, E. Sole1, A. Sionis1, J. Cinca1, J. Padro5, E. Roig1. [^1^]_]Cardiology, Hospital Sant Pau, Barcelona, Spain, 2Institut d’Investigacions Biomèdiques de Barcelona, IIBB-CSIC, Barcelona, Spain, 3Bioquimca, Hospital Sant Pau, Barcelona, Spain, 4Immunology, Hospital Sant Pau, Barcelona, Spain, 5Cardiac Surgery, Hospital Sant Pau, Barcelona, Spain

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation *]

 

Location:

Maryland Suite

[*Target Audience: *]

LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Bryan A Whitson, MD, and Dirk Van Raemdonck, MD, PhD

 

[*2:00 PM (250) *]Treating Donor Lung Inflammation by Blocking Interleukin-1Β – An In Vitro Therapy Testing Platform for Ex Vivo Lung Perfusion; _]A. Andreasson^1^, D. Karamanou1, C. Gillespie2, L. Borthwick3, K. Jiwa1, P. Henderson1, F. Özalp1, T. Butt1, S. C. Clark1, H. Pauli1, P. A. Corris1, S. Ali3, J. H. Dark1, A. J. Fisher1. [^1^]_]Institute of Transplantation, Newcastle upon Tyne, United Kingdom, 2School of Mathematics & Statistics, Newcastle University, Newcastle upon Tyne, United Kingdom, 3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

 

[*2:15 PM (251) *]Donation After Circulatory Death (DCD) versus Donation After Brain Death (DBD): Contrasting Donor and Recipient Characteristics in the ISHLT DCD Lung Transplant (LTx) Registry; _]B. Levvey^1^, G. Snell1, L. Edwards2, J. Stehlik3, M. Erasmus4, A. Glanville5, M. Hertz6, P. Hopkins7, D. Chambers7, M. Musk8, M. Budev9, D. Mason10, V. Puri11, R. Yusen11, F. D’Ovidio12, S. Keshavjee13, M. Cypel13, D. Van Raemdonck14. [^1^]_]Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2United Network for Organ Sharing, Richmond, VA, 3University of Utah, Salt Lake City, UT, 4Univeristair Medisch Centrum, Gronigen, Netherlands, 5St Vincent’s Hospital, Sydney, Australia, 6University of Minnesota Medical Center, Minneapolis, MN, 7Prince Charles Hospital, Brisbane, Australia, 8Royal Perth Hospital, Perth, Australia, 9The Cleveland Clinic Foundation, Clevland, OH, 10Baylor University Medical Center, Dallas, TX, 11Barnes Jewish Hospital-Washington University, St Louis, IL, 12New York-Presbyterian Columbia, New York City, NY, 1Toronto General Hospital & Hospital for Sick Children, Toronto, ON, Canada, 14Department of Thoracic Surgery, University Hospitals, Leuven, Belgium

 

[*2:30 PM (252) *]Long-Term Persistence of Alveolar Macrophages in Donor Lungs after Human Lung Transplantation; _]D. Nayak^1^, F. Zhou1, D. Kreisel1, R. Hachem2, T. Mohanakumar3. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Medicine, Washington University School of Medicine, St. Louis, MO, 3Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

[*2:45 PM (253) *]Does Donor Age Impact Recipient Survival Post-Lung Transplant: A Study of the International Society of Heart and Lung Transplantation Database; _]A. M. Bernhardt^1^, A. P. Levin2, J. Stehlik3, C. Benden4, L. Edwards5, H. Reichenspurner1, F. M. Wagner1. [^1^]_]Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Columbia University Medical Center, New York City, NY, 3School of Medicine Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, 4Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland, 5United Network for Organ Sharing, Richmond, VA

 

[*3:00 PM (254) *]Airway Inflammation in the Donor Prior to Explant Increases the Risk of Primary Graft Dysfunction; _]E. M. Lowery^1^, M. Yong1, L. Ramirez2, S. Kliethermes3, S. Jeffrey4, E. J. Kovacs2. [^1^]_]Medicine, Loyola University Chicago, Chicago, IL, 2Surgery, Loyola University Chicago, Chicago, IL, 3Public Health, Loyola University Chicago, Chicago, IL, 4Cardiovascular Surgery, Loyola University Med Center, Maywood, IL

 

[*3:15 PM (255) *]Donor Derived Exosomes Expressing Lung Associated Self-antigens (Collagen V and K alpha 1 Tubulin) in Acute and Chronic Rejection Following Human Lung Transplantation; _]M. Gunasekaran^1^, Z. Xu1, D. Nayak1, M. Sharma1, R. Hachem2, T. Mohanakumar3. [^1^]_]Surgery, Washington University School of Medicine, St. Louis, MO, 2Medicine, Washington University School of Medicine, St. Louis, MO, 3Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 31: Pediatric Early Post Transplant Problems *]

 

Location:

Virginia Suite

[*Target Audience: *]

PEDS, HTX, MCS

 

[*Chairs: *]

Janet N Scheel, MD, and Kurt R Schumacher, MD

 

[*2:00 PM (256) *]Regional Variation in the Use of 1A Status Exceptions for Pediatric Heart Transplant Candidates: Is This Equitable?; _]J. Godown^1^, M. McKane1, B. A. Mettler2, D. A. Dodd1. [^1^]_]Pediatric Cardiology, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN, 2Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN

 

[*2:15 PM (257) *]The Use of Urgent Listing Exceptions in Pediatric Heart Transplantation: Is Waitlist Survival Equivalent to Standard Criteria Patients?; _]R. R. Davies, M. A. McCulloch, S. Haldeman, S. S. Gidding, C. Pizarro. [_Nemours/A.I. duPont Hospital for Children, Wilmington, DE

 

[*2:30 PM (258) *]Mechanical Circulatory Support after Pediatric Heart Transplantation; _]J. D. Simmonds^1^, E. Pruitt2, D. C. Naftel2, D. Gupta3, D. Dodd4, S. D. Zangwill5, J. K. Kirklin2, L. Addonizio6. [^1^]_]Great Ormond Street Hospital for Children, London, United Kingdom, 2University of Alabama at Birmingham, Birmingham, AL, 3Congenital Heart Center, University of Florida, Gainesville, FL, 4Division of Cardiology, Vanderbilt Heart and Vascular Institute, Nashville, TN, 5Phoenix Children’s Heart Center, Phoenix, AZ, 6Columbia University College of Physicians and Surgeons, New York, NY

 

[*2:45 PM (259) *]A Novel Donor Risk Scoring System to Predict 1-Year Mortality in Pediatric Heart Transplantation; _]F. Zafar^1^, R. D. Jaquiss2, C. S. Almond3, A. Lorts4, C. Chin4, R. Rizwan1, R. Bryant 3rd1, J. S. Tweddell1, D. L. Morales1. [^1^]_]Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC, 3Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA, 4Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*3:00 PM (260) *]Development and Validation of a Major Adverse Transplant Event (MATE) Score to Predict Graft Loss after Pediatric Heart Transplantation; _]C. S. Almond^1^, J. W. Rossano2, H. Hoen1, C. Castleberry3, S. Auerbach4, L. Yang1, A. K. Lal5, M. D. Everitt4, E. Pahl6, M. Fenton7, S. A. Hollander1, D. B. McElhinney1, D. N. Rosenthal1, K. P. Daly8, M. Desai1. [^1^]_]Stanford University, Palo Alto, CA, 2Children’s Hospital of Philadelphia, Philadelphia, PA, 3Washington University/St. Louis, St. Louis, MO, 4Denver Children’s Hospital, Denver, CO, 5Primary Children’s Hospital, Salt Lake City, UT, 6Lurie Children’s Hospital, Chicago, IL, 7Great Ormond Street Children’s Hospital, London, United Kingdom, 8Boston Children’s Hospital, Boston, MA

 

[*3:15 PM (261) *][Early Neurologic Outcomes after Pediatric Heart Transplantation; _]C. Cammock, C. Castleberry, S. Choudhry, K. Simpson, C. Canter. _Pediatric Cardiology, St Louis Children’s Hospital, St. Louis, MO

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment *]

Location:

Delaware Suite

[*Target Audience: *]

ID, HTX, LTX, MCS, NHSAH

 

[*Chairs: *]

Aric L Gregson, MD, and Amparo Sole, MD, PhD

 

[*2:00 PM (262) *]Clinical Characteristics and Outcomes of Mycobacterium abscessus Isolation in Lung Transplant Candidates and Recipients: A Systematic Review; _]O. Morrissey^1^, G. Snell2, B. Levvey2, G. Westall2, A. Cheng1, H. Bills3. [^1^]_]Department of Infectious Diseases, The Alfred Hospital, Melbourne, Australia, 2Lung Transplant Service, The Alfred Hospital, Melbourne, Australia, 3Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

 

[*2:15 PM (263) *]Universal Versus Culture-Directed Pre-Emptive Treatment (CDPET) among Lung Transplant Recipients: A Propensity-Score Matched Analysis; _]B. Hamandi^1^, C. Fegbeutel2, F. P. Silveira3, E. A. Verschuuren4, P. Ussetti5, P. V. Chin-Hong6, A. Sole7, C. Holmes-Liew8, E. M. Billaud9, P. A. Grossi10, O. Manuel11, D. J. Levine12, R. G. Barbers13, D. Hadjiliadis14, L. G. Singer15, S. Husain1. [^1^]_]University Health Network, Toronto, ON, Canada, 2Hannover Medical School, Hannover, Germany, 3University of Pittsburgh, Philadelphia, PA, 4University Medical Center Groningen, University of Gron, Groningen, Netherlands, 5Hospital Puerta de Hierro, Madrid, Spain, 6University of California, San Francisco, San Francisco, CA, 7University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain, 8Royal Adelaide Hospital, Adelaide, Australia, 9APHP Hopital Européen G Pompidou, Paris Descartes, France, 10University of Insubria, Varese, Italy, 11University Hospital of Lausanne, Lausanne, Switzerland, 12University of Texas Health Science Center San Antonio, San Antonio, TX, 13KECK Medical Center of University of Southern California, Los Angeles, CA, 14University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, 15University Health Network, University of Toronto, Toronto, ON, Canada

 

[*2:30 PM (264) *]Interim Analysis: A Study of QuantiFERON-CMV-Directed CMV Prophylaxis Versus Standard-of-Care to Reduce Late CMV Reactivation in Patients Undergoing Lung Transplantation; _]G. P. Westall^1^, Y. Cristiano1, A. Y. Peleg2, M. Paraskeva1, B. Levvey1, H. Whitford1, G. Snell1. [^1^]_]Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 2Department of Infectious Disease, Alfred Hospital, Melbourne, Australia

 

[*2:45 PM (265) *]A Pre-Transplant Humoral Immunity Score to Identify Risk of Severe Infection in Heart Recipients. A Multicenter Study; _]J. Carbone^1^, J. Fernandez-Yañez2, M. Gomez-Sanchez3, M. Crespo-Leiro4, L. Almenar5, G. Rabago6, J. Segovia7, J. Lopez8, L. Garcia-Guereta9, S. Mirabet10, J. Navarro1, E. Sarmiento1. [^1^]_]Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Hospital Universitario Doce de Octubre, Madrid, Spain, 4Complexo Hospitalario Universitario A Coruña, La Coruña, Spain, 5Hospital Universitario La Fe, Valencia, Spain, 6Clínica Universitaria de Navarra, Navarra, Spain, 7Hospital Universitario Puerta de Hierro, Madrid, Spain, 8Hospital Clínico Universitario, Valladolid, Spain, 9Hospital Universitario La Paz, Madrid, Spain, 10Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 

[*3:00 PM (266) *][Quantiferon Monitor: A Novel Assay for Prediction of Infectious Risk in Heart Transplant Recipients; _]L. Potena, L. Righini, V. Manfredini, L. Borgese, D. Sgreccia, A. Chiereghin, G. Piccirilli, M. Masetti, T. Lazzarotto, F. Grigioni. _University of Bologna, Bologna, Italy

 

[*3:15 PM (267) *]Positron Emission Tomography Accurately Diagnosis Ventricular Assist Device Infection; _]E. Feller^1^, A. Shah2. [^1^]_]Medicine/Cardiology, University of Maryland, Baltimore, MD, 2School of Medicine, University of Maryland, Baltimore, MD

 

 

2:00 PM – 3:30 PM

[*Concurrent Session 33: “A Bipartisan Effort”: Antibodies and Complement in Heart and Lung Allografts *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

PATH, BSI, HF, HTX, LTX, PEDS

 

[*Chairs: *]

Elizabeth N Pavlisko, MD, and Patrick Bruneval, MD

 

[*2:00 PM (268) *][PU.1 and CD34 Immunohistochemistry for the Diagnosis of Antibody-Mediated Rejection in the Heart; _]G. A. Fishbein, Y. P. Hung, R. N. Mitchell, R. F. Padera. _Department of Pathology, Brigham and Women’s Hospital, Boston, MA

 

[*2:15 PM (269) *]Histologic Features of Mixed Rejection in Heart Transplantation: More Than Just Cellular + Antibody-Mediated Rejection?; _]D. V. Miller1, A. G. Kfoury2, G. L. Snow3, M. Revelo4, A. Lal5, J. Stehlik2, S. H. McKellar6, J. C. Fang2, W. Caine6, K. Ashfar2, S. G. Drakos2, O. Wever-Pinzon2, K. M. Molina5, M. H. Hammond^4^. [^1^]_]UTAH Cardiac Transplant Program, Murray, UT, 2Cardiology, UTAH Cardiac Transplant Program, Murray, UT, 3Biostatistics, UTAH Cardiac Transplant Program, Murray, UT, 4Pathology, UTAH Cardiac Transplant Program, Murray, UT, 5Pediatric Cardiology, UTAH Cardiac Transplant Program, Murray, UT, 6Cardiac Surgery, UTAH Cardiac Transplant Program, Murray, UT

 

[*2:30 PM (270) *]Clearance of C3d Immunostaining Occurs More Often and Earlier Than Clearance of C4d after Antibody Mediated Rejection: An Earlier Marker for Resolving Rejection?; _]D. V. Miller^1^, M. Revelo1, A. G. Kfoury1, G. L. Snow2, K. Afshar3, D. Budge3, R. Alharethi3, S. G. Drakos3, J. N. Nativi3, E. H. Hammond1. [^1^]_]Pathology, Intermountain Central Lab, Salt Lake City, UT, 2Biostatistics, Intermountain Central Lab, Salt Lake City, UT, 3Cardiology, Intermountain Central Lab, Salt Lake City, UT

 

[*2:45 PM (271) *]Intrapulmonary Local Production of Antibodies Specific to Donor Major Histocompatibility Complex Class I in Association with the Progression of Chronic Rejection in Lung Allografts; _]E. Miyamoto^1^, M. Sato2, H. Motoyama1, A. Aoyama1, T. Menju1, K. Shikuma1, T. Sowa1, M. Saito1, A. Takahagi1, S. Tanaka1, M. Takahashi1, K. Ohata1, T. Kondo1, K. Hijiya1, T. F. Chen-Yoshikawa1, T. Sato1, M. Sonobe1, H. Date1. [^1^]_]Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan, 2Thoracic Surgery, The University of Tokyo, Tokyo, Japan

 

[*3:00 PM (272) *]Complement-Fixing Donor Specific Antibody and Pathologic Findings in Lung Allografts; _]L. Chhatwani^1^, J. Mooney1, K. Patel1, A. Emtiazjoo2, A. Lawrence1, G. Berry3, D. Tyan3, G. Dhillon1. [^1^]_]Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 2Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL, 3Department of Pathology, Stanford University, Stanford, CA

 

[*3:15 PM (273) *]Insufficient Post-Transplant Immunosuppression Induces Restrictive Allograft Syndrome-Like Fibrosis in the Pleura and Lung Parenchyma After Lung Transplantation; _]E. Miyamoto^1^, M. Sato2, H. Motoyama1, A. Aoyama1, T. Menju1, K. Shikuma1, T. Sowa1, M. Saito1, A. Takahagi1, S. Tanaka1, M. Takahashi1, K. Ohata1, T. Kondo1, K. Hijiya1, T. F. Chen-Yoshikawa1, T. Sato1, M. Sonobe1, H. Date1. [^1^]_]Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan, 2Thoracic Surgery, The University of Tokyo, Tokyo, Japan

 

 

2:00 PM – 3:30 PM

[*Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH *]

 

Location:

Washington Ballroom 1

 

[*Target Audience: *]

PH, ALL

 

[*Chairs: *]

Reda E. Girgis, MD, and Walter Klepetko, MD

 

Session Summary: The session will focus on the opportunities, pitfalls, and challenges in bridging patients with PAH and advanced lung disease complicated by PH to lung transplantation.

 

2:00 PM

Prognosis of PAH: Eligibility and Timing of Transplant Referral

 

Antonio Roman, MD, Hospital Universitari Vall d’Hebron, Barcelona, Spain

 

2:15 PM

The LAS for PAH: Impact of New Revisions

 

Sangeeta Bhorade, MD, Northwestern Memorial Hospital, Chicago, IL, USA

 

2:30 PM

PH and the risk of Primary Graft Dysfunction in Lung Transplantation

 

James Lee, MD, University of Pennsylvania, Philadelphia, PA, USA

 

2:45 PM

Matching Bridging Strategies to Unique Clinical Situations in PH and Lung Transplant

 

Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

 

3:00 PM

Perioperative and Early Postoperative Challenges in PH and Lung Transplantation

 

Martin Strueber, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

 

3:15 PM

PANEL DISCUSSION

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS *]

 

Location:

Salons 2-3

[*Target Audience: *]

MCS, HTX, NHSAH

 

[*Chairs: *]

Shashank S Desai, MD, and Yuriy Pya, MD

 

[*4:00 PM (274) *]Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope Dependent Advanced Heart Failure Patients: Insights from the ROADMAP Study; _]D. E. Lanfear^1^, W. C. Levy2, J. Stehlik3, J. D. Estep4, J. G. Rogers5, K. B. Shah6, A. J. Boyle7, J. Chuang8, D. J. Farrar8, R. C. Starling9. [^1^]_]Henry Ford Hospital, Detroit, MI, 2University of Washington, Seattle, WA, 3University of Utah, Salt Lake City, UT, 4Houston Methodist Hospital, Houston, TX, 5Duke University, Durham, NC, 6Virginia Commonwealth University, Richmond, VA, 7Piedmont Hospital, Atlanta, GA, 8St. Jude Medical, Pleasanton, CA, 9Cleveland Clinic, Cleveland, OH

 

[*4:15 PM (275) *]Physician Prediction of Outcomes in Ambulatory Patients with Advanced Heart Failure; _]M. M. Kittleson^1^, C. B. Patel2, R. S. Cantor3, A. D. DeVore4, A. V. Ambardekar5, J. T. Thibodeau6, L. M. Cadaret7, S. V. Pamboukian8, J. Teuteberg9, R. C. Forde-McLean10, M. M. Mountis11, M. Palardy12, G. C. Stewart13, M. A. Hamilton1. [^1^]_]Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, 2Division of Cardiology, Duke University Medical Center, Durham, NC, 3Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, 4Cardiology, Duke Clinical Research Institute, Durham, NC, 5Medicine-Cardiology, University of Colorado, Aurora, CO, 6Internal Medicine/Cardiology, UT Southwestern, Dallas, TX, 7Internal Medicine, The University of Iowa, Iowa City, IA, 8Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, 9Heart and Vascular Intstitute, The University of Pittsburgh, Pittsburgh, PA, 10Cardiology, University of Pennsylvania, Philadelphia, PA, 11Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 12Internal Medicine/Cardiovascular, The University of Michigan, Ann Arbor, MI, 13Advanced Heart Disease, Brigham and Women’s Hospital, Boston, MA

 

[*4:30 PM (276) *]Effect of Body Mass Index on Outcomes of Heart Transplant Candidates Supported by Continuous-Flow Left Ventricular Assist Devices (CF-LVADs); _]V. K. Topkara^1^, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, B. Cagliostro1, G. Parkis1, S. Restaino1, F. Latif1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*4:45 PM (277) *]Red Cell Distribution Width (RDW) Predicts 90-Day Mortality in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients; _]V. K. Topkara^1^, A. R. Garan1, V. Ton1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, D. Jennings1, F. Castagna1, B. Cagliostro1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*5:00 PM (278) *]Heart Failure Etiology Influences Outcomes after Continuous-Flow LVAD Implantation; _]S. Maltais^1^, N. A. Haglund2, M. E. Davis2, J. Cowger3, P. Shah4, F. D. Pagani5, K. D. Aaronson5, S. M. Dunlay1, J. M. Stulak1. [^1^]_]Mayo Clinic, Rochester, MN, 2Vanderbilt, Nashville, TN, 3St-Vincent Hospital, Indianapolis, IN, 4Inova Fairfax, Virginia, VA, 5Michigan, Michigan, MI

 

[*5:15 PM (279) *]Survival Following Orthotopic Heart Transplantation in Bridge-to-Transplant Heartware HVAD versus Heartmate II Patients; _]J. Magruder^1^, J. C. Grimm1, T. C. Crawford1, R. J. Tedford2, S. D. Russell2, C. M. Sciortino1, G. J. Whitman1, A. S. Shah3. [^1^]_]Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD, 2Division of Cardiology, Johns Hopkins, Baltimore, MD, 3Department of Cardiac Surgery, Vanderbilt, Nashville, MD

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, HF, NHSAH, PHARM

 

[*Chairs: *]

Nir Uriel, MD, and Nader Moazami, MD

 

[*4:00 PM (280) *]Aspirin Responsiveness Predicts Mucosal Bleeding Events in Patients with Continuous-Flow Left Ventricular Assist Devices; _]V. K. Topkara^1^, A. B. Eisenberger1, A. R. Garan1, D. Jennings1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, B. Cagliostro1, M. Flannery2, R. Te-Frey2, A. L. Uryevick2, F. Latif1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*4:15 PM (281) *]Genomic Reprogramming of the Platelet Transcriptome with Chronic LVAD Support; _]A. Koliopoulou^1^, M. T. Rondina2, H. Javan2, S. Men2, S. G. Drakos3, J. Stehlik3, S. H. McKellar1, A. S. Weyrich2, C. H. Selzman1. [^1^]_]Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 2Molecular Medecin Program, University of Utah, Salt Lake City, UT, 3Division of Cardiovascular Medecine, University of Utah, Salt Lake City, UT

 

[*4:30 PM (282) *]Coagulation Factors Abnormalities in LVAD Patients with Anti-Factor 10a and PTT Discordance; _]S. Adatya^1^, S. Roy2, M. Fitzpatrick2, P. Eckman2, G. Sayer1, S. Kalantari Tannenbaum1, T. Thenappan2, R. John2, M. Pritzker2, U. Nir1. [^1^]_]Cardiology, University of Chicago, Chicago, IL, 2Cardiology, University of Minnesota, Minneapolis, MN

 

[*4:45 PM (283) *]Bleeding Complications after Left Ventricular Assist Device Implantation: Association of Events and Impact on Survival; _]S. Maltais1, J. VanMeeteren^1^, S. Dunlay1, N. Haglund2, F. Pagani3, K. Aaronson3, J. Cowger4, P. Shah5, J. Stulak1. [^1^]_]Mayo Clinic, Rochester, MN, 2Vanderbilt, Nashville, TN, 3Michigan, Michigan, MI, 4St-Vincent Hospital, Indianapolis, IN, 5Inova Fairfax, Virginia, VA

 

[*5:00 PM (284) *]Use of Four-Factor Prothrombin Concentrate Complex in LVAD Recipients Undergoing Transplantation: Impact on Blood Loss, Blood Use, Blood Bank Costs and Clinical Outcomes; _]D. J. Goldstein^1^, J. Uehlinger2, J. Szymanski2, K. Mohandas2, R. Walsh2, S. Karim2, E. Marks2, E. Himchak2, R. Gupta2, D. Wu2. [^1^]_]Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Pathology, Montefiore Medical Center, Bronx, NY

 

[*5:15 PM (285) *]Aortic Root Thrombus Formation in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs); _]J. A. Fried^1^, S. Fukuhara1, A. R. Garan1, M. Yuzefpolskaya1, H. Takayama1, F. Castagna1, A. M. Clemons1, S. Singh1, D. Jennings1, B. Cagliostro1, L. Effner2, M. A. Farr1, R. Bijou1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1, H. Takayama2, K. Takeda2, V. K. Topkara1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant *]

 

Location:

Salon 1

[*Target Audience: *]

HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Adriana Torres, MD, and Marco A Caccamo, DO

 

[*4:00 PM (286) *][Outcomes in Patients Older Than 60 Years of Age Undergoing Orthotropic Heart Transplantation Since Broadening of Eligibility Criteria; _]S. Rao, C. Hawyard, P. MacDonald, A. Jabbour, E. Kotlyar, A. Keogh. _Heart and Lung Transplantation Unit, St Vincent’s Hospital, Sydney, Australia

 

[*4:15 PM (287) *]Neoplasia after Heart Transplantation. Differences in Incidence and Prognosis between Genders. Data from the Spanish Post-Heart Transplant Tumor Registry; _]M. G. Crespo-Leiro^1^, J. Segovia Cubero2, J. F. Delgado-Jiménez3, E. Roig-Minguell4, E. Barge-Caballero1, I. Sousa-Casasnovas5, L. Almenar-Bonet6, F. González-Vilchez7, J. González-Costello8, B. Díaz-Molina9, J. M. Sobrino-Márquez10, G. Rábago11, J. M. Arizón del Prado12, F. Pérez-Villa13, T. Blasco Peiró^14^, L. de la Fuente-Galán15, I. P. Garrido Bravo16, J. Muñiz17. [^1^]_]Complexo Hospitalario Universitario A Coruña e Instituto de Investigación Biomédica de A Coruña (INIBIC), La Coruna, Spain, 2Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Hospital Universitari i Politècnic La Fe, Valencia, Spain, 7Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 8Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona, Spain, 9Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 10Hospital Universitario Virgen del Rocio, Sevilla, Spain, 11Clínica Universidad de Navarra, Pamplona, Navarra, Spain, 12Hospital Universitario Reina Sofía, Córdoba, Spain, 13Hospital Clinic i Provincial, Barcelona, Spain, 14Hospital Universitario Miguel Servet, Zaragoza, Spain, 15Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 16Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 17Instituto Universitario de Ciencias de la Salud e Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, La Coruna, Spain

 

[*4:30 PM (288) *]Donor Age Associated with Short-Term and Recipient Age Associated with Long-Term Mortality in Heart Transplantation; _]H. Bergenfeldt^1^, J. Stehlik2, L. Lund3, B. Andersson4, J. Nilsson1. [^1^]_]Cardiothoracic Surgery, Skane University Hospital, Lund, Sweden, 2Division of Cardiovascular Medicine, University of Utah, School of Medicine, Salt Lake City, UT, 3Cardiology, Karolinska Institutet, Stockholm, Sweden, 4Surgery, Skane University Hospital, Lund, Sweden

 

[*4:45 PM (289) *]The Obesity Epidemic and Its Effect on Donor Body Mass Index and Recipient Survival-A UNOS Database Review of Heart Transplantation; _]Y. Ravi^1^, E. M. Stock2, P. C. Rosas3, B. A. Whitson4, E. A. Amulraj1, R. C. Scott5, S. Emani6, S. Bansal7, C. B. Sai-Sudhakar1. [^1^]_]Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M, Temple, TX, 2Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, 3Medical Physiology, Texas A&M, Temple, TX, 4Cardiac Surgery, The Ohio State University, Columbus, OH, 5Cardiology-Internal Medicine, Scott & White, Texas A&M, Temple, TX, 6Cardiology-Internal Medicine, The Ohio State University, Columbus, OH, 7Cardiac Surgery, Mayo Clinic, Jacksonville, FL

 

[*5:00 PM (290) *]Outcomes of Heart Transplantation in Adults with Sarcoidosis: UNOS Registry Analysis; _]E. C. DePasquale1, A. Iyengar1, A. Nsair1, K. Pandya^2^, M. Deng1, A. Ardehali1. [^1^]_]David Geffen Sch Med, Los Angeles, CA, 2UCLA, Los Angeles, CA

 

[*5:15 PM (291) *][Cytomegalovirus Infection after Cardiac Transplantation; _]O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma. _University of British Columbia, Vancouver, BC, Canada

 

 

4:00 PM – 5:30 PM

Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression

 

Location:

Maryland Suite

[*Target Audience: *]

LTX, BSI, ID, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Massaki Sato, MD, and Kevin M. Chan, MD

 

[*4:00 PM (292) *][Shortened Allograft Epithelial Telomere Length – A Lasting Legacy of Donor Age and Smoking History; _]S. T. Yerkovich, M. Tan, L. Samson, A. Fiene, P. Hopkins, D. Chambers. _The Prince Charles Hospital, Brisbane, Australia

 

[*4:15 PM (293) *][Implication of Human Leukocyte Antigen (HLA) Mismatching on Survival and CLAD After Lung Transplantation; _]G. Chery, A. Copeland, M. Durham, S. Palmer, L. Snyder. _Department of Medicine, Duke University School of Medicine, Durham, NC

 

[*4:30 PM (294) *]FVC, TLC and CT as Independent Predictors for Prognosis after Onset of CLAD; _]H. L. Schultz^1^, S. Verleden2, R. Vos2, B. Vanaudenaerde2, G. Verleden2, M. Perch1, A. Holm3, M. Iversen1. [^1^]_]Dept of Cardiology, Section for Lung Transpantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Lab of Lung Transplantation, Department of Pneumonology, University of Leuven, Leuven, Belgium, 3Department of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

 

[*4:45 PM (295) *]Baseline Lung Allograft Dysfunction Negatively Impacts Survival Following Lung Transplantation; _]J. Liu1, K. Jackson2, J. Weinkauf1, A. Kapasi1, A. Hirji1, B. Laing2, J. Mullen2, D. Freed2, J. Nagendran2, S. Meyer2, D. Lien1, K. Halloran^1^. [^1^]_]Medicine, University of Alberta, Edmonton, AB, Canada, 2Surgery, University of Alberta, Edmonton, AB, Canada

 

[*5:00 PM (296) *]Evaluation of an FVC-Based Definition of Restrictive Chronic Lung Allograft Dysfunction (CLAD) in a Multi-Center Cohort; _]M. T. Durheim^1^, D. M. Wojdyla1, C. L. Green1, S. Keshavjee2, K. McCurry3, A. O. Lidor4, R. D. Davis5, S. M. Palmer1, J. L. Todd1. [^1^]_]Duke Clinical Research Institute, Durham, NC, 2University of Toronto, Toronto, ON, Canada, 3Cleveland Clinic, Cleveland, OH, 4Johns Hopkins University, Baltimore, MD, 5Florida Hospital Transplant Institute, Orlando, FL

 

[*5:15 PM (297) *]A Multicenter Study on Long-Term Outcomes after Lung Transplantation Comparing Donation after Circulatory Death and Donation after Brain Death; _]V. van Suylen^1^, B. Luijk2, R. A. Hoek3, E. A. van de Graaf2, E. A. Verschuuren4, C. Van De Wauwer1, J. A. Bekkers5, R. C. Meijer6, W. van der Bij4, M. E. Erasmus1. [^1^]_]Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands, 2Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 3Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, Netherlands, 4Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, Netherlands, 5Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, 6Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 38: New Insights in Pulmonary Hypertension *]

 

Location:

Virginia Suite

[*Target Audience: *]

PH, BSI, HF, HTX, LTX, MCS, PEDS, PH, PHARM

 

[*Chairs: *]

Ryan J Tedford, MD, and Antonio B Roman, MD, PhD

 

[*4:00 PM (298) *]Subclinical Pulmonary Hypertension Is Common and Associated with Increased Mortality in a Large Electronic Medical Record-Based Cohort; _]T. R. Assad^1^, I. M. Robbins1, A. R. Hemnes1, M. Xu1, B. A. Maron2, G. Choudhary3, Q. S. Wells1, E. Farber-Eger1, E. Hess4, A. E. Baron4, T. M. Maddox4, E. L. Brittain1. [^1^]_]Vanderbilt University Med Center, Nashville, TN, 2VA Boston Health Care System and Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, 3Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI, 4VA Eastern Colorado Health Care System, Denver, CO

 

(299) WITHDRAWN

 

[*4:15 PM (387) *][Right Ventricular Dyssynchrony and Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension: Insights Form Echocardiography and Cardiopulmonary Exercise Test; _]R. Badagliacca, R. Poscia, M. Reali, B. Pezzuto, S. Papa, G. Manzi, S. Sciomer, F. Fedele, C. D. Vizza. _Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy

 

[*4:30 PM (300) *][Exercise Hemodynamics in PAH: Lessons Utilizing an Indwelling Hemodynamic Monitor; _]R. L. Benza, P. Correa-Jaque, D. V. Thompson, A. Raina, R. Agarwal, G. Sokos, M. Kanwar, M. Patarroyo-Aponte, S. Murali, M. Doyle, J. White, R. Biederman. _Cardiology, Allegheny Gen Hosp, Pittsburgh, PA

 

[*4:45 PM (301) *]Right Ventricular Reserve Limitation in Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension; _]S. Hsu^1^, B. A. Houston1, E. Tampakakis1, A. C. Bacher1, P. S. Rhodes2, S. C. Mathai3, R. L. Damico3, T. M. Kolb3, L. K. Hummers4, A. A. Shah4, Z. McMahan4, S. L. Zimmerman5, F. M. Wigley4, P. M. Hassoun3, D. A. Kass1, R. J. Tedford1. [^1^]_]Cardiology, Johns Hopkins University, Baltimore, MD, 2Physiology, Johns Hopkins University, Baltimore, MD, 3Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5Radiology, Johns Hopkins University, Baltimore, MD

 

[*5:00 PM (302) *]Influence of Pulmonary Hypertension on Adverse Outcomes Following Non-Cardiac Surgery; _]D. P. McGlothlin^1^, J. G. Zaroff1, A. C. Goh1, D. H. See2, S. B. Tate2, C. Conell3. [^1^]_]Cardiology, Kaiser Permanente San Francisco Med Ctr, San Francisco, CA, 2Internal Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, 3Division of Research, Kaiser Permanente San Francisco Med Ctr, Oakland, CA

 

[*5:15 PM (303) *]Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study; _]V. F. Tapson^1^, R. Channick2, K. Chin3, L. Di Scala4, H. Farber5, S. Gaine6, N. Galiè^7^, H. A. Ghofrani8, I. Lang9, V. McLaughlin10, R. Preiss4, L. J. Rubin11, G. Simonneau12, O. Sitbon12, M. M. Hoeper13. [^1^]_]Cedars-Sinai Medical Center, Los Angeles, CA, 2Massachusetts General Hosp, Boston, MA, 3UT Southwestern Med Ctr, Dallas, TX, 4Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 5Pulmonary Hypertension Center, Boston Univ School of Medicine, Boston, MA, 6National Pulmonary Hypertension Unit, Mater Misericordiae Univ Hospital, Dublin, Ireland, 7Istituto di Malattie dell’Apparato Cardiovascolare, Univ of Bologna, Bologna, Italy, 8Univ of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, 9Medical Univ of Vienna, Dept of Internal Medicine II, Division of Cardiology, Allgemeines Krankenhaus, Vienna, Austria, 10Univ of Michigan Health System Division of Cardiovascular Medicine, Ann Arbor, MI, 11Division of Pulmonary and Critical Care Medicine, Univ of California, San Diego, CA, 12Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France, 13Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover, Germany

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 39: Junior Faculty and Trainee Council’s Clinical Case Dilemmas: The Best of the Best *]

Location:

Delaware Suite

[*Target Audience: *]

CASE, ALL

 

[*Chairs: *]

Mitesh V Thakrar, MD, and Hermann Reichenspurner, MD, PhD

 

[*4:00 PM *]

[*(304) *]Will Relaxation Improve Things? _]K. B. Berfield^1^, J. Huang2, G. S. Aldea2, J. W. Smith2, N. A. Mokadam2, J. D. Pal2. [^1^]_]University of Washington, Seattle, WA, 2Univ of Washington, Seattle, WA

 

4:05 PM

EXPERT DISCUSSANT

David O. Taylor, MD, Cleveland Clinic, Cleveland, OH, USA

 

4:09 PM

MODERATED DISCUSSION

 

[*4:15 PM *]

[*(305) *]Can Anything Make It Better? _]J. M. Friedland-Little1, R. J. Gajarski2, K. R. Schumacher^3^. [^1^]_]Cardiology, Seattle Children’s Hospital, Seattle, WA, 2Cardiology, Nationwide Children’s Hospital, Columbus, OH, 3Pediatric Cardiology, University of Michigan, Ann Arbor, MI

 

4:20 PM

EXPERT DISCUSSANT

 

Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada

 

4:24 PM

MODERATED DISCUSSION

 

[*4:30 PM *]

[*(306) *][Are You Ready to Take the Next Step? _]J. Steiner, S. Wiafe, J. Camuso, K. Milley, D. D’Alessandro, J. Garcia, G. Lewis. _MGH, Boston, MA

 

4:35 PM

EXPERT DISCUSSANT

 

Sharon Hunt, MD, Stanford University, Stanford, CA, USA

 

4:39 PM

MODERATED DISCUSSION

 

[*4:45 PM *]

[*(307) *]Why Don’t These Drugs Work Anymore? _]R. M. La Hoz^1^, J. Le1, M. Mohanka2, J. V. Philley3, K. Kowalske4, A. Banga2, S. Bollineni2, V. Kaza2, M. Wait5, F. Torres2. [^1^]_]Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, TX, 2Division of Pulmonary and Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX, 3Department of Medicine, University of Texas Health Science Center, Tyler, TX, 4Department of Physical Medicine & Rehabilitation, UT Southwestern Medical Center, Dallas, TX, 5Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX

 

4:50 PM

EXPERT DISCUSSANT

 

Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

 

4:54 PM

MODERATED DISCUSSION

 

[*5:00 PM *]

[*(308) *]Who’s Going to Fix This Now That It’s Broken? _]S. S. Thomas^1^, R. Gallagher1, J. Steiner1, T. H. Song2, I. Palacios1, S. Elmariah1, S. Wiafe2, N. Roy2, G. Cudemus3, M. J. Semigran1, G. D. Lewis1, J. P. Garcia2, K. Rosenfield1. [^1^]_]Cardiology, Massachusetts General Hospital, Boston, MA, 2Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 3Anesthesia, Critical Care and Pain Management, Massachusetts General Hospital, Boston, MA

 

5:05 PM

EXPERT DISCUSSANT

 

George Wieselthaler, MD, University of California, San Francisco, CA, USA

 

5:09 PM

MODERATED DISCUSSION

 

[*5:15 PM *]

[*(309) *][Does Size Matter Anymore? _]Y. Goda. _Department of Thoracic Surgery Kyoto University, Kyoto, Japan

 

5:20 PM

EXPERT DISCUSSANT

 

Shaf Keshavjee, MD, Toronto General Hospital, Toronto, ON, Canada

 

5:24 PM

MODERATED DISCUSSION

 

 

4:00 PM – 5:30 PM

[*Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

PHARM, HTX, ID, LTX, MCS, NHSAH

 

[*Chairs: *]

Adam B Cochrane, PharmD, and Haifa Lyster, MSc

 

[*4:00 PM (310) *][Evaluation of Anticoagulation and Non-Surgical Major Bleeding in Recipients of Continuous-Flow Left Ventricular Assist Devices; _]T. Veasey, S. Strout, K. Rieger, C. Floroff, M. Brisco, J. Cook, J. Toole, M. Craig, A. VanBakel, D. Heyward, W. Uber, H. Meadows. _Medical University of South Carolina, Charleston, SC

 

[*4:15 PM (311) *]A Multidisciplinary Team-Based Process Improves Outpatient Anticoagulation Quality in Patients with Continuous-Flow Left-Ventricular Assist Devices; _]Y. Kuyumjian1, J. Leverock2, M. M. Miyares1, B. Bednar2, S. Chaparro3, A. Panos3, W. Baker4, D. L. Jennings^5^. [^1^]_]Jackson Memorial Hospital, Miami, FL, 2Miami Transplant Institute, Miami, FL, 3University of Miami, Miami, FL, 4University of Connecticut, Storrs, CT, 5Columbia University Medical Center, New York, NY

 

[*4:30 PM (312) *]Post Transplant Thrombosis and Atrial Arrhythmia May Be Safely Managed by Direct Oral Anticoagulants in Cardiac Transplant Patients; _]M. Kim, S. Gabardi, K. R. Townsend, D. S. Page, E. L. Woodcome, M. M. Givertz. [_Brigham & Women’s Hospital, Boston, MA

 

[*4:45 PM (313) *]Durability of Bortezomib for Treatment of Antibody Mediated Rejection in Cardiac Transplantation; _]A. B. Cochrane^1^, J. R. Giaquinto2, S. Desai1, P. Shah1. [^1^]_]Inova Transplant Center, Inova Fairfax Hospital, Falls Church, VA, 2Butler University, Indianapolis, IN

 

[*5:00 PM (314) *]Do Your Patients Take Their Tablets?… High Prevalence of Non-Adherence to Immunosuppression in Lung Transplant Recipients (LTR); _]A. Madden^1^, S. Ivulich1, M. Paraskeva2, G. Snell2, M. Dooley1. [^1^]_]Pharmacy, Alfred Hospital, Prahran, Australia, 2Respiratory Medicine, Alfred Hospital, Prahran, Australia

 

[*5:15 PM (315) *]Effect of Aerosolized Antipseudomonals on Pseudomonas Recurrence and Bronchiolitis Obliterans Syndrome after Lung Transplantation; _]C. A. Moore1, J. M. Pilewski1, K. M. Robinson1, M. R. Morrell1, C. J. Gries2, A. Zeevi1, J. F. McDyer1, C. R. Ensor^1^. [^1^]_]University of Pittsburgh, Pittsburgh, PA, 2Florida Hospital, Orlando, FL

 

 

6:00 PM – 7:00 PM

[*Mini Oral 7: Patient Management and Outcomes in MCS *]

[
Location]:

Thurgood Marshall

[*Target Audience: *]

MCS, HF, NHSAH

 

[*Chairs: *]

Gregory A Ewald, MD, and Ruchan Akar, MD

 

[*6:00 PM (316) *][Characteristics and Outcomes of African American LVAD Recipients: A Single Center Experience; _]F. H. Sheikh, D. T. Majure, M. E. Rodrigo, S. M. Jani, M. Hofmeyer, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC

 

[*6:05 PM (317) *][Infectious Complications after Cardiac Transplantation in Patients Bridged to Transplantation with Mechanical Circulatory Support Devices Versus Medical Therapy; _]B. Varr, S. W. Restaino, M. Farr, P. Colombo, Y. Naka, D. M. Mancini. _Cardiology, Columbia University, New York, NY

 

[*6:10 PM (318) *]Multicenter Canadian Experience with the Heartware HVAD – 5 Year Update; _]W. E. Stansfield^1^, A. D. Nagpal2, W. D. Kent3, R. G. MacArthur4, R. J. Baskett5, A. Cheung6, M. Toma7, V. Rao1. [^1^]_]Surgery, University of Toronto, Toronto, ON, Canada, 2Surgery, University of Western Ontario, London, ON, Canada, 3Surgery, University of Calgary, Calgary, AB, Canada, 4Surgery, University of Alberta, Edmonton, AB, Canada, 5Surgery, Dalhousie University, Halifax, NS, Canada, 6Surgery, University of British Columbia, Vancouver, BC, Canada, 7Medicine, University of British Columbia, Vancouver, BC, Canada

 

[*6:15 PM (319) *]Surgical Management of Driveline Infection in Continuous Flow Left Ventricular Assist Devices; _]S. Taghavi^1^, D. Tandon2, A. G. Diamant2, A. Keith1, G. A. Ewald3, S. J. Lawrence4, M. F. Masood1, K. R. Balsara1, A. Itoh1. [^1^]_]Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO, 2Washington University School of Medicine, Saint Louis, MO, 3Division of Cardiology, Washington University School of Medicine, Saint Louis, MO, 4Division of Infectious Disease, Washington University School of Medicine, Saint Louis, MO

 

[*6:20 PM (320) *][The Value of PET-CT Scans in Patients with Ventricular Assist Devices; _]A. M. Bernhardt, M. J. Barten, A. Schaefer, B. Sill, F. M. Wagner, H. Reichenspurner, T. Deuse. _Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany

 

[*6:25 PM (321) *]Predictors of Long Term Survival on Left Ventricular Assist Device Support; _]J. R. Spratt^1^, S. Roy2, D. Plack3, R. J. Cogswell2, K. Liao1, R. John1. [^1^]_]Department of Surgery, University of Minnesota, Minneapolis, MN, 2Department of Medicine, University of Minnesota, Minneapolis, MN, 3University of Minnesota Medical School, Minneapolis, MN

 

[*6:30 PM (322) *]Risk of Death or Rehospitalization After LVAD and Baseline Cognitive Status; _]K. Bryce^1^, D. E. Lanfear1, C. T. Williams1, J. Lindenfeld2, L. A. Allen3, C. McIlvennan3. [^1^]_]Henry Ford Hospital, Detroit, MI, 2Vanderbilt University, Nashville, TN, 3University of Colorado, Denver, CO

 

[*(323) *]MOVED TO CONCURRENT SESSION 47

 

[*6:35 PM (693) *]When Antibiotics Are Not Enough: Frequency, Etiology and Durability of the Surgical Management of Driveline Infections; _]M. Lander^1^, L. Lagazzi2, R. L. Kormos2, G. O’Shea2, S. Weaver2, T. Schweke2, M. Shullo1, J. J. Teuteberg1. [^1^]_]Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:40 PM (324) *][Effects of LVADs on Exercise Performance in Heart Failure; _]W. K. Cornwell. _Cardiology, Univ of Texas SW, Coppell, TX

 

[*6:45 PM (325) *]Left Ventricular, Biventricular and Total Artificial Heart Support are Associated with Similar Levels of Allosensitization in Bridge-to-Transplant Patients: An Analysis of the UNOS Database; _]M. Yuzefpolskaya^1^, P. N. Trinh2, A. R. Garan1, K. Takeda3, H. Takayama3, D. M. Mancini1, Y. Naka1, V. K. Topkara1, K. Wong1, F. Castagna1, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*6:50 PM (326) *]Log Files from the HVAD: What Can Daily and Long-Term Changes in Flow Tell Us about Patients?; _]A. Potter^1^, S. Anderson1, J. Teuteberg2, R. Kormos2, J. Holtz2. [^1^]_]Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, 2Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:55 PM (327) *]Electrical Remodeling After Continuous-Flow Left Ventricular Assist Device Implantation; _]K. Wong1, V. K. Topkara1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, D. Jennings1, R. Te-Frey3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, P. C. Colombo1, A. R. Garan^1^. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

 

6:00 PM – 7:00 PM

[*Mini Oral 8: Technology, Physiology and Complications in MCS *]

 

Location:

Salon 1

[*Target Audience: *]

MCS, HTX, NHSAH

 

[*Chairs: *]

Bart Meyns, MD, PhD, and Michael S Kiernan, MD

 

[*6:00 PM (328) *]Generating Pulsatility by Pump Speed Modulation with Continuous-Flow Total Artificial Heart in Awake Calves; _]K. Fukamachi^1^, J. H. Karimov1, G. Sunagawa1, D. J. Horvath1, N. Byram1, B. D. Kuban1, R. Dessoffy1, S. Sale2, N. Moazami3. [^1^]_]Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH, 2Cardiothoracic Anesthesiology, Cleveland Clinic Foundation, Cleveland, OH, 3Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH

 

[*6:05 PM (329) *][Impact of Left Atrial Appendage Occlusion on Thromboembolic Complications in Patients Supported by the Heartmate II Left Ventricular Assist Device; _]R. S. Lewis, M. Mangum, L. Wang, M. Puhlman, K. Evenson, J. Remick, G. Ott, J. Abraham. _Center for Advanced Heart Failure, Providence St. Vincent Medical Center, Portland, OR

 

[*6:10 PM (330) *]Resource Utilization and Hospital Readmission Rates Associated with Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices; _]A. Carnicelli, A. Thakkar, D. Deicicchi, A. Storm, J. Connors, G. Couper, M. Mehra, J. Groarke, M. M. Givertz. [_Brigham & Women’s Hospital, Boston, MA

 

[*6:15 PM (331) *][Does Preoperative Atrial Fibrillation Increase the Incidence of Thromboembolic Complications in Patients Supported with Long-Term LVADs?; _]L. Xuereb, B. Kaur, S. Akrawe, H. W. Nemeh, J. Borgi, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cadiac Surgery, Henry Ford Hospital, Detroit, MI

 

[*(332) *]MOVED TO CONCURRENT SESSION 41

 

[*6:20 PM (1066) *][LVAD Outflow Cannula Systolic Slope in Patients with Left Ventricular Assist Devices: A Marker of Myocardial Contractility; _]J. Grinstein, E. Kruse, G. Sayer, G. H. Kim, N. Sarswat, N. Sarswat, S. Adatya, T. Ota, V. Jeevanandam, V. Mor-Avi, R. M. Lang, N. Uriel. _University of Chicago, Chicago, IL

 

[*6:25 PM (333) *][Biologically-Inspired Spiral Laminar-Flow Generation and Its Role in Cardiovascular Implantable Devices; _]P. S. Huang Zhang, J. Kresh. _Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA

 

[*6:30 PM (334) *]Association of Body Mass Index and Thrombosis in Left Ventricular Assist Device Recipients; _]A. Keibel^1^, C. Abouzeid1, A. Yoon2, M. W. Fong2, H. Yousaf2, L. P. Grazette1. [^1^]_]Medicine, Keck Hospital of USC, Los Angeles, CA, 2Cardiology, Keck Hospital of USC, Los Angeles, CA

 

[*6:35 PM (335) *][The Impact of Angiotensin II Type 1 Receptor Antibodies on Morbidity and Mortality of Heart Mate II Supported Patients; _]M. Urban, J. Pirk, P. Ivak, I. Netuka. _Cardiac Surgery, IKEM, Prague, Czech Republic

 

[*6:40 PM (336) *]Gynecological Complications in Female Patients with Left Ventricular Assist Device Support; _]E. Hisamatsu^1^, O. Seguchi1, N. Okada1, K. Kuroda1, H. Sunami1, S. Nakajima1, T. Sato1, H. Hata2, M. Yanase1, T. Fujita2, N. Fukushima1, J. Kobayashi2, T. Nakatani1. [^1^]_]Department of Advanced Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*6:45 PM (337) *]Rate Responsive Pacing Improves Aerobic Exercise Capacity and 6 min Walk in CF-LVAD Patients; _]C. Guerrero-Miranda^1^, M. Pamirsad2, S. Madan1, A. Negassa3, O. Saeed1, J. Shin1, S. Murthy1, D. Goldstein4, D. Sims1, S. Patel1, U. Jorde1. [^1^]_]Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 2Cardiothoracic Surgery, University Heart Center, Hamburg, Germany, 3Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 4Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

 

[*6:50 PM (338) *]MELD Score Is the Most Significant Parameter Predicting Outcome in Patients Receiving Long-Term Ventricular Assist Device After Extracorporeal Life Support; _]D. Saeed, M. Abdeen, A. Albert, B. Maxhera, A. Lichtenberg. [_Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

 

[*6:55 PM (339) *]Evidence of Mild Hepatic Dysfunction Identifies Patients Most Likely to Experience Improvement in Renal Function Following Mechanical Circulatory Support; _]M. A. Brisco^1^, M. R. Zile1, W. Tang2, J. M. Testani3. [^1^]_]Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC, 2Cardiology, Cleveland Clinic Foundation, Cleveland, OH, 3Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT

 

 

6:00 PM – 7:00 PM

[*Mini Oral 9: Risk Factors and Lung Transplant Outcomes *]

 

Location:

Maryland Suite

[*Target Audience: *]

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Ramsey R Hachem, MD, and Are M Holm, MD, PhD

 

[*6:00 PM (340) *]Association of Anti DQ Donor Specific Antibody with Antibody Mediated Rejection in Lung Transplantation; _]A. Roux^1^, I. Lelan Bendib1, S. Holifanjaniaina2, K. Thomas3, C. Picard1, D. Grenet1, S. De Miranda1, B. Douvry1, L. Beaumont Azuar1, E. Sage4, J. Devaquet5, C. Elise6, M. Le Guen1, C. Suberbielle Boissel7, C. Gautreau7, M. Stern1, M. Rossetti8, A. M. Hamid1, F. Parquin6. [^1^]_]Pneumology, Adult CF Center and Lung Transplantation, Foch Hospital, Suresnes, France, 2Pathology Department, Foch Hospital, Suresnes, France, 3Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, 4Thoracic Surgery, Foch Hospital, Suresnes, France, 5Intensive Care Medecine, Foch Hospital, Suresnes, France, 6Thoracic Intensive Care Unit, Foch Hospital, Suresnes, France, 7[_ Laboratoire Régional d'histocompatibilité, Saint- Louis Hospital, Paris, France, 8_]Department of Pathology and Laboratory Medecine, UCLA, Los Angeles, CA

 

[*6:05 PM (341) *]Early Donor Specific Antibodies Correlate with a Distinct Peripheral Cellular Immune Phenotype after Lung Transplantation; _]A. Knoefel^1^, T. Nakagiri1, F. Ius1, J. Salman1, W. Sommer1, M. Avsar1, K. Jansson1, L. Pauksch1, G. Preissler2, R. Hatz2, C. Kühn1, I. Tudorache1, C. Falk3, T. Welte4, J. Gottlieb4, A. Haverich1, G. Warnecke1. [^1^]_]HTTG, MHH, Hannover, Germany, 2Thoraxchirurgie, LMU, München, Germany, 3Institute of Transplant Immunology, MHH, Hannover, Germany, 4Pneumology, MHH, Hannover, Germany

 

[*6:10 PM (342) *]The Prognostic Value of Blood Eosinophilia on Survival After Restrictive CLAD Diagnosis; _]S. E. Verleden^1^, D. Ruttens1, E. Vandermeulen1, H. Bellon1, D. Van Raemdonck1, B. Vanaudenaerde1, G. Verleden1, C. Benden2, R. Vos1. [^1^]_]KU Leuven, Leuven, Belgium, 2University Hospital Zurich, Zurich, Switzerland

 

[*6:15 PM (343) *]Outcomes in Lung Transplant Recipients with Mycobacterium Abscessus Infection; _]Y. Hamad^1^, J. M. Pilewski2, J. D’Cunha3, E. J. Kwak1. [^1^]_]Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:20 PM (344) *]Analysis of the Airways Virome after Lung Transplantation and Its Association with Clinical Outcomes; _]B. C. Keller^1^, G. Zhao2, L. Droit2, C. Desai2, S. A. Handley2, R. R. Hachem3, D. E. Byers3, H. W. Virgin2. [^1^]_]Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 2Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, 3Internal Medicine, Washington University School of Medicine, Saint Louis, MO

 

[*6:25 PM (345) *]Impact of Donor Positive End Expiratory Pressure on Lung Utilization Rates and Short and Long Term Outcomes; _]C. Towe1, F. Zafar2, J. Johnson1, J. S. Tweddell2, R. Bryant III2, D. L. Morales2, M. G. Schecter^1^. [^1^]_]Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*6:30 PM (346) *][Donor Derived Variables as Predictors of Prolonged Hospital Stay after Transplant Surgery among Patients with Lung Transplantation; _]A. Banga, M. Mohanka. _UT Southwestern Medical Center, Dallas, TX

 

[*6:35 PM (347) *][Sarcopenia of Respiratory Muscle in Lung Transplantation Patients Is Not a Poor Predictor of Early Survival; _]J. Lee, K. Nam, S. Lee, H. Jung, J. Suh, C. Lee, S. Haam, J. Hur, H. Paik. _Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of

 

[*6:40 PM (348) *]Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients; _]F. Ius^1^, W. Sommer1, R. Poyanmehr1, I. Tudorache1, C. Kuehn1, M. Avsar1, T. Siemeni1, J. Salman1, U. Molitoris1, M. Greer2, M. Verboom3, D. Boethig1, N. Schwerk4, T. Welte2, A. Haverich1, G. Warnecke1, J. Gottlieb2. [^1^]_]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 3Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 4Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany

 

[*6:45 PM (349) *]Bilateral Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension: Cardiac Remodelling at One Year; _]J. Salman^1^, I. Tudorache1, F. Ius1, W. Sommer1, T. Siemeni1, M. Avsar1, C. Kuehn1, U. Molitoris1, C. Bara1, J. Gottlieb2, T. Welte2, A. Haverich1, G. Warnecke1. [^1^]_]Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Pneumology, Hannover Medical School, Hannover, Germany

 

[*6:50 PM (350) *][Importance of Thoracic Shape for Postoperative Pulmonary Function in Living Donor Lobar Lung Transplantation; _]R. Miyoshi, T. F. Chen-Yoshikawa, A. Takahagi, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Kyoto University Hospital, Kyoto, Japan

 

[*6:55 PM (351) *][_ Interleukin 12-Dependent CMV-Specific CD4+ T Cell Proliferation, T-bet Induction and Effector Function During Primary Infection Are Key Determinants for Early Immune Control in Lung Transplant Recipients; ]I. Popescu1, M. R. Pipeling1, H. Mannem1, P. D. Shah2, J. B. Orens2, J. F. McDyer^1^. [1_]UPMC, Pittsburgh, PA, 2Johns Hopkins University, Baltimore, MD

 

 

6:00 PM – 7:00 PM

[*Mini Oral 10: Heart Transplantation and Heart Failure *]

 

Location:

Virginia Suite

[*Target Audience: *]

HTX, BSI, HF, LTX, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Peter MacDonald, MD, PhD, and Jack G Copeland, MD

 

[*(352) *]WITHDRAWN

 

[*6:00 PM (585) *]Multicenter Evaluation of a National Organ Sharing Policy for Highly Sensitized Patients Listed for Heart Transplantation in Canada; _]B. Clarke^1^, A. Ducharme2, N. Giannetti3, D. Kim4, M. McDonald5, O. Kiamanesh6, P. Pflugfelder7, M. Rajda8, M. Senechal9, E. Stadnick10, M. Toma6, S. Zieroth11, D. Isaac1. [^1^]_]Libin Cardiovascular Institute/University of Calgary, Calgary, AB, Canada, 2Montreal Heart Institute/Universite de Montreal, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4University of Alberta Hospital, Edmonton, AB, Canada, 5Toronto General Hospital, University of Toronto, Toronto, ON, Canada, 6St. Pauls Hospital, University of British Columbia, Vancouver, BC, Canada, 7London Health Science Centre, University of Western Ontario, London, ON, Canada, 8QE II Health Science Centre, Dalhousie University, Halifax, NS, Canada, 9Universite Laval, Quebec, QC, Canada, 10Ottawa Heart Institute, University of Ottawa, Ottawa, ON, Canada, 11St Boniface Hospital, University of Manitoba, Winnipeg, MB, Canada

 

[*6:05 PM (353) *]Survival After Heart Transplant for Previously Palliated Complex Congenital Cardiac Patients; _]H. Copeland^1^, K. Lane2, C. Shen3, Z. Hashmi1, G. Makdisi1, T. Wozniak1, I. Wang1. [^1^]_]Cardiothoraci Surgery Transplant, Indiana University, Indianapolis, IN, 2Biostatistics, Indiana University, Indianapolis, IN, 3Biostatistics, Indiana University School of Medicine, Indianapolis, IN

 

[*6:10 PM (354) *][Donor and Recipient Risk Factors for Combined Heart-Lung Transplantation; _]A. Cheng, J. R. Trivedi, V. H. Van Berkel, H. T. Massey, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

 

[*6:15 PM (355) *]Combined Heart and Kidney Transplant: A 23 Year Experience; _]L. S. Czer^1^, M. Awad1, M. A. De Robertis1, J. Mirocha1, J. Patel1, D. H. Chang1, M. Kittleson1, J. Kobashigawa1, F. Esmailian1, S. Jordan2, A. Trento1. [^1^]_]Heart Institute, Cedars-Sinai Med Ctr, Los Angeles, CA, 2Cedars-Sinai Med Ctr, Los Angeles, CA

 

[*6:20 PM (356) *]Heart-Lung Transplantation for Congenital Heart Disease: A 25 Years Single Center Experience; _]D. Bobylev^1^, J. Salman1, W. Sommer1, I. Tudorache1, F. Ius1, T. Siemeni1, C. Kuehn1, M. Avsar1, C. Bara1, A. Horke1, D. Boethig1, N. Schwerk2, J. Gottlieb3, A. Haverich1, G. Warnecke1. [^1^]_]Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Pediatric Pulmonology and Neonatology, Hannover Medical School, Hannover, Germany, 3Pulmonary Medicine, Hannover Medical School, Hannover, Germany

 

[*6:25 PM (357) *][Heart-Lung Transplantation: A Viable Option for Systemic Sclerosis; _]L. K. Stern, R. G. Kiel, M. Janmohamed, L. Klein, T. De Marco, V. N. Selby. _Cardiology, University of California, San Francisco, San Francisco, CA

 

[*6:30 PM (358) *]Repeated Levosimendan Infusions in Refractory Heart Failure. Single Center Experience.; _]E. Perna, E. Ammirati, F. M. Turazza, M. Cipriani, L. D’Angelo, G. Foti, A. Garascia, F. Macera, G. Masciocco, M. Frigerio. [_A. DeGasperis CardioCenter, Niguarda-Ca’ Granda Hospital, Milan, Italy

 

[*6:35 PM (359) *][The Hemodynamic Effects of Milrinone in the Beta-Blocker Era; _]S. Kalantari Tannenbaum, J. Grinstein, B. Smith, K. Marinescu, N. Sarswat, S. Adatya, G. Sayer, G. H. Kim, T. Ota, V. Jeevanandam, N. Uriel. _Cardiology, University of Chicago, Chicago, IL

 

[*6:40 PM (360) *][Value of N-Terminal Pro-Brain Natriuretic Peptide in the Assessment of Aerobic Capacity in Heart Failure Patients; _]J. Huang. _Department of Heart Transplant Center, Fuwai Hospital, Peking Union Medical College, Beijing, China

 

[*6:45 PM (361) *]Correlation of GDF-15 with Worsening Functional Capacity and Echocardiographic Parameters in Idiopathic Dilated Cardiomyopathy; _]N. Nair^1^, E. Gongora2. [^1^]_][_ Cardiology, S &W, Temple , TX, Texas Tech Health Scieces Center, Lubbock, TX, 2_][_ Cardiology, S &W, Temple , TX, Memorial Heart and Vascular Center, Hollywood, FL _]

 

[*6:50 PM (362) *]Vepoloxamer (Purified Sodium-Free Poloxamer-188) Improves LV Systolic Function in Dogs with Advanced Heart Failure and Protects Failing Cardiomyocytes from Calcium Overload; _]H. N. Sabbah^1^, R. C. Gupta2, M. Emanuele3. [^1^]_]Henry Ford Hospital, Detroit, MI, 2Medicine, Henry Ford Hospital, Detroit, MI, 3Mast Therapeutics, Inc., San Diego, CA

 

[*6:55 PM (363) *][_ Impact of Health Literacy on Knowledge and Self-Care in Heart Failure Patients, Pre- and Post-Intervention; ]J. McConnery, J. MacIver, C. Alba, F. Foroutan, H. J. Ross. _Heart Failure and Transplantation, University Health Network, Toronto, ON, Canada

 

 

6:00 PM – 7:00 PM

[*Mini Oral 11: Models in Transplantation: From Mouse to Rat to Pig to Human *]

Location:

Delaware Suite

[*Target Audience: *]

BSI, HTX, LTX, MCS

 

[*Chairs: *]

Marcelo Cypel, MD, and William E Stansfield, M.D.

 

[*6:00 PM (364) *]Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with Splenic B-Cell Reduction: A Study of Multiparameter Flow Cytometry; _]I. Kim, G. D. Wu, N. Chai, A. S. Klein, S. Jordan. [_Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

 

[*6:05 PM (365) *]Assessment of Neonatal Tolerance to Blood Group A-Antigen in a Mouse Model of ABO-Incompatible Heart Transplantation; _]B. Motyka1, B. Lamarche1, K. Labonte1, S. Wang1, J. Pearcey1, K. Tao1, M. Mengel2, B. Sis2, P. J. Cowan3, L. J. West^4^. [^1^]_]Dept. Pediatrics, University of Alberta, Edmonton, AB, Canada, 2Dept. Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada, 3St Vincent’s Hospital, Melbourne, Australia, 4Dept. Pediatrics, Surgery, Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada

 

[*6:10 PM (366) *]Impact of Methylprednisolone on the Development of Myocardial Edema in Hearts Donated After Circulatory Death During Ex Vivo Perfusion; _]J. K. Sandha^1^, C. White2, A. Müller3, E. Ambrose4, J. Thliveris5, I. Dixon4, R. Arora6, G. Tian7, L. Hryshko4, J. Nagendran2, D. H. Freed2. [^1^]_]Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 2Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, 3Physiology, University of Alberta, Edmonton, AB, Canada, 4Institute of Cardiovascular Sciences, St. Boniface Research Centre, Winnipeg, MB, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Cardiac Surgery, St. Boniface Research Centre, University of Manitoba, Winnipeg, MB, Canada, 7National Research Council Institute for Biodiagnostics, Winnipeg, MB, Canada

 

[*6:15 PM (367) *]Cytokine Filtration Modulates Pulmonary Metabolism and Edema Formation During Ex Vivo Lung Perfusion; _]I. Iskender^1^, T. Cosgun1, S. Arni1, M. Trinkwitz2, S. Fehlings2, N. Cesarovic2, T. Frauenfelder2, W. Weder1, I. Inci1. [^1^]_]Department of Thoracic Surgery, University Hospital Zurich – University of Zurich, Zurich, Switzerland, 2University Hospital Zurich – University of Zurich, Zurich, Switzerland

 

[*6:20 PM (368) *][_ Pre- and Reconditioning of DCD Donor Lungs on Ex-Vivo Lung Perfusion by Methylprednisolone; ]A. Martens^1^, D. E. Van Raemdonck2, B. M. Vanaudenaerde3, S. E. Verleden3, G. M. Verleden3, R. Vos3, A. P. Neyrinck1. [1_]Cardiovascular Sciences – Anesthesiology and Algology, KU Leuven, Leuven, Belgium, 2Department of Clinical and Experimental Medicine – Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium, 3Department of Clinical and Experimental Medicine – Pneumology, KU Leuven, Leuven, Belgium

 

[*6:25 PM (369) *][Cyclosporine A Can Mitigate Mitochondrial Dysfunction in Lung Grafts during Ex Vivo Lung Perfusion: A Potent Contributor for Better Preconditioning; _]S. Haam, K. Noda, J. D’Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:30 PM (370) *]Prolonged Warm Ischemia Prevents Lung Allograft Acceptance in Lung Transplantation from Donation after Cardiac Death in the Mouse; _]Y. Hirano^1^, S. Sugimoto1, T. Kurosaki2, S. Otani2, K. Miyoshi1, M. Yamane1, T. Oto2, S. Miyoshi1. [^1^]_]Department of General Thoracic Surgery, Okayama University Hospital, Okayama City, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama City, Japan

 

[*6:35 PM (371) *][Protective Effect of Imatinib on Ischemia-Reperfusion Injury in Rat Lung; _]S. Tanaka, T. F. Chen-Yoshikawa, T. Menju, M. Saito, A. Takahagi, E. Miyamoto, M. Takahashi, K. Ohata, T. Kondo, K. Hijiya, H. Motoyama, A. Aoyama, H. Date. _Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine, Kyoto, Japan

 

[*6:40 PM (372) *][Lung Storage in Hydrogen-Rich Saline Attenuates Lung Ischemia-Reperfusion Injury; _]M. Takahashi, T. F. Chen-Yoshikawa, M. Saito, S. Tanaka, E. Miyamoto, A. Takahagi, K. Ohata, T. Kondo, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Graduate School of Medicine, Kyoto University, Kyoto, Japan

 

[*6:45 PM (373) *][MHC-Inbred CLAWN Miniature Swine as Preclinical Large Animal Model for Lung Transplantation; _]H. Sahara, M. Sekijima, T. Iwanaga, Y. Ichinari, A. Shimizu, K. Yamada. _Division of Organ Replacement and Xenotransplantation Surgery, Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan

 

[*(374) *]MOVED TO CONCURRENT SESSION 18

 

[*6:50 PM (477) *][Circulating Cytokines vs. Leukocytes: A Therapeutic Target during Ex Vivo Lung Perfusion; _]K. Noda, S. Haam, D. Zaldonis, J. D’Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*6:55 PM (375) *]Recapitulating T Cell Development in the Immature Environment of the Neonate to Induce Transplant Tolerance; _]R. A. Bascom1, K. Tao1, L. J. West^2^. [^1^]_]University of Alberta, Edmonton, AB, Canada, 2Pediatrics, Surgery, Medical Microbiology/Immunology, University of Alberta, Edmonton, AB, Canada

 

 

6:00 PM – 7:00 PM

[*Mini Oral 12: Applied Health Research and Pulmonary Hypertension *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

NHSAH, EEP, HTX, LTX, MCS, PEDS, PH

 

[*Chairs: *]

Caron L Burch, MSN, and Ioana R Preston, MD

 

[*6:00 PM (376) *]Associations Among Care Dependency, Cognition, and Self-Efficacy in Patients with Left Ventricular Assist Devices (LVADs); _]J. Casida^1^, H. Wu2. [^1^]_]School of Nursing, University of Michigan, Ann Arbor, MI, 2Goldfarb School of Nursing, Barnes-Jewish College, St. Louis, MO

 

[*6:05 PM (377) *]Care Giver Support for Heart Transplant: Does the Type of Provider Matter?; _]E. Stimpson, A. Velleca, T. Kao, L. Kim, M. Kittleson, J. Patel, L. Czer, D. Chang, M. Hamilton, D. Ramzy, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*6:10 PM (378) *]Effects of Pre-Transplant Depression and Anxiety Symptoms on Morbidity and Mortality Post-Heart Transplant: A Retrospective Cohort Study; _]F. R. Epstein^1^, A. Lucero2. [^1^]_]Heart Transplant, Kaiser Permanente Northern California, Santa Clara, CA, 2Internal Medicine, Kaiser Permanente Northern California, Santa Clara, CA

 

[*6:15 PM (379) *]Variability in Depressive Symptoms Among Heart Transplant Patients Across Different Countries: A Cross-Sectional Study; _]N. Duerinckx^1^, S. De Geest2, L. Berben2, K. Denhaerynck2, C. Russell3, R. Helmy2, J. Vanhaecke4, M. G. Crespo-Leiro5, F. Dobbels1. [^1^]_]Departement of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, Leuven, Belgium, 2Institute of Nursing Science, Basel, Switzerland, 3School of Nursing and Health Studies, Missouri, KS, 4Department of Cardiology, University Hospitals of Leuven, Leuven, Belgium, 5Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain

 

[*6:20 PM (380) *][Functional Outcomes and Quality of Life in Patients Undergoing Extracorporeal Membrane Oxygenation Pre or Post Lung Transplantation – An Observational Study; _]K. Hayes, C. L. Hodgson, V. A. Pellegrino, G. Snell, B. Tarrant, L. M. Fuller, A. E. Holland. _The Alfred Hospital, Melbourne, Australia

 

[*6:25 PM (381) *][Nurse Practitioners Provide Safe and Effective Care to Patients in the First Year after Cardiac Transplantation in a Combined Nurse Practitioner-Physician Clinic; _]C. M. Murks, T. RIley, J. Powers, G. Sayer, M. Reilly, B. Valentine-Bates, J. Legaretta, G. Kim, N. Sarswat, S. Adatya, N. Uriel. _Medicine, University of Chicago, Chicago, IL

 

[*6:30 PM (382) *]Inflammatory Cytokines and Markers of Vascular Remodeling and Angiogenesis Are Associated with Functional Capacity, Hospitalizations and NT-ProBNP Levels in Patients with Pulmonary Arterial Hypertension; _]R. A. Davey^1^, Y. Rao2, K. Shen2, R. L. Benza1, A. Raina1. [^1^]_]Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 2United Therapeutics, Triangle Park, NC

 

[*6:35 PM (383) *]Elevated Diastolic Pulmonary Gradient Is Common in the Acute Respiratory Distress Syndrome but Does Not Predict Mortality; _]T. Metkus^1^, E. Tampakakis1, C. Mullin1, T. Kolb1, S. Mathai1, R. Damico1, V. Selby2, T. De Marco2, P. Hassoun1, R. Brower1, R. Tedford1. [^1^]_]Johns Hopkins Hospital, Baltimore, MD, 2University of California San Francisco, San Francisco, CA

 

[*6:40 PM (384) *]Short-Term Venoarterial Extracorporeal Membrane Oxygenation for Endobronchial Hemorrhage after Pulmonary Endarterectomy; _]S. Guth^1^, C. B. Wiedenroth1, T. Kramm1, T. Risch2, M. Wollenschlaeger3, M. J. Richter4, H. A. Ghofrani4, M. Arlt2, E. Mayer1. [^1^]_]Department of Thoracic Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany, 2Department of Anesthesiology, Kerckhoff-Clinic, Bad Nauheim, Germany, 3Perfusion Service, Kerckhoff-Clinic, Bad Nauheim, Germany, 4Department of Pulmonology, Kerckhoff-Clinic, Bad Nauheim, Germany

 

[*6:45 PM (385) *]Searching for CTEPH; a Swedish National Follow-Up after en Episode of Acute Pulmonary Embolism; _]T. Andersson1, B. Carlberg2, F. Larsen3, S. Soderberg^1^. [^1^]_]Department of Public Health and Clinical Medicine, Cardiology, Umea University, Umea, Sweden, 2Department of Public Health and Clinical Medicine, Medicine, Umea University, Umea, Sweden, 3Department of Clinical Physiology, Karolinska University Hopsital, Stockholm, Sweden

 

[*6:50 PM (386) *]Incremental Benefit of Echocardiographic Imaging and Cardiopulmonary Exercise Test in Prognostic Evaluation of Idiopathic Pulmonary Arterial Hypertension; _]R. Badagliacca^1^, S. Papa1, G. Valli1, B. Pezzuto1, R. Poscia1, G. Manzi1, E. Giannetta2, S. Sciomer1, F. Fedele1, C. D. Vizza1. [^1^]_]Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, 2Experimental Medicine, Sapienza University of Rome, Rome, Italy

 

[*(387) *]MOVED TO CONCURRENT SESSION 38

 

[*6:55 PM (986) *]Impaired Right Ventricular Function after Exercise Assessed by First-Pass Radionuclide Angiography in Pulmonary Hypertension; _]P. Hsu1, Y. Wu2, M. Cheng3, Y. Lin4, J. Chen5, H. Hsu^5^. [^1^]_]Nuclear Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan, 2Cardiology Division of Cardiovascular Medical Center and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan, 3Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 4Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 5Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

 

 

*ANNUAL MEETING SCIENTIFIC PROGRAM *

SATURDAY, APRIL 30, 2016

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle *]

 

Location:

Thurgood Marshall

 

[*Target Audience: *]

MCS, ALL

 

[*Chairs: *]

Pascal N. Leprince, MD, PhD, and Palak Shah, MD, MS

[
*Session Summary: *] This session will address the challenges of the diagnosis, pre- and post-operative management, and long-term consequences of right ventricular dysfunction after left ventricular mechanical support.

7:00 AM

How Do We Assess RV Function and Predict RV Dysfunction After LVAD?

 

Michael S. Kiernan, MD, Tufts Medical Center, Boston, MA, USA

 

7:15 AM

Q & A

 

7:20 AM

Peri-operative Approach to RV Dysfunction

 

Tobias Deuse, MD, PhD, University of California – San Francisco, San Francisco, CA, USA

 

7:35 AM

Q & A

 

7:40 AM

What If We Guess Wrong? The Approach to Chronic RV Dysfunction

 

Susan M Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

 

7:55 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure *]

 

Location:

Maryland Suite

 

[*Target Audience: *]

HF, HTX, MCS, NHSAH, PEDS, PH

 

[*Chairs: *]

Richard Cheng, MD and Choon Pin Lim, MD

[
*Session Summary: *]Valvular heart disease is emerging as a progressively more common cause of congestive heart failure. Proper timing is crucial in managing these patients. However, it is not uncommon to find patients with valvular disease and advanced heart failure that may have missed the surgical window. The question often arises “Does left or right ventricle dysfunction become so far advanced that surgery is impossible? The advent of percutaneous devices may advance the timing of mechanical intervention further with potential improvement in outcomes and delay the need of mechanical support or transplant. This session will provide guidance on how to approach these patients based on current knowledge and the future in an area that is evolving.

7:00 AM

Lost Cause: When is the Ventricle Too Poor to Fix the Aortic Valve?

 

Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Centre NRW, Bad Oeynhausen, Germany

 

7:12 AM

Q & A

 

7:15 AM

The Forgotten Valve: Lessons to be Learned in Tricuspid Regurgitation

 

Ivan Knezevic, MD, University Clinical Centre, Ljubljana, Slovenia

 

7:27 AM

Q & A

 

7:30 AM

Medical / Percutaneous Treatment of Mitral Valve Disease: The Future Beckons

 

Sofia C Masri, MD, University of Washington, Seattle, WA, USA

 

7:42 AM

Q & A

 

7:45 AM

Mitral Intervention with Poor LVEF: Worth the Risk?

 

Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival *]

 

Location:

Virginia Suite

 

[*Target Audience: *]

LTX, ALL

 

[*Chairs: *]

Fabienne Dobbels, MSc, PhD, and Cynthia J. Gries, MD, MSc

[
*Session Summary: *]This session will discuss how quality of life outcomes such as sense of wellbeing, functional status and relief from disability that clinicians and patient’s consider fundamental, define the net benefit of lung transplantation.

7:00 AM

What is Health-Related Quality of Life Really, and Does Lung Transplant Improve It?

 

Christiane Kugler, RN, PhD, University Witten, Witten, Germany

 

7:12 AM

Neurocognitive Changes After Lung Transplantation – Are They Important?

 

Patrick Smith, PhD, MPH, Duke University, Durham, NC, USA

 

7:24 AM

Integrating Quality of Life and Survival Outcomes in Lung Transplantation

 

Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA

 

7:36 AM

How to Assess Functional Impairment and Disability Post Lung Transplant

 

Jonathan P Singer, MD, University of California, San Francisco, CA, USA

 

7:48 AM

PANEL DISCUSSION

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It *]

Location:

Delaware Suite

 

[*Target Audience: *]

NHSAH, HF, HTX, LTX, MCS

 

[*Chairs: *]

Maria C Gazzaneo, MD, and Kevin C. Carney, MSN, CRNP, CCTC

[
*Session Summary: *]Ambulation of patients supported on ECMO is a relatively new concept. This session will explore the risks and benefits of mobilizing adult patients supported on ECMO with a focus on the importance of the team approach.

7:00 AM

What Lessons Can We Learn From Our Children?

 

Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

 

7:12 AM

Medical Considerations in the Ambulation of ECMO patients

 

Enrique Diaz Guzman Zavala, MD, University of Alabama, Birmingham, AL, USA

 

7:24 AM

It Takes a Village: Implementing Ambulatory ECMO in the Adult Setting

 

Bryan Boling, RN, BSN, DNPc, University of Kentucky, Lexington, KY, USA

 

7:36 AM

Physiotherapy Considerations in the Ambulation of ECMO Patients

 

Kate Hayes, BPhysio (Hons), MPhysio (Cardio), PhD©, The Alfred Hospital, Melbourne, Australia

 

7:48 AM

PANEL DISCUSSION

 

 

7:00 AM – 8:00 AM

[*Sunrise Symposium 11: Controversies in Pediatric Heart Failure *]

 

Location:

Washington Ballroom 2

 

[*Target Audience: *]

PEDS, HF, NHSAH, PHARM

 

[*Chairs: *]

Joshua D. Sparks, MD, and Thomas Moller, MD, PhD

[
*Session Summary: *]Pediatric heart failure therapy is coming of age. Medication, MCS and SCD prevention will be discussed. The new heart failure registry’s importance in informing treatment decisions in the future will be considered.

7:00 AM

Pharmaceutical Options – Are The New Ones Any Better?

 

Robert E. Shaddy, MD, The Children’s Hospital, Philadelphia, PA, USA

 

7:12 AM

Q & A

 

7:15 AM

Who Dies Suddenly And Can We Prevent It?

 

Robert G. Weintraub, FRACP, FACC, Royal Children’s Hospital, Melbourne, Australia

 

7:27 AM

Q & A

 

7:30 AM

Making Palliative Care Part of the Plan

 

Elizabeth Blume, MD, Children’s Hospital, Boston, MA, USA

 

7:42 AM

Q & A

 

7:45 AM

Will the New ISHLT Pediatric Heart Failure Registry (iPHFR) Save Lives or Just Create More Work?

 

Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

 

7:57 AM

Q & A

 

 

7:00 AM – 8:00 AM

Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond

 

Location:

Washington Ballroom 1

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Mandeep R. Mehra, MD, MBBS, FACC, FACP, and Patricia Ging, PharmD

[
*Session Summary: *]The goal of this session is to examine the role of precision medicine in transplantation. From understanding whether pharmacogenetics can both guide dosing of immunosuppressants and predict adverse effects to how in the modern era we have medications that alter gene expression.

7:00 AM

Pharmacogenetics: Is It Ready for Prime Time?

 

Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

 

7:15 AM

Q & A

 

7:20 AM

Genetic Predictors of Medication-Induced Adverse Effects

 

Christina Aquilante, PharmD, University of Colorado, Aurora, CO, USA

 

7:35 AM

Q & A

 

7:40 AM

Therapeutic Gene Modulation – What Can We Learn From CF?

 

Denis Hadjiliadis, MD, University of Pennsylvania, Philadelphia, PA, USA

 

7:55 AM

Q & A

 

 

8:00 AM – 9:30 AM

Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, HTX, NHSAH

 

[*Chairs: *]

Cumara C Sivathasan, MBBS, FRCS, and Jennifer A Cowger, MD, MS

 

[*8:00 AM (388) *]Destination Therapy in a Single European Country. Insights from the ITAMACS Registry; _]G. Feltrin^1^, F. Pappalardo2, G. Gerosa3, C. F. Russo4, M. Rinaldi5, M. Maccherini6, A. Apostolo7, G. Faggian8, U. Livi9, A. Iacovoni10, M. Massetti11, F. Musumeci12, G. Di Giammarco13, G. Ambrosio14, A. Loforte15, D. Pini16, C. Falletta17, C. Amarelli18, A. Grimaldi19, F. M. Pagani20, G. leonardi21, A. Frigo22, L. Rizzato23, A. Nanni Costa24. [^1^]_]Veneto Regional Centre for Transplant Coordination, Padova, Italy, 2Cardioth. Dept, San Raffaele Hospital, Vita Salute Univ, Milan, Italy, 3Cardiac, Thoracic, Vascular Sciences, Univ Hospital of Padova, Padova, Italy, 4Dept of Cardiovascular Surgery, A. De Gasperis Cardio Center Niguarda Hospital, Milan, Italy, 5Surgical Sciences, Univ of Turin, Turin, Italy, 6Cardiothoracic Dept, Le Scotte Hospital, Siena, Italy, 7Centro Cardiologico Fondazione Monzino IRCCS, Milan, Italy, 8Cardiac Surgery Unit, Univ Hospital of Verona, Verona, Italy, 9Cardiothoracic Department, Univ Hospital of Udine, Udine, Italy, 10Cardiovascular Dept, Hospital Papa Giovanni XXIII, Bergamo, Italy, 11Cardiac Surgery Unit, Sacro Cuore Univ, Rome, Italy, 12Dept of Cardiac Surgery, San Camillo Forlanini Hospital, Rome, Italy, 13Dept of Neurosciences Imaging and Clinical Sciences, Univ of Chieti, Chieti, Italy, 14Cardioth. Dept, Univ Hospital of Perugia, Perugia, Italy, 15Dept of Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna, Italy, 16Dept of Cardiology, Humanitas Research Hospital, Milan, Italy, 17Dept for Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS ISMETT, Palermo, Italy, 18Dept of Cardiovascular Surgery and Transplantation, Monaldi Hospital, Naples, Italy, 19Cardiac Surgery, Univ of Bari, Bari, Italy, 20Dept of Cardiac Surgery, IRCCS Foundation Policlinico San Matteo, Pavia, Italy, 21[_ Univ Hospital "V- Emanuele", Catania, Italy, 22_]Cardiac, Thoracic, Vascular Sciences, Univ of Padova, Padova, Italy, 23Veneto Region, National Centre for Transplant Coordination, Rome, Italy, 24National Centre for Transplant Coordination, Rome, Italy

 

[*(389) *]WITHDRAWN

 

[*8:15 AM (332) *]Mechanical Circulatory Support for the Fontan Circulation; _]L. C. Reardon^1^, H. Laks2, R. Biniwale2, A. Hageman3, R. Bolanos3, K. Delacruz3, A. Salimbangon3, K. Wetzlar4, G. Derk3, J. Aboulhosn5. [^1^]_]Departments of Adult and Pediatric Cardiology, UCLA, Los Angeles, CA, 2Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA, 3UCLA, Los Angeles, CA, 4Department of Mechanical Engineering, UCLA, Los Angeles, CA, 5Department of Cardiology, UCLA, Los Angeles, CA

 

[*8:30 AM (390) *]Permanent Atrial Fibrillation and 1-Year Clinical Outcome in Patients with Left Ventricular Assist Device Implants; _]C. U. Oezpeker, M. Morshuis, M. Schoenbrodt, A. Zittermann, J. Gummert. [_Cardiac Surgery, HDZ-NRW, Bad Oeynhausen, Germany

 

[*8:45 AM (391) *]Differential Assessment of von Willebrand Factor Dysfunction in Durable Mechanical Circulatory Support: A Plead for Standardization; _]S. Maltais^1^, D. Gailani2, M. E. Davis2, A. Matafonov2, N. A. Haglund2. [^1^]_]Mayo Clinic, Rochester, MN, 2Vanderbilt, Nashville, TN

 

[*9:00 AM (392) *]Relationship of Factor II and Factor X Activity with International Normalized Ratio (INR) in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients: A Cross-Sectional Study; _]V. K. Topkara^1^, A. B. Eisenberger1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, V. Ton1, F. Castagna1, A. M. Clemons1, M. Flannery2, R. Te-Frey2, A. L. Uryevick2, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*9:15 AM (393) *]Multi-Institutional Analysis of Temporal Patterns and Nature of Neurological Events after Left Ventricular Assist Device Implant; _]J. M. Stulak^1^, S. Dunlay1, S. Sharma1, N. Haglund2, F. D. Pagani3, K. Aaronson3, P. Shah4, J. Cowger5, S. Maltais1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Surgery, Vanderbilt Heart, Nashville, TN, 3Cardiovascular Surgery, University of Michigan, Ann Arbor, MI, 4Cardiovascular Surgery, Inova Fairfax, Falls Church, VA, 5Cardiovascular Surgery, St. Vincent’s Hospital, Indianapolis, IN

 

 

8:00 AM – 9:30 AM

[*Concurrent Session 42: Difficult Decisions in Mechanical Support *]

 

Location:

Maryland Suite

[*Target Audience: *]

MCS, HTX, NHSAH

 

[*Chairs: *]

Alejandro M Bertolotti, MD, and Jerry D Estep, MD

 

[*8:00 AM (394) *]Utilization and Outcomes of Ventricular Assist Device Support in Adult Congenital Heart Disease: An Analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS); _]C. J. VanderPluym^1^, P. Eghtesady2, B. G. Maxwell3, J. M. Gelow4, L. J. Burchill5, S. Maltais6, R. S. Cantor7, E. D. Blume1. [^1^]_]Cardiology, Boston Children’s Hospital, Boston, MA, 2Surgery – Cardiothoracic, Washington University School of Medicine, St. Louis, MO, 3Anesthesiology, Randall Children’s Hospital, Portland, OR, 4Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, 5Cardiology, Knight Cardiovascular Institute at Oregon Health Science University, Portland, OR, 6Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, 7Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL

 

[*8:15 AM (395) *][ECMO with Multiple-Organ Failure: Can Liver Dialysis Improve Survival?; _]B. Sparks, H. Hirose, N. Cavarocchi. _Department of Surgery, Thomas Jefferson University, Philadelphia, PA

 

[*8:30 AM (396) *][Characteristics and In-Hospital Outcomes of Adults Undergoing Extracorporeal Membrane Oxygenation; _]C. K. McIlvennan, D. P. Kao. _University of Colorado, Aurora, CO

 

[*8:45 AM (397) *]Outcomes of Continuous-Flow Left Ventricular Assist Device Insertion for Acute Myocardial Infarction and Cardiogenic Shock: Importance of Bridging Strategy; _]H. Ikegami^1^, K. Takeda1, H. Takayama1, A. R. Garan2, V. K. Topkara2, S. Fukuhara1, P. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1. [^1^]_]Department of Surgery, Division of Cardiothoracic Surgery, Columbia University, New York, NY, 2Department of Medicine, Division of Cardiology, Columbia University, New York, NY

 

[*9:00 AM (398) *]Equivalent Mortality but Higher Morbidity in Patients Receiving Temporary Mechanical Support Prior to Permanent LVAD Implantation; _]L. E. Johnston^1^, G. Ailawadi1, E. A. Downs1, J. B. Rich2, A. M. Speir3, M. A. Quader4, J. L. Kennedy5, L. T. Yarboro1, J. A. Kern1, S. Mazimba5. [^1^]_]Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, 2Sentara Heart Hospital, Norfolk, VA, 3Inova Heart and Vascular Center, Falls Church, VA, 4Virginia Commonwealth University, Richmond, VA, 5University of Virginia, Charlottesville, VA

 

[*9:15 AM (399) *]Outcome of Patients Treated with Left Ventricular Assist Device (LVAD) as Bridge to Transplantation (BTT) or Bridge to Candidacy (BTC) vs. Marginal Heart Transplantation; _]A. Loforte^1^, A. Montalto2, G. Jafrancesco1, M. Cefarelli1, P. Lilla Della Monica2, F. Grigioni3, M. Masetti3, L. Potena3, F. Sbaraglia2, V. Polizzi2, G. Marinelli1, F. Musumeci2. [^1^]_]Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy, 3Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy

 

 

8:00 AM – 9:30 AM

[*Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant *]

 

Location:

Virginia Suite

[*Target Audience: *]

HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM

 

[*Chairs: *]

Finn Gustafsson, MD, PhD, and Jan F Gummert, MD, PhD

 

[*8:00 AM (400) *][LVAD BTT Risk Score Predicts 1-Year Mortality in Patients Bridged to Transplant with a CF-Left Ventricular Assist Device (LVAD); _]G. Ashrith, D. T. Nguyen, J. Amione-Guerra, B. H. Trachtenberg, A. Bhimaraj, B. Bruckner, E. E. Suarez, A. Gaber, E. A. Graviss, M. H. Park, J. D. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX

 

[*8:15 AM (401) *]Impact of Mechanical Circulatory Support Before Cardiac Transplantation on Early and Late Rejection, Allograft Vasculopathy and Survival: Analysis of the ISHLT Adult Heart Transplant Registry; _]S. K. Bhagra^1^, J. Duero Posada1, C. Manlhiot2, J. Murray2, A. Dipchand3, J. Stehlik4, H. Ross1. [^1^]_]Cardiology, Toronto General Hospital, Toronto, ON, Canada, 2Cardiovascular Data Management Center, The Hospital for Sick Children, Toronto, ON, Canada, 3Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, 4Cardiology, University of Utah, Salt Lake City, UT

 

[*8:30 AM (402) *][Continuous Flow Left Ventricular Assist Device as a Risk Factor for Intraoperative Vasoplegia during Orthotopic Heart Transplantation; _]L. Truby, K. Takeda, M. Farr, M. Lippel, M. Yuzefpolskaya, P. Colombo, H. Takayama, D. Mancini, Y. Naka. _Columbia University College of Physicians and Surgeons, New York, NY

 

[*8:45 AM (403) *]Obesity and Wait-List Outcomes in Patients with Continuous Flow Left Ventricular Assist Devices as Bridge to Transplantation; _]S. G. Al-Kindi^1^, M. Kattea1, M. Farhoud1, M. Ginwalla1, C. ElAmm2, M. Zacharias2, R. Benatti2, B. Sareyyupoglu1, S. Park2, B. Medalion1, S. Deo1, G. H. Oliveira1. [^1^]_]University Hospitals Case Medical Center, Cleveland, OH, 2Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH

 

[*9:00 AM (404) *]Does Left Ventricular Assist Device Mechanics Impact Pre Cardiac Transplant Allosensitization and Post-Transplant Survival?; _]S. Allana, J. Liou, E. Jacobs, T. Ellis, P. Rahko, S. Akhter, R. Dhingra. [_University of Wisconsin-Madison, Madison, WI

 

[*9:15 AM (405) *]Outcome of Patients Having Multiple Mechanical Circulatory Support Devices before Orthotopic Heart Transplantation; _]B. Li^1^, K. Takeda1, P. A. Kurlansky1, S. Fukuhara1, M. Wright1, S. Sreekanth1, J. Han1, C. Chiuzan2, L. K. Truby3, A. R. Garan3, V. Topkara3, M. Yuzefpolskaya3, P. C. Colombo3, M. A. Farr3, H. Takayama1, Y. Naka1. [^1^]_]Surgery, Columbia University Medical Center, New York, NY, 2Biostatistics, Columbia University Medical Center, New York, NY, 3Medicine, Columbia University Medical Center, New York, NY

 

 

8:00 AM – 9:30 AM

[*Concurrent Session 44: Lung Transplantation – Advanced Diagnostics! *]

Location:

Delaware Suite

[*Target Audience: *]

LTX, BSI, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Allan R Glanville, MBBS, MD, FRACP, and Arne Neyrinck, MD, PhD

 

[*8:00 AM (406) *]Microarray Analysis of Endobronchial Lung Transplant Biopsies: Detection of T-cell Mediated Inflammation in a Safer Biopsy; _]K. Halloran^1^, J. Chang1, V. Ramassar2, J. Weinkauf1, A. Kapasi1, A. Hirji1, D. Lien1, J. Reeve2, P. Halloran2. [^1^]_]Medicine, University of Alberta, Edmonton, AB, Canada, 2Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, AB, Canada

 

[*8:15 AM (407) *]Mitochondria Release Leads from Human Lung Transplant Recipients Promotes Primary Graft Dysfunction; _]D. Scozzi^1^, X. Lin1, X. Wang1, M. Ibrahim1, M. Zhu1, A. Krupnick1, D. Kreisel1, M. Miller2, A. Gelman1. [^1^]_]Surgery, Washington University, St. Louis, MO, 2Pathology and Immunology, Washington University, St. Louis, MO

 

[*8:30 AM (408) *]Endothelial-Bound TLR-Dependent CX3CR1+CCR2-Ly6Clow Monocytes in Donor Lungs Mediate Primary Graft Dysfunction Following Murine Lung Transplantation; _]S. Chiu^1^, Z. Zheng2, H. Sun1, M. M. DeCamp1, D. Kreisel3, G. S. Budinger4, H. Perlman5, A. Misharin4, A. Bharat1. [^1^]_]Thoracic Surgery, Northwestern University, Chicago, IL, 2Transplant Surgery, Northwestern University, Chicago, IL, 3Thoracic Surgery, Washington University, St. Louis, MO, 4Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL, 5Rheumatology, Northwestern University, Chicago, IL

 

[*8:45 AM (409) *]Normothermic Donor Lung Preservation with Portable EVLP Maintains IL-33-Driven Epithelial Integrity and Suppresses Inflammation in the Recipient; _]B. Wiegmann^1^, C. Falk2, M. Seyda3, C. Neudörfl2, C. Kühn1, I. Tudorache1, M. Avsar1, A. Haverich1, G. Warnecke1. [^1^]_]Dpt. for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, 3Division of Transplant Surgery, Harvard Medical School, Boston, MA

 

[*9:00 AM (410) *]Long Pentraxin3 Deficiency Enhance Chronic Lung Allograft Dysfunction in a Mouse Orthotopic Lung Transplantation Model; _]M. Yoshida^1^, H. Oishi1, T. Martinu1, D. Hwang1, T. McKee2, X. Bai1, Z. Guan1, H. Cho1, S. Juvet1, M. Cypel1, S. Keshavjee1, M. Liu1. [^1^]_]Surgery, Latner Thoracic Surgery Laboratories, Division of Thoracic Surgery, Toronto, ON, Canada, 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

 

[*9:15 AM (411) *]Biological Effects of Mesenchymal Stem Cell (MSC) Therapy in Patients with Chronic Lung Allograft Dysfunction (CLAD); _]A. Z. Zubair^1^, A. L. Russell1, R. C. Lefavor1, C. M. Desmond1, C. A. Keller2. [^1^]_]Laboratory Medicine and Pathology, Mayo Clinic Transplant Center, Jacksonville, FL, 2Transplant, Mayo Clinic, Jacksonville, FL

 

 

8:00 AM – 9:30 AM

[*Concurrent Session 45: Pediatric Heart Failure *]

 

Location:

Washington Ballroom 2

[*Target Audience: *]

PEDS, HF, HTX

 

[*Chairs: *]

Yuk M Law, MD, and Heather T Henderson, MD

 

[*8:00 AM (412) *]Risk Factors at Presentation Predict Outcomes of Pediatric Myocarditis: A Contemporary Multi-Center Cohort; _]S. C. West^1^, G. J. Boyle2, R. J. Butts3, S. R. Deshpande4, K. Gambetta5, K. R. Knecht6, A. K. Lal7, Y. Law8, A. C. Prada-Ruiz9, M. Richmond10. [^1^]_]Pediatric Cardiology, Children’s Hosp of Pittsburgh, Pittsburgh, PA, 2Cleveland Clinic Children’s Hosp, Cleveland, OH, 3Pediatrics, Medical Univ of South Carolina, Charleston, SC, 4Pediatric Cardiology, Children’s Healthcare, Emory Univ, Atlanta, GA, 5Ann & Robert H. Lurie Children’s Hosp, Chicago, IL, 6Univ of Arkansas for Medical Sciences, Little Rock, AR, 7Pediatric Cardiology, Primary Children’s Hosp, Univ of Utah, Salt Lake City, UT, 8Seattle Children’s Hosp, Seattle, WA, 9Cleveland Clinic Children’s Hosp, Cleveland, OH, 10Morgan Stanley Children’s Hosp of Columbia Univ, New York City, NY

 

[*8:15 AM (413) *]A Prospective Randomised Open-Label Clinical Trial of Rapid versus Prolonged Captopril Initiation and Up-Titration in Paediatric Cardiology Inpatients; _]S. L. Roche^1^, K. Timberlake2, C. Manlhoit3, M. Balasingam4, J. Wilson4, K. George4, B. W. McCrindle4, P. F. Kantor5. [^1^]_]Adult Congenital Heart Disease, Univ of Toronto, Toronto, ON, Canada, 2Pharmacy, Hosp for Sick Children, Toronto, ON, Canada, 3Cardiology, Univ of Toronto, Toronto, ON, Canada, 4The Labatt Family Heart Center, Hosp for Sick Children, Toronto, ON, Canada, 5Paediatric Cardiology, Stollery Children’s Hosp, Edmonton, AB, Canada

 

[*8:30 AM (414) *]Utilization and Safety of Long-Term Carvedilol in Pediatric Dilated Cardiomyopathy: A Multicenter Study from the Pediatric Cardiomyopathy Registry; _]J. W. Rossano^1^, C. E. Canter2, D. T. Hsu3, E. Pahl4, D. Dodd5, S. A. Webber5, J. A. Towbin6, S. D. Colan7, P. F. Cantor8, L. J. Addonizio9, J. L. Jefferies10, M. D. Everitt11, S. M. Ware12, T. Lee13, A. Lal14, J. Messere7, J. D. Wilkinson15, S. E. Lipshultz15. [^1^]_]Cardiology, Children’s Hosp of Philadelphia, Philadelphia, PA, 2Cardiology, Washington Univ, St. Louis, MO, 3Cardiology, Children’s Hosp at Montefiore, New York, NY, 4Ann and Robert H. Lurie Children’s Hosp of Chicago, Chicago, IL, 5Cardiology, Vanderbilt Univ, Nashville, TN, 6Cardiology, St. Jude Children’s Research Hosp and Le Bonheur Children’s Hosp, Memphis, TN, 7Cardiology, Boston Children’s Hosp, Boston, MA, 8Cardiology, Stollery Children’s Hosp, Edmonton, AB, Canada, 9Cardiology, Columbia Univ Medical Center, New York, NY, 10Cardiology, Cincinnati Children’s Hosp Medical Center, Cincinnati, OH, 11Cardiology, Children’s Hosp of Colorado, Denver, CO, 12Indiana Univ School of Med, Indianapolis, IN, 13Columbia Univ Mec Center, New York, NY, 14Cardiology, Primary Children’s Hosp, Salt Lake City, UT, 15Wayne State Univ School of Med, Detroit, MI

 

[*8:45 AM (415) *][Outpatient Subcutaneous Treprostinil for Pediatric Single Ventricle Patients; _]S. L. Siehr, M. Ogawa, A. Romfh, D. N. Rosenthal, J. A. Feinstein. _Pediatric Cardiology, Stanford University Lucile Packard Children’s Hospital, Palo Alto, CA

 

[*9:00 AM (416) *]Readmission Following Acute Myocarditis in Pediatric Patients; _]K. R. Knecht^1^, G. Boyle2, R. Butts3, S. R. Deshpande4, K. Gambetta5, A. K. Lal6, M. Richmond7, S. C. West8, C. Prada-Ruiz2. [^1^]_]Univ of Arkansas for Med Sciences, Little Rock, AR, 2Cleveland Clinic Children’s Hosp, Cleveland, OH, 3Med Univ of South Carolina, Charleston, SC, 4Emory Univ, Atlanta, GA, 5Children’s Hosp of Chicago, Chicago, IL, 6Primary Children’s Hosp, Salt Lake City, UT, 7Columbia Univ, New York, NY, 8Children’s Hosp, Pittsburg, PA

 

[*9:15 AM (417) *]Variability in Resource Utilization and Outcomes in Cardiomyopathy and Heart Failure Related Hospitalizations among Pediatric Hospitals in the United States: Potential Role for a Collaborative Learning Network; _]P. Shamszad^1^, C. S. Almond2, K. P. Daly3, A. Lorts4, J. F. Price5, D. N. Rosenthal2, J. W. Rossano1. [^1^]_]Children’s Hosp of Phildelphia, Philadelphia, PA, 2Lucile Packard Children’s Hosp, Palo Alto, CA, 3Boston Children’s Hosp, Boston, MA, 4Cincinnati Children’s Hosp Medical Center, Cincinnati, OH, 5Texas Children’s Hosp, Houston, TX

 

 

8:00 AM – 9:30 AM

[*Concurrent Session 46: From ‘Jeans’ to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics *]

Location:

Washington Ballroom 1

[*Target Audience: *]

BSI, HF, HTX, LBCS, LTX, MCS

 

[*Chairs: *]

Edward Cantu, MD, and Joshua Diamond, MD

 

[*8:00 AM (418) *][Regulated Necrotic Cell Death Mediated by Calpain and RIPK Is Induced by Prolonged Hypothermic Ischemia Followed by Normothermic Reperfusion; _]H. Kim, S. Keshavjee, M. Liu. _Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada

 

[*8:15 AM (419) *]The Donor Heart after Withdrawal of Life Support; _]M. J. Kearns, A. Cheung, J. Bashir, M. A. Seidman, J. H. Boyd. [_UBC Centre for Heart & Lung Innovation, Vancouver, BC, Canada

 

[*8:30 AM (420) *]Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury; _]R. Finnegan1, P. Zhu1, S. Stephenson1, S. Nadig2, C. Atkinson^3^. [^1^]_]Departments of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 2Departments of Surgery, Medical University of South Carolina, Charleston, SC, 3Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC

 

[*8:45 AM (421) *]Reproducibility of Genomic Data Using Standards-Cell Free DNA to Monitor Rejection after Heart Transplantation; _]S. Agbor-Enoh^1^, I. Tunc1, J. Doveikis1, K. Khush2, I. De Vlaminck3, A. Davis1, X. Wang1, M. A. Solomon1, J. Zhu1, H. A. Valantine1. [^1^]_]Nat’l Inst. of Health, Bethesda, MD, 2Stanford University School of Medicine, Palo Alto, CA, 3Cornell University, Ithaca, NY

 

[*9:00 AM (422) *]Genomic Research Alliance for Transplantation (GRAfT): A Model for Long Term Transplant Studies in Thoracic Organ Transplantation; _]S. Agbor-Enoh1, U. Fideli1, J. Doveikis1, J. Zhu1, I. Tunc1, P. Shah^2^, S. Russell3, E. Feller4, K. Shah5, M. Rodrigo6, P. Shah7, S. Pham8, A. Iacono9, S. Nathan10, J. Orens11, N. GRAfT Investigators1, H. Valantine1. [^1^]_]Nat’l Inst. of Health, Bethesda, MD, 2Johns Hopkins Hospital, Baltimore, MD, 3Cardiology, Johns Hopkins Hospital, Baltimore, MD, 4Cadiology, University of Maryland Medical Center, Baltimore, MD, 5Cardiology, Virginia Commonwealth University, Richmond, VA, 6Cardiology, Medstar Washington Hospital Center, Washington, DC, 7Cardiology, INOVA Fairfax Hospital, Fairfax, VA, 8Cadiothoracic Surgery, University of Maryland Medical Center, Baltimore, MD, 9Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, 10Pulmonary and Critical Care Medicine, INOVA Fairfax Hospital, Fairfax, VA, 11Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD

 

[*9:15 AM (423) *]The Epigenomic Landscape of Dilated Cardiomyopathy; _]S. Lin^1^, Y. Lin2, J. D. Lee3, P. Chang3, M. Shi3, E. DePasquale1, A. Nsair1, M. Deng1, P. E. Oyer3, T. Quertermous3, M. P. Snyder3. [^1^]_]UCLA, Los Angeles, CA, 2Washington University, St. Louis, MO, 3Stanford, Stanford, CA

 

 

9:45 AM – 11:45 AM

[*Plenary Session – Pushing New Scientific Frontiers: It’s In Our Heritage *]

 

Location:

Thurgood Marshall

 

[*Target Audience: *]

ALL

 

[*Chairs: *]

Jeffrey J. Teuteberg, MD, and Maryl R. Johnson, MD

 

9:45 AM

AWARDS PRESENTATIONS

 

10:05 AM

Lifetime Achievement Award to Adrian and Jean Kantrowitz

 

Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

 

10:15 AM

The Influence of the Microbiota in Immunity and Transplantation

 

Jonathan S Bromberg, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA

 

10:40 AM

(424) FEATURED ABSTRACT: *]S. Maltais^1^, A. Kilic2, S. Nathan3, M. Keebler4, S. Emani5, J. Ransom6, J. N. Katz7, B. Sheridan8, A. Brieke9, G. Egnaczyk10, J. W. Entwistle11, R. Adamson12, J. Stulak1, N. Uriel13, J. B. O’Connell14, D. J. Farrar14, K. S. Sundareswaran14, I. Gregoric3. [^1^]_]Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Division of Cardiac Surgery, Ohio State University Medical Center, Columbus, OH, 3Memorial Hermann-Texas Medical Center, Houston, TX, 4Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN, 5Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH, 6Baptist Health Heart and Transplant Institute, Little Rock, AR, 7Heart and Vascular Center, University of North Carolina, Chapel Hill, NC, 8Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC, 9University of Colorado School of Medicine, Denver, CO, 10Christ Hospital, Cincinnati, OH, 11Thomas Jefferson University, Philadelphia, PA, 12Sharp Memorial Hospital, San Diego, CA, 13University of Chicago Medical Center, Chicago, IL, 14St.Jude Medical, Pleasanton, CA

 

10:50 AM

Expert Discussant Q & A

 

Jan D Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

 

10:55 AM

Precision Medicine in Organ Transplantation: Moving from Off the Rack to Bespoke

 

Alexandre Loupy, MD, PhD, Necker Hospital, Paris, France

 

11:15 AM

PRESIDENT’S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (PRO)

 

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women’s Hospital, Boston, MA, USA

 

11:30 AM

PRESIDENT’S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (CON)

 

Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

 

 

12:00 PM – 1:30 PM

[*Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS *]

 

Location:

Thurgood Marshall

[*Target Audience: *]

MCS, HF, NHSAH, PH)

 

[*Chairs: *]

J. Eduardo Rame, MD, and Evgenij V Potapov, MD, PhD

 

[*12:00 PM (425) *]The Worldwide Experience of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease; _]D. L. Morales^1^, R. Rizwan1, F. Zafar1, C. Villa2, J. L. Jefferies2, R. Bryant 3rd1, F. A. Arabia3, A. Lorts2. [^1^]_]Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA

 

[*(426) *]WITHDRAWN

 

[*12:15 PM (323) *]Association of Late Aortic and Tricuspid Valve Regurgitation and Outcomes While on Left Ventricular Assist Device Therapy; _]J. M. Stulak^1^, V. Tchantchaleishvili2, S. Dunlay3, S. Sharma1, L. D. Joyce1, D. L. Joyce1, R. C. Daly1, S. Maltais1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Surgery, University of Rochester, Rochester, NY, 3Cardiovascular Diseases, Mayo Clinic, Rochester, MN

 

[*12:30 PM (427) *]Totally Percutaneous RVAD/ECMO Configuration Provides Versatile Support for RV Failure; _]A. Siddique^1^, J. E. Baus2, H. Merritt1, E. L. O’Leary3, T. R. Ryan1, N. T. McCain1, E. R. Lyden4, J. Y. Um1, M. J. Moulton1. [^1^]_]Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, 2Anesthesia, University of Nebraska Medical Center, Omaha, NE, 3Internal medicine, University of Nebraska Medical Center, Omaha, NE, 4Biostatistics, University of Nebraska Medical Center, Omaha, NE

 

[*12:45 PM (428) *]Mitral Regurgitation Is Associated with Right Ventricular Pulsatile Loading and Early Right Heart Failure After Left Ventricular Assist Device; _]E. W. Grandin^1^, A. A. Gulati2, G. S. Troutman1, P. Zamani1, J. A. Mazurek1, E. Y. Birati1, J. W. Wald1, K. B. Margulies1, P. Atluri3, J. E. Rame1. [^1^]_]Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 3Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

 

[*1:00 PM (429) *][Elevated Transpulmonary Gradient Is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension Treated with Continuous-Flow Left Ventricular Assist Devices (CF-LVAD); _]J. Amione-Guerra, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Torre-Amione, M. H. Park, J. D. Estep, G. Ashrith. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*1:15 PM (430) *][Pulmonary Hypertension Results in Worse Post-Transplant Survival in Left Ventricular Assist Device Patients; _]E. M. Schumer, M. C. Black, J. R. Trivedi, A. Cheng, H. T. Massey, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

 

 

12:00 PM – 1:30 PM

[*Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient *]

 

Location:

Maryland Suite

[*Target Audience: *]

MCS, HTX, NHSAH)

 

[*Chairs: *]

Annemarie Kaan, MCN, RN, and Sean P Pinney, MD

 

[*12:00 PM (431) *]A National Survey of Palliative Care Services within INTERMACs Centers; _]S. V. Pamboukian1, R. Tucker1, K. Swetz1, D. Kavalieratos2, J. N. Dionne-Odom1, J. Palmore1, P. Blood^1^, K. R. Allen1, C. Bourgeois1, G. A. Mancarella1, A. Kono3, M. A. Bakitas1. [^1^]_]University of Alabama at Birmingham, Birmingham, AL, 2University of Pittsburgh, Pittsburgh, PA, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

 

[*12:15 PM (432) *]Patient-Caregiver Relationships and Outcomes after LVAD Implantation; _]M. S. Koeckert^1^, P. F. Vining1, A. Reyentovich2, S. D. Katz2, A. DeAnda1, D. E. Smith1, L. B. Balsam1. [^1^]_]Cardiothoracic Surgery, NYU Medical Center, New York, NY, 2Cardiology, NYU Medical Center, New York, NY

 

[*12:30 PM (433) *]Pre-Operative Predictors for Admission to a Rehabilitation Facility after LVAD Implantation and Its Impact on Long Term Survival; _]F. John1, R. Sembrano2, S. Roy3, S. Gupta4, R. Nayak2, D. Plack5, R. Cogswell^3^. [^1^]_]Pediatrics, University of Minnesota, Minneapolis, MN, 2Physical Medicine and Rehabilitation, University of Minnesota, Minneapolis, MN, 3Cardiology, University of Minnesota, Minneapolis, MN, 4Medicine, University of Minnesota, Minneapolis, MN, 5Cardiac Surgery, University of Minnesota, Minneapolis, MN

 

[*12:45 PM (434) *]Assessment of Cognitive Function Prior to and After Implantation of Left Ventricular Assist Device; _]C. K. McIlvennan^1^, K. Bryce2, J. Lindenfeld3, L. A. Allen1, D. E. Lanfear2. [^1^]_]University of Colorado, Aurora, CO, 2Henry Ford, Detroit, MI, 3Vanderbilt, Nashville, TN

 

[*1:00 PM (435) *][Substantial Reduction in Driveline Infection Rates with the Modification of Driveline Dressing Protocols; _]M. Lander, N. Kunz, E. Dunn, K. Lockard, G. O’Shea, S. Weaver, T. Schweke, M. A. Shullo, L. Lagazzi, R. L. Kormos, J. J. Teuteberg. _Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*1:15 PM (436) *]Survival and Thrombotic Events in Left Ventricular Assist Device Patients Are Not Influenced by Socioeconomic Status; _]S. B. Waters^1^, B. C. Sheridan2, R. Watkins3, M. Duva3, P. P. Chang1, J. N. Katz1. [^1^]_]Cardiology, University of North Carolina, Chapel Hill, NC, 2Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC, 3Transplant, University of North Carolina, Chapel Hill, NC

 

 

12:00 PM – 1:30 PM

Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems

 

Location:

Virginia Suite

[*Target Audience: *]

HTX, BSI, ID, MCS, NHSAH, PATH, PEDS, PHARM

 

[*Chairs: *]

Javier Segovia, MD, PhD, and Ivan Knezevic, MD

 

[*12:00 PM (437) *]Vasoplegia After Heart Transplantation: Unraveling the Enigma; _]F. Esmailian, P. Perry, M. Luu, J. Patel, M. Kittleson, L. Czer, T. Aintablian, P. Zarrini, A. Velleca, J. Rush, F. Arabia, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*12:15 PM (438) *]Application of the ISHLT Criteria for Primary Graft Dysfunction After Cardiac Transplantation: Risk Factors and Outcomes from a High-Volume Center; _]B. Lima^1^, J. J. Squiers2, G. Saracino3, T. Chamogeorgakis1, J. C. MacHannaford1, A. E. Rafael1, G. V. Gonazalez-Stawinksi1, S. A. Hall4, J. M. DiMaio2. [^1^]_]Cardiac and Thoracic Surgery, Baylor University Medical Center, Dallas, TX, 2Baylor Research Institute, Baylor Scott & White Health, Dallas, TX, 3Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, 4Department of Internal Medicine, Division of Cardiology, Baylor University Medical Center, Dallas, TX

 

[*12:30 PM (439) *]Recipient and Donor Risk Factors Associated with Primary Graft Failure Requiring Temporary Mechanical Circulatory Support < 24 Hours After Heart Transplantation; _]M. Farr^1^, K. Takeda2, H. Takayama2, L. Truby1, S. W. Restaino1, M. Lippel1, R. Givens1, F. Latif1, R. Sorabella2, K. Clerkin1, P. Colombo1, B. Kalesan3, Y. Naka2, D. Mancini1. [^1^]_]Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY, 3Epidemiology, Columbia University Medical Center, New York, NY

 

[*12:45 PM (440) *]Monocyte-Derived Macrophages Contribute to Primary Graft Dysfunction Following Cardiac Transplantation; _]K. J. Lavine^1^, W. Li2, M. Lam1, D. Kreisel2. [^1^]_]Cardiology, Washington University, St Louis, MO, 2Surgery, Washington University, St Louis, MO

 

[*1:00 PM (441) *]Extracoporeal Membrane Oxygenator or Ventricular Assist Device for Primary Graft Failure after Orthotopic Heart Transplantation?; _]B. Li^1^, K. Takeda1, P. A. Kurlansky1, L. K. Truby2, S. Fukuhara1, P. F. Delle1, S. Sreekanth1, J. Han1, C. M. Mauro3, A. R. Garan2, V. K. Topkara2, M. Yuzefpolskaya2, P. C. Colombo2, M. A. Farr2, H. Takayama1, Y. Naka1. [^1^]_]Surgery, Columbia University Medical Center, New York, NY, 2Medicine, Columbia University Medical Center, New York, NY, 3Biostatistics, Columbia University Medical Center, New York, NY

 

[*1:15 PM (442) *]ECMO for Primary Graft Failure Following Orthotopic Heart Transplantation; _]Y. Xia^1^, S. Forest1, R. Bello1, W. Jakobleff1, E. Borukhov1, U. Jorde2, D. Goldstein1. [^1^]_]Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

 

 

12:00 PM – 1:30 PM

[*Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation: Are We Getting It Right? *]

Location:

Delaware Suite

[*Target Audience: *]

LTX, BSI, ID, NHSAH, PATH, PHARM

 

[*Chairs: *]

Laurie D Snyder, MD, and Goran Dellgren, MD, PhD

 

[*12:00 PM (443) *]Impact of Multi-Drug Resistant Bacteria Detected De Novo Early after Lung Transplantation on Morbidity and Mortality; _]W. Sommer^1^, F. Ius1, L. Friedrich2, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, M. Greer1, A. Haverich1, G. Warnecke1. [^1^]_]Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Department of Hospital Hygiene, Hannover Medical School, Hannover, Germany

 

[*12:15 PM (444) *]IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation; _]F. Ius^1^, W. Sommer1, M. Verboom2, C. Erdfelder1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, U. Molitoris1, M. Greer3, R. Blasczyk2, M. Hallensleben2, N. Schwerk4, T. Welte3, A. Haverich1, J. Gottlieb3, G. Warnecke1. [^1^]_]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 4Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany

 

[*12:30 PM (445) *]Effect of De Novo Donor Specific Antibodies on the Incidence of Acute Cellular Rejection beyond One Year of Lung Transplantation; _]N. Sinha^1^, D. Nguyen2, A. Gaber3. [^1^]_]Pulmonary Transplant, Houston Methodist Hospital, Houston, TX, 2Biostatistics, Houston Methodist Hospital, Houston, TX, 3JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX

 

[*12:45 PM (446) *]Metabolic Profile of Broncho-Alveolar Lavage Fluid in Lung Transplant Recipients Suggests Potential Early Biomarkers of Bronchiolitis Obliterans Syndrome; _]V. A. Poroyko^1^, A. Ulanov2, J. Becker3, O. Latif3, E. Garrity3, D. Gozal1, S. Bhorade4. [^1^]_]Pediatrics, Univ of Chicago, Chicago, IL, 2Univ of Illinois, Chicago, IL, 3Univ of Chicago, Chicago, IL, 4Northwestern University, Chicago, IL

 

[*1:00 PM (447) *]C4d-Negative Antibody-Mediated Rejection After Lung Transplantation; _]P. R. Aguilar^1^, R. D. Yusen1, C. A. Witt1, D. E. Byers1, D. Kreisel2, E. P. Trulock1, T. Mohanakumar3, R. Hachem1. [^1^]_]Pulmonary/Critical Care Medicine, Washington University, St. Louis, MO, 2Cardiothoracic Surgery, Washington University, St. Louis, MO, 3Surgery, Washington University, St. Louis, MO

 

[*1:15 PM (448) *]Outcomes in Lung Transplantation Following Allogeneic Stem-Cell Transplantation: A Pan-European Experience; _]M. Greer^1^, G. Riise2, L. Hansson3, M. Iversen4, P. Hämmäinen5, A. Roux6, S. Hirschi7, E. Lhuillier8, M. Reynaud-Gaubert9, F. Philit10, J. Claustre11, M. Stern6, J. Gottlieb1, P. Jaksch12, A. Holm13. [^1^]_]Hanover Medical School, Hannover, Germany, 2Sahlgrenska University Hospital, Gothenburg, Sweden, 3Skåne University Hospital, Lund, Sweden, 4Rigshospitalet, Copenhagen, Denmark, 5Helsinki University Hospital, Helsinki, Finland, 6Hospital Foch, Suresnes, France, 7Strasbourg University Hospital, Strasbourg, France, 8Hospital Bichat, Paris, France, 9University North Hospital, Marseille, France, 10Hospital Louis Pradel, Bron, France, 11University Hospital Grenoble, Grenoble, France, 12University Hospital Vienna, Vienna, Austria, 13Oslo University Hospital Rikshospitalet, Oslo, Norway

 

 

12:00 PM – 1:30 PM

Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism

 

Location:

Washington Ballroom 2

[*Target Audience: *]

HF, BSI, HTX, NHSAH

 

[*Chairs: *]

Kiran Khush, MD, MAS, and Manreet Kanwar, MD

 

[*12:00 PM (449) *]Discharge ST2 Predicts Heart Failure Readmissions in Patients with Acute Decompensated Heart Failure (ADHF); _]J. Amione-Guerra^1^, A. S. Cruz-Solbes1, A. M. Cordero-Reyes1, A. Soliman1, B. H. Trachtenberg1, G. Ashrith1, M. E. El-Beheary1, J. Baird2, V. Nambi3, A. Bhimaraj1, J. D. Estep1. [^1^]_]Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX, 2Critical Diagnostics, San Diego, CA, 3Baylor College of Medicine, Houston, TX

 

[*12:15 PM (450) *][Modulation of Local and Systemic Relaxin-2 in Patients with End-Stage Chronic Heart Failure; _]I. Werner, V. Kina, M. Lupinski, U. A. Stock, A. Moritz, A. Beiras-Fernandez. _Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany

 

[*12:30 PM (451) *]Clinical Genetics in Cardio-Oncology; _]K. Dhar^1^, Y. Yi2, N. M. Weedman2, J. Kittrell2, S. Pandey2, J. Y. Um3, J. D. Eudy2, B. D. Lowes4. [^1^]_]Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, 4Cardiology, University of Nebraska Medical Center, Omaha, NE

 

[*12:45 PM (452) *]Cardiac Serum Biomarkers in Friedreich Ataxia May Reflect Fibrosis, Myocyte Injury, and Degree of Hypertrophy; _]C. Bui^1^, R. B. Wilson2, D. R. Lynch3, J. W. Rossano3, O. Elci3, K. Y. Lin3. [^1^]_]Baylor College of Medicine, Houston, TX, 2University of Pennsylvania, Philadelphia, PA, 3Children’s Hospital of Philadelphia, Philadelphia, PA

 

[*1:00 PM (453) *]Low Partial Pressure of End-Tidal Carbon Dioxide Predicts the Future Ventricular Assist Device Implantation in Patients with Chronic Advanced Heart Failure; _]O. Seguchi^1^, A. Nakano2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, T. Fujita3, J. Kobayashi3, M. Kitakaze4, N. Fukushima1, T. Nakatani1. [^1^]_]Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Clinical Reserch, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan, 4Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*1:15 PM (454) *]LVOT VTI Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort; _]C. Tan^1^, A. Srivastava1, D. Rubenson1, M. R. Smith1, R. Mohan2, J. T. Heywood1. [^1^]_]Cardiology, Scripps Clinic, La Jolla, CA, 2Cardiology, Cedars Sinai Medical Center, Los Angeles, CA

 

 

12:00 PM – 1:30 PM

[*Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension *]

Location:

Washington Ballroom 1

[*Target Audience: *]

PH, BSI, HF, LTX, PEDS, PH, PHARM

 

[*Chairs: *]

Bradley Maron, MD, and C. Dario Vizza, MD

 

[*12:00 PM (455) *]Polymer Based Nanotherapeutics Prevent the Progression of Pulmonary Hypertension in a Rat Model; _]V. Segura-Ibarra^1^, J. Amione-Guerra2, A. S. Cruz-Solbes2, K. A. Youker2, G. Torre-Amione2, G. Ashrith2, E. Blanco1. [^1^]_]Nanomedicine, Houston Methodist Research Institue, Houston, TX, 2Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*12:15 PM (456) *]Incidence and Outcomes of Children with Idiopathic Pulmonary Arterial Hypertension – Results from a Bi-National Population Based Study; _]M. Rose1, P. M. Alexander^2^, C. O’Donnell3, S. Vidmar4, R. Justo5, M. Richardson6, G. Sholler7, S. Hope8, J. Ramsay9, D. J. Penny10, I. King11, R. G. Weintraub1. [^1^]_]Cardiology, The Royal Children’s Hospital, Melbourne, Australia, 2Cardiology, Boston Children’s Hospital, Boston, MA, 3Cardiology, Starship Children’s Hospital, Auckland, New Zealand, 4Clinical Epidemiology and Biostatistics Unit, Murdoch Children’s Research Institute, Melbourne, Australia, 5Cardiology, Lady Client Children’s Hospital, Brisbane, Australia, 6Cardiology, Women’s and Children’s Hospital, Adelaide, Australia, 7Cardiology, The Children’s Hospital at Westmead, Sydney, Australia, 8Cardiology, Monash Medical Centre, Melbourne, Australia, 9Cardiology, Princess Margaret Hospital, Perth, Australia, 10Cardiology, Texas Children’s Hospital, Houston, TX, 11Cardiology, Murdoch Children’s Research Institute, Melbourne, Australia

 

[*12:30 PM (457) *]Characteristics and Outcomes of 30-Day Hospital Readmissions in Children with Pulmonary Hypertension: A Multi-Institutional Analysis; _]J. D. Awerbach^1^, B. S. Moffett2, G. B. Mallory Jr.3, S. Kim2, A. G. Cabrera1. [^1^]_]Pediatric Cardiology, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, 2Pharmacy, Texas Children’s Hospital, Houston, TX, 3Pediatric Pulmonology, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX

 

[*12:45 PM (458) *][Use of PAH-Specific Therapy in World Health Organization Group III Pulmonary Hypertension: A Systematic Review and Meta-Analysis; _]K. W. Prins, J. Markowitz, M. Pritzker, S. Duval, T. Thenappan. _Cardiovascular Division, University of Minnesota, Minneapolis, MN

 

[*1:00 PM (459) *][Outcome of Patients with Chronic Thromboembolic Disease in the Absence of Pulmonary Hypertension on Echocardiogram; _]L. Donahoe, J. Thenganatt, K. McRae, A. Bykova, J. Moric, J. Granton, M. De Perrot. _Toronto General Hospital, Toronto, ON, Canada

 

[*1:15 PM (460) *][Pre-operative Determinants of Reperfusion Lung Injury after Pulmonary Thromboendarterectomy; _]T. M. Fernandes, D. S. Poch, D. G. Papamatheakis, P. F. Fedullo, N. H. Kim, W. R. Auger, K. M. Kerr. _Division of Pulmonary and Critical Care, University of California, San Diego, La Jolla, CA

 

 

POSTER SESSION 1

WEDNESDAY, APRIL 27, 2016

6:00 PM – 7:00 PM

Exhibit Hall B & C

 

[+BASIC SCIENCE +]

 

Target Audience:

BSI, HF, HTX, LTX, MCS, PATH, PEDS

Poster Discussants:

Derek Byers, Marcelo Cypel, Stephan Ensminger, Andrew Gelman, Aric Gregson, Christian Heim, Julia Klesney-Tait, Elizabeth Lendermon, Tereza Martinu, Thalachallour Mohanakumar, Simon Pecha, Masaaki Sato, Esther Shao, Heather Strah, Stijn Verleden

[*(461) *][Ex Vivo Expanded Human Regulatory T Cells Suppress Allograft Induced Immune Responses in a Humanized Mouse Mode; _]L. Pauksch, W. Sommer, K. Jansson, A. Knoefel, T. Nakagiri, A. Haverich, G. Warnecke. _Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

 

[*(462) *][Presence of Endothelial to Mesenchymal Transition in End Stage Human Myocardial Samples-Documentation in Human Heart Failure for the First Time; _]C. Uribe, A. S. Cruz-Solbes, K. Youker, A. M. Cordero-Reyes, J. Amione-Guerra, B. H. Trachtenberg, G. Ashrith, J. D. Estep, G. Torre-Amione, E. E. Suarez, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*(463) *]Kinetics of Dendritic and Polyfunctional T Cell Responses in a Mouse Minor Mismatched Orthotopic Single Lung Transplant Model; _]S. C. Juvet^1^, H. Oishi2, B. Joe3, K. Potluri3, S. Keshavjee2, T. Martinu4. [^1^]_]University Health Network, Toronto, ON, Canada, 2Surgery, University Health Network, Toronto, ON, Canada, 3Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 4Medicine, University Health Network, Toronto, ON, Canada

 

[*(464) *][Reconditioning of Prolonged Warm Ischemic Lungs by High-Dose Bronchodilator Inhalation during Ex Vivo Lung Perfusion in a Canine Lung Transplantation Model; _]K. Hijiya, T. F. Chen-Yoshikawa, T. Kondo, H. Motoyama, A. Ohsumi, D. Nakajima, J. Sakamoto, K. Ohata, M. Takahashi, S. Tanaka, E. Miyamoto, A. Aoyama, H. Date. _Thoracic Surgery, Kyoto Univ, Kyoto, Japan

 

[*(465) *][_ Elevation in Activin A to Follistatin Ratios Following Lung Transplantation- A Potential Mediator and Therapeutic Target for CLAD?; ]M. A. Trotter^1^, M. Loskot1, B. J. Levvey1, T. Phan1, R. E. O’Hehir2, G. P. Westall1, D. M. de Krester3, G. I. Snell1. [1_]Lung Transplantation Service, The Alfred, Melbourne, Australia, 2Allergy, Immunology and Respiratory Medicine, The Alfred, Melbourne, Australia, 3Monash Institute of Medical Research, Monash University, Melbourne, Australia

 

[*(466) *]MicroRNA Analysis in a Mouse Heterotopic Tracheal Transplant Model; _]Y. Watanabe^1^, C. Ogura2, K. Hatanaka3, Y. Okada1, T. Watanabe1, H. Oishi1, Y. Matsuda1, H. Notsuda1, A. Harada2, M. Aoki2, T. Nagata2, K. Kariatsumari2, Y. Nakamura1, M. Sato2, T. Kondo1. [^1^]_]Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, 2Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, 3Department of Molecular and Cellular Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

 

[*(467) *]Polymerized Human Serum Albumin as an Osmotic Molecule to Support Ex-Vivo Lung Perfusion; _]B. A. Whitson^1^, E. Eren1, E. Beal1, D. Hayes, Jr2, A. F. Palmer3, S. M. Black4. [^1^]_]Department of Surgery, Wexner Med Ctr, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH

 

[*(468) *][Influence of Fatty Acids, Acetate, and Ketones on Myocardial Substrate Selection and TCA Cycle Intermediates During Hypothermic Machine Perfusion of Donor Hearts; _]C. Holmes, L. Powell, M. Peltz, M. Jessen. _Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX

 

[*(469) *][Lung Microbiome Predicts Myeloid Derived Suppressor Cell Response in Lung Transplant; _]N. S. Sharma, K. M. Wille, C. Hoopes, E. Diaz-Guzman, V. J. Thannickal, J. Deshane. _Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL

 

[*(470) *]Variable Effects of Serotonin Receptor Antagonists on the Development of Transplant Vasculopathy in Murine Aortic Allografts; _]C. Heim^1^, A. Gocht1, J. Distler2, B. Spriewald2, M. Ramsperger-Gleixner1, M. Weyand1, S. Ensminger3. [^1^]_]Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany, 2Department of Medicine, University of Erlangen, Erlangen, Germany, 3Department of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany

 

[*(471) *][The Establishment of an Ex Vivo Lung Perfusion in a Rat Lung Transplantation Model; _]A. Ohsumi, T. Kanou, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, Toronto, ON, Canada

 

[*(472) *]The Interleukin 4 Receptor-α Potentiates the Effect of Oncostatin M Receptor on the Release of FGF23 by Cardiomyocytes; _]M. H. Richter^1^, R. Maringanti1, J. M. Adrian-Segarra2, H. Lautze3, M. Schönburg1, W. Skwara1, S. Hein1, A. van Linden1, T. Kubin2, T. Braun2, S. Kostin2, T. Walther1. [^1^]_]Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 2[_ Heart and Lung Research, Max- Planck- Institute, Bad Nauheim, Germany, 3_]Anesthesiology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany

 

[*(473) *]Combined Heart and Liver Retrieval after Circulatory Death with Normothermic Machine Reperfusion in a Porcine Model; _]H. Chew1, J. Cao^1^, K. Fernandez1, L. Gao1, J. Villanueva1, M. Hicks1, A. Jabbour1, H. Pleass1, K. Dhital2, P. Macdonald1. [^1^]_]Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia, 2Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia

 

[*(474) *]Refinement of Ex Vivo Lung Perfusion Techniques for Better Microvasculature Maintenance in Lung Grafts; _]K. Noda^1^, S. Haam1, Y. Wu2, J. D’Cunha1, J. D. Luketich1, N. Shigemura1. [^1^]_]Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA

 

[*(475) *][A Novel Nanoscale Formulation of Hydrophobic Src Tyrosine Kinase Inhibitor PP2 Prevents Pulmonary Ischemia Reperfusion Induced Acute Lung Injury; _]T. Kanou, S. Pacheco, M. Chen, G. Zehong, X. Bai, D. Hwang, M. Cypel, S. Keshavjee, M. Liu. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Instituite, Toronto, ON, Canada

 

[*(476) *][Donor Versus Recipient Origin of Fibroblasts in Murine Lung Allograft Fibrosis; _]C. Konoeda, T. Martinu, S. Juvet, G. Zehong, M. Yoshida, H. Oishi, P. Duchesneau, T. K. Waddell, M. Liu, S. Keshavjee. _Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada

 

[*(477) *]MOVED TO MINI ORAL SESSION 11

 

[*(478) *]Development of an Unsupervised Classification with Multi-Level Analysis of the Heart Transplant Endomyocardial Biopsy; _]E. Chang^1^, G. Fishbein1, N. Jackson1, M. Bakir1, D. Liem1, G. Bondar1, S. Litovsky2, J. Tallaj2, C. Starling1, P. Ping1, E. Reed1, M. Deng1, E. Tabak3, M. Cadeiras1. [^1^]_]UCLA, Los Angeles, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3New York University, New York, NY

 

[*(479) *]WITHDRAWN

 

[*(480) *]Electrophysiological Investigations of Human iPS Cell-Derived Engineered Heart Tissue in a Guinea Pig Infarction Model; _]S. Pecha^1^, F. Weinberger2, K. Breckwoldt2, A. Hansen2, H. Reichenspurner1, T. Eschenhagen2. [^1^]_]Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany

 

[*(481) *]WITHDRAWN

 

[*(482) *][aPC Pretreatment of hEPCR-Expressing PAECs Attenuates Endothelial Cell Damage and Thrombosis; _]C. T. Laird, B. French, D. G. Harris, X. Cheng, D. Ayares, R. N. Pierson, A. Azimzadeh. _University of Maryland School of Medicine, Baltimore, MD

 

[*(483) *]Control of Cardiomyocyte Proliferation Through p53/Mdm2-Regulated MicroRNAs; _]S. Stanley-Hasnain^1^, L. Hauck2, D. Grothe2, F. Billia2. [^1^]_]Toronto General Research Institute, Toronto, ON, Canada, 2Research, Toronto General Research Institute, Toronto, ON, Canada

 

[*(484) *][Characteristic Trends during DCD Withdrawal; _]H. Chew, L. Gao, J. Villanueva, A. Doyle, J. Cao, G. Kumarasinghe, M. Hicks, A. Jabbour, K. Dhital, P. Macdonald. _Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia

 

[*(485) *]Post-Conditioning with Cyclosporine: Impact on Ischemia Reperfusion Injury in a Rodent Model of Donor Heart Preservation; _]L. Gao^1^, J. Villanueva1, H. Chew1, J. Cao1, M. Hicks2, A. Jabbour3, P. S. Macdonald3. [^1^]_]Transplant, Victor Chang Cardiac Research Institute, Sydney, Australia, 2Clinical Pharmacology & Toxicology, St Vincents Hospital, Sydney, Australia, 3Heart & Lung Transplantation, St Vincents Hospital, Sydney, Australia

 

[*(486) *][Ex Vivo Treatment of Donors with Nebulized N-Acetylcysteine Partially Improved Post-Transplant Lung Function; _]Y. Yamada, I. Iskender, S. Arni, S. Hillinger, T. Cosgun, W. Jungraithmayr, W. Weder, I. Inci. _Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

 

[*(487) *][The Impact of Sevoflurane Preconditioning in Experimental Mouse Lung Transplantation; _]Y. Yamada, I. Laube, J. Jang, J. Bonvini, B. Beck-Schimmer, W. Weder, W. Jungraithmayr. _Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

 

[*(488) *][Role of Heat Shock Proteins in Pharmacological Preconditioning for Lung Ischemia Reperfusion Injury; _]A. Shimamoto, M. Takao, H. Shimpo. _Mie Univ Graduate School of Medicine, Tsu, Japan

 

[*(489) *][Temporal Assessment of Endothelial to Mesenchymal Transition as a Contributor to Fibrosis in a Mouse Model of Heart Failure; _]A. S. Cruz-Solbes, C. Uribe, K. A. Youker, A. M. Cordero-Reyes, J. Amione-Guerra, G. Ashrith, B. H. Trachtenberg, J. D. Estep, G. Torre-Amione, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*(490) *]Identification of Hypoxic Cells in Lung Grafts for Future Cell Targeted Therapy for Obliterans Bronchiolitis; _]K. Noda^1^, H. Hara2, S. Haam1, J. D’Cunha1, J. D. Luketich1, N. Shigemura1. [^1^]_]Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Surgery, University of Pittsburgh, Pittsburgh, PA

 

[*(491) *]Impact of Myocardial Load on the Preservation of Donor Heart Function during Ex Vivo Perfusion; _]C. W. White^1^, S. Shan2, S. Hatami3, V. Gurtu3, A. Kinnaird3, N. Matsumura3, N. Aboelnazar3, J. R. Dyck3, G. D. Lopaschuk3, E. Michelakis3, J. Nagendran3, D. H. Freed3. [^1^]_]Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Alberta, Edmonton, AB, Canada

 

[*(492) *]Ex Vivo Testing of New Genetical Modifications for Cardiac Xenotransplantation; _]J. Abicht^1^, T. A. Mayr1, K. Fischer2, B. Reichart3, H. Niemann4, A. Panelli1, S. Guethoff5, P. Brenner5, A. Schnieke2. [^1^]_]Anaesthesiology, Ludwig Maximilian University, Munich, Germany, 2Chair of Livestock Biotechnology, School of Life Sciences Weihenstephan, Technical University, Munich, Germany, 3Walter-Brendel-Centre, Ludwig Maximilian University, Munich, Germany, 4Institute of Farm Animal Genetics, Friedrich-Loeffler-Institute (FLI), Mariensee, Germany, 5Cardiac Surgery, Ludwig Maximilian University, Munich, Germany

 

[*(493) *]Mitochondrial Proteins Possess Antigenicity and Can Cause Rejection; _]T. Deuse^1^, X. Hu2, D. Wang2, M. Stubbendorff2, R. Itagaki2, A. Grabosch2, L. Graeves2, M. Alawi3, A. Gruenewald2, X. Hua2, J. Velden4, H. Reichenspurner1, R. C. Robbins5, R. Jaenisch6, I. Weissman7, S. Schrepfer2. [^1^]_]CT Surgery, University Heart Center Hamburg, Hamburg, Germany, 2TSI Lab, University Heart Center Hamburg, Hamburg, Germany, 3Heinrich Pette Institute, University Medical Center Hamburg, Hamburg, Germany, 4Pathology, University Medical Center Hamburg, Hamburg, Germany, 5CT Surgery, Stanford University School of Medicine, Stanford, CA, 6Whitehead Institute, Boston, MA, 7Stem Cell Institute, Stanford University School of Medicine, Stanford, CA

 

[*(494) *]Allogeneic and Xenogeneic Immunity Is Potently Suppressed by Expanded Regulatory T Cells (Tregs) from Human Thymus; _]E. Dijke1, R. Hoeppli2, K. Seeberger3, I. Larsen1, I. Rebeyka4, D. Ross4, G. Korbutt3, M. Levings2, L. West^1^. [^1^]_]Pediatrics/Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, 2Surgery, University of British Columbia, Vancouver, BC, Canada, 3Surgery, University of Alberta, Edmonton, AB, Canada, 4Surgery/Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada

 

[*(495) *]Targeting Human Follicular T-B Cell Interactions to Prevent Antibody Mediated Allo-Immune Responses; _]C. C. Baan^1^, B. S. Rakké^1^, G. N. de Graav1, K. de Leur1, F. J. Dor2, M. Franquesa1. [^1^]_]Internal Medicine, Erasmus MC, Rotterdam, Netherlands, 2Surgery, Erasmus MC, Rotterdam, Netherlands

 

[*(496) *]Mass Cytometric Deep Cellular Profiling of BAL in Human Lung Transplantation; _]S. C. Juvet^1^, T. Martinu1, L. Levy1, B. Joe2, C. Guidos3, S. Keshavjee4. [^1^]_]Medicine, University Health Network, Toronto, ON, Canada, 2Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 3Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada, 4Surgery, University Health Network, Toronto, ON, Canada

 

[*(497) *]WITHDRAWN

 

[*(498) *]Xenogeneic Lung Transplantation: Extending Life-Supporting Organ Function Using Multi-Transgenic Donor Pigs and Targeted Drug Treatments; _]L. Burdorf^1^, C. Laird1, N. O’Neill1, S. S. Dahi1, N. Kubicki1, T. Zhang1, D. Harris1, D. Parsell1, E. Rybak1, J. Rabin1, I. Tatarov1, C. J. Phelps2, D. L. Ayares2, A. M. Azimzadeh1, R. N. Pierson III1. [^1^]_]Surgery, University of Maryland, Baltimore, MD, 2Revivicor, Blacksburg, VA

 

[*(499) *]mTOR Inhibitors Ameliorate Ischemia-Reperfusion Injury through Endothelin-A Modulation and Reduction of Free Radical Production; _]I. Werner^1^, A. Hernandez-Sierra2, S. Brunner1, A. Kornberger1, A. Moritz1, A. Beiras-Fernandez1. [^1^]_]Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany, 2Nephrology, Universidad Autonoma de Bucaramanga, Bucaramanga, Colombia

 

[*(500) *][_ CD8+ IL-17 Responses and Obliterative Airway Disease Persist in T-bet-/- Mouse Recipients of Lung Transplant Treated with Low Dose Azithromycin Therapy; ]E. A. Lendermon^1^, J. M. Dodd-o2, L. Guo1, T. A. Coon1, C. R. Ensor3, C. P. O’Donnell1, J. F. McDyer1. [1_]Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 2Department of Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Pharmacy, University of Pittsburgh, Pittsburgh, PA

 

[*(501) *]Modulation of Nesfatin, Visfatin and Resistin in Patients Undergoing Heart Transplantation; _]A. Beiras-Fernandez^1^, S. Reinwand1, S. Kreth2, A. Beiras3, A. Moritz1, I. Werner1. [^1^]_]Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany, 2Anaesthesia, Klinikum Grosshadern, Munich, Germany, 3Histology, University of Santiago, Santiago, Spain

 

[*(502) *]Modulation of Leukocyte-Endothelium Interactions with rATGs after Ischemia-Reperfusion Injury in an Experimental Human Perfusion Model; _]A. Beiras-Fernandez^1^, A. Hernandez-Sierra1, E. Thein2, A. Moritz1, I. Werner1. [^1^]_]Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany, 2Institute for Surgical Research, Ludwig-Maximilians-University, Munich, Germany

 

[*(503) *]The Immunobiology of the Y Chromosome in Embryonic Stem Cell Transplantation for Tissue and Organ Regeneration; _]S. T. Kueppers1, X. Hu1, T. Deuse2, D. Wang1, H. Reichenspurner2, S. Schrepfer^1^. [^1^]_]TSI Lab, University Heart Center Hamburg, Hamburg, Germany, 2CT Surgery, University Heart Center Hamburg, Hamburg, Germany

 

[*(504) *]A Nude Mouse Model of Allosensitization Induced by Adoptive Transfer of Splenic T Helper Cells; _]I. Kim, N. Chai, S. Jordan, A. Klein, G. D. Wu. [_Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

 

[*(505) *][Relationship between Grafts’ Quality, Glucose Consumption and IL-6 Production during Ex Vivo Lung Perfusion; _]K. Noda, S. Haam, J. D’Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*(506) *][Does a Leukocyte Filter Show Benefit in Ex-Vivo Lung Perfusion?; _]J. G. Luc, N. Aboelnazar, S. Hatami, A. Haromy, V. Vasanthan, C. W. White, D. H. Freed, J. Nagendran. _Department of Surgery, University of Alberta, Edmonton, AB, Canada

 

[+HEART TRANSPLANTATION +]

[+Target Audience: +]

HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM

Poster Discussants:

Markus Barten, Lavanya Bellumkonda, Tuvia Ben-Gal, Jennifer Cook, Eugene DePasquale, Tobias Deuse, Claudia Gidea, Gonzalo Gonzalez-Stawinski, Francisco Gonzalez-Vilchez, Shelley Hall, Sharon Hunt, Ivan Knezevic, Brian Lima, Donna Mancini, Marco Masetti, Daniela Pini, Keshava Rajagopal, Vivek Rao, Yazhini Ravi, George Sokos, Hannah Valantine, Melana Yuzefpolskaya

[*(507) *]The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients; _]J. van Setten1, N. de Jonge^1^, M. V. Holmes2, K. K. Khush3, N. K. Sweitzer4, P. Garcia-Pavia5, J. W. Rossano2, D. L. Dries6, L. Potena7, A. Zuckermann8, J. D. Christie2, D. S. Wilkes9, D. Lederer10, K. C. Meyer11, A. R. Glanville12, P. Corris13, A. Fisher13, S. M. Palmer14, J. A. Belperio15, R. A. de Weger1, H. G. Otten1, E. A. van de Graaf1, B. Keating2, F. W. Asselbergs1. [^1^]_]UMC Utrecht, Utrecht, Netherlands, 2University of Pennsylvania, Philadelphia, PA, 3Stanford University, Stanford, CA, 4University of Wisconsin-Madison, Madison, WI, 5Puerta de Hierro University Hospital, Madrid, Spain, 6Yale Center for Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation, New Haven, CT, 7University of Bologna, Bologna, Italy, 8Medical University of Vienna, Vienna, Austria, 9Indiana University School of Medicine, Indianapolis, IN, 10Columbia University, New York, NY, 11University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, 12St Vincent’s Hospital, Sydney, Australia, 13Newcastle University, Newcastle upon Tyne, United Kingdom, 14Duke University School of Medicine, Durham, NC, 15UCLA, Los Angeles, CA

 

[*(508) *]Tissue Characterization Using Novel CMR Based T1 and T2 Mapping Detects Early Myocardial Injury in Heart Transplant Recipients; _]M. Imran^1^, L. Wang1, J. McCrohon1, C. Yu1, J. Huang1, C. Holloway1, J. Otton2, K. Moffat3, R. Grover1, J. Ross3, E. Kotlyar1, A. Keogh1, C. Hayward1, P. Macdonald1, A. Jabbour1. [^1^]_]Cardiology, St. Vincent`s Hospital, Sydney, Australia, 2Cardiology, Liverpool Hospital, Sydney, Australia, 3Medical Imaging, St. Vincent`s Hospital, Sydney, Australia

 

[*(509) *]Donor-Specific HLA-DQ Antibodies May Contribute to Poor Graft Outcome After Heart Transplantation; _]N. Selimovic, O. Omrani, J. Alburaiki, M. Al-Awwami. [_Heart Centre, King Faisal Specialist Hospital&Research, Riyadh, Saudi Arabia

 

[*(510) *]The Impact of Late Antibody Mediated Rejection with Graft Dysfunction on Cardiac Allograft Vasculopathy and Survival; _]K. J. Clerkin^1^, S. W. Restaino1, C. C. Marboe2, E. R. Vasilescu2, E. Zorn3, D. M. Mancini1. [^1^]_]Cardiology, Columbia University Medical Center, New York, NY, 2Pathology, Columbia University Medical Center, New York, NY, 3Immunology, Columbia University Medical Center, New York, NY

 

[*(511) *]The Number of Human Leukocyte Antigen DR Mismatch Is Associated with Early Post-Transplant Acute Cellular Rejection Among Heart Transplantation Recipients; _]D. Nitta^1^, K. Kinugawa2, T. Imamura3, M. Endo4, H. Maki1, E. Amiya1, M. Hatano1, O. Kinoshita5, K. Nawata5, M. Ono5, I. Komuro1. [^1^]_]Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Internal Medicine 2, Graduate School of Medicine and Pharmaceutical Sciences,University of Toyama, Toyama, Japan, 3Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 4Department of Organ Transplantation, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 5Department of Cardiothoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

 

[*(512) *]Gene Expression Profiling to Predict and Define Cardiac Allograft Acute Cellular Rejection; _]D. Bodez^1^, H. Hocini2, N. Tchitcheck3, P. Tisserand2, N. Benhaiem4, C. Barau5, M. Kharoubi6, A. Guellich6, S. Guendouz6, C. Radu7, J. Couetil8, J. Dubois-Randé^1^, E. Teiger1, L. Hittinger9, Y. Lévy10, T. Damy1. [^1^]_]Cardiology, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France, 2Equipe 16, INSERM U955, IMRB, and VRI at H. Mondor Hospital, Créteil, France, 3Immunology of Viral Infections and Autoimmune Diseases Research Unit, UMR1184, IDMIT Infrastructure, Fontenay-aux-Roses, France, 4Pathology, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France, 5Platform of Biological Resources, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France, 6Cardiology, Henri Mondor APHP Teaching Hospital, Créteil, France, 7Cardiac Surgery, Henri Mondor APHP Teaching Hospital, Créteil, France, 8Cardiac Surgery, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France, 9Cardiology, Henri Mondor APHP Teaching Hospital, IMRB and UPEC, Créteil, France, 10Clinical Immunology, Henri Mondor APHP Teaching Hospital, IMRB, and VRI, Créteil, France

 

[*(513) *][Diagnostic Value of Quantitative Tissue Markers (T2 Mapping and ECV) for Acute Cardiac Rejection Diagnosis: A Preliminary Experience; _]E. Vermes, C. Pantaleaon, J. Pucheux, A. Mirza, A. Delhommais, A. Sirinelli. _Heart Surgery, CHU Trousseau, Tours, France

 

[*(514) *]Organ Preservation and Reperfusion Influence on Outcome after Heart Transplantation; _]V. Jernryd^1^, C. Metzsch2, B. Andersson3, J. Nilsson1. [^1^]_]Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 2Cardiothoracic Anaesthesiology, Lund University and Skane University Hospital, Lund, Sweden, 3Surgery, Lund University and Skane University Hospital, Lund, Sweden

 

[*(515) *]Elevated Rho Kinase (ROCK) Activity Correlates with Acute Rejection in Heart Transplant Recipients; _]B. Chung^1^, J. Chavez2, D. Zhang3, G. Sayer1, S. Adatya1, N. Sarswat1, D. Rodgers1, J. Zhou1, L. Zhang1, M. Knapp1, E. Karrar1, N. Uriel1, J. Liao1. [^1^]_]University of Chicago, Chicago, IL, 2Northwestern University, Chicago, IL, 3University of Washington, Seattle, WA

 

[*(516) *]Telomere Length in Aortal Tissue and Heart Allograft Rejection in Patients after Transplantation; _]J. Vymetalova^1^, D. Dlouha2, J. A. Hubacek2, V. Lanska3, I. Malek1. [^1^]_]Cardiology, IKEM, Prague, Czech Republic, 2Center for Experimental Medicine, IKEM, Prague, Czech Republic, 3Statistical Unit, IKEM, Prague, Czech Republic

 

[*(517) *]Loss of Correlation Between Naive and Memory Class-Switched B-Cells in Heart Recipients with Acute Cellular Rejection; _]J. Carbone^1^, A. Gallego1, N. Lanio1, L. Calahorra1, I. Sousa2, E. Sarmiento1. [^1^]_]Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

 

[*(518) *][High Grade Cellular Rejection and Infection Post Heart Transplantation: Is There a Link?; _]A. Deka, J. Sturgess, B. Costello, E. Campos, B. Mohamedali. _Department of Cardiovascular Disease, Rush University Medical Center, Chicago, IL

 

[*(519) *]Trends of Early and Late Rejection Rates Following Heart Transplantation Over the Past Two Decades: Real World Data from a National Tertiary Center Registry; _]Y. Peled^1^, M. Katz2, Y. Har-Zahav1, Y. Shemesh1, M. Arad3, Y. Kassif1, N. Shlomo4, I. Goldenberg2, D. Freimark3, J. Lavee1. [^1^]_]Heart Transplantation Unit, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel, 2Cardiology Department, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel, 3Heart Failure Unit, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel, 4Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel

 

[*(520) *]Prolonged Ischemic Time of Donor Hearts: Indication for Additional Cardioplegic Preservation Before Graft Implantation ?; _]U. Boeken^1^, A. Albert1, A. Mehdiani1, G. Petrov1, B. Sowinski1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

 

[*(521) *]Risk Stratification for Developing Cardiovascular Allograft Vasculopathy in Heart Transplant Recipients: Evaluation by Annual Intravascular Ultrasound; _]T. Sato^1^, O. Seguchi1, H. Ishibashi-Ueda2, M. Yanase1, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, T. Watanabe1, S. Nakajima1, H. Hata3, T. Fujita1, N. Fukushima1, J. Kobayashi3, T. Nakatani1. [^1^]_]Transplantation, National Cardiovascular Center, Osaka, Japan, 2Pathology, National Cardiovascular Center, Osaka, Japan, 3Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

 

[*(522) *]Perfusion Cardiac Magnetic Resonance Imaging in Cardiac Allograft Vasculopathy; _]S. Chih^1^, A. M. Crean2, A. C. Alba2, C. S. Fan3, C. Manlhiot3, H. J. Ross2. [^1^]_]University of Ottawa Heart Institute, Ottawa, ON, Canada, 2Toronto General Hospital – University Health Network, Toronto, ON, Canada, 3Cardiovascular Data Management Centre – University of Toronto, Toronto, ON, Canada

 

[*(523) *]What Are the Important Factors for Cardiac Vasculopathy Development After Heart Transplantation?; _]M. Sobieszczanska-Malek^1^, J. Korewicki1, M. Karczmarz1, K. Komuda1, S. Szymanska2, P. Bekta3, A. Parulski4, M. Jasinska5, M. Kuśmierczyk4, T. Zielinski1. [^1^]_]Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland, 2Pathology, The Children’s Memorial Health Institute, Warsaw, Poland, 3Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland, 4Cardiosurgery and Transplantology, Institute of Cardiology, Warsaw, Poland, 5Anesthesiology, Institute of Cardiology, Warsaw, Poland

 

[*(524) *]Impact on Graft Survival of Medical Treatment and Percutaneous Coronary Intervention in Cardiac Allograft Vasculopathy; _]G. Galli^1^, A. A. Constantinescu1, J. J. Brugts1, R. van Domburg1, P. C. van de Woestijne2, A. A. Balk1, K. Caliskan1, O. C. Manintveld1. [^1^]_]Cardiology, Erasmus MC, Rotterdam, Netherlands, 2Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands

 

[*(525) *][Cardiac Allograft Vasculopathy Assessed by 64 Slice Dual-Source Coronary Computed Tomographic Angiography: Retrospective Analysis of a Monocentric Experience; _]T. Dominici, M. Cottini, F. Sbaraglia, A. Pergolini, P. Lilla Della Monica, G. Di Stefano, V. Polizzi, M. Feccia, V. Buffa, V. Buffa, F. Musumeci. _Cardiac Surgery and Heart Transplantation Unit, San Camillo Forlanini Hospital Rome, Rome, Italy

 

[*(526) *]Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients; _]S. Varnado1, J. Y. Um2, H. Vongooru3, R. Zolty3, B. D. Lowes3, A. Burdorf3, B. Fenske1, A. Huntsberry1, A. Siddique2, M. J. Moulton2, E. Raichlin^1^. [^1^]_]University of Nebraska Medical Center, Omaha, NE, 2Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, 3Cardiology, University of Nebraska Medical Center, Omaha, NE

 

[*(527) *]Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy?; _]J. Patel, M. Kittleson, L. Czer, T. Aintablian, M. Johl, T. Daun, B. Kearney, D. Chang, B. Azarbal, M. Hamilton, F. Esmailian, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(528) *]The Clinical Application of Non-Invasive Assessment of Coronary Flow Reserve via Rubidium PET in Heart Transplant Patients; _]M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, K. Norland, N. Perry, D. Chang, F. Arabia, M. Hamilton, B. Azarbal, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(529) *]Coronary Physiology Assessment After Heart Transplantation; _]O. Solberg^1^, K. Stavem2, A. Ragnarsson3, E. Gude1, A. K. Andreassen1, L. Gullestad1, K. Karason4, D. Ioanes4, L. Aaberge1. [^1^]_]Dep of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Dep of Pulmonary Medicine, Akershus University Hospital Lørenskog, Akershus, Norway, 3Dep of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 4Dep of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

 

[*(530) *]Rejection and Cardiac Allograft Vasculopathy Are Both Associated with Increased Incidence of Sudden Cardiac Death Post-Heart Transplant: A Meta-Analysis; _]F. Foroutan1, A. Alba^1^, N. Ng Fat Hing1, C. Fan2, C. Manlhiot2, H. J. Ross1. [^1^]_]Cardiology, Toronto General Hospital, Toronto, ON, Canada, 2Cardiovascular Data Management Centre, University of Toronto, Toronto, ON, Canada

 

[*(531) *][Opitcal Coherence Tomography Guided Allograft Vasculoptahy Interventions: A New Frontier; _]I. +]F. Édes, [+Á. Hajas, B. Sax, D. Becker, B. Merkely. _Heart and Vascular Center, Semmelweis University, Budapest, Hungary

 

[*(532) *]Evaluating Potential Risk Factors for Worsening Cardiac Allograft Vasculopathy; _]K. Hord^1^, R. Dolan1, Y. Huang2, A. Knezevic2, D. Gupta3. [^1^]_]Emory University School of Medicine, Atlanta, GA, 2Rollins School of Public Health, Emory University, Atlanta, GA, 3Cardiology, Emory University School of Medicine, Atlanta, GA

 

[*(533) *]Immunosuppression and Cardiac Allograft Vasculopathy: A Multivariate Odds Ratio Analysis; _]K. Hord1, R. Dolan^1^, Y. Huang2, A. Knezevic2, D. Gupta3. [^1^]_]Emory University School of Medicine, Atlanta, GA, 2Rollins School of Public Health, Emory University, Atlanta, GA, 3Cardiology, Emory University School of Medicine, Atlanta, GA

 

[*(534) *][Dobutamine Stress Echocardiography to Detect Early Cardiac Allograft Vasculopathy; _]K. J. Clerkin, A. R. Garan, M. A. Farr, S. W. Restaino, F. Latif, M. Yuzefpolskaya, P. C. Colombo, D. M. Mancini. _Cardiology, Columbia University Medical Center, New York, NY

 

[*(535) *]Cardiac Allograft Donor Age Is Associated with Increased Baseline Coronary Plaque Burden but Not with Its Progression as Assessed by Intravascular Ultrasound; _]R. Cheng, B. Azarbal, C. Vanichsarn, J. Patel, D. Chang, M. Kittleson, J. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(536) *][Elevated Levels of Gut Microbe Metabolite Trimethylamine N-Oxide (TMAO) Levels Are Aassociated with Graft Arterial Disease Following Murine Heart Transplantation; _]S. M. Zeltzer, X. Wang, Z. Wang, S. Goparaju, N. Dvorina, W. Baldwin, S. Hazen, W. Tang. _Cellular and Molecular Biology, Cleveland Clinic Cleveland Clinic, Cleveland, OH

 

[*(537) *][Steps towards Personalization of Clinical Care in Era of Precision Medicine. Time Dependent Immune Phenomapping in Heart Transplantation and Emergence of Anti-HLA Class I and II Antibodies; _]M. Bakir, N. Jackson, E. Chang, D. Henriquez, C. Tseng, C. Starling, T. Khuu, D. Cruz, E. DePasquale, R. Ardehali, J. Zhang, J. Schaenman, B. Kubak, M. Kwon, A. Ardehali, E. Reed, M. Deng, M. Cadeiras. _Cardiology, UCLA, Los Angeles, CA

 

[*(538) *][Proteinuria the First Year After Heart Transplantation Is Associated with a Higher Rate of Decline in Glomerular Filtration Rate; _]C. Soderlund, E. Lofdahl, G. Radegran. _Department of Clinical Sciences Lund, Cardiology, Lund, Sweden

 

[*(539) *][Assessment of Cotinine Shows a Dose-Dependent Effect of Smoke Exposure on the Long Term Survival after Heart Transplantation; _]K. Uyanik-Uenal, A. Aliabadi, J. Goekler, O. Salameh, T. Haberl, K. Freystaetter, P. Kinsperger, R. Moayedifar, G. Laufer, A. Zuckermann. _Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

 

[*(540) *]Safety and Efficacy of Immunoadsorption in Heart Transplantation Program; _]T. Gazdic^1^, I. Malek2, L. Pagacova3, A. Slavcev4, M. Hegarova2, L. Hoskova2, M. Kubanek2, J. Pirk1. [^1^]_]Cardiovascular Surgery, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 2Cardiology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 3Haematology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 4Immunogenetics, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

 

[*(541) *]Predictive Value of HLA and MICA Antibodies Monitoring during First Year after Heart Transplantation; _]T. Gazdic^1^, I. Malek2, M. Rodova3, A. Slavcev3, V. Lanska4, L. Voska5, J. Pirk1. [^1^]_]Cardiovascular Surgery, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 2Cardiology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 3Immunogenetics Department, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 4Statistical Unit, Institution for Clinical and Experimental Medicine, Prague, Czech Republic, 5Clinical and Transplant Pathology Department, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

 

[*(542) *]Evolutive Tendency and Prognostic Value of Galectin-3 Serum Levels After Heart Transplantation; _]N. Suarez-Fuentetaja, E. Barge-Caballero, M. Paniagua-Martin, G. Barge-Caballero, D. Couto-Mallon, D. Vasquez-Echeverri, G. Marron-Linares, Z. Grille-Cancela, J. Vazquez-Rodriguez, M. Crespo-Leiro. [_Cardiology Department, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain

 

[*(543) *]Tricuspid Annuloplasty Definitely Improves Patient Outcomes in the First Year After Heart Transplantation; _]M. Borkon1, S. Aggarwal1, G. Dryton^1^, A. Kao2, K. Allen1, R. Davis1, A. Pak1, E. Thompson1, A. Magalski2, B. Austin2, T. Khumari2, S. Lawhorne2, K. Gosch1. [^1^]_]Department of CV Surgery, Saint Luke’s Mid America Heart Institute, Kansas City, MO, 2Department of Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO

 

[*(544) *][Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients; _]A. W. Panakos, D. R. Kramer, M. McCarey, P. J. Mather. _Internal Medicine, Thomas Jefferson University, Philadelphia, PA

 

[*(545) *][Early and Long Term Results of Heart Transplantation after Reoperative Sternotomy; _]D. E. Sert, U. Kervan, S. Kocabeyoglu, E. Unal, K. Kavasoglu, M. Ozatik, F. Pac, S. Kucuker, M. Pac. _Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

 

[*(546) *]Temporal Changes on the Risk of New Onset Diabetes Following Cardiac Transplantation Over 30 Years; _]N. Iannino^1^, S. de Denus1, A. Nasri1, A. Räkel2, M. Carrier1, A. Ducharme1, K. Lachance3, N. Racine1, G. Pelletier1, A. Fortier4, M. White1. [^1^]_]Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada, 2Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 3Sanofi Canada, Laval, QC, Canada, 4Montreal Health Innovations Coordinating Center, Montreal, QC, Canada

 

[*(547) *]Reduction in Post-Heart Transplant ICU and Total Length of Stay by Standardization of Care Via a Multidisciplinary Approach; _]R. K. Cheng^1^, J. D. Pal2, N. A. Mokadam2, V. Chaudhari3, T. F. Dardas1, K. D. O’Brien1, J. W. Smith2, S. Moore1, W. C. Levy1, S. C. Masri1, A. Stempien-Otero1, C. Mahr1, D. P. Fishbein1. [^1^]_]Cardiology, University of Washington, Seattle, WA, 2Cardiac Surgery, University of Washington, Seattle, WA, 3Medicine, University of Washington, Seattle, WA

 

[*(548) *]Use of a Highly Sensitive Assay for Cardiac Troponin T as an Adjunct to Diagnose Acute Rejection after Cardiac Transplant; _]U. Boeken^1^, A. Mehdiani1, C. Ballazs1, C. Sowa1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

 

[*(549) *]Outcomes in Patients Older than 65 Years of Age Post Heart (HT) & Heart-Kidney Transplant (HKT); _]A. Iyengar, C. Eisenring, A. Nsair, M. Deng, L. Reardon, A. Ardehali, E. DePasquale. [_University of California – Los Angeles, Los Angeles, CA

 

[*(550) *][Relationship Between Brachial Artery Flow-Mediated Dilation and Clinical Characteristics of Heart Transplant Recipients; _]T. Watanabe, O. Seguchi, M. Yanase, T. Fujita, T. Sato, H. Sunami, S. Nakajima, K. Nishimura, E. Hisamatsu, K. Kuroda, N. Okada, K. Wada, H. Hata, H. Ishibashi-Ueda, Y. Miyamoto, J. Kobayashi, N. Fukushima, T. Nakatani. _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*(551) *]Poor Blood Pressure Control Is Independently Associated with Renal Dysfunction After Heart Transplant; _]M. Osnard^1^, A. D. Althouse2, L. Krall2, C. Newman2, C. Grabowski2, F. Speicher2, R. Zomak2, L. Lagazzi2, R. Kormos2, M. Shullo2, J. Teuteberg2. [^1^]_]University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*(552) *]Post Heart Transplant Cancer Diagnosis Association with Human Leukocyte Antigen-G Genotypes; _]J. Lazarte^1^, L. Goldraich2, C. Manlhiot3, V. Rao3, D. Delgado2. [^1^]_]Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada, 3Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

 

[*(553) *][Association between Karnofsky Functional Scale and Survival in Patients Listed for Heart Transplantation; _]S. G. Al-Kindi, M. Farhoud, M. Kattea, M. Ginwalla, C. ElAmm, M. Zacharias, R. Benatti, B. Sareyyupoglu, S. Deo, S. Park, G. H. Oliveira. _University Hospitals Case Medical Center, Cleveland, OH

 

[*(554) *]The Impact of Donor Specific Antibodies on Antibody Mediated Rejection; _]K. J. Clerkin^1^, S. W. Restaino1, E. R. Vasilescu2, E. Zorn3, C. C. Marboe2, D. M. Mancini1. [^1^]_]Cardiology, Columbia University Medical Center, New York, NY, 2Pathology, Columbia University Medical Center, New York, NY, 3Immunology, Columbia University Medical Center, New York, NY

 

[*(555) *]Body Mass Index Adversely Affects Survival in Left Ventricular Assist Device Bridged Patients Undergoing Heart Transplantation; _]S. Deo^1^, S. Kumar2, S. Altarabsheh3, J. Kerner1, J. Benavides1, B. Sareyyupoglu1, B. Medalion1, Y. Elgudin1, C. Elamm4, M. Ginwalla4, R. Benatti4, M. Zacharias4, G. H. Oliveira4, G. C. Fonarow5, S. J. Park1. [^1^]_]Cardiac Surgery, University Hospitals, Cleveland, OH, 2Advanced Heart Failure, UT Health Sciences Center, Houston, TX, 3Cardiac Surgery, Queen Alia Heart Institute, Amman, Jordan, 4Cardiology, University Hospitals, Cleveland, OH, 5[_ Cardiology, Adamson- UCLA Cardiomyopathy Center, Los Angeles, CA _]

 

[*(556) *][Association of Heart Transplant Recipient Age and Body Mass Index with Microcirculatory Remodeling; _]G. Cohen, C. Strehl, H. Luikart, W. F. Fearon, K. Khush. _Stanford University, Stanford, CA

 

[*(557) *]Clinical Implication of Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: Do We Really Have to Care All the DSA Positive Patients?; _]T. Sato^1^, O. Seguchi1, Y. Kanaumi2, M. Yanase1, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, S. Nakajima1, H. Hata3, T. Fujita3, H. Ishibashi-Ueda4, N. Fukushima1, J. Kobayashi3, T. Nakatani1. [^1^]_]Transplantation, National Cardiovascular Center, Osaka, Japan, 2Transfusion Medicine, National Cardiovascular Center, Osaka, Japan, 3Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan, 4Pathology, National Cardiovascular Center, Osaka, Japan

 

[*(558) *]Higher Rate of Hospitalizations for Infection and Cancer Than Rejection in Low Risk Heart Transplant Patients Followed by Gene Expression Profiling; _]J. J. Teuteberg^1^, M. A. Shullo1, P. J. Berman2, N. Haglund3, M. A. Wigger3, G. A. Ewald4. [^1^]_]University of Pittsburgh, Pittsburgh, PA, 2Tampa General Hospital, Tampa, FL, 3Vanderbilt University, Nashville, TN, 4Washington University, St. Louis, MO

 

[*(559) *][Evaluation of Left Ventricular Myocardial Mechanics in Heart Transplant Recipients Using Three-Dimensional Speckle Tracking Echocardiography; _]A. Assabiny, A. Kovacs, A. Kosztin, B. F. Farkas, M. Tokodi, B. Sax, B. Merkely. _Heart and Vascular Center, Semmelweis University, Budapest, Hungary

 

[*(560) *][Significant Tricuspid Insufficiency After Cardiac Transplantation: Which Risk Factor Has the Most Influence; _]V. Hajiyev, C. Knosalla, M. Dandel, M. Pasic, S. Buz, R. Hetzer. _Cardiathoracic Surgery, German Heart Institute in Berlin, Berlin, Germany

 

[*(561) *]Our Experience with the Use of Allomap in Multiple Organ Recipients; _]S. Carey^1^, G. Saracino2, A. Jamil1, S. Hall1. [^1^]_]Advanced Heart and Lung, Baylor University Medical Center, Dallas, TX, 2Baylor University Medical Center, Dallas, TX

 

[*(562) *]Limiting the Number of Endomyocardial Biopsies Does Not Impact One Year Survival Following Heart Transplantation; _]K. Balakrishnan1, R. Ratnagiri^2^, S. Rao3, M. Tungaturu3. [^1^]_]Cardiac Surgery, Fortis Malar Hospital, Chennai, India, 2Cardiology, Fortis Malar Hospital, Chennai, India, 3Cardiac Anaesthesia, Fortis Malar Hospital, Chennai, India

 

[*(563) *][Vibration Controlled Transient Elastography for Identification of Hepatic Fibrosis in Patients Evaluated for Cardiac Transplantation or Left Ventricular Assist Device: A Pilot Study; _]D. Vucicevic, E. P. Kransdorf, D. E. Steidley, H. E. Vargas, E. J. Carey. _Mayo Clinic Arizona, Scottsdale, AZ

 

[*(564) *]Cardiac Troponin T in Heart Donors: Impact on Morbidity and Mortality After Transplantation; _]U. Boeken^1^, A. Albert1, A. Mehdiani1, G. Petrov1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

 

[*(565) *]When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era; _]J. A. Kobashigawa1, J. Patel1, M. Kittleson1, L. Czer1, T. Aintablian1, M. Yang1, S. Sana^1^, J. Rush1, E. Stimpson1, D. Geft1, D. Ramzy1, N. Reinsmoen2. [^1^]_]Cedars-Sinai Heart Institute, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA

 

[*(566) *]Characteristics and Co-Morbidities in Heart Transplant Recipients Who Survive into Their Eighties; _]D. Tabachnick1, J. Stehlik2, E. Gilbert2, J. Nativi-Nicolau2, J. Fang2, O. Wever-Pinzon^2^, S. Drakos2, D. Budge3, B. Kfoury3, R. Alharethi3, W. Caine4, C. Selzman1, S. McKellar1. [^1^]_]Department of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 2Department of Cardiology, University of Utah, Salt Lake City, UT, 3Department of Cardiology, Intermountain Medical Center, Salt Lake City, UT, 4Department of Cardiothoracic Surgery, Intermountain Medical Center, Salt Lake City, UT

 

[*(567) *]Preoperatively Impaired Renal Function Does Not Affect Long-Term Survival in Heart Transplanted Patients; _]O. Kolsrud^1^, K. Karason2, E. Holmberg3, S. Ricksten4, M. Felldin5, O. Samuelsson5, G. Dellgren6. [^1^]_]Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Oncology, Sahlgrenska Academy, Gothenburg, Sweden, 4Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, 5Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden, 6Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

 

[*(568) *]How to Achieve Improved Outcome after Heart Transplantation?; _]G. Dellgren^1^, H. Liden1, S. Bartfay2, S. Ricksten3, J. Gäbel1, H. Rexius1, E. Bolano2, K. Karason2. [^1^]_]Cardiothoracic Surgery, Sahlgrenska Univ Hospital, Goteborg, Sweden, 2Cardiology, Sahlgrenska Univ Hospital, Goteborg, Sweden, 3Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska Univ Hospital, Goteborg, Sweden

 

[*(569) *]Predictors of Normal Coronary Angiography in Older Donors: Results from a Prospective National Study; _]C. Cantrellle1, C. Lefeuvre2, T. Genet3, C. Legeai1, C. Jasseron1, I. Pipien1, E. Epailly4, D. Angoulvant3, O. Bastien1, R. Dorent^1^. [^1^]_]Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, 2Cardiology, Hôpital la Pitié-Salpêtrière, Paris cedex 13, France, 3Cardiology, Hopital Trousseau, Tours, France, 4Cardiology, Hopital Civil, Strasbourg, France

 

[*(570) *]Optimal Timing of Heart Transplantation After HeartMate II Left Ventricular Assist Device Implantation; _]R. J. Steffen1, E. H. Blackstone1, N. G. Smedira1, E. G. Soltesz1, K. J. Hoercher1, L. Thuita2, R. C. Starling3, M. Mountis3, N. Moazami^1^. [^1^]_]Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH

 

[*(571) *]The Fate of Donor Hearts Rejected for Transplant: A Single Institutional Experience; _]D. J. Hall1, C. R. Matthews^2^, J. M. Aranda3, M. A. Ahmed3, J. A. Hill3, A. D. Szady3, J. R. Vilaro2, C. T. Klodell1, T. M. Beaver1. [^1^]_]Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, 2College of Medicine, University of Florida, Gainesville, FL, 3Division of Cardiovascular Medicine, University of Florida, Gainesville, FL

 

[*(572) *]Donor Heart Turn Down, Is It Rational?; _]J. Patel, M. Kittleson, L. Czer, D. Chang, T. Aintablian, E. C. Norris, A. Velleca, J. Rush, E. Stimpson, A. Hage, A. Trento, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(573) *][The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation; _]O. Kiamanesh, A. Khosla, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma. _University of British Columbia, Vancouver, BC, Canada

 

[*(574) *][Risk Factors of Waiting List Mortality for Patients Awaiting Heart Transplant; _]J. R. Trivedi, E. Schumer, M. Black, H. T. Massey, A. Cheng, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

 

[*(575) *]Impact of Size Mismatch on Heart Transplant Outcomes; _]K. Murphy^1^, E. P. Kransdorf2, S. Wilansky2, O. E. Pajaro3, D. E. Steidley2. [^1^]_]Division of Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, 2Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, 3Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ

 

[*(576) *]WITHDRAWN

 

[*(577) *]Pre-Operative Pulmonary Hypertension Does Impact Long Term Outcomes Following Heart Transplantation: Review of the United Network for Organ Sharing Database; _]M. L. Irons^1^, A. C. Gaffey1, C. W. Chen1, A. Vaidya2, M. A. Acker1, P. Atluri1. [^1^]_]Division of Cardiovascular Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

 

[*(578) *]Does Pulmonary Hypertension Affect Survival after Heart Transplantation Based on Recipient Body Mass Index?; _]P. C. Rosas1, E. Stock2, E. A. Amulraj3, S. Emani4, R. C. Scott5, C. B. Sai-Sudhakar3, Y. Ravi^3^. [^1^]_]Medical Physiology, Texas A&M University, Temple, TX, 2Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, 3Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, 4Internal Medicine, The Ohio State University, Columbus, OH, 5Cardiology-Internal Medicine, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX

 

[*(579) *]Influence of Duration of Continuous-Flow Ventricular Assist Device Support on Post-Transplant Outcome – Results Using the United Network for Organ Sharing Database; _]A. M. Bernhardt^1^, A. P. Levin2, A. Schaefer1, F. M. Wagner1, H. Reichenspurner1. [^1^]_]Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Columbia University Medical Center, New York City, NY

 

[*(580) *][A Novel Cardiac Allocation Score for Predicting Wait-List and Post Transplant Survival; _]S. Margelis, P. Karas, E. Granger, P. Spratt, P. Jansz, C. Hayward, A. Jabbour, A. Keogh, E. Kotlyar, P. Macdonald, K. Dhital. _St Vincent’s Hospital, Sydney, Australia

 

[*(581) *]Changing Characteristics of Heart Transplant Donors and Their Effect on Recipient Mortality; _]Y. Ravi^1^, E. M. Stock2, P. C. Rosas3, R. C. Scott4, E. A. Amulraj1, S. Emani5, C. B. Sai-Sudhakar1. [^1^]_]Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, 2Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, 3Medical Physiology, Texas A&M University, Temple, TX, 4Cardiology-Internal Medicine, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, 5Cardiology-Internal Medicine, The Ohio State University, Columbus, OH

 

[*(582) *]Impact of Donor Hypernatremia on Outcome After Cardiac Transplantation; _]U. Boeken^1^, A. Albert1, A. Mehdiani1, G. Petrov1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

 

[*(583) *]Hypertonic Saline Solution Preserves Left Ventricular Function and Inhibit Myocardial Injury Triggered by Brain Death in Rats; _]L. F. Moreira, D. M. Magalhães, F. L. Zanoni, C. J. Correia, R. Simas, P. Sannomiya. [_Department of Cardiovascular Surgery, Heart Institute (Incor), University of Sao Paulo Medical School, Sao Paulo, Brazil

 

[*(584) *]Thyroid Hormone Use During Cardiac Transplant Organ Procurement; _]L. B. Cooper^1^, C. A. Milano1, M. Williams1, W. Swafford1, D. Croezen2, A. B. Van Bakel3, J. G. Rogers1, C. B. Patel1. [^1^]_]Duke University, Durham, NC, 2Carolina Donor Services, Durham, NC, 3Medical University of South Carolina, Charleston, SC

 

[*(585) *]MOVED TO MINI ORAL SESSION 10

 

[*(586) *][Evaluation of Thoracic Exception Policy for Highly Sensitized Patients; _]S. McKean. _Clinical, Advanced Practice, Donor Network West, San Ramon, CA

 

[*(587) *]The Interval between Brain Stem Death and Cardiac Assessment Influences the Retrieval of Hearts for Transplantation; _]R. V. Venkateswaran^1^, J. Lannon2, E. Wong2, M. Berman3, N. Howell4, J. Payne5, J. Dark6, N. R. Banner7. [^1^]_]Director of Transplantation, Wythenshawe Hospital NHS Trust, Manchester, United Kingdom, 2Statistics Department, NHS Blood and Transplant, Bristol, United Kingdom, 3Consultant Transplant Surgeon, Papworth Hospital NHS Trust, Cambridge, United Kingdom, 4Consultant Transplant Surgeon, University Hospital Birmingham NHS Trust, Birmingham, United Kingdom, 5Consultant Cardiologist, Golden Jubilee Hospital, Glasgow, United Kingdom, 6Consultant Transplant Surgeon, Freeman Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, 7Consultant Cardiologist, Harefield Hospital NHS Trust, London, United Kingdom

 

[*(588) *]A Comparison of ECMO, LVAD and Biventricular Support in Bridging to Heart Transplant in the OPTN Database; _]S. C. Silvestry^1^, J. Rogers2, L. B. Edwards3, E. Robbins-Callahan3, D. M. Meyer4. [^1^]_]Thoracic Transplant, Florida Hospital Transplant Institute, Orlando, FL, 2Cardiology, Duke University, Durham, NC, 3UNOS, Richmond, VA, 4Cardiac Surgery, UT Southwestern, Dallas, TX

 

[*(589) *]The Role of Japanese Medical Consultant System on Improving Outcomes of Cardiac Recipients from Old Donors or Donors Who Died of Post-Resuscitation and Anoxia; _]N. Fukushima^1^, M. Ono2, Y. Saiki3, T. Ooka4, Y. Tanoue5, S. Saito6, S. Fukushima7. [^1^]_]Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, 2Department of Cardiovascular Surgery, Tokyo University, Tokyo, Japan, 3Department of Cardiovascular Surgery, Tohoku University, Sendai, Japan, 4Department of Cardiac Surgery, Hokkaido University, Sapporo, Japan, 5Department of Cardiovascular Surgery, Kyushu University, Fukuoka, Japan, 6Department of Cardiac Surgery, Tokyo Wemen’s Medical University, Tokyo, Japan, 7Department of Cardiovascular Surgery, Osaka University, Suita, Japan

 

[*(590) *][The Paradoxical Relationship between Donor Distance from Transplant Center and Survival after Heart Transplantation; _]T. C. Crawford, J. Magruder, J. C. Grimm, K. J. Zehr, K. Mandal, J. V. Conte, G. J. Whitman, R. S. Higgins, D. E. Cameron, W. A. Baumgartner, C. M. Sciortino. _Cardiac Surgery, Johns Hopkins University, Baltimore, MD

 

[*(591) *]The Use of Social Media Application Software Using Smartphones in Donor Heart Evaluation; _]K. Balakrishnan1, M. Tungaturu^2^, S. Rao2, R. Ratnagiri3. [^1^]_]Cardiac Surgery, Fortis Malar Hospital, Chennai, India, 2Cardiac Anesthesia, Fortis Malar Hospital, Chennai, India, 3Cardiology, Fortis Malar Hospital, Chennai, India

 

[*(592) *][Retrieval Team Initiated Early Donor Management (Scouting) Increases Donor Heart Acceptance Rate for Transplantation; _]C. Barbero, A. Ravaglioli, A. Page, B. Parizkova, M. Berman, C. Sudarshan, S. Large, S. Tsui. _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom

 

[*(593) *]Time-Varying Mortality Risk Score for Candidates Awaiting Cardiac Transplantation; _]V. B. Cruz1, R. Steffen2, M. Koprivanac^3^, R. C. Starling2, D. O. Taylor2, K. Hoercher2, J. Rajeswaran4, N. Smedira2, E. Soltesz2, E. H. Blackstone2, N. Moazami2. [^1^]_]Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, 2Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 3General Surgery, Cleveland Clinic, Cleveland, OH, 4Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

 

[*(594) *]Marijuana and Listing for Heart Transplant: A Global Survey; _]J. Neyer, A. Uberoi, M. Hamilton, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(595) *][Donor Age for Heart Transplantation Does Not Affect Short or Mid-Term Outcomes; _]T. Chamogeorgakis, S. Joseph, S. Hall, G. Saracino, S. Carey, P. Kale, M. Sherwood, G. Gonzalez-Stawinski, B. Lima. _Baylor University Medical Center, Dallas, TX

 

[+LUNG TRANSPLANTATION +]

[+Target Audience: +]

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Laveena Chhatwani, Fabio De Robertis, Kumud Dhital, Joshua Diamond, Cassie Kennedy, Lorriana Leard, Anne Olland, Michael Perch, Antonio Roman, Pali Shah, Ciara Shaver, Wiebke Sommer, Bart Vanaudenaerde, Keith Wille

[*(596) *]Assessment of FEV1 Decline after Lung Transplantation Using Functional Respiratory Imaging; _]E. M. Barbosa1, F. Ferreira2, W. Vos2, C. Van Holsbeke2, L. Nuyttens3, W. De Backer4, J. De Baker2, J. C. Lee^1^. [^1^]_]Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, 2FluidDA, Kontich, Belgium, 3FluidDA USA, North Brunswick, NJ, 4University Hospital Antwerp, Edegem, Belgium

 

[*(597) *]Lung Transplant Outcome: Eplets Compatibility and DSA Development; _]D. C. Walton1, S. J. Hiho1, L. S. Cantwell1, M. B. Diviney1, G. I. Snell2, M. A. Paraskeva2, G. P. Westall^2^. [^1^]_]Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia

 

[*(598) *]A Single Donor TARC/CCL17 Promotor Polymorphism Correlates with Serum TARC/CCL17 Levels and Is Associated with Impaired Clinical Outcome after Lung Transplantation; _]K. Budding^1^, J. van Setten2, O. A. van Rossum1, E. A. van de Graaf3, T. Kardol-Hoefnagel1, E. D. Oudijk4, C. E. Hack1, H. G. Otten1. [^1^]_]Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands, 3Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 4Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, Netherlands

 

[*(599) *][Bile Acid Aspiration Associates with CLAD and Affects the Bronchial District Lipid Profile: Targeted Bile Acid Metabolomics and Lipidomics in Bronchial Washing; _]D. Briganti, C. Kim, B. Aramini, R. Nandakumar, B. Zhou, R. Chan, S. Sreekanth, K. Raza, H. Robbins, L. Shah, S. Arcasoy, J. Sonett, G. Di Paolo, S. Cremers, F. D’Ovidio. _Columbia University, New York City, NY

 

[*(600) *]Delayed Non-Myeloablative Irradiation after Lung Transplantation to Induce Allograft Acceptance in a Large Animal Model; _]J. Hahn1, K. Jansson^1^, W. Sommer1, M. Avsar1, J. Salman1, T. Siemeni1, A. Knoefel1, L. Pauksch1, B. Schröder2, A. Haverich1, G. Warnecke1. [^1^]_]Medical School Hannover (MHH), Hannover, Germany, 2Tierärztliche Hochschule, Hannover, Germany

 

[*(601) *][The Presence of Complement (C4d) Broncho-Alveolar Lavage in Phenotypes of Chronic Lung Allograft Dysfunction; _]E. Vandermeulen, S. E. Verleden, D. Ruttens, H. Bellon, D. E. Van Raemdonck, R. Vos, G. M. Verleden, B. M. Vanaudenaerde. _Department of Pneumology, KULeuven, Leuven, Belgium

 

[*(602) *][Molecular Detection of Community Acquired Respiratory Viral Infections (CARV) and the Risk of BOS in Lung Transplant (LTx) Recipients; _]B. C. Bemiss, D. E. Byers, C. A. Witt, P. R. Aguilar, R. D. Yusen, E. P. Trulock, R. R. Hachem. _Washington University School of Medicine, Saint Louis, MO

 

[*(603) *]Natural History of Chronic Lung Allograft Dysfunction (CLAD) and Impact of Azithromycin (AZ) in Lung Transplant (LT) Recipients; _]A. Moniodis1, K. Townsend^2^, A. Rabin3, O. Aloum4, J. Stempel4, P. Burkett5, P. Camp6, M. Divo5, S. El-Chemaly5, H. Mallidi6, I. Rosas5, F. Anne5, S. Koo4, H. Goldberg5. [^1^]_]Pulmonary and Critical Care, Brigham and Women’s Hospital, Brookline, MA, 2Lung Transplant Program, Pharmacy Department, Brigham and Women’s Hospital, Brookline, MA, 3Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, 4Transplant Infectious Disease, Brigham and Women’s Hospital, Boston, MA, 5Lung Transplant Program, Brigham and Women’s Hospital, Boston, MA, 6Lung Transplant Program, Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA

 

[*(604) *]FVC and FEV1 Decline in Chronic Lung Allograft Dysfunction (CLAD) Phenotypes; _]J. L. Todd^1^, C. A. Finlen Copeland1, M. Neely2, S. M. Palmer1. [^1^]_]Medicine, Duke Univ Med Ctr, Durham, NC, 2Biostatistics and Bioinformatics, Duke Univ Med Ctr, Durham, NC

 

[*(605) *][Long-Term Outcome of Double Lung Retransplantation After Heart and Lung Transplantation for Chronic Lung Allograft Dysfunction; _]L. Marien, O. Mercier, J. Le Pavec, J. Guihaire, S. Mussot, D. Fabre, L. Lamrani, P. Dartevelle, E. Fadel. _Centre Chirurgicale Marie Lannelongue, Paris, France

 

[*(606) *][_ Role of CD4+CD25highCD127- Treg Cells in Long Term Outcome of Lung Recipients; ]D. Piloni^1^, M. Morosini2, S. Magni2, A. Balderacchi2, L. Scudeller3, E. Cova2, T. Oggionni2, G. Stella2, C. Tinelli3, F. Antonacci2, F. Meloni1. [1_]Department of Internal Medicine, University of Pavia, Pavia, Italy, 2Cardiothoracic and Vascular Dept., Pneumology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 3Clinical Epidemiology and Biometric Unit, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

 

[*(607) *][_ Impact of Persistent Versus Transient Donor Specific HLA- Antibodies on Graft Outcome Following Lung Transplantation; ]D. Sroussi, C. Gauvain, E. Lhuillier, C. Dupin, G. Dauriat, G. Jebrak, P. Mordant, G. Thabut, H. Mal, C. Suberbielle, O. Brugière. [_Hôpital Bichat, Paris, France]

 

[*(608) *]Short Term Safety and Tolerance of Mesenchymal Stem Cells (MSC) Infusion as Cell Therapy for Patients Experiencing Treatment-Refractory Moderate Chronic Lung Allograft Dysfunction (CLAD); _]C. A. Keller^1^, A. L. Russell2, R. C. Lefavor2, C. M. Desmond2, K. E. Hurst1, H. A. David-Robinson1, D. G. Kontras1, A. C. Zubair2. [^1^]_]Transplant Department, Mayo Clinic, Jacksonville, FL, 2Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL

 

[*(609) *]Serial Parametric Response Mapping to Diagnose Bronchiolitis Obliterans Syndrome; _]S. E. Verleden^1^, R. Vos1, E. Vandermeulen1, D. Ruttens1, H. Bellon1, D. Van Raemdonck1, G. M. Verleden1, C. Galban2, V. Lama2, B. Ross2, B. Vanaudenaerde1. [^1^]_]KU Leuven, Leuven, Belgium, 2University of Michigan, Michigan, MI

 

[*(610) *]Bronchial & Alveolar Lipidomic Profile as a Marker of the Immunological and Functional Status of the Lung Allograft; _]D. Briganti^1^, C. Kim1, B. Aramini1, R. Chan1, B. Zhou1, S. Sreekanth1, K. Raza1, H. Robbins1, L. Shah1, S. Arcasoy1, J. Sonett1, F. Meloni2, G. Di Paolo1, F. D’Ovidio1. [^1^]_]Columbia University, New York City, NY, 2Università di Pavia, Pavia, Italy

 

[*(611) *][Association of Prolonged Hospital Stay during Transplant Surgery with Long Term Outcomes among Patients with Lung Transplantation; _]M. Mohanka, A. Banga. _UT Southwestern Medical Center, Dallas, TX

 

[*(612) *]Serum miRNAs as Potential Biomarkers for the Bronchiolitis Obliterans Syndrome after Lung Transplantation; _]K. Budding^1^, M. Rossato1, E. A. van de Graaf2, T. R. Radstake1, H. G. Otten1. [^1^]_]Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands

 

[*(613) *][_ Influence of Non-Donor Specific Antibodies on Chronic Lung Allograft Dysfunction -A New Risk Factor in Lung Transplantation? -; ]L. Mori^1^, J. D. Smith2, A. Montero-Fernandez3, A. Rice3, A. Sabashnikov4, M. Zeriouh5, M. Carby1, A. Reed1, A. R. Simon4, A. Popov4, S. Soresi1. [1_]Lung Failure & Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, 2Tissue Typing, Heart & Science Centre, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, 3Department of Histopathology, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, 4[_ Department of Cardiothoracic Surgery &Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, 5_]Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany

 

[*(614) *]A National Survey of Practice and Perceptions Regarding Anti-Fibrotic Medication in Lung Transplant Recipients; _]C. M. Patterson1, M. Durheim^2^, S. Palmer2, C. Finlen Copeland2, L. Snyder3. [^1^]_]Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, 2Duke University, Durham, NC, 3Duke University Med Ctr, Durham, NC

 

[*(615) *]How Important Is Coronary Artery Disease When Considering Lung Transplant Candidates?; _]M. Koprivanac^1^, M. Budev2, M. Kelava3, G. Pettersson2, K. McCurry2, D. Johnston1, P. Houghtaling1, E. Blackstone2, S. Murthy2. [^1^]_]General Surgery/Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH, 2Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH, 3Anesthesiology, Cleveland Clinic, Cleveland, OH

 

[*(616) *][Racial and Ethnic Differences in Pre-Transplantation Panel Reactive Antibodies and Outcome Following Lung Transplantation; _]K. M. Wille, N. S. Sharma, B. Wei, F. Siric, C. Hoopes, E. Diaz-Guzman. _Univ of Alabama at Birmingham, Birmingham, AL

 

[*(617) *]Pulmonary Transplantation for End-Stage Silicosis: A Single Center Experience; _]W. Mao, X. Nie, W. Xia, M. Zheng, J. Chen. [_Department of Lung Transplant Center, Key Laboratory of Human Organ Transplant in Jiangsu Province, Nanjing Medical University affiliated Wuxi People’s Hospital, Wuxi, China

 

[*(618) *][Depression, Quality of Life, and Mortality Early Following Lung Transplantation; _]P. J. Smith, J. Blumenthal, J. Mathew, B. M. Hoffman, S. Rivelli, M. Durheim, S. M. Palmer. _Duke University Medical Center, Durham, NC

 

[*(619) *]Outcome of Patients with End-Stage Pulmonary Hypertension Who Received Double Lung Transplantation Instead of Heart-Lung Transplantation: A Comparative Retrospective Study; _]A. Gruner1, T. Kortchinsky1, O. Mercier2, S. Rezaiguia-Delclaux1, E. Fadel2, F. Stephan^1^. [^1^]_]Reanimation Adulte, Hopital Marie Lannelongue, Le Plessis Robinson, France, 2Pole Thoracique et Vasculaire-Transplantation Pulmonaire, Hopital Marie Lannelongue, Le Plessis Robinson, France

 

[*(620) *]Lung Transplant Recipient Survival Following Urgent Inpatient Candidacy Evaluation; _]R. L. Sagana^1^, L. J. Stuckey2, J. Berry3, H. Collins1, A. Heinle1, L. Roaden1, D. Stepka1, A. Chang4, J. Lin4, K. Chan1. [^1^]_]Internal Medicine, University of Michigan, Ann Arbor, MI, 2Pharmacy, University of Michigan, Ann Arbor, MI, 3Transplant Center, University of Michigan, Ann Arbor, MI, 4Thoracic Surgery, University of Michigan, Ann Arbor, MI

 

[*(621) *][De Novo Anti-HLA Class II Donor Specific Antibodies after Lung Transplantation Are Associated with Mortality after Lung Transplant Failure; _]B. Bahar, D. F. Dilling, Z. Du. _Loyola University Medical Center, Maywood, IL

 

[*(622) *]What Timing Is Best for Revascularization in Lung Transplant Candidates with Coronary Artery Disease? Pre-Lung Transplantation vs Intra-Lung Transplantation; _]T. Yoshizumi^1^, J. Gomez-Abraham1, A. Shiose1, F. Cordova2, G. Criner2, Y. Toyoda1. [^1^]_]Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, 2Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA

 

[*(623) *][Sequential Bronchoalveolar Lavages Reflect Distinct Pulmonary Compartments: Clinical and Research Implications in Lung Transplantation; _]L. Levy, S. C. Juvet, L. G. Singer, S. Azad, B. Joe, M. Cypel, S. Keshavjee, T. Martinu. _Toronto Lung Transplant Program, Toronto, ON, Canada

 

[*(624) *]Lung Transplantation and Concomitant Treatment of Significant Coronary Artery Disease: Insights from a Single-Center Experience; _]F. Ius^1^, T. Siemeni1, W. Sommer1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, J. Optenhoefel1, J. Puntigam1, U. Molitoris1, M. Greer2, T. Welte2, A. Haverich1, J. Gottlieb2, G. Warnecke1. [^1^]_]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

 

[*(625) *][The Optimal Number of Transbronchial Biopsies Needed to Evaluate Rejection in the Lung Allograft; _]H. Inaty, A. Jawad, C. Lane, W. Tsuang, J. Turowski, O. Akindipe, A. Mehta, M. Budev, M. Machuzak. _Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH

 

[*(626) *]Early Diagnosis of Gastroesophageal Reflux Disease After Lung Transplantation Using the RSI and Impact of Surgical Techniques: Minimally Invasive or Clamshell Incision, What Is Better?; _]S. Soresi1, A. Padukone^2^, A. Sabashnikov2, M. Zeriouh3, M. Carby1, A. Reed1, A. Simon2, A. Popov2. [^1^]_]Lung Failure & Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, 2[_ Department of Cardiothoracic Surgery &Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, 3_]Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany

 

[*(627) *][V/Q SPECT CT in Screening for Pulmonary Embolus Following Lung Transplantation; _]O. Kadwani, C. Fowler, P. Dalal, M. Carby. _Transplant Medicine, Royal Brompton and Harefield NHS Trust, London, United Kingdom

 

[*(628) *][Is Routine Respiratory Viral PCR Testing in Lung Transplant Recipients Helpful?; _]K. Timov, E. Karimi, J. Salaie, A. Ball, K. Santhanakrishnan, M. Al-Aloul. _Cardiothoracic Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom

 

[*(629) *]Altered Surfactant Turn-Over Immediately after Lung Transplantation Is Associated with Impaired Graft Function at Three Months; _]L. Thakuria^1^, R. Romano1, G. Koster2, V. Goss2, P. Townsend2, A. Simon1, A. Popov1, F. de Robertis1, S. Soresi1, M. Carby1, A. Reed1, N. Marczin3, M. Griffiths4, A. Postle2. [^1^]_]Dept of Cardiothoracic Transplantation, Harefield Hospital, Harefield, United Kingdom, 2Southampton Centre for Biomedical Research, Southampton General Hospital, Southampton, United Kingdom, 3Anaesthesia, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom, 4Intensive Care Unit, The Royal Brompton Hospital, London, United Kingdom

 

[*(630) *][Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Outcomes after Lung Transplantation; _]R. Tomic, A. Keenan, E. Dincer, H. Kim. _Pulmonary and Critical Care Medicine, University of Minnesota, Minneapolis, MN

 

[*(631) *]Impact of Pre-Transplant Sensitization on the Development of Anti-HLA Antibodies after Lung Transplantation: A Prospective Pilot Study; _]S. Z. Cao^1^, A. Courtwright2, Y. Cui2, A. M. Lamattina2, S. Fried3, I. Wood4, I. Guleria1, P. Camp1, A. Chandraker1, E. Milford1, S. El-Chemaly1, H. J. Goldberg1. [^1^]_]Harvard Medical School, Boston, MA, 2Division of Pulmonary and Critical Care Medicine, Brigham and Woman’s Hospital, Boston, MA, 3Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Brigham and Woman’s Hospital, Boston, MA, 4Clinical Laboratory Division, Tissue Typing Laboratory, Brigham and Woman’s Hospital, Boston, MA

 

[*(632) *][Bronchial Disorders and Complications after Lung Transplant: Analysis of Risk Factors and Predictive Model of Onset; _]M. Schiavon, F. Calabrese, U. Fantoni, D. Gregori, G. Marulli, M. Loy, F. Lunardi, F. Calabrese, F. Rea. _Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy

 

[*(633) *]Peri-Operative Transfusion Practices in Lung Transplant Patients; _]P. Nair^1^, S. Al-Soufi1, D. Lowe1, D. Behan2, M. Harkess3, J. Breeding1, D. Boyd4, K. Dhital5, P. Spratt1, A. Glanville6. [^1^]_]Intensive Care Unit, St Vincent’s Hospital, Sydney, Australia, 2Haematology, St Vincent’s Hospital, Sydney, Australia, 3Cardiopulmonary Transplant Unit, St Vincent’s Hospital, Sydney, Australia, 4Anaesthetics, St Vincent’s Hospital, Sydney, Australia, 5Cardiothoracic Surgery, St Vincent’s Hospital, Sydney, Australia, 6Thoracic Medicine and Transplant, St Vincent’s Hospital, Sydney, Australia

 

[*(634) *]Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database; _]F. Ius^1^, M. Mehwald-Goeke1, W. Sommer1, M. Verboom2, C. Erdfelder1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, D. Boethig1, M. Greer3, B. Gohrbandt4, N. Schwerk5, J. Gottlieb3, T. Welte3, A. Haverich1, G. Warnecke1. [^1^]_]Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 4Department of Cardiovascular and Thoracic Surgery, Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany, 5Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany

 

[*(635) *][Impact of Operator and Anesthesia Choice on Bronchoscopic Biopsy Yield and Complications; _]L. Frye, T. Pena, A. Lanfranco, J. Lee. _Hospital of the University of Pennsylvania, Philadelphia, PA

 

[*(636) *]Outcome of Single Lung Transplantation for Lymphangioleiomyomatosis; _]T. Watanabe^1^, H. Mitomo1, S. Eba1, H. Notsuda1, Y. Watanabe1, H. Oishi1, H. Niikawa1, Y. Matsuda1, M. Noda1, T. Sado1, A. Sakurada1, Y. Hoshikawa1, M. Akiba1, T. Kondo1, K. Seyama2, Y. Okada1. [^1^]_]Tohoku Univesity, Miyagi, Japan, 2Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan

 

[*(637) *]Microarray Analysis of Transbronchial Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-cell Mediated Inflammation; _]K. Halloran^1^, J. Chang2, V. Ramassar2, A. Kapasi1, J. Weinkauf1, A. Hirji1, D. Lien1, J. Reeve2, P. Halloran2. [^1^]_]Medicine, University of Alberta, Edmonton, AB, Canada, 2Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, AB, Canada

 

[*(638) *]Usage of Aprotinin (Trasylol) in Bilateral Lung Transplantation – Friend or Foe?; _]L. Ong^1^, S. Abraham2, G. Parry3, S. C. Clark1. [^1^]_]Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 2Anaesthetics and Intensive Care Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 3Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

 

[*(639) *][Early Acute Kidney Injury in Lung Transplantation Is Associated with Significant Mortality; _]A. T. Logan, J. P. Casale, C. T. Doligalski. _Pharmacy, Tampa General Hospital, Tampa, FL

 

[*(640) *]Extracorporeal Photopheresis in Chronic Lung Allograft Disfunction:Data Support Their Use?; _]M. Aguilar Pérez^1^, R. Laporta Hernandez1, M. Lazaro Carrasco de la Fuente1, C. De Miguel2, j. Bueno Cabrera2, P. Ussetti Gil1. [^1^]_]Pulmonary Department, Universitary Puerta de Hierro Majadahonda Hospital, Madrid, Spain, 2Blood Bank. Hematology Department, Universitary Puerta de Hierro Majadahonda Hospital, Madrid, Spain

 

[*(641) *]Quantitation of the Effect of Azole Antifungals on Tacrolimus Clearance; _]D. R. Darley^1^, L. Carlos2, S. Hennig3, A. R. Glanville1. [^1^]_]Thoracic Medicine, St Vincent’s Hospital Darlinghurst, Sydney, Australia, 2Department of Pharmacy, St Vincent’s Hospital Darlinghurst, Sydney, Australia, 3School of Pharmacy, University of Queensland, Brisbane, Australia

 

[*(642) *]IVIG Infusions Deplete Donor-Specific HLA Antibodies in Lung Transplant Recipients; _]J. Kukreja^1^, D. Kopchaliiska2, G. Dincheva1, E. Bush1, L. Leard3, M. Brzezinski4, S. Hays3, J. Singer3, R. Rajalingam2. [^1^]_]Division of Cardiothoracic Surgery, Univ of California, San Francisco, CA, 2Immunogenetics and Transplantation Laboratory, Univ of California, San Francisco, CA, 3Division of Pulmonary Medicine, Univ of California, San Francisco, CA, 4Department of Anesthesia, Univ of California, San Francisco, CA

 

[*(643) *]Desensitization Therapy Before Lung Transplantation; _]P. R. Aguilar^1^, C. A. Witt1, B. C. Bemiss1, A. S. Krupnick2, D. Kreisel2, R. D. Yusen1, E. P. Trulock1, T. Mohanakumar3, R. R. Hachem1. [^1^]_]Pulmonary/Critical Care Medicine, Washington University, St. Louis, MO, 2Cardiothoracic Surgery, Washington University, St. Louis, MO, 3Surgery, Washington University, St. Louis, MO

 

[*(644) *][Intravenous Immunoglobulin in Sensitized Lung Transplant Recipients and Early Outcomes; _]E. C. Benedetti, G. Chery, M. Hartwig, A. Hulbert, J. Reynolds, L. Snyder. _Duke University Hospital, Durham, NC

 

[*(645) *]Trough Blood Concentrations Are an Accurate Indicator of Tacrolimus Exposure Early Post Lung Transplantation; _]D. R. Darley^1^, L. Carlos2, A. R. Glanville1. [^1^]_]Thoracic Medicine, St Vincent’s Hospital Darlinghurst, Sydney, Australia, 2Department of Pharmacy, St Vincent’s Hospital Darlinghurst, Sydney, Australia

 

[*(646) *][Pre-Treatment High Titer DSA Is Associated with Non-Responsiveness to Carfilzomib-Based AMR Therapy in Lung Transplant Recipients; _]A. Zeevi, M. Marrari, M. R. Morrell, S. A. Yousem, J. M. Pilewski, J. D’Cunha, J. F. McDyer, C. R. Ensor. _University of Pittsburgh, Pittsburgh, PA

 

[*(647) *]Prolonged Administration of Twice Daily Bolus Intravenous Tacrolimus Early after Lung Transplantation; _]Y. Hirano^1^, S. Sugimoto1, T. Mano1, T. Kurosaki2, S. Otani2, K. Miyoshi1, M. Yamane1, S. Miyoshi1, T. Oto2. [^1^]_]General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

 

[+MECHANICAL CIRCULATORY SUPPORT +]

[+Target Audience: +]

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Keith Aaronson, David DeNofrio, Doug Horstmanshof, Valluvan Jeevanandam, Charles Klodell, Ugolino Livi, Mathias Loebe, Claudius Mahr, Simon Maltais, Paul Mohasci, Samer Najjar, Takeshi Nakatani, Sanem Nalbantgil, Francis Pagani, Christopher Salerno, Murat Sargin, Josef Stehlik, George Wieselthaler

 

[*(648) *]Diagnosis and Management of Pump Thrombosis in Patients with Continuous-Flow Ventricular Assist Devices; _]S. Ertugay^1^, C. Engin1, A. Daylan1, E. Pektok2, P. Ozturk1, S. Nalbantgil3, T. Yagdi1, M. Ozbaran1. [^1^]_]Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey, 2Cardiovascular Surgery, Istanbul Bilim University Medical School Hospital, Istanbul, Turkey, 3Cardiology, Ege University Medical School Hospital, Izmir, Turkey

 

[*(649) *]Thrombolysis for Pump Thrombosis after LVAD: Weighing Benefits and Risks; _]A. Kornberger1, U. A. Stock^1^, C. Reyher2, T. Bingold2, B. Assmus3, A. Moritz1, A. Beiras-Fernandez1. [^1^]_]Thoracic, Cardiac and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany, 2Anaesthesia and Intensive Care, University Hospital Frankfurt, Frankfurt, Germany, 3Cardiology, University Hospital Frankfurt, Frankfurt, Germany

 

[*(650) *][Clopidogrel Does Not Increase Incidence of Bleeding in LVAD Patients; _]A. Bhatia, G. Sayer, S. Adatya, G. Kim, N. Sarswat, T. Ota, V. Jeevanandam, N. Uriel. _University of Chicago, Chicago, IL

 

[*(651) *]Risk Factors of Gastrointestinal Bleeding after Continuous Flow Left Ventricular Assist Device; _]O. Balcioglu1, S. Ertugay^2^, P. Ozturk2, C. Engin2, S. Nalbantgil3, S. Nalbantgil3, T. Yagdi2, M. Ozbaran2. [^1^]_]Cardiovascular Surgery, Near East University Medical School Hospital, Nicosia, Cyprus, 2Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey, 3Cardiology, Ege University Medical School Hospital, Izmir, Turkey

 

[*(652) *][LVAD Support Increases Plasma Iron Species: Implications for a Pathophysiologic Relationship between LVAD-Associated Hemolysis and Thrombosis; _]D. Zhang, J. Kang, G. Redline, J. Howard, M. Acker, P. Atluri, C. R. Bartoli. _University of Pennsylvania, Philadelphia, PA, PA

 

[*(653) *][Danazol as a Treatment to Reduce Reoccurrence of Hospitalization for Gastrointestinal Bleeding in Patient with Continuous Flow Left Ventricular Assist Device; _]C. Falls, M. Guglin. _Cardiology, University of Kentucky, Lexington, KY

 

[*(654) *][The Use of Heparin in the Setting of Elevated LDH and Suspected LVAD Pump Thrombus; a Single Center Experience; _]J. Spadafore, M. Marranca, M. Amity, L. Staley, L. Schroedl, E. Boldea, O. Pajaro. _Cardiovascular Surgery, Mayo Clinic Arizona, Phoenix, AZ

 

[*(655) *]Preoperative Risk Factors for Stroke After HeartWare Left Ventricular Assist Device Implantation: Texas Heart Institute Experience; _]M. Ono^1^, S. K. Singh2, W. E. Cohn1, A. B. Civitello1, O. Frazier1. [^1^]_]Texas Heart Institute, Houston, TX, 2Baylor College of Medicine, Houston, TX

 

[*(656) *][Microbubbles in Patients with LVADs: Echocardiographic Markers for LVAD Pump Thrombosis?; _]L. A. Letarte, Z. Wang, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, S. W. Boyce, S. S. Najjar, D. T. Majure. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC

 

[*(657) *]Clinical Variables Associated with Gastrointestinal Bleeding in Patients Supported by Continuous-Flow Left Ventricular Assist Devices; _]M. Stegman^1^, N. Balasubramanian2, N. Papillon3, E. E. Coglianese4. [^1^]_]Loyola University Stritch School of Medicine, Maywood, IL, 2Department of Clinical Research, Loyola University Medical Center, Maywood, IL, 3Loyola University Medical Center, Maywood, IL, 4Division of Cardiology, Loyola University Medical Center, Maywood, IL

 

[*(658) *]The Clinical Relevance of Transcranial Doppler Detection of Micro-Embolic Signals in Patients with Heartmate II; _]O. Seguchi^1^, K. Saito2, K. Fukuma2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, T. Fujita3, K. Nagatsuka2, J. Kobayashi3, N. Fukushima1, T. Nakatani1. [^1^]_]Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Cerebrovascular Medicine and Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*(659) *]ABO Blood Group and Left Ventricular Assist Device Therapy: A Multi-Institutional Analysis Detects Significant Differences in Outcomes; _]J. M. Stulak^1^, S. Schettle1, S. Dunlay1, N. A. Haglund2, M. E. Davis2, P. Shah3, J. Cowger4, K. D. Aaronson5, F. D. Pagani5, S. Maltais1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, 3Cardiovascular Surgery, Inova Fairfax Hospital, Falls Church, VA, 4Cardiovascular Surgery, St. Vincent’s Hospital, Indianapolis, IN, 5Cardiovascular Surgery, University of Michigan Health System, Ann Arbor, MI

 

[*(660) *]Intermittent Low Speed Software (Lavare Cycle) May Not Reduce the Incidence of Gastro-Intestinal Bleeding Events in Patients with HeartWare HVAD; _]B. Maxhera1, A. Albert1, G. Petrov1, R. Westenfeld2, A. Lichtenberg1, D. Saeed^1^. [^1^]_]Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

 

[*(661) *]Clinical Predictors of Pump Thrombosis in Explanted Ventricular Assist Devices; _]K. L. Koch1, A. Abou El Ela2, R. Hasan2, E. Sarosi3, F. Pagani4, J. Haft^4^. [^1^]_]Medical School, University of Michigan, Ann Arbor, MI, 2Cardiology, University of Michigan, Ann Arbor, MI, 3Wesleyan, Middletown, CT, 4Cardiac Surgery, University of Michigan, Ann Arbor, MI

 

[*(662) *]Effect of an Institutional Protocol for Gastrointestinal Bleeding in Left Ventricular Assist Device Patients; _]A. H. Healy^1^, J. Colarusso1, S. H. McKellar1, A. Koliopoulou1, S. G. Drakos2, C. H. Selzman1. [^1^]_]Surgery, University of Utah, Salt Lake City, UT, 2Medicine, University of Utah, Salt Lake City, UT

 

[*(663) *][Severity of Hemolysis Is Associated with Death and Ischemic Stroke during Veno-Arterial Extracorporeal Membrane Support; _]O. Saeed, W. Jakobleff Jr., M. Chau, S. Rangasamy, M. Algodi, M. Makkiya, M. Cruz, S. Patel, S. Murthy, D. Sims, J. Shin, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

 

[*(664) *][Speed Reduction Does Not Restore High Molecular Weight Von Willebrand Multimers during Heart Mate II Support: An In-Vivo Analysis; _]S. Patel, J. Patel, J. Rand, D. Goldstein, U. Jorde, O. Saeed. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

 

[*(665) *]A Multicenter Evaluation of Octreotide for Ventricular Assist Device Related Gastrointestinal Bleeding; _]G. B. Smallfield^1^, S. Gunda1, S. Emani2, M. K. Kanwar3, N. Uriel4, P. C. Colombo5, P. A. Uber1, M. L. Sears1, K. B. Shah1. [^1^]_]Virginia Commonwealth University, Richmond, VA, 2Ohio State University, Colombus, OH, 3Allegheny General Hospital, Pittsburgh, PA, 4University of Chicago, Chicago, IL, 5Columbia, New York, NY

 

[*(666) *][Eptifibatide in the Treatment of Pump Thrombosis: What Is the Prescription?; _]L. M. Peters, D. T. Majure, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, E. J. Molina, S. W. Boyce, S. S. Najjar. _MedStar Washington Hospital Center, Washington, DC

 

[*(667) *]Abnormal Pre-Operative Mixing Studies Identify VAD Patients at High Risk for Spontaneous Bleeding; _]J. D. Remick^1^, L. Holton2, M. Mangum1, K. Evenson1, R. Lewis1, M. Puhlman1, C. Moore3, G. Ott1, J. Abraham1. [^1^]_]Center for Advanced Heart Disease, Providence Heart & Vascular Institute, Portland, OR, 2Department of Medicine, Providence St. Vincent Medical Center, Portland, OR, 3Hematology and Oncology, Providence Cancer Center, Portland, OR

 

[*(668) *]Correlation of LVAD Outflow Graft Orientation with Aortic Root Thrombosis Rationalized by Patient Specific Computational Fluid Dynamics Simulations; _]M. Kassi^1^, C. Karmonik2, J. Engelke3, C. Eshelbrenner1, H. Rehman4, T. Belousova1, A. Bhimaraj1, J. Estep1, S. Chang1. [^1^]_]Cardiology, Houston Methodist Hospital, Houston, TX, 2Research Instituite, Houston Methodist Hospital, Houston, TX, 3Houston Methodist Research Instituite, Houston, TX, 4Internal Medicine, Houston Methodist Hospital, Houston, TX

 

[*(669) *][Drive Line Infections Are Not Associated with an Increased Incidence of Thromboembolic Complications in Patients on Continuous Flow LVAD Support; _]L. Xuereb, B. Kaur, S. Akrawe, J. Rashty, H. W. Nemeh, J. Borgi, C. Tita, Y. Selektor, M. Velez, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cardiac Surgery, Henry Ford Hospital, Detroit, MI

 

[*(670) *][The Incidence of Spontaneous Intracranial Hemorrhage Is Associated with Infection in Patients with Mechanical Circulatory Support; _]T. Raymond, S. Mawri, G. Jacobsen, Y. Selektor, M. Velez, C. Williams, H. Nemeh, J. Borgi, J. Morgan, D. Lanfear, C. Tita. _Henry Ford Hospital, Detroit, MI

 

[*(671) *]Pre-Implant GI Evaluation and 12 Month Risk of GI Bleeding among Patients with CF-LVAD; _]V. Thohan^1^, F. X. Downey2, C. John2, N. Z. Sulemanjee1, O. M. Cheema1, T. E. Hastings1. [^1^]_]Aurora Cardiovascular Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI, 2Aurora Cardiovascular Surgical Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI

 

[*(672) *]A Novel Technique to Study Arteriovenous Malformations in Left Ventricular Assist Device Patients with Gastrointestinal Bleeding; _]R. Agarwal^1^, M. J. Passineau2, R. Mitre3, C. Wu2, P. Correa-Jaque2, G. Lentz2, R. L. Benza1. [^1^]_]Cardiology/Heart Failure and Transplantation, Allegheny General Hospital, Pittsburgh, PA, 2Allegheny Singer Research Institute, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 3Section of Gastroenterology, Allegheny General Hospital, Pittsburgh, PA

 

[*(673) *][Three-Fold Increase in Bleeding Rate in LVAD Patients Bridged with Enoxaparin for Sub-Therapeutic INR; _]A. Bhatia, G. T. Sayer, S. Adatya, G. Kim, N. Sarswat, T. Ota, V. Jeevanandam, N. Uriel. _Internal Medicine, University of Chicago, Chicago, IL

 

[*(674) *][Use of Rosendaal Method for Calculating Time above Therapeutic INR Range as a Tool to Assess Relative Bleeding Risk in Patients with Left Ventricular Assist Devices; _]A. Rauf, A. K. Johnson, T. K. Buchmiller, N. C. Ridge, A. C. Miller, H. H. Choi, S. Stoker, R. Alharethi, W. T. Caine, D. Budge, K. Afshar, B. Y. Rasmusson, B. B. Reid, A. G. Kfoury. _Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT

 

[*(675) *]The Effect of Preoperative Serum Iron Levels on Thromboembolic Events after Left Ventricular Assist Device Implantation; _]A. Arghami^1^, S. Maltais1, J. A. Schirger2, L. D. Joyce1, D. L. Joyce1, R. C. Daly1, J. M. Stulak1. [^1^]_]Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic, Rochester, MN

 

[*(676) *]Usefulness of a Multipronged Strategy to Prevent Device Thrombosis in HeartMate II Left Ventricular Assist Devices; _]P. C. Colombo^1^, M. Yuzefpolskaya1, D. Jennings1, J. Z. Willey2, M. Flannery3, B. Cagliostro1, A. R. Garan1, Y. Naka3, H. Takayama3, K. Takeda3, F. Castagna1, D. M. Mancini1, A. B. Eisenberger1, V. K. Topkara1. [^1^]_]Medicine, Columbia University, New York, NY, 2Neurology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*(677) *][Elevated Levels of 11-dehydrothromboxane B2 in Urine Is Associated with an Increased Risk of Bleeding in Patients Supported with a Continuous Flow-Left Ventricular Assist Device; _]D. Gupta, A. Pekarek, R. Cole, D. Nguyen, S. R. Laskar, A. L. Smith, K. Wittersheim, J. D. Vega. _Emory University School of Medicine, Atlanta, GA

 

[*(678) *][Reoperation for Bleeding Does Not Adversely Impact Long-Term Outcomes in LVAD Recipients; _]L. Xuereb, B. Kaur, S. Akrawe, J. Rashty, H. W. Nemeh, J. Borgi, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cadiac Surgery, Henry Ford Hospital, Detroit, MI

 

[*(679) *]Intestinal Microbiota Changes in Left Ventricular Assist Device Supported Patients with Gastrointestinal Bleeding; _]R. Y. Loyaga-Rendon^1^, R. Kumar2, D. Acharya1, S. V. Pamboukian1, J. Tallaj1, F. Siric3, C. Hoopes3, W. Holman3, J. Kirklin3, C. Morrow4. [^1^]_]Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, 2Center for Clinical and Translational Sciences, University of Alabama at Birmingham, Birmingham, AL, 3Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, 4Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL

 

[*(680) *]Aortic Valve Opening Status and Gastrointestinal Bleeding Risk in Patients with HeartWare HVAD; _]B. Maxhera1, A. Albert1, G. Petrov1, R. Westenfeld2, A. Lichtenberg1, D. Saeed^1^. [^1^]_]Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

 

[*(681) *]Triple Antithrombotic Therapy in Patients with Left Ventricular Assist Devices: A Single Center Experience; _]A. L. Bennett^1^, M. Pfeffer2, S. Thai3, B. Baetz3, P. Campbell4, H. Patel1, C. Eiswirth1, H. Ventura1, S. Krim1. [^1^]_]John Ochsner Heart and Vascular Center, Ochsner Medical Center, New Orleans, LA, 2University of Queensland-Ochsner Clinical School, New Orleans, LA, 3Ochsner Medical Center, New Orleans, LA, 4Baptist Health Transplant Institute, Little Rock, AR

 

[*(682) *][Impact of Atrial Fibrillation on Pump Thrombosis and Thromboembolic Events in Long-Term Left Ventricular Assist Device Therapy; _]D. Pedde, S. Soltani, F. Kaufmann, M. Müller, P. Pergantis, V. Falk, T. Krabatsch, E. Potapov. _DHZB, Berlin, Germany

 

[*(683) *]A Single Center Experience of Device Exchange for Continuous Flow Left Ventricular Assist Device Thrombosis; _]K. J. Morine^1^, D. Mehak1, J. N. Upshaw1, D. T. Pham2, N. K. Kapur1, A. R. Vest1, D. DeNofrio1, M. S. Kiernan1. [^1^]_]Tufts Medical Center, Boston, MA, 2Northwestern Memorial Hospital, Chicago, IL

 

[*(684) *]Continuous-Flow LVAD Support Alters Gastrointestinal Vascularity: A Likely Contributor to LVAD-Associated Gastrointestinal Bleeding; _]J. Kang^1^, P. Kwiatkowski2, M. Acker1, P. Atluri1, P. McConnell2, C. R. Bartoli1. [^1^]_]University of Pennsylvania, Philadelphia, PA, PA, 2The Ohio State University, Columbus, OH, OH

 

[*(685) *]Discharge Lactate Dehydrogenase (LDH) Level Predicts Early Device Thrombosis in Patients with HEARTMATE II Left Ventricular Assist Devices: A Retrospective Cohort Analysis; _]V. K. Topkara^1^, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Givens1, J. A. Fried1, F. Castagna1, B. Cagliostro1, M. Flannery2, J. Z. Willey3, S. Restaino1, F. Latif1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY, 3Neurology, Columbia University, New York, NY

 

[*(686) *][Elevated Preoperative Plasma Free Hemoglobin and Hemin May Predict LVAD Thrombosis; _]D. Zhang, J. Kang, G. Redline, J. Howard, M. Acker, P. Atluri, C. R. Bartoli. _University of Pennsylvania, Philadelphia, PA, PA

 

[*(687) *]The Use of Integrilin Alone or in Combination with Heparin or Argatroban for Suspected Pump Thrombosis in Patients with Left Ventricular Assist Devices; _]A. Bitar, D. Abramov, R. Vijayakrishnan, A. Lenneman, J. Trivedi, T. H. Massey, A. Cheng, M. Slaughter, E. J. Birks. [_Jewish Hospital/University of Louisville, Louisville, KY

 

[*(688) *][ABO Blood Group and Bleeding Post-LVAD; _]R. T. Cole, D. Gupta, J. Lee, J. Gandhi, C. Lambert, Y. Garcia-Bengochea, P. Sandesara, M. Yin, A. Smith, S. Laskar, A. Morris. _Cardiology, Emory Univ Sch of Med, Atlanta, GA

 

[*(689) *][Impact of Reduced Antiplatelet Therapy on Early Hematologic Adverse Events During Heart Mate II Support; _]O. Saeed, V. Alapati, A. Luke, A. Delaconcha, S. Murthy, J. Shin, D. Sims, S. Patel, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

 

[*(690) *][New Method to Route the Driveline of Implantable Left Ventricular Assisted Device for Prevention from Driveline Infection; _]S. Yoshitake, K. Nawata, O. Kinoshita, Y. Hoshino, Y. Itoda, A. Yamamoto, M. Kimura, H. Yamauchi, M. Ono. _Cardiac Surgery, Tokyo University Hospital, Tokyo, Japan

 

[*(691) *]Surgical Treatment of Mediastinitis with Omentoplasty in Ventricular Assist Device Patients: Report of Referral Center Experience; _]M. Pieri^1^, G. Arlt2, M. Müller2, V. Falk2, T. Krabatsch2, E. Potapov2. [^1^]_]San Raffaele Hospital, Milan, Italy, 2Deutsches Herzzentrum Berlin, Berlin, Germany

 

[*(692) *]Infectious Complications in Extracorporeal Membrane Oxygenation (ECMO) Patients; _]P. Nair^1^, D. Austin2, S. Kerr3, S. Al-Soufi1, M. Connellan4, P. Spratt4. [^1^]_]Intensive Care Unit, St Vincent’s Hospital, Sydney, Australia, 2Intensive Care Unit, Alfred Hospital, Melbourne, Australia, 3Kirby Institute, UNSW, Sydney, Australia, 4Cardiothoracic Surgery, St Vincent’s Hospital, Sydney, Australia

 

[*(693) *]MOVED TO MINI ORAL SESSION 07

 

[*(694) *]Surgical Management of Driveline Infections in Patients with Ventricular Assist Devices; _]M. Pieri^1^, A. Scandroglio1, G. Arlt2, V. Falk2, T. Krabatsch2, E. Potapov3. [^1^]_]San Raffaele Hospital, Milan, Italy, 2Deutsches Herzzentrum Berlin, Berlin, Germany, 3Deutsches Herzzentrum Berlin, Berlin, Italy

 

[*(695) *][Left Ventricular Assist Device Related Infections: Does the Time of Onset Matter?; _]A. L. Lehnert, A. Hart, S. Branam, S. Brouse, M. Guglin. _University of Kentucky HealthCare, Lexington, KY

 

[*(696) *]Increased Driveline Infection with Betadine Antisepsis: Considerations for Chlorhexidine Intolerant Patients; _]A. Y. Son^1^, L. H. Stein1, A. Reyentovich2, S. D. Katz2, D. E. Smith1, A. DeAnda, Jr.1, L. B. Balsam1. [^1^]_]Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, 2Medicine, Division of Cardiology, NYU Langone Medical Center, New York, NY

 

[*(697) *]Effect of Tunneling Method on Driveline Infection: Looking Beyond the Silicone-Skin Interface (SSI) Registry; _]A. Y. Son^1^, L. H. Stein1, A. DeAnda, Jr.1, D. E. Smith1, S. D. Katz2, A. Reyentovich2, L. B. Balsam1. [^1^]_]Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, 2Medicine, Division of Cardiology, NYU Langone Medical Center, New York, NY

 

[*(698) *]Driveline Angle Is Crucial to Prevent Exit Site Infection in Patients with HeartMate II; _]Y. Matsumoto^1^, T. Fujita1, H. Hata1, Y. Shimahara1, S. Nakajima2, T. Sato2, O. Seguchi2, M. Yanase2, N. Fukushima2, T. Nakatani2, J. Kobayashi1. [^1^]_]Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan, 2Transplantation, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan

 

[*(699) *]Comparison of Device-Related Infections between Two Continuous Flow Ventricular Assist Devices; _]S. L. Porenta^1^, K. R. Shively1, T. F. Dardas1, R. K. Cheng2, J. D. Pal1, W. C. Levy2, D. P. Fishbein2, J. A. Bjelkengren1, J. A. Beckman1, C. Mahr2, N. A. Mokadam1, R. M. Rakita3. [^1^]_]Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA, 2Cardiology, University of Washington Medical Center, Seattle, WA, 3Infectious Disease, University of Washington Medical Center, Seattle, WA

 

[*(700) *][Left Ventricular Assist Device – Related Infection: Long-Term Treatment Efficacy with Pump Exchange; _]A. S. Abou el ela, S. M. Peer, J. W. Haft, F. D. Pagani. _Cardiac Surgery, University of Michigan, Ann Arbor, MI

 

[*(701) *]MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome?; _]J. Moriguchi, L. Czer, H. Henry, R. Jocson, C. Runyan, T. Aintablian, E. Passano, D. Chang, D. Geft, F. Arabia. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(702) *]Immunocompetence Status as Related to Infection in Heart Transplants after Ventricular Assist Device Implantation; _]J. Carbone^1^, M. Ruiz2, A. Gonzalez Pinto2, J. Barrios3, J. Hortal3, J. Fernandez-Yañez4, I. Sousa4, P. Diez4, J. Navarro1, E. Sarmiento1. [^1^]_]Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Heart Surgery, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Anesthesiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 4Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

 

[*(703) *]Distal Limb Perfusion – A Necessary Third Cannula in Extracorporeal Membrane Oxygenation; _]S. Zipfel^1^, S. Pecha1, S. Hakmi1, S. Braune2, S. Kluge2, M. Kubik1, H. Reichenspurner1, T. Deuse1. [^1^]_]Heart an Vascular Surgery, Hamburg Heart Center, Hamburg, Germany, 2Intensive Care Medicine, Universital Hospital of Hamburg, Hamburg, Germany

 

[*(704) *][Hemolysis Is Associated with an Elevated Blood Pressure During Heart Mate II Support; _]O. Saeed, S. Patel, P. Vlismas, A. Luke, A. Delaconcha, S. Murthy, J. Shin, D. Sims, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

 

[*(705) *]Readmission During Long-Term Follow-Up After Left Ventricular Assist Device Implantation; _]H. Vidula^1^, V. Kutyifa1, B. Johnson2, D. Harrington2, A. Papernov1, J. Alexis1. [^1^]_]Medicine, Univ of Rochester, Rochester, NY, 2Biostatistics, Univ of Rochester, Rochester, NY

 

[*(706) *]Right Ventricular Failure in Patients with Left Ventricular Assist Devices Is Associated with Downregulated Chemokine Receptors and Altered Right Ventricular Pressure Waveforms; _]T. N. Bachman^1^, R. Vanderpool2, M. Jacus3, A. Nayak4, O. Hunter5, A. Inashvili4, L. Lagazzi6, J. Teuteberg6, C. McTiernan2, K. Hanley-Yanez7, D. McNamara6, R. Kormos6, M. Simon2. [^1^]_]University of Pittsburgh, Pittsburgh, PA, 2Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 3Bioengineering, University of Pittsburgh, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5School of Medicine, University of Pittsburgh, Pittsburgh, PA, 6Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 7Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA

 

[*(707) *]Readmission within 30 Days after Left Ventricular Assist Device Implantation Is Associated with Increased Long-Term Mortality; _]S. Gupta^1^, S. Roy2, R. Cogswell2, T. Thenappan2, K. Liao3, R. John3. [^1^]_]Medicine, University of Minnesota Health, Minneapolis, MN, 2Cardiology, University of Minnesota Health, Minneapolis, MN, 3Cardiothoracic Surgery, University of Minnesota Health, Minneapolis, MN

 

[*(708) *]Comparing Changes in Aortic and Mitral Valve Function with Axial (AX) Versus Centrifugal (CR) Left Ventricular Assist Devices; _]A. Rauf^1^, M. Al-Sarie2, J. Wever-Pinzon3, R. Alharethi1, J. Stehlik3, S. G. Drakos3, A. K. Johnson1, A. C. Miller1, H. H. Choi1, S. Stoker1, W. T. Caine1, D. Budge1, K. Afshar1, B. B. Reid1, A. G. Kfoury1. [^1^]_]Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT, 2Mechanical Circulatory Support, University of Utah Hospital, Salt Lake City, UT, 3University of Utah Hospital, Salt Lake City, UT

 

[*(709) *]Aortic Valve Opening Status and Stroke Risk in Patients with HeartWare HVAD; _]D. Saeed^1^, A. Albert1, B. Maxhera1, R. Westenfeld2, G. Petrov1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

 

[*(710) *]Worsening Aortic Regurgitation During HeartWare HVAD Support Is Common Despite Optimization of Pump Speed and Use of the Lavare Cycle; _]V. Naruka^1^, S. J. Pettit2, J. K. Parameshwar2, S. S. Tsui2, C. Lewis2. [^1^]_]Papworth Hospital and University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 2Transplant Unit, Papworth Hospital, Cambridge, United Kingdom

 

[*(711) *][Evaluating Predictive Parameters for Right Ventricular Failure During LVAD Implantation in a Single Center Patient Cohort; _]A. Schaefer, D. Reichart, A. M. Bernhardt, M. J. Barten, F. M. Wagner, T. Deuse, H. Reichenspurner. _Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

 

[*(712) *]Inflow Restriction in the HeartMate II LVAD: A Late Complication; _]T. B. Icenogle^1^, A. Coletti1, N. Nair1, D. Sato1, P. R. Huber2, D. F. Lubbe2, D. Hollenbaugh2, A. Schmidt1. [^1^]_]Mechanical Heart and Heart Transplantation, Providence Sacred Heart Medical Center, Spokane, WA, 2Providence Spokane Cardiology, Providence Sacred Heart Medical Center, Spokane, WA

 

[*(713) *]Combined Therapy of Ventricular Assist Device and Extracorporeal Membrane Oxygenator for Profound Acute Cardiopulmonary Failure; _]K. Fujita^1^, K. Takeda1, B. Li1, C. Mauro1, P. Kurlansky1, S. Sreekanth1, J. Han1, L. Truby1, R. Garan2, V. Topkara2, M. Yuzefpolskaya2, P. Colombo2, Y. Naka1, H. Takayama1. [^1^]_]Department of Surgery, Columbia University Medical Center, New York, NY, 2Department of Medicine, Columbia University Medical Center, New York, NY

 

[*(714) *]Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients; _]M. Kittleson, J. Patel, L. Czer, E. Passano, T. Aintablian, C. Runyan, N. Huie, D. Chang, F. Esmailian, J. Moriguchi, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(715) *]Incidence and Outcomes After Stroke on Rotary Flow Ventricular Assist Device Support; _]M. Bishawi^1^, J. Joseph1, B. Yerokun1, D. Ranney1, P. Winterton1, J. Schroder1, M. Daneshmand1, D. Bowles1, J. Rogers2, C. Milano1. [^1^]_]Department of Surgery, Duke University, Durham, NC, 2Department of Medicine, Duke University, Durham, NC

 

[*(716) *]Predictors of Readmission in Long-Term Continuous Flow Left Ventricular Assist Device Support; _]J. Han^1^, K. Takeda1, C. M. Mauro2, P. A. Kurlansky1, A. R. Garan3, V. K. Topkara3, S. Sreekanth1, M. Yuzefpolskaya3, P. C. Colombo3, H. Takayama1, Y. Naka1. [^1^]_]Division of Cardiothoracic Surgery, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, 2Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, 3Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY

 

[*(717) *]Worsening Renal Function after Ventricular Assist Device Placement Is Associated with Twice the Risk of Death over 3 Years; _]J. E. Holtz^1^, A. N. Potter2, N. C. Macpherson1, D. Nguyen1, R. L. Kormos1, J. J. Teuteberg1, J. A. Kellum1. [^1^]_]University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

 

[*(718) *][Circulating Biomarkers of Hemolysis Are Not Significantly Increased among Patients Supported with Micro-Axial Flow Catheters; _]M. Esposito, R. O’Kelly, N. Aghili, S. Annamalai, A. Hamadeh, M. Kiernan, A. Vest, D. DeNofrio, N. K. Kapur. _Cardiology, Tufts Medical Center, Boston, MA

 

[*(719) *]Retained Blood Syndrome Impacts Outcomes after Left Ventricular Assist Device Implantation; _]S. Maltais^1^, E. M. Boyle2, M. E. Davis3, J. M. Stulak1, L. P. Perrault4, N. A. Haglund3. [^1^]_]Mayo Clinic, Rochester, MN, 2St-Charles Medical Center, Bend, OR, 3Vanderbilt, Nashville, TN, 4Montreal Heart, Montreal, QC, Canada

 

[*(720) *][RV Longitudinal Strain Predicts RV Failure and Other Adverse Events Post LVAD Implantation; _]M. Gibson, F. Sliwinski, J. Silva, E. Adler. _UC San Diego Medical Center, San Diego, CA

 

[*(721) *]The Impact of LVAD Complications on Short-Term Outcomes after Heart Transplantation; _]H. Shah^1^, M. Kahanda1, J. Schilling2, S. LaRue2, J. Shuster3, S. Sitner3. [^1^]_]Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO, 2Cardiology, Barnes Jewish Hospital/Washington University, Saint Louis, MO, 3Cardiology, Barnes Jewish Hospital, Saint Louis, MO

 

[*(722) *][Outflow Graft Obstruction of the Heart Ware HVAD Left Ventricular Assist Device: A Single Center Case Series; _]R. K. Young, D. T. Majure, F. H. Sheikh, M. E. Rodrigo, G. Weigold, S. S. Najjar, S. W. Boyce. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, MD

 

[*(723) *]Survival and Driveline Infection Rates in Patients on Chronic Immunosuppressive Therapy Who Undergo Left Ventricular Assist Device Implantation; _]J. R. Spratt^1^, S. Roy2, D. Plack3, R. John1, K. Liao1, R. J. Cogswell2. [^1^]_]Department of Surgery, University of Minnesota, Minneapolis, MN, 2Department of Medicine, University of Minnesota, Minneapolis, MN, 3University of Minnesota, Minneapolis, MN

 

[*(724) *][Fatal Flaw – Driveline Fracture as a Rare but Serious Complication of Mechanical Circulatory Support with Left Ventricular Assist Devices; _]Y. Boyechko, T. Tribble, M. Guglin. _Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY

 

[*(725) *][_Risk Factors for the Development of Severe Hyperbilirubinemia after Left Ventricular Assist Device Implantation; _]R. Cogswell^1^, S. Gupta

2, B. Ramu1, M. Burns1, C. Martin1, T. Thenappan1, R. John3. 1Cardiology, University of Minnesota, Minneapolis, MN, 2Medicine, University of Minnesota, Minneapolis, MN, 3Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

 

[*(726) *]Use of Tissue Plasminogen Activator (tPA) to Successfully Treat HeartWare LVAD (HVAD) Pump Thrombosis; _]L. L. Staley^1^, L. Schroedl1, D. E. Steidley2, R. Scott2, J. Spadafore1, M. E. Amity1, E. Boldea1, L. Lanza1, P. DeValeria1, B. W. Hardaway2, E. F. Kransdorf2, O. Pajaro1. [^1^]_]Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Cardiology/Transplant, Mayo Clinic, Phoenix, AZ

 

[*(727) *]New Definition, Same Old Problem: Characterizing the Condition of Right Heart Failure in INTERMACS; _]J. Teuteberg^1^, R. L. Kormos1, F. D. Pagani2, M. S. Kiernan3, D. C. Naftel4, S. L. Myers4, S. V. Pamboukian4, J. K. Kirklin4. [^1^]_]Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Michigan, Ann Arbor, MI, 3Tufts Medical Center, Boston, MA, 4University of Alabama at Birmingham, Birmingham, AL

 

[*(728) *][Avoiding Readmission After LVAD Implantation: Can We Predict It?; _]S. J. Forest, Y. Xia, D. J. Goldstein. _Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

 

[+PATHOLOGY +]

[+Target Audience: +]

PATH, HF, HTX, ID, LTX, MCS

Poster Discussants:

Fiorella Calabrese, Robert Padera, Katharina Wassilew

[*(729) *]Identification of MicroRNA Expression Profile of Different Types of Rejection During the First Year After Heart Transplantation with Next Generation Sequencing Technology; _]A. Di Francesco^1^, M. Fedrigo1, F. De Pascale2, C. Castellani1, G. Feltrin1, G. Toscano1, A. Fraiese1, E. Benazzi3, A. Nocco3, G. Thiene1, M. Valente1, G. Gerosa1, G. Valle2, A. Angelini1. [^1^]_]Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, 2CRIBI Biotechnology Centre, University of Padova, Padova, Italy, 3Organ and Tissue Transplantation Immunology, Fondazione IRCSS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

 

[*(730) *][Pathology of Ventricular Assist Devices: A Tertiary Care Center’s 15-Year Experience; _]G. A. Fishbein, R. F. Padera. _Department of Pathology, Brigham and Women’s Hospital, Boston, MA

 

[*(731) *]Creating Standardized Reporting for Non-Rejection Lung Transplant Pathology to Improve Interobserver Agreement; _]E. N. Pavlisko^1^, C. F. Farver2, D. M. Hwang3, W. D. Wallace4, P. B. Illei5, A. V. Arrossi2, D. N. Howell1, J. Todd6. [^1^]_]Department of Pathology, Duke University Medical Center, Durham, NC, 2Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 4Department of Pathology, University of California, Los Angeles, Los Angeles, CA, 5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC

 

[*(732) *]Histomorphology and C4d Expression Are Poor Predictors of Antibody-Mediated Rejection (AMR) in Lung Transplant Recipients; _]C. Kwong1, R. Essendrop1, E. Dixon2, S. Mehrotra1, E. M. Lowery2, J. P. Gagermeier3, K. M. Mirza1, V. Ananthanarayanan^1^. [^1^]_]Pathology, Loyola University Medical Center, Maywood IL, IL, 2Pulmonary and Critical Care, Loyola University Medical Center, Maywood IL, IL, 3Pulmonary and Critical care, Loyola University Medical Center, Maywood IL, IL

 

[*(733) *]Airway Centered Neutrophils in Post-Transplant Transbronchial Biopsies: A Poor Predictor of Infection; _]P. Sojitra^1^, A. Muralidhar2, S. Quddus2, S. Mehrotra1, V. Ananthanarayanan1. [^1^]_]Pathology, Loyola University Medical Center, Maywood, IL, 2Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

 

[*(734) *]Ultrastructural Examination of Lung Transplant Allografts for Pulmonary Alveolar Proteinosis; _]A. C. Roden^1^, J. J. Maleszewski1, M. P. Alexander1, P. C. Abell Aleff2, E. S. Yi1, J. P. Scott3. [^1^]_]Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, 2Biochemistry & Molecular Biology, Mayo Clinic Rochester, Rochester, MN, 3Pulmonary & Critical Medicine, Mayo Clinic Rochester, Rochester, MN

[* *]

POSTER SESSION 2

THURSDAY, APRIL 28, 2016

6:00 PM – 7:00 PM

Exhibit Hall B & C

[+ECONOMICS, ETHICS, PUBLIC POLICY +]

 

[+Target Audience: +]

EEP, HF, HTX, MCS, NHSAH

Poster Discussants:

Gundeep Dhillon, Fabienne Dobbels, Steven Tsui

[* (735) *]Expensive Taste: US Medicare Policy Regarding Destination Therapy VADs Leads to Additional Medical Costs; _]S. Emani^1^, B. Lampert1, S. Smith1, A. Pleister1, S. Wissman2, K. MacBrair2, A. Bergman2, B. Whitson3, A. Kilic3. [^1^]_]Division of Cardiology, Ohio State University, Columbus, OH, 2Ohio State University, Columbus, OH, 3Division of Cardiothoracic Surgery, Ohio State University, Columbus, OH

 

[*(736) *]Financial Impact of Extracorporeal Life Support on Survivors Versus Non-Survivors; _]T. R. Ryan^1^, A. F. Burdorf2, B. D. Lowes2, J. Y. Um1, A. Siddique1, H. M. Merritt-Genore1, S. L. Varnado3, M. J. Moulton1. [^1^]_]Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine – Cardiology, University of Nebraska Medical Center, Omaha, NE, 3Clinical Pharmacy, University of Nebraska Medical Center, Omaha, NE

 

[*(737) *][Success of Left Ventricular Assist Device Therapy in Rural United States Residents; _]N. Rajagopalan, A. L. Hart, S. M. Branam, M. Sekela, M. Guglin. _University of Kentucky, Lexington, KY

 

[*(738) *]Need and Supply of Heart Replacement Therapy in Italy, with U.S. as Benchmark; _]M. Frigerio1, G. Feltrin^2^. [^1^]_]A. DeGasperis CardioCenter, Niguarda Ca’ Granda Hospital, Milan, Italy, 2Regional Center for Transplant Coordination, Veneto Region, Padua, Italy

 

[*(739) *]Morbid Obesity in Heart Transplant Does Not Affect One Year Survival; _]M. Sherwood^1^, S. Joseph2, G. Saracino2, T. Chamogeorgakis2, G. V. Gonzalez-Stawinski2, S. Hall2, B. Lima2. [^1^]_]Heart Failure/Cardiac Transplant, Baylor Univerisity Medical Center at Dallas, Dallas, TX, 2Baylor Univerisity Medical Center at Dallas, Dallas, TX

 

[*(740) *]Outcome of Heart Transplantation in Patients Supported by ECMO: Is the APACHE IV Score a Predictor of Survival?; _]A. Lechiancole, S. Sponga, I. Vendramin, M. Maiani, E. Spagna, R. Sappa, U. Livi. [_Cardio-Thoracic Surgery of Udine, Cardio-Thoracic Surgery of Udine, Udine (UD), Italy

 

[*(741) *]Impact of Advanced Heart Failure on Hospital Readmissions in the Elderly; _]L. Miller^1^, M. R. Mehra2, J. D. Rich3, J. B. Oconnell4, R. Bostic4. [^1^]_]Cardiovascular, Morgan Heart Institute, Clearwater, FL, 2Cardiovascular, Brigham and Women’s Hosptial, Boston, MA, 3Cardiology, Northwestern University, Chicago, IL, 4Thoratec Corporation, Pleasanton, CA

 

[*(742) *]Establishing Institutional Costs in the Year Before and After VAD Implant and Before Heart Transplant; _]R. A. Prichard^1^, P. Newton2, S. Goodall3, L. Kershaw4, P. M. Davidson5, T. Homer6, F. McNeil6, C. S. Hayward1. [^1^]_]Heart Lung Clinic, St Vincent’s Hospital, Sydney, Australia, 2Centre for Cardiovascular and Chronic Care, University of Technology, Sydney, Australia, 3Centre for Health Economic Research and Evaluation, University of Technology, Sydney, Australia, 4St Vincent’s Hospital, Sydney, Australia, 5Department of Acute and Chronic Care, Johns Hopkins University, Baltimore, MD, 6HeartWare International, Framingham, MA

 

[*(743) *]Ethical Analysis of Withdrawing Total Artificial Heart Support; _]E. S. DeMartino^1^, S. E. Wordingham2, D. P. Sulmasy3, J. M. Stulak4, B. A. Boilson5, K. R. Fuechtmann6, N. Singh7, O. E. Pajaro8, P. S. Mueller9. [^1^]_]Pulmonary and Critical Care Medicine, Biomedical Ethics, Mayo Clinic, Rochester, MN, 2Palliative Medicine, Mayo Clinic, Scottsdale, AZ, 3Department of Medicine, MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL, 4Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 5Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 6Augsburg College, Minneapolis, MN, 7University of Wisconsin, Madison, WI, 8Cardiovascular Surgery, Mayo Clinic, Scottsdale, AZ, 9General Internal Medicine, Biomedical Ethics, Mayo Clinic, Rochester, MN

 

[*(744) *]Cost-Effectiveness Comparison of Intra Aortic Balloon Pump versus Left Ventricular Assist Devices as Bridge to Heart Transplant (BTT) Strategies; _]J. Amione-Guerra^1^, K. J. Elizondo1, A. S. Cruz-Solbes1, K. Kostick2, L. Loza1, A. Bhimaraj1, B. H. Trachtenberg1, G. Ashrith1, M. H. Park1, D. P. Bernard1, J. D. Estep1. [^1^]_]Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX, 2Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX

 

[+HEART FAILURE +]

 

[+Target Audience: +]

HF, BSI, MCS, NHSAH, PHARM

Poster Discussants:

Sharon Chih, Monica Colvin, Choon Pin Lim, Maryse Palardy, Michael Pham, Stuart Russell

[*(745) *][Beneficial Effects of Sildenafil in a Patients with Severe Tricuspid Regurgitation; Improvement in Quality of Life and Exercise Capacity; _]K. Kim. _Sejong General Hospital, Seoul, Korea, Republic of

 

[*(746) *]Perceived Health Status in Adult Fontan Patients: The Impact of Previous Heart Failure Hospitalization; _]L. J. Burchill^1^, W. M. Wilson2, H. J. Ross3, R. M. Wald4, A. H. Kovacs5. [^1^]_]Adult Congenital Heart Program, Knight Cardiovascular Institute, Oregon Health Science University, Portland, OR, 2Adult Congenital Heart Program, Royal Melbourne Hospital, Melbourne, Australia, 3Cardiac Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada, 4Toronto Congenital Cardiac Center for Adults, University Health Network, Toronto General Hospital, Toronto, ON, Canada, 5Adult Congenital Heart Program, Knight Cardiovascular Institute, Portland, OR

 

[*(747) *]Impact of Education Alone vs. Education and Medical Intervention vs. Standard Treatment in Re-Hospitalization for Heart Failure; _]J. Jimenez^1^, M. Salinero2, V. Pope2, L. Reyes2, C. Khanal2, M. Matos2, E. Stone2. [^1^]_]MCVI-South Miami Hospital, Miami, FL, 2Cardiology, MCVI-South Miami Hospital, Miami, FL

 

[*(748) *]Heart Failure Patients’ Quality of Life and Perception of Palliative Care; _]J. A. Anderson^1^, B. D. Lowes2, G. Canaris1, H. Vongooru2, R. Zolty2, E. Raichlin2, T. Diederich2. [^1^]_]Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Cardiology, University of Nebraska Medical Center, Omaha, NE

 

[*(749) *]Association of sST2 with GDF-15 and Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy; _]N. Nair^1^, E. Gongora2. [^1^]_]Cardiology, S and W Hospital , Temple ,TX , Texas Tech Health Sciences Center, Lubbock, TX, 2Cardiology, S and W Hospital , Temple ,TX , Memorial Cardiac and Vascular Institute, Hollywood, FL

 

[*(750) *]GDF-15 Correlates Positively with Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy; _]N. Nair^1^, E. Gongora2. [^1^]_][_ Cardiology, S &W, Temple , TX, Texas Tech Health Scieces Center, Lubbock, TX, 2_][_ Cardiology, S &W, Temple , TX, Memorial Heart and Vascular Center, Hollywood, FL _]

 

[*(751) *][Characterization of Patients with Predominantly Intramural Coronary Amyloidosis; _]F. Kamdar, J. Valent, C. D. Tan, E. R. Rodriguez, M. Hanna. _Cleveland Clinic, Cleveland, OH

 

[*(752) *]Echocardiographic Predictors of Admission among Ambulatory Patients with HFrEF; _]V. Thohan, N. Z. Sulemanjee, O. M. Cheema, T. E. Hastings, D. L. Zwicke. [_Aurora Cardiovascular Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI

 

[*(753) *]Right Ventricular T1 Mapping: A Feasibility Study; _]B. H. Freed^1^, E. Semaan2, B. C. Benefield2, B. Spottiswoode2, C. Brady1, B. Allen2, S. J. Shah1, J. C. Carr2, M. Markl2, J. D. Collins2. [^1^]_]Cardiology, Northwestern University, Chicago, IL, 2Radiology, Northwestern University, Chicago, IL

 

[*(754) *]Fick Cardiac Index Predicts Disease Progression in UNOS Status 2 Patients; _]K. P. Murphy^1^, A. R. Vest2, N. K. Kapur2, D. DeNofrio2, M. S. Kiernan2. [^1^]_]Internal Medicine, Tufts Medical Center, Boston, MA, 2Cardiology, Tufts Medical Center, Boston, MA

 

[*(755) *]Utility of Wireless Pulmonary Artery Pressure Measurement System (CardioMEMS®) in Heart Failure Patients with Non-Cardiac Advanced Organ Failure or Organ Replacement; _]R. Araujo-Gutierrez, S. H. Ibarra-Cortez, M. Park, J. D. Estep, G. Ashrith, G. Torre-Amione, A. Bhimaraj, B. H. Trachtenberg. [_Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

 

[*(756) *][Prevalence of Advanced Heart Failure (AdHF) Utilizing the Latest Published Definitions Yields Higher Than Previously Published Data; _]A. J. Creamer. _Heart Failure, Houston Methodist, Houston, TX

 

[*(757) *]Monocyte Gene Expression before and after LVAD Implantation; _]N. Uriel^1^, D. E. Rodgers1, G. Sayer1, N. Sarswat1, G. H. Kim1, V. Jeevanandam1, J. Yee2, S. Adatya1. [^1^]_]Cardiology, University of Chicago, Chicago, IL, 2CareDx, Brisbane, CA

 

[*(758) *][Are All Patients Equal in Response to Intra-Aortic Balloon Counterpulsation?; _]D. A. Baran, M. Cohen, G. K. Visweswaran, M. DiVita, A. Seliem, A. Dave, N. Wasty, J. E. Swinden, K. Liaquat. _Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ

 

[*(759) *]Biventricular Impella Support: A Contemporary Approach to Acute Mechanical Circulatory Support for Cardiogenic Shock Due to Biventricular Failure; _]N. Aghili^1^, Y. Bader1, C. Kimmelstiel1, A. Weintraub1, M. Kiernan1, A. Vest1, D. DeNofrio1, D. Pham2, N. Kapur1. [^1^]_]Tufts Medical Center, Boston, MA, 2Northwestern Memorial Hospital, Chicago, IL

 

[*(760) *][Surgical Therapy in End Stage Heart Failure: Should We Change Our Vision?; _]A. Forni, B. Chiominto, G. Faggian. _Cardiac Surgery, University Hospital of Verona, Verona, Italy

 

[*(761) *][Role of a Multidisciplinary Shock Team in the Management of Cardiogenic Shock; _]B. Ko, A. Tandar, T. Kang, S. McKellar, J. Stehlik, G. Stoddard, J. Morshedzadeh, A. Koliopoulou, E. Gilbert, J. Nativi-Nicolau, O. Wever-Pinzon, J. Fang, C. Selzman, F. Welt, S. Drakos. _Cardiovascular Division, University of Utah, Salt Lake City, UT

 

[+HEART TRANSPLANTATION +]

 

[+Target Audience: +]

HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM

Poster Discussants:

Alejandro Bertolotti, Robert Chen, Marisa Crespo-Leiro, Mani Daneshmand, Juan Delgado Jimenez, Howard Eisen, Maryjane Farr, Jan Gummert, A. G. Kfoury, Nicolas Manito, Sonia Mirabet, Jignesh Patel, Jacob Schroder, Rajamiyer Venkateswaran

[*(762) *]Thymoglobulin Provides Protection Against Ischemia Reperfusion in the Immediate Post-Transplant Period; _]J. A. Kobashigawa, M. Kittleson, J. Patel, T. Aintablian, P. Zarrini, A. Lipson, T. Kao, T. Daun, D. Chang, A. Trento, A. Hage, L. Czer. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(763) *]Immunosuppressant Regimen over Time and Their Association with Rejection, Graft Failure, and Mortality; _]Y. Ravi^1^, E. Stock2, P. C. Rosas3, A. K. Hasan4, L. Nikolaidis5, S. Bansal6, B. A. Whitson7, R. C. Scott5, C. B. Sai-Sudhakar1. [^1^]_]Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, 2Center for Applied Health Research, Scott & White, Texas A&M, Central Texas VA, Temple, TX, 3Medical Physiology, Texas A&M, Temple, TX, 4Cardiology-Internal Medicine, The Ohio State University, Columbus, OH, 5Cardiology-Internal Medicine, Scott & White, Texas A&M, Temple, TX, 6Cardiac Surgery, Mayo Clinic, Jacksonville, FL, 7Cardiac Surgery, The Ohio State University, Columbus, OH

 

[*(764) *]Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe; _]M. Luu, J. Patel, M. Kittleson, L. Czer, T. Aintablian, K. Norland, N. Perry, D. Chang, M. Hamilton, D. Geft, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(765) *][Early Post-Operative Acute Kidney Injury in Heart Transplant Recipients: Who Gets It, and Does It Matter?; _]J. P. Casale, C. T. Doligalski, A. T. Logan. _Tampa General Hospital, Tampa, FL

 

[*(766) *]Long-term Effect on Albuminuria and Glomerular Filtration Rate of a Calcineurin Inhibitor-Free Everolimus Based Immunosuppressive Regimen after Heart Transplantation; _]L. M. Nelson^1^, A. K. Andreassen2, B. Andersson3, E. Gude2, H. Eiskjær4, G. Raadegran5, G. Dellgren6, L. Gullestad2, F. Gustafsson1. [^1^]_]Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark, 5The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, 6Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

 

[*(767) *][Impact of Treatment with m-TOR Inhibitors on Platelet Reactivity in Heart Transplant Patients Treated with Clopidogrel. Preliminary Results; _]J. Gonzalez-Costello, J. Ferreiro, J. Roca, A. Marcano, I. Rodríguez, J. Salazar-Mendiguchia, I. Tatjer, A. Miralles, N. Manito, A. Cequier. _Hospital Universitari de Bellvitge, Barcelona, Spain

 

[*(768) *]Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation; _]M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, A. Velleca, B. Kearney, D. Chang, M. Hamilton, F. Esmailian, X. Zhang, N. Reinsmoen, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(769) *]Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do?; _]M. Kittleson, J. Patel, L. Czer, T. Aintablian, T. Daun, M. Johnson, D. Chang, A. Trento, D. Geft, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(770) *]Lack of Rejection Despite Period of No Immunosuppression: The NoTac Case Series; _]D. A. Baran^1^, P. Rao2, D. Deo2, K. Liaquat1, J. Pieretti1, C. Gidea1, M. Munagala1, M. J. Zucker1. [^1^]_]Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ, 2Sharing Network Laboratory, New Providence, NJ

 

[*(771) *][_ Towards Reduced Nephrotoxicity Following Heart Transplantation by Extended-Release Calcineurin Inhibition- A Single Center Observational Study; ]S. Keymel1, B. Stanske1, V. Veulemans1, U. Boeken^2^, D. Saeed2, A. Lichtenberg2, M. Kelm1, R. Westenfeld1. [1_]Cardiology, University Hospital, Duesseldorf, Germany, 2Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

 

[*(772) *]Novel Effect of Everolimus in Heart Transplant Recipients – Attenuation of Myocardial Hypertrophy and Improvement of Diastolic Function; _]T. Imamura^1^, K. Kinugawa1, D. Nitta2, M. Hatano2, Y. Itoda3, M. Kimura3, O. Kinoshita3, H. Yamauchi3, K. Nawata3, M. Ono3. [^1^]_]Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

 

[*(773) *]Alloantibody Desensitization Therapy in Bridge-to-Transplant Patients on Continuous-Flow Left Ventricular Assist Device Support; _]D. Bejar^1^, P. C. Colombo1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, M. Maurer1, E. Zorn1, F. Latif1, S. Restaino1, M. A. Farr1, Y. Naka2, D. M. Mancini1, V. K. Topkara1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*(774) *][_ CD38+DR+ Expression on Peripheral Monocytes and TLR2 Expression on Plasmocytoid Dendritic Cells May Be Early Markers for Severe Infection in Heart Transplantation; ]J. Carbone^1^, A. Gallego1, L. Calahorra1, I. Sousa2, P. Diez2, E. Sarmiento1. [1_]Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

 

[*(775) *]Outcomes of Rheumatic Heart Disease Following Heart Transplantation: ISHLT Registry Data; _]J. M. Dan^1^, J. Silva Enciso2, L. Edwards3, L. H. Lund4, S. Aslam1. [^1^]_]Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, CA, 2Medicine, Division of Cardiovascular Medicine, University of California, San Diego, San Diego, CA, 3United Network for Organ Sharing, Richmond, VA, 4Medicine and Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

 

[*(776) *][Outcomes of Heart Transplantation after Long-Term Circulatory Support by Ventricular Assist Devices with Driveline/Pump Infection; _]K. Nawata, O. Kinoshita, M. Kimura, H. Yamauchi, Y. Itoda, S. Yoshitake, Y. Hoshino, M. Ono. _The Department of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan

 

[*(777) *]Cytomegalovirus Seropositivity Is Associated with Increased One Year Acute Rejection in Heart Transplant Recipients; _]Y. Xia^1^, R. Bello1, S. Forest1, D. Sims2, S. Patel3, D. Goldstein1. [^1^]_]Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Medicine, Montefiore Medical Center, Bronx, NY, 3Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

 

[*(778) *][CMV Reactivation Using Valganciclovir vs Valacyclovir in Moderate Risk Heart Transplant Recipients; _]S. Varnado, H. Brink, J. Balk, E. Raichlin, B. Lowes, H. Vongooru, A. Burdorf, J. Um, M. Moulton, A. Siddique, R. Zolty. _Nebraska Medicine, Omaha, NE

 

[*(779) *]Initial Experience of Heart Transplantation in India; _]K. krishan^1^, M. Shinde1, A. Asija1, P. Sinha1, R. Chand2, A. Koppula1. [^1^]_]Cardiovascular Surgery, Max Super Speciality Hospital, Saket, New Delhi, India, 2Cardiovascular Anaesthesia, Max Super Speciality Hospital, Saket, New Delhi, India

 

[*(780) *]Treatment of Sleep Apnea with Heart Transplantation: Does It Help?; _]J. Patel, M. Kittleson, L. Czer, T. Aintablian, R. Sharoff, B. Kim, A. Velleca, B. Kearney, D. Chang, B. Azarbal, D. Chang, M. Hamilton, A. Trento, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(781) *]Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production; _]J. Moriguchi, M. Kittleson, J. Patel, L. Czer, T. Aintablian, R. Jocson, C. Runyan, D. Chang, B. Azarbal, F. Arabia, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(782) *]A Novel Risk Score to Predict Prolonged Post-Operative Length of Stay after Heart Transplantation; _]T. C. Crawford^1^, J. Magruder1, J. C. Grimm1, N. Patel1, C. M. Sciortino1, K. J. Zehr1, K. Mandal1, J. V. Conte1, R. S. Higgins1, D. E. Cameron1, R. J. Tedford2, S. D. Russell2, G. J. Whitman1. [^1^]_]Cardiac Surgery, Johns Hopkins University, Baltimore, MD, 2Cardiology, Johns Hopkins University, Baltimore, MD

 

[*(783) *]Simple Technique for Open Sternal Wound Closure after Cardiac Transplant or LVAD; _]U. Bansal^1^, A. Bansal2, J. K. Bhama3. [^1^]_]School of Medicine, University of Pittsburgh, Pittsburgh, PA, 2John Ochsner Heart & Vascular Institute, Ochsner Clinic, New Orleans, LA, 3Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA

 

[*(784) *][Post Heart Transplant Abandoned Lead Fragments: How to Avoid It?; _]S. Hakmi, S. Pecha, A. Bernhardt, T. Deuse, M. Barten, F. Wagner, H. Reichenspurner. _Cardiovascular Surgery, Univiversity Heart Center Hamburg, Hamburg, Germany

 

[*(785) *]The Prognostic Impact of One-Year Hemodynamics on Long-Term Survival After Heart Transplantation; _]E. Bollano^1^, K. Karason1, C. Hjalmarsson1, S. Bartfay1, B. Daka2, B. Andersson1, G. Dellgren3. [^1^]_]Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Primary Health Care, Sahlgrenska Academy at Gotheburg University, Gothenburg, Sweden, 3Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

 

[*(786) *]Desensitization in Total Artificial Heart Patients; _]J. Neyer, M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, R. Jocson, C. Runyan, D. Chang, J. Moriguchi, A. Trento, J. A. Kobashigawa, F. Arabia. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(787) *]Palliative Care Integration into Cardiac Transplant Recipient Care: A Retrospective Case Series; _]H. Groninger^1^, M. Aggarwal2, K. Walker3, A. M. Kelemen1, R. M. Holder1, J. T. Panke1, G. Ruiz4. [^1^]_]Medicine, MedStar Washington Hospital Center, Washington, DC, 2Medicine, MedStar Georgetown University Hospital, Washington, DC, 3Palliative Care, MedStar Health, Columbia, MD, 4Advanced Heart Failure, MedStar Heart and Vascular Institute, Washington, DC

 

[*(788) *]Risk of Post-Transplant Renal Dysfunction Is Increased in Patients Supported with Continuous-Flow Left Ventricular Assist Devices; _]V. K. Topkara^1^, P. N. Trinh2, A. Masoumi1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, J. Haythe1, M. Maurer1, F. Latif1, S. Restaino1, M. A. Farr1, D. M. Mancini1, Y. Naka3, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*(789) *]Heart Transplantation in Seniors: The Impact of Age on Outcomes?; _]Y. Lin^1^, S. S. Kushwaha2, B. S. Edwards2, N. L. Pereira2, D. L. Joyce1, J. M. Stulak1, L. D. Joyce1, R. C. Daly1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Disease, Mayo Clinic, Rochester, MN

 

[*(790) *]Heterotopic Heart Transplantation in Argentina; _]C. Burgos, M. C. Rodriguez, C. Elisa, O. Mugianesi, J. Magistretti, M. Burgos, G. Bortman, S. V. Perrone. [_Cardiovascuar Surgery & Transplant, Hospital Italiano de Mendoza, Guaymallen – Mendoza, Argentina

 

[*(791) *]Psychiatric Morbidity in De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression; _]B. S. Bürker^1^, U. F. Malt2, E. Gude3, L. Gullestad3, A. Relbo3, I. Grov3, A. K. Andreassen3, A. E. Fiane4, I. R. Haraldsen1. [^1^]_]Department of Psychosomatic Medicine, Oslo University Hospital – Rikshospitalet, Oslo, Norway, 2Department of Research and Education, Oslo University Hospital – Rikshospitalet, Oslo, Norway, 3Department of Cardiology, Oslo University Hospital – Rikshospitalet, Oslo, Norway, 4Department of Cardiothoracic Surgery, Oslo University Hospital – Rikshospitalet, Oslo, Norway

 

[*(792) *]Transplantation versus Ventricular Assist Device for the Management of End-Stage Heart Failure: An Observational Comparison of Clinical and Economic Outcomes; _]N. Aissaoui1, M. Morshuis^2^, H. Maoulida3, J. Salem4, M. Brunn3, S. Varnous5, J. Gummert2, I. Durand-Zaleski3, P. Leprince5, J. Fagon1. [^1^]_]Hopital Européen Georges Pompidou, Paris, France, 2Department of Thoracic & Cardiovascular Surgery, Heart and Diabetes Centre NRW, Ruhr-University of Bochum, Bad Oeynhausen, Germany, 3Epidémiologie Clinique, Évaluation Économique et Populations Vulnérables, UMRS 1123, URC, Hotel Dieu, Paris, France, 4Pharmacology and CIC-1421; INSERM, CIC-1421, GHPS, Paris, France, 5Cardiac Surgery, GHPS, Paris, France

 

[*(793) *][Clinical Usage of Marginal Donor Hearts in Transplantation: Experiences from Wuhan Union Hospital; _]n. Dong. _Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, WuHan, China

 

[*(794) *]WITHDRAWN

 

[*(795) *][Impact of Number of Pregnancies on Allosensitization and Heart Transplant Outcomes; _]S. G. Al-Kindi, P. Thakker, M. Farhoud, M. Kattea, M. Ginwalla, C. ElAmm, M. Zacharias, R. Benatti, S. V. Deo, B. Sareyyupoglu, S. Park, B. Medalion, G. H. Oliveira. _Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH

 

[*(796) *]Extra-Corporeal Membrane Support as Bridge to Transplant – An Outcome Analysis of United Network for Organ Sharing Registry; _]S. K. Zalawadiya^1^, W. Cotts1, G. Bhat1, J. Lindenfeld2. [^1^]_]Advanced Heart Failure/ Transplant Cardiology, Advocate Christ Medical Center, Oak Lawn, IL, 2Advanced Heart Failure/ Transplant Cardiology, Vanderbilt Medical Center, Nashville, TN

 

[*(797) *][Risk of Tumor Transmission After Thoracic Allograft Transplantation from Adult Donors with Central Nervous System Neoplasm-A UNOS Database Study; _]C. F. Hynes, K. Ramakrishnan, F. A. Alfares, K. M. Endicott, K. Hammond-Jack, D. Zurakowski, R. A. Jonas, D. S. Nath. _Children’s National Medical Center, Washington, DC

 

[*(798) *]Use of Prothrombin Complex Concentrates (PCCs) in Patients Undergoing Heart Transplant Surgery: Clinical Experience at a University Hospital; _]S. L. Rao1, Y. P. Salamanca^1^, W. E. Pae2. [^1^]_]Department of Anesthesiology & Perioperative Medicine, PennState Hershey Medical Center, Hershey, PA, 2Department of Surgery, PennState Hershey Medical Center, Hershey, PA

 

[*(799) *]Patients Save Lives: Donor Designation at the PCP Office; _]M. D. Enos. [_Center for Organ Recover & Education, Pittsburgh, PA

 

[*(800) *][Cardiac Surgery after Heart Transplantation – Elective Operation or Last Exit Strategy?; _]J. Goekler, A. Aliabadi, O. Salameh, T. Haberl, K. Uyanik-Ünal, G. Laufer, A. Zuckermann. _Cardiac Surgery, Medical University Vienna, Vienna, Austria

 

[*(801) *]Population Profile Submitted to Cardiac Transplantation in a Brazilian Hospital: Comparison Involving the Registry of ISHLT; _]G. C. Lima, S. Mangini, B. Alves, J. Vieira, L. Pires, F. Vianna, F. Brito, J. Xavier, R. Poffo, F. Bacal. [_Hospital Israelita Albert Einstein, São Paulo, Brazil

 

[*(802) *][Recipient Related Predictors of Mortality after Heart Transplantation: Results from a Contemporary Irish National Cohort; _]N. Ryan, M. Barrett, A. Eisaka, B. Parlon, J. Egan, N. G. Mahon, J. Mc Carthy, J. McGuinness, L. Noelke, C. M. Halley, J. O. O’Neill. _National Transplant Unit, Mater Misericordiae University Hospital, Dublin 7, Ireland

 

[*(803) *]Comparison of the Clinical Outcomes After De-Novo Heart Transplantation Between Adults with and without Congenital Heart Disease; _]A. Taylor1, J. Lannon2, T. Dominguez1, N. R. Banner3, D. Crossland4, J. Parameshwar5, R. Taylor2, R. Thompson6, R. Venkateswaran7, N. Al Attar8, M. Burch^1^. [^1^]_]Cardiology, Great Ormond Street Hospital, London, United Kingdom, 2Statistics, NHSBT, Bristol, United Kingdom, 3Cardiology, Royal Brompton and Harefield, London, United Kingdom, 4Cardiology, Freeman Hospital, Newcastle, United Kingdom, 5Cardiology, Papworth Hospital, Cambridge, United Kingdom, 6Transplant, Queen Elizabeth Birmingham Hospital, Birmingham, United Kingdom, 7Surgery, Wythenshaw Hospital, Manchester, United Kingdom, 8Surgery, Golden Jubilee Hospital, Glasgow, United Kingdom

 

[*(804) *]Prothrombin Complex Concentrate Reduces Intraoperative Blood Product Utilization in Heart Transplantation; _]D. Enter^1^, M. Marsh2, N. Cool2, J. Kruse1, Z. Li1, A. Andrei1, A. Iddriss1, P. M. McCarthy1, C. Malaisrie1, A. Anderson3, J. Rich3, D. Pham1. [^1^]_]Cardiac Surgery, Northwestern University, Chicago, IL, 2Pharmacy, Northwestern University, Chicago, IL, 3Cardiology, Northwestern University, Chicago, IL

 

[*(805) *]The Impact of Gender Mismatching on Early and Late Outcomes Following Heart Transplantation; _]Y. Peled^1^, J. Lavee1, M. Arad2, Y. Shemesh1, Y. Kassif1, Y. Har-Zahav1, I. Goldenberg3, D. Freimark2. [^1^]_]Heart Transplantation Unit, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, 2Heart Failure Unit, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, 3Cardiology Department, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel

 

[*(806) *][Prolonged Left Ventricular Assist Device Support Does Not Affect Post-Transplantation Survival; _]A. Cheng, J. R. Trivedi, E. M. Schumer, M. S. Slaughter, H. T. Massey. _Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY

 

[*(807) *]Effects of Increasing Donor Age on the Risk of Permanent Pacing after Orthotopic Heart Transplantation; _]F. Akca1, T. Szili-Torok2, R. Muslem^2^, S. Akin2, O. Manintveld2, A. Constantinescu2, O. Birim1, K. Caliskan2. [^1^]_]Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands, 2Cardiology, Erasmus MC, Rotterdam, Netherlands

 

[*(808) *]Impact of Donor to Recipient Weight Ratios on Outcome After Cardiac Transplantation; _]U. Boeken^1^, A. Albert1, A. Mehdiani1, C. Sowa1, C. Ballazs1, R. Westenfeld2, P. Akhyari1, A. Lichtenberg1. [^1^]_]Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

 

[*(809) *]Severity of Hypertension After Heart Transplant: Does It Impact Outcome?; _]J. Patel, M. Kittleson, L. Czer, T. Aintablian, R. Sharoff, G. Rodriguez, B. Kearney, N. Perry, A. Hage, F. Esmailian, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(810) *]Renal Function at One Year after Cardiac Transplantation but Not Acute Kidney Injury Is Highly Associated with Long-Term Survival and Loss of Renal Function; _]G. Fortrie^1^, O. C. Manintveld2, A. A. Constantinescu2, P. C. van de Woestijne3, M. G. Betjes1. [^1^]_]Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands, 2Cardiology, Erasmus MC, Rotterdam, Netherlands, 3Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands

 

[*(811) *][Usefulness of the “Impact Score” to Predict One-Year Mortality in a Hispanic Heart Transplant Cohort at a Single Center in Latin America; _]A. M. Bertolotti, M. Peradejordi, L. Favaloro, D. O. Absi, F. Renedo, A. Guazzone, R. Ratto, M. Candioti, R. Favaloro. _Intrathoracic Transplantation and Heart Failure Division, University Hospital Favaloro Foundation, Buenos Aires, Argentina

 

[*(812) *]Impact of Recipient Body Mass Index on Orthotopic Heart Transplantation Outcomes; _]A. Loforte^1^, M. Cefarelli1, G. Murana1, G. Jafrancesco1, J. Alfonsi1, E. Pilato1, S. Martin Suarez1, L. Potena2, F. Grigioni2, G. Marinelli1. [^1^]_]Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy

 

[*(813) *]Retrospective Single Centre Comparison of Outcomes between Standard Criteria and Marginal Criteria Brain Dead Heart Transplantation; _]H. Chew^1^, P. Lo2, J. Cao1, N. Sugianto3, K. Dhital4, E. Granger4, C. Hayward5, A. Jabbour5, P. Jansz4, A. Keogh5, E. Kotlyar5, P. Spratt4, P. Macdonald5. [^1^]_]Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia, 2University of New South Wales, Sydney, Australia, 3St Vincents Hospital, Sydney, Australia, 4Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia, 5Cardiology, St Vincents Hospital, Sydney, Australia

 

[*(814) *]Sarcopenia as a Predictor of Postoperative Hospital Stay in Heart Transplant Recipients; _]B. McGrath^1^, D. Vucicevic1, E. Kransdorf1, D. Steidley1, O. Pajaro2, E. Carey3. [^1^]_]Division of Cardiovascular Diseases, Mayo Clinic Hospital, Phoenix, AZ, 2Division of Cardiothoracic Surgery, Mayo Clinic Hospital, Phoenix, AZ, 3Division of Hepatology, Mayo Clinic Hospital, Phoenix, AZ

 

[*(815) *]Increased Donor Selectivity Does NOT Decrease Primary Graft Failure After Heart Transplantation; _]P. Delle^1^, L. K. Soni1, Y. Coppleson1, P. Kurlansky1, S. Sreekanth1, J. Han1, B. Li1, A. R. Garan2, V. Topkara2, M. Yuzefpolskaya2, P. Colombo2, M. Farr2, K. Takeda1, Y. Naka1, H. Takayama1. [^1^]_]Surgery, Columbia Presbyterian Medical Center, New York, NY, 2Cardiology, Columbia Presbyterian Medical Center, New York, NY

 

[*(816) *][Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction Following Heart Transplantation: A Single Center Experience; _]N. Rajagopalan, D. R. Dennis, T. S. Mooney, T. Tribble, M. Guglin, M. Sekela. _University of Kentucky, Lexington, KY

 

[*(817) *]Primary Graft Failure Following Cardiac Transplantation Is Associated with Elevated Pre-Transplant Levels of Pro-Inflammatory Factors; _]D. Chatterjee^1^, K. J. Clerkin1, K. J. Rogers1, D. Mancini1, Y. Naka1, H. Takayama2, K. Takeda2, P. C. Colombo2, G. Vlad3, R. Vasilescu3, B. Levin4, M. A. Farr1, S. Restaino1, E. Zorn1. [^1^]_]Dept. of Medicine, Columbia University, New York, NY, 2Dept. of Surgery, Columbia University, New York, NY, 3Dept. of Pathology & Cell Biology, Columbia University, New York, NY, 4Dept. of Biostatistics, Columbia University, New York, NY

 

[*(818) *]Primary Graft Dysfunction after Heart Transplantation with High Frequency of Marginal Donor Hearts; _]H. Hata^1^, T. Fujita1, H. Ishibashi-Ueda2, N. Fukushima3, T. Nakatani3, J. Kobayashi1. [^1^]_]Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, 2Pathology, National Cerebral and Cardiovascular Center, Suita, Japan, 3Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan

 

[*(819) *]Prognostic Value of High Sensitivity Troponin-T to Identify Patients at Risk of Primary Graft Dysfunction After Heart Transplantation; _]A. Méndez^1^, J. Ordonez-Llanos2, S. Mirabet1, J. Galan3, M. Maestre3, V. Brossa1, M. Rivilla3, L. Lopez1, T. Koller3, A. Sionis1, E. Roig1. [^1^]_]Cardiology, Hospital de Sant Pau, Barcelona, Spain, 2Biochemistry, Hospital de Sant Pau, Barcelona, Spain, 3Anesthesiology, Hospital de Sant Pau, Barcelona, Spain

 

[*(820) *][_ Chronic Lung Disease Fev1/Fvc <70% and Primary Graft Dysfunction; a Marker for Prolonged Intubation Immediately Post-Transplantation; ]J. Patel, M. Kittleson, L. Czer, T. Aintablian, E. Stimpson, T. Daun, T. A. Manayan, G. Rodriguez, D. Chang, D. Ramzy, J. A. Kobashigawa. [_Cedars-Sinai Heart Institute, Los Angeles, CA]

 

[*(821) *]WITHDRAWN

 

[*(822) *]Cardiac Allograft Sinus Tachycardia Is Associated with Impaired Exercise Tolerance; _]S. Varnado1, J. Y. Um2, H. Vongooru3, R. Zolty3, B. D. Lowes3, A. Huntsberry1, A. Burdorf3, B. Fenske3, A. Siddique2, M. J. Moulton2, E. Raichlin^3^. [^1^]_]Nebraska Medicine, Omaha, NE, 2Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, 3Cardiology, University of Nebraska Medical Center, Omaha, NE

 

[*(823) *]Heart-to-Heart: Using Patients’ Native Hearts to Promote Lifestyle Change Post-Transplant; _]S. Carey^1^, S. Driver2, M. Reynolds3, J. Ko4, W. Roberts4, B. Lima4, S. Hall4. [^1^]_]Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, 2Rehabilitation Research, Baylor Institute for Rehabilitation, Dallas, TX, 3Baylor Institute for Rehabilitation, Dallas, TX, 4Baylor University Medical Center, Dallas, TX

 

[*(824) *]Long-Term Outcome of Bridge to Recovery in Patients with Advanced Heart Failure Due to Idiopathic Cardiomyopathy; _]C. Urabe^1^, O. Seguchi2, S. Nakajima2, H. Sunami2, T. Sato2, H. Hata3, M. Yanase2, T. Fujita3, J. Kobayashi3, N. Fukushima2, T. Nakatani2. [^1^]_]National Cerebral and Cardiovascular Center, Suita, Japan, 2Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan, 3Adult Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan

 

[*(825) *]Education Status as a Predictor of Outcomes in Orthotopic Heart Transplantation; _]M. Delibasic^1^, N. Dobrilovic2, J. Raman2, B. Mohamedali3. [^1^]_]Internal Medicine, Mercy Hospital and Medical Center, Chicago, IL, 2Cardiovascular and Thoracic Surgery Department, Rush University Medical Center, Chicago, IL, 3Section of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL

 

[*(826) *]Quality of Life after Urgent Heart Transplantation; _]B. Diaz Molina^1^, J. Lambert1, F. González Vilchez2, F. Fernández Cadenas3, M. Bernardo1, E. Velasco1, M. Martín1, C. Morís1. [^1^]_]Cardiology, Hospital Universitario Central De Asturias, Oviedo, Spain, 2Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Digestive Diseases, Hospital Alvarez-Buylla, Mieres, Spain

 

[*(827) *]Impact of Reduced Creatinine Clearance on Early Heart Transplantation Outcomes: A Propensity Score Adjusted Analysis; _]H. Gasparovic^1^, D. Unic2, L. Svetina1, J. Samardzic1, M. Cikes1, Z. Baricevic1, B. Skoric1, T. Kopjar1, D. Anic1, V. Ivancan1, Z. Sutlic2, B. Biocina1, D. Milicic1. [^1^]_]University Hospital Rebro Zagreb, Zagreb, Croatia, 2University Hospital Dubrava, Zagreb, Croatia

 

[+LUNG TRANSPLANTATION +]

 

[+Target Audience: +]

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Clemens Aigner, Cecilia Chaparro, Laura Frye, Jens Gottlieb, Cynthia Gries, Are Martin Holm, Erika Lease, Gabriel Loor, Haifa Lyster, Monique Malouf, Hermann Reichenspurner, Robin Vos, David Weill, Stephanie Yerkovich

[*(828) *][Comparison of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) Between Living-Donor Lobar Lung Transplantation and Cadaveric Lung Transplantation; _]T. F. Chen-Yoshikawa, T. Kondo, A. Ohsumi, M. Saito, A. Takahagi, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Thoracic Surgery, Kyoto University, Kyoto, Japan

 

[*(829) *]Prevalence of Antibody Mediated Rejection in Lung Transplant Recipients with Clinical Dysfunction and/or Histological Damage: The PADOVA Experience; _]F. Calabrese^1^, S. E. Vuljan1, F. Lunardi1, N. Nannini1, M. Seveso1, M. Loy2, E. Ruffoni2, M. Damin2, F. Rigon2, E. Cozzi2, F. Rea1. [^1^]_]University of Padova, Padova, Italy, 2Padova Hospital, Padova, Italy

 

[*(830) *]Outcomes of Suspected Antibody-Mediated Rejection Post-Lung Transplantation; _]A. Hirji^1^, H. Zhao1, M. B. Ospina2, J. M. Tikkanen1, K. J. Tinckam1, L. G. Singer1, C. Chaparro1. [^1^]_]University of Toronto, Toronto, ON, Canada, 2School of Public Health, University of Alberta, Edmonton, AB, Canada

 

[*(831) *]Lung Transplantation in Septuagenarians; _]A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. [_University of California – Los Angeles, Los Angeles, CA

 

[*(832) *]A Strategy of Performing Coronary Artery Bypass Grafting (CABG) Prior to Wait-Listing Candidates for Lung Transplantation (LT) Is Safe and Feasible; _]N. Sinha^1^, S. Scheinin2, A. Siddiqui3, A. Goodarzi1, T. Kaleekal1, J. Youssef1, A. Gaber4. [^1^]_]Pulmonary Transplant, Houston Methodist Hospital, Houston, TX, 2DeBakey Cardiovascular Center/Cardiothoracic Surgery, Houston Methodist Hospital, Houston, TX, 3Pulmonary, Houston Methodist Hospital, Houston, TX, 4JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX

 

[*(833) *]Lung Transplantation on Pirfenidone: A Single Center Experience; _]A. Mortensen1, L. Cherrier^1^, R. Walia2. [^1^]_]St. Joseph’s Hospital & Medical Center, Phoenix, AZ, 2Norton Thoracic Institute, St. Joseph’s Hospital & Medical Center, Phoenix, AZ

 

[*(834) *]Combined Lung-Liver Transplantation: An Analysis of the UNOS Database; _]A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. [_University of California – Los Angeles, Los Angeles, CA

 

[*(835) *][Lung Transplantation for Systemic Sclerosis: Long-Term Survival, Freedom from BOS and Readmission Rates; _]A. Venado, D. Huang, J. R. Greenland, S. Hays, J. A. Golden, R. J. Shah, J. Kukreja, J. P. Singer, L. A. Leard. _Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA

 

[*(836) *]ECMO as a Bridge to Lung Transplantation: An Analysis of the UNOS Database; _]A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. [_University of California – Los Angeles, Los Angeles, CA

 

[*(837) *]WITHDRAWN

 

[*(838) *]WITHDRAWN

 

[*(839) *]Pulmonary Hypertension in COPD: A Survival Analysis of Patients Listed for Lung Transplantation; _]I. Timofte^1^, M. Terrin2, M. Wijesinha3, P. Sanchez4, R. Pierson4, E. Barr3, J. Kim1, Z. Kon4, S. Pham4, A. Iacono5. [^1^]_]Pulmonary and Critical Care, UMMC, Baltimore, MD, 2: Epidemiology and Public Health, UMMC, Baltimore, MD, 3Epidemiology and Public Health, UMMC, Baltimore, MD, 4Surgery, UMMC, Baltimore, MD, 5Medicine, UMMC, Baltimore, MD

 

[*(840) *]Gender Differences in Long-Term Survival during the LAS Era: A Single Institution Analysis of 848 Transplant Recipients; _]G. Loor^1^, R. Brown2, R. Kelly1, K. Rudser2, S. Shumway1, C. Holley1, I. Cich3, M. Hertz4. [^1^]_]Surgery, University of Minnesota, Minneapolis, MN, 2Biostatistics Division, University of Minnesota, Minneapolis, MN, 3University of Minnesota, Minneapolis, MN, 4Medicine, University of Minnesota, Minneapolis, MN

 

[*(841) *]Lung Transplantation in the LAS Era: Long-Term Analysis; _]A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. [_University of California – Los Angeles, Los Angeles, CA

 

[*(842) *]Uncontrolled DCD with Prolonged Ex Vivo Lung Perfusion (EVLP): A Feasible Model for Donor Lung Recovery and Allocation; _]J. R. Spratt^1^, L. M. Mattison2, P. A. Iaizzo1, T. Iles1, W. D. Payne3, G. Loor4. [^1^]_]Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, 2Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, 3LifeSource, Minneapolis, MN, 4Department of Surgery, University of Minnesota, Minneapolis, MN

 

[*(843) *]Detection of Lung-Specific Exosome in Perfusates of Ex Vivo Lung Perfusion System; _]T. Okamoto^1^, M. Mitsuhashi2, B. Soliman1, K. Abu-Elmagd1, K. R. McCurry3. [^1^]_]Transplant Center, Cleveland Clinic, Cleveland, OH, 2NanoSomix, Aliso Viejo, CA, 3Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

 

[*(844) *]Lung Transplantation after Ex-Vivo Lung Perfusion in Two Scandinavian Centres; _]T. Nilsson1, M. Zemtsovski2, A. Wallinder3, I. Henriksson2, S. Ricksten1, H. Møller-Sørensen2, G. C. Riise4, M. Perch5, M. Iversen5, G. Dellgren^6^. [^1^]_]Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska Univ Hospital, Goteborg, Sweden, 2Cardiothoracic Anesthesia, Rigshospitalet, Copenhagen, Denmark, 3Cardiothoracic Surgery, Sahlgrenska Univ Hospital, Goteborg, Sweden, 4Transplant Institute, Sahlgrenska Univ Hospital, Goteborg, Sweden, 5Lung Transplant Unit, Rigshospitalet, Copenhagen, Denmark, 6Sahlgrenska Univ Hospital, Goteborg, Sweden

 

[*(845) *]Carbapenem-Resistant Klebsiella Pneumoniae in Lung Transplantation Recipients; _]L. Morlacchi1, V. Rossetti1, P. Tarsia^1^, C. Travierso1, L. Rosso2, M. Nosotti2, F. Blasi1. [^1^]_]Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 2U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

 

[*(846) *]Donor Derived Disease Transmission Events in Thoracic Organ Transplantation: Data Reviewed by the OPTN Ad Hoc Disease Transmission Advisory Committee; _]J. M. Schaenman^1^, A. Wilk2, S. Tlusty2, M. A. Nalesnik3, M. G. Michaels4, C. Wolfe5, D. Kaul6. [^1^]_]UCLA School of Medicine, Los Angeles, CA, 2United Network for Organ Sharing, Richmond, VA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Duke University School of Medicine, Durham, NC, 6University of Michigan Medical School of Medicine, Ann Arbor, MI

 

[*(847) *]Trichosporon Infection in Lung Transplant Patients: An Emerging Fungal Infection?; _]S. V. Campos^1^, J. N. Almeida Jr2, M. N. Samano3, R. M. Carraro1, A. N. Costa1, R. O. Teixeira1, J. Afonso-Jr1, P. L. Camargo1, L. Abdalla3, L. M. Fernandes3, P. M. Pêgo-Fernandes3. [^1^]_]Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 2Central Laboratory Division, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 3Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil

 

[*(848) *]Fungal Colonization and Infection in Lung Transplant Recipients Receiving Posaconazole Prophylaxis; _]B. E. Cowan^1^, J. P. Singer1, R. J. Shah1, L. E. Leard1, J. Kukreja2, P. V. Chin-Hong1, K. Watkins3, R. Boettger3, J. A. Golden1, S. R. Hays1. [^1^]_]Department of Medicine, University of California, San Francisco, San Francisco, CA, 2Department of Surgery, University of California, San Francisco, San Francisco, CA, 3Department of Pharmacy, University of California, San Francisco, San Francisco, CA

 

[*(849) *]Not Donor’s but Recipient’s Airway Organisms Are Relevant to Post-Lung Transplant Pneumonia; _]K. Miyoshi, Y. Konishi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. [_Department of Thoracic Surgery / Organ Transplant Centre, Okayama University Hospital, Okayama, Japan

 

[*(850) *]Use of Oral Ribavirin for Respiratory Viral Infections in Lung Transplant Patients; _]B. Garcia^1^, N. Sharma1, K. Johnson2, E. Diaz1, K. Wille1, J. Salgado3. [^1^]_][_ Pulmonary, Allergy, and Critical Care Medicine, University of Alabama- Birmingham, Birmingham, AL, 2_]Internal Medicine, University of Florida, Gainesville, FL, 3Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL

 

[*(851) *]Assessment of CMV Specific T-Cell Immunity by the Quantiferon-CMV Assay in Lung Transplant Recipients: Brazilian Pilot Study; _]S. V. Campos^1^, A. Mamana2, M. N. Samano3, P. M. Pêgo-Fernandes3, C. M. Machado4. [^1^]_]Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 2Tropical Medicine Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil, 3Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 4Institute of Tropical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil

 

[*(852) *]Outcomes Associated with Ganciclovir-Resistant Cytomegalovirus in Lung Transplant Recipients; _]S. Hammad, L. Shah, M. Restivo, H. Robbins, J. Scheffert. [_NewYork-Presbyterian Hospital, New York, NY

 

[*(853) *]Posaconazol Tablets in Lung Transplant Recipients: Plasma Trough Levels and Influencing Factors; _]D. Stelzer^1^, F. Ihle2, A. Weber3, N. Kneidinger2, F. Ceelen2, G. Zimmermann2, R. Schramm4, H. Winter5, L. Frey6, M. Andraschko3, M. Vogeser7, J. Behr2, C. Neurohr2. [^1^]_]Department of Internal Medicine V, Pharmacy, University of Munich, Munich, Germany, 2Department of Internal Medicine V, University of Munich, Munich, Germany, 3Pharmacy, University of Munich, Munich, Germany, 4Department of Cardiac Surgery, University of Munich, Munich, Germany, 5Department of Thoracic Surgery, University of Munich, Munich, Germany, 6Department of Anesthesiology, University of Munich, Munich, Germany, 7Institute of Laboratory Medicine, University of Munich, Munich, Germany

 

[*(854) *]Up to Six Years Experience of Lobar Lung Transplantation; _]D. T. Reichart^1^, B. Sill1, C. Oelschner1, M. Oldigs2, H. Klose3, M. Barten1, H. Reichenspurner1, T. Deuse1. [^1^]_]Univ Hamburg Heart Center, Hamburg, Germany, 2Lung Clinic Grosshandsdorf, Großhandsdorf, Germany, 3University Clinic Hamburg, Hamburg, Germany

 

[*(855) *]10 Year Survival After Lung Transplantation: A Single Center Experience; _]H. Copeland^1^, D. Gutteridge2, D. Roe2, K. Lane3, C. Shen3, Z. Hashmi1, C. Hage2, I. Wang1, M. Duncan2, T. Wozniak1. [^1^]_]Surgery, Indiana University, Indianapolis, IN, 2Medicine, Indiana University, Indianapolis, IN, 3Biostatistics, Indiana University, Indianapolis, IN

 

[*(856) *]Combined Lung-Liver Transplantation: The United States Experience; _]S. Pasupneti^1^, A. Lawrence1, L. Chhatwani1, K. Patel1, R. Ha2, J. Boyd2, G. Dhillon1, J. Mooney1. [^1^]_]Pulmonary and Critical Care Medicine, Stanford University Hospitals, Stanford, CA, 2Cardiothoracic Surgery, Stanford University Hospitals, Stanford, CA

 

[*(857) *][Lung Transplantation from Donation after Circulatory Determined Dead (DCD) Donors: A Single Centre Experience; _]C. Barbero, S. Messer, P. Catarino, D. Thomas, C. Sudarshan, A. Ali, M. Berman, Y. Abu-Omar, D. P. Jenkins, J. Dunning, S. Tsui. _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom

 

[*(858) *]Risk Factors for De Novo Malignancy Following Lung Transplantation; _]J. Magruder^1^, T. C. Crawford1, J. C. Grimm1, B. Kim1, A. S. Shah2, E. L. Bush1, R. S. Higgins1, C. A. Merlo3. [^1^]_]Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD, 2Department of Cardiac Surgery, Vanderbilt, Nashville, TN, 3Division of Pulmonary and Critical Care Medicine, Johns Hopkins, Baltimore, MD

 

[*(859) *][Gene Expression Profiling of Bronchoalveolar Lavage Cells during Aspergillus Colonization of the Lung Allograft; _]S. S. Weigt, X. Wang, V. Palchevskiy, N. Patel, A. DerHovanessian, M. Y. Shino, D. Sayah, A. L. Gregson, J. P. Lynch III, R. Saggar, D. J. Ross, A. Ardehali, D. Elashoff, J. A. Belperio. _UCLA, Los Angeles, CA

 

[*(860) *]Outcomes in Lung Transplant Recipients with COPD with and without Alpha-1-Antitrypsin Deficiency: Single Center Experience Over Four Decades; _]J. R. Spratt^1^, R. Z. Brown2, K. Rudser2, U. Goswami3, J. Patil4, I. Cich5, S. J. Shumway6, M. I. Hertz4, G. Loor6. [^1^]_]Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, 2Division of Biostatistics, University of Minnesota, Minneapolis, MN, 3Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, 4Department of Medicine, University of Minnesota, Minneapolis, MN, 5University of Minnesota Medical School, Minneapolis, MN, 6Department of Surgery, University of Minnesota, Minneapolis, MN

 

[*(861) *][Intermediate-Term Change of Pulmonary Function and Lung Volume after Bilateral Living Donor Lobar Lung Transplantation; _]A. Takahagi, T. F. Chen-Yoshikawa, T. Kondo, M. Saito, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, H. Motoyama, K. Hijiya, A. Aoyama, H. Date, H. Date. _Thoracic Surgery, Kyoto University Gradual School, Kyoto, Japan

 

[*(862) *]Thoracic Cavity Volume Change after Lung Transplantation According to the Underlying End-Stage Lung Disease; _]C. Park^1^, S. Haam2, T. Kim1, H. Paik3, J. Lee3. [^1^]_]Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, 3Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

 

[*(863) *]Characteristics of Various Categories of Controlled Donors after Circulatory Death Do Not Affect Outcome after Lung Transplantation; an Analysis of ISHLT DCD Registry Data; _]D. Van Raemdonck^1^, B. Levvey2, L. Edwards3, J. Stehlik4, M. Erasmus5, A. Glanville6, M. Hertz7, P. Hopkins8, D. Chambers8, M. Musk9, M. Budev10, D. Mason11, V. Puri12, R. Yusen12, F. D’Ovidio13, S. Keshavjee14, M. Cypel14, G. Snell2. [^1^]_]Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 3United Network for Organ Sharing, Richmond, VA, 4University of Utah, Salt Lake City, UT, 5Cardiothoracic Surgery, Universitair Medisch Centrum, Groningen, Netherlands, 6St Vincent’s Hospital, Sydney, Australia, 7University of Minnesota Medical Center, Minneapolis, MN, 8Prince Charles Hospital, Brisbane, Australia, 9Royal Perth Hospital, Perth, Australia, 10The Cleveland Clinic Foundation, Cleveland, OH, 11Baylor University Medical Center, Dallas, TX, 12Barnes Jewish Hospital Washington University, St Louis, MO, 13Columbia University Medical Center, New York, NY, 14Thoracic Surgery, The Toronto General Hospital & Hospital for Sick Children, Toronto, ON, Canada

 

[*(864) *]Cervical Neoplasia in Female Lung Transplant Recipients: Inadequate Screening and a High Burden of Disease; _]M. Paraskeva^1^, S. R. Davis2, R. J. Bell2, A. M. Storch3, P. Robinson2. [^1^]_]Alfred Hospital, Melbourne, Australia, 2Women’s Health Program, Department of Preventative Medicine, Monash University, Melbourne, Australia, 3Monash University, Melbourne, Australia

 

[*(865) *]Body Mass Index in Lung Transplant Candidates: A Single Center Results; _]M. A. Kashem^1^, A. Shiose1, J. Gomez-Abraham1, T. Yoshizumi1, F. Cordova2, G. Criner2, Y. Toyoda1. [^1^]_]Cardiovascular Surgery, Temple University, Philadelphia, PA, 2Thoracic and Pulmonary Medicine, Temple University, Philadelphia, PA

 

[*(866) *]Soluble CD14 and LBP as Markers for Primary Graft Dysfunction; _]K. Ramphal^1^, E. Cantu1, M. Porteous1, M. Oyster1, S. Kawut1, D. J. Lederer2, R. Shah3, S. Arcasoy2, L. Snyder4, M. Hartwig4, S. Palmer4, K. M. Wille5, L. Ware6, P. Shah7, M. Crespo8, C. Hage9, A. Weinacker10, V. Lama11, Y. Suzuki1, J. Orens7, J. D. Christie1, J. Diamond1. [^1^]_]University of Pennsylvania, Philadelphia, PA, 2Columbia University, New York, NY, 3University of California San Francisco, San Francisco, CA, 4Duke University, Durham, NC, 5University of Alabama Birminghma, Birmingham, AL, 6Vaderbilt University, Nashville, TN, 7Johns Hopkins University, Baltimore, MD, 8University of Pittsburgh, Pittsburgh, PA, 9Indiana University, Indianapolis, IN, 10Stanford University, Stanford, CA, 11University of Michigan, Ann Arbor, MI

 

[*(867) *]Systemic Inflammatory State of the Organ Donor and Risk for Primary Graft Dysfunction Following Lung Transplantation; _]E. M. Lowery^1^, M. Yong1, L. Ramirez2, N. Balasubramanian3, S. Kliethermes3, J. Schwartz4, E. J. Kovacs2. [^1^]_]Medicine, Loyola University Chicago, Chicago, IL, 2Surgery, Loyola University Chicago, Chicago, IL, 3Public Health, Loyola University Chicago, Chicago, IL, 4Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

 

[*(868) *][Involvement of Rho-Kinase in Lung Ischemia-Reperfusion Injury Pathogenesis: Molecular Analysis in an Isolated Rat Lung Perfusion Model; _]K. Ohata, T. Chen-Yoshikawa, T. Menju, M. Saito, A. Takahagi, E. Miyamoto, S. Tanaka, M. Takahashi, T. Kondo, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

 

[*(869) *]Primary Graft Dysfunction in Lung Transplantation: A Detailed Predictive Model; _]A. Iyengar, A. Bhutani, O. Kwon, D. Ross, A. Ardehali. [_University of California – Los Angeles, Los Angeles, CA

 

[*(870) *]Elevated Plasma PAI-1 Levels in the Donor Are Associated with the Development of Primary Graft Dysfunction in Lung Transplant Recipients; _]B. C. Hamilton^1^, G. R. Dincheva1, J. Abbott2, H. Zhuo2, J. A. Golden3, S. R. Hays3, M. Brzezinski4, J. P. Singer3, M. A. Matthay2, J. Kukreja1. [^1^]_]Department of Surgery, Division of Cardiothoracic Surgery, UCSF, San Francisco, CA, 2Department of Medicine and Anesthesia, Cardiovascular Research Institute, UCSF, San Francisco, CA, 3Department of Medicine, Pulmonary and Critical Care, UCSF, San Francisco, CA, 4Department of Anesthesia, UCSF, San Francisco, CA

 

[*(871) *][Obese Recipients of Lung Transplant Have an Increased Risk of Primary Graft Dysfunction; _]I. Bello, L. Romero, M. Deu, A. Jauregui, J. Pérez, J. Ochoa, V. Díaz, L. Sanchez, F. Ascanio, J. Solé. _Thoracic Surgery, H. Universitario Vall d ‘Hebron, Barcelona, Spain

 

[*(872) *]Pre-Transplant Frailty Is Associated with Hospital Readmissions and Rejection Following Lung Transplantation; _]M. Wilson^1^, A. Vakil1, E. Beam1, P. Chong2, R. Razonable1, S. Dunlay1, P. Kandel1, C. Undavalli1, C. Kennedy1. [^1^]_]Mayo Clinic, Rochester, MN, 2University of North Carolina, Chapel Hill, NC

 

[*(873) *]The Prevalence and Prognostic Significance of Frailty in Patients with Advanced Lung Disease Referred for Lung Transplantation; _]E. Montgomery^1^, P. S. Macdonald2, A. R. Glanville1, M. Malouf1, A. Havryk1, M. Plit1, M. Benzimra1, A. L. Rigby1, M. Harkess1, N. DeTullio1, A. L. Smith1, A. Hogan1, P. S. Tunnicliff1, S. Jha3. [^1^]_]Lung Transplant Program, St Vincent’s Hospital, Sydney, Australia, 2Heart Transplant Program, St Vincent’s Hospital, Sydney, Australia, 3Centre for Cardiovascular and Chronic Care, University of Technology, Sydney, Australia

 

[*(874) *][Frailty in Transplantation. The FIT Study; _]K. E. Morley, H. Chung, J. S. Parmar. _Transplant Continuing Care Unit, Papworth Hospital, Cambridge, United Kingdom

 

[*(875) *]Pregnancy Outcomes in 30 Lung Transplant Recipients; _]S. Constantinescu^1^, L. Coscia2, D. Armenti2, M. Moritz3. [^1^]_]Medicine, Temple University School of Medicine, Philadelphia, PA, 2National Transplantation Pregnancy Registry, Philadelphia, PA, 3Lehigh Valley Health Network, Allentown, PA

 

[+MECHANICAL CIRCULATORY SUPPORT +]

 

[+Target Audience: +]

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Ruchan Akar, Komarakshi Balakrishnan, Jay Baumwol, Shashank Desai, Gregory Ewald, Daniel Goldstein, George Javorsky, Manreet Kanwar, Jason Katz, Marc Katz, Brent Lampert, Nader Moazami, Chetan Patel, Edwardo Rame, Stephan Schubert, Palak Shah, Scott Silvestry, Cumara Sivathasan, Jeffrey Teuteberg, Neil Wrightson

[*(876) *]Outcome of CentriMag Extracorporeal Mechanical Circulatory Support Use in Critical Cardiogenic Shock (INTERMACS 1) Patients; _]V. Mehta^1^, J. Hasan1, K. Oommen1, S. Shaw2, S. G. Williams2, J. Barnard1, N. Yonan1, R. V. Venkateswaran3. [^1^]_]Cardiothoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom, 2Cardiology, University Hospital of South Manchester, Manchester, United Kingdom, 3Director of Transplantation, Cardiothoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom

 

[*(877) *]WITHDRAWN

 

[*(878) *]Right Ventricular Failure Post LVAD Implantation Corrected with Biventricular Support: An In-Vitro Model; _]S. Shehab^1^, S. M. Allida2, P. J. Newton2, P. M. Davidson3, P. S. MacDonalds1, P. C. Jansz1, C. S. Hayward1. [^1^]_]Cardiology, St. Vincent’s Hospital, Sydney, Australia, 2Centre of Cardiovascular and Chronic Care, University of technology, Syndey, Sydney, Australia, 3School of Nursing, John Hopkins University, Sydney, MD

 

[*(879) *]The Effect of Inflow Cannula Length on the Intraventricular Flow Field of the EvaHeart LVAD-Assisted Heart; _]K. May-Newman^1^, J. Moon1, V. Ramesh1, B. Herold1, R. Montes1, J. Campos1, P. Isingoma1, R. Benkowski2. [^1^]_]Bioengineering, San Diego State University, San Diego, CA, 2B-Squared Medical Device Solutions, LLC, Fort Worth, TX

 

(880) WITHDRAWN

 

[*(881) *]Modulation of Autonomic Tone Assessed by Heart Rate Variability in Advanced Heart Failure Patients Treated with an Extra-Aortic Counterpulsation (EACP) System: A Single Center Experience; _]A. Kao^1^, D. Georgakopoulos2, J. Smith1, D. Pomfret3, S. Aggarwal4. [^1^]_]Medicine, Saint Luke’s Cardiovascular, Kansas City, MO, 2Sunshine Heart, Eden Prairie, MN, 3Sunshine Heart, Kansas City, MN, 4Cardiovascular and Thoracic Surgery, Saint Luke’s Mid-America Heart and Lung, Kansas City, MO

 

[*(882) *]Off-Pump HeartWare HVAD Left Ventricular Assist Device Implantation; _]R. Moayedifar^1^, J. Riebandt1, T. Haberl1, K. Dimitrov1, D. Wiedemann1, T. Schlöglhofer2, H. Schima2, G. Laufer1, D. Zimpfer1. [^1^]_]Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria, 2Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria

 

[*(883) *]Association between Intraventricular Position of Inflow Cannula and Clinical Outcomes in LVAD Recipients; _]A. Anselmi^1^, S. Collin2, J. Verhoye1, P. Haigron2, E. Flécher1. [^1^]_]Division of Thoracic, and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France, 2INSERM, U1099, Rennes, F-35000, France; Université de Rennes 1, LTSI, Rennes, France

 

[*(884) *][Computed-Tomography Guided Apex Marking for Lateral Thoracotomy LVAD Implantation; _]D. Acharya, R. Loyaga-Rendon, S. Pamboukian, J. Tallaj, W. Holman, J. Kirklin, S. Singh. _University of Alabama at Birmingham, Birmingham, AL

 

[*(885) *]GLP In-Vivo Study and Durability Testing for Miniaturized EVAHEART KAIZEN (EVA-kai) System; _]H. Kanebako. [_R & D Group, Sun Medical Technology Research Corp., Suwa, Japan

 

[*(886) *][A Single Center Evolution of Surgical Experience on HeartWare LVAD Minimally Invasive Implantation in High Risk Patients; _]L. Bagozzi, A. Guariento, J. Bejko, M. Carrozzini, M. Comisso, G. Bortolussi, M. Gallo, V. Tarzia, G. Gerosa, T. Bottio. _Department of Cardiology and Cardiovascular Surgery, University of Padua, Padova, Italy

 

[*(887) *][Left Ventricular Unloading in Relation to Cannula Position during Invasive Hemodynamic Ramp Test in Axial Flow Pumps; _]K. K. Marinescu, S. Adatya, N. Sarswat, G. Kim, S. Kalantari Tannenbaum, G. Sayer, N. Uriel. _University of Chicago, Chicago, IL

 

[*(888) *]Left Ventricular Assist Device Implantation by Lateral Thoracotomy to the Descending Aorta: A Propensity Matched Analysis to Standard Sternotomy Approach; _]M. Ozbaran1, T. Yagdi1, C. Engin^1^, S. Nalbantgil2, S. Ertugay1, P. Ozturk1. [^1^]_]Cardiovascular Surgery, Ege Unv. Hospital, Izmir, Turkey, 2Cardiology, Ege Unv. Hospital, Izmir, Turkey

 

[*(889) *][Pathological Substrate of intermittent Low Speed Process on the Native Aortic Valve of Patients Assisted with Left Ventricular Assist Device; _]J. Bejko, M. Fedrigo, A. Di Francesco, G. Gerosa, T. Bottio, A. Angelini, G. Thiene. _Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy

 

[*(890) *]Novel Minimally Invasive Surgical Approach Using External Ventricular Assist Device and Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock; _]K. Takeda^1^, R. A. Garan2, V. K. Topkara1, J. Han1, S. Sreekanth1, P. A. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1, H. Takayama1. [^1^]_]Cardiac Surgery, Columbia University, NY, NY, 2Cardiology, Columbia University, NY, NY

 

[*(891) *]ECPELLA: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device; _]O. Akanni1, K. Takeda1, L. Truby2, P. Kurlansky1, J. Han^1^, S. Sreekanth1, A. R. Garan2, V. K. Topkara2, M. Yuzefpolskaya2, P. Colombo2, A. Kirtane2, Y. Naka1, H. Takayama1. [^1^]_]Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY, 2Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY

 

[*(892) *]Initial Experience with a Percutaneous Dual Lumen Single Cannula Strategy for Temporary Right Ventricular Assist Device Support Following Durable LVAD Therapy; _]J. K. Bhama^1^, A. Bansal2, F. Zahr1, R. Patel2, S. Desai2, J. Goerbig-Campbell1, V. Cotarlan1, S. Krishnan1. [^1^]_]Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA, 2John Ochsner Heart & Vascular Institute, Ochsner Clinic, New Orleans, LA

 

[*(893) *][_ Sustainability of Pulmonary Hypertension Reversal Before and After Heart Transplantation in Patients Bridged with Continuous-Flow LVADs: Axial- vs Centrifugal-Flow; ]M. Al-Sarie, A. Rauf, C. Selzman, A. Kfouri, J. Doty, S. H. McKellar, A. Koliopoulou, J. Wever-Pinzon, Z. Abu Saleh, S. Wright, O. Wever-Pinzon, J. Nativi-Nicolau, J. Stehlik, S. G. Drakos. [_UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT]

 

[*(894) *]LVAD Implantation in Patients on ECLS; _]M. J. Morshuis^1^, A. Koster2, M. Schönbrodt1, J. Gummert1. [^1^]_]Cardiothoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany, 2Anaesthesiology, Heart Center NRW, Bad Oeynhausen, Germany

 

[*(895) *]Is the Diameter of the Outflow Graft the Crucial Difference in Stroke Rates Between Heartmate II and HVAD? A Computational Fluid Dynamics Study; _]K. Balakrishnan^1^, S. Bhat2, J. Mathew2, R. Krishnakumar2. [^1^]_]Cardiac Surgery, Fortis Malar Hospital, Chennai, India, 2Engineering Design, Indian Institute of Technology, Chennai, India

 

[*(896) *]Minimally Invasive Heartware HVAD Implantation with Outflow Graft Anastomosis to the Left Subclavian Artery; _]J. Riebandt^1^, D. Wiedemann1, T. Haberl1, T. Schloeglhofer2, R. Moayedifar1, K. Dimitrov1, G. Laufer1, D. Zimpfer1. [^1^]_]Cardiac Surgery, Medical Univ Vienna, Vienna, Austria, 2Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria

 

[*(897) *]Effect of HeartMate PHP on Resting Hemodynamics in Low Cardiac Output Patients Undergoing Elective High-Risk PCI; _]U. Jorde^1^, K. Ŝmudka2, A. Witkowski3, J. Granada4, B. Vesga4, A. Ebner5, A. Ochala6, N. van Mieghem7, R. van Geuns7, M. Zembala8, J. Maly9, P. Sood10, D. Dudek11. [^1^]_]Montefiore Medical Center, Bronx, NY, 2John Paul II Hospital, Krakow, Poland, 3Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland, 4Instituto del Corazon, Bucaramanga, Colombia, 5Sanatorio Italiano, Asuncion, Paraguay, 6Samodzielny Publiczny Szpital, Katowice, Poland, 7Erasmus Medical Center, Rotterdam, Netherlands, 8Slaskie Centrum Chorob Serca w Zabrzu, Zabrze, Poland, 9IKEM (Institute for Clinical and Experimental Medicine), Prague, Czech Republic, 10Thoratec Corporation, Pleasanton, CA, 11Montefiore Medical Center, Krakow, Poland

 

[*(898) *][Acute Hemodynamic Effects of Percutaneously-Deployed Axillary Intra-aortic Balloon Counterpulsation Pumps in Patients with Advanced Heart Failure; _]S. Annamalai, L. Buiten, V. Paruchuri, M. Esposito, K. Morine, R. O’Kelly, C. Kimmelstiel, M. Kiernan, A. Vest, J. Shih, D. Denofrio, N. K. Kapur. _Cardiology, Tufts Medical Center, Boston, MA

 

[*(899) *][Evaluation of Changes in Flow Associated with HeartMate II Inflow Cannula Angle Change ; _]J. H. Karimov, M. Tong, N. Byram, G. Sunagawa, R. Dessoffy, N. Moazami, R. Starling, K. Fukamachi. _The Cleveland Clinic, Cleveland, OH

 

[*(900) *]Acoustic Analysis of a Continuous-Flow Left Ventricular Assist Device before and after Suspected Pump Thrombosis; _]F. Castagna1, S. Pan2, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, K. Ross3, M. Torres3, R. A. Blum1, S. Singh1, D. M. Mancini1, Y. Naka3, P. C. Colombo1, S. Bulek4, V. K. Topkara^1^. [^1^]_]Medicine, Columbia University, New York, NY, 2Medicine, New York University, New York, NY, 3Surgery, Columbia University, New York, NY, 4Qualcomm Technology Inc, Auburn Hills, MI

 

[*(901) *]Extracorporeal Membrane Oxygenation Support Systems as Treatment for Refractory Cardiogenic Shock: Strategies and Predictors of Mortality; _]A. Loforte^1^, G. Murana1, G. Jafrancesco1, M. Cefarelli1, J. Alfonsi1, E. Pilato1, S. Martin Suarez1, F. Grigioni2, G. Frascaroli3, G. Marinelli1. [^1^]_]Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 3Anesthesiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy

 

[*(902) *]Validity and Reliability of a Next Generation Non-Invasive Blood Pressure Monitor in Patients with Continuous-Flow Left Ventricular Assist Device; _]F. Castagna^1^, B. J. McDonnell2, M. Yuzefpolskaya1, V. K. Topkara1, A. R. Garan1, J. Z. Willey3, P. N. Trinh4, K. Wong1, B. Cagliostro1, M. Flannery5, D. M. Mancini1, H. Takayama5, K. Takeda5, Y. Naka5, J. R. Cockcroft2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Cardiology, Cardiff Metropolitan University, Cardiff, United Kingdom, 3Neurology, Columbia University, New York, NY, 4Epidemiology, Columbia University, New York, NY, 5Surgery, Columbia University, New York, NY

 

[*(903) *][Role of Mechanical Support in Post Myocardial Infarction Septal Defects Percutaneous Repair; _]A. Sundara Raman, B. Metz, B. Kar, A. Nascimbene, I. Gregoric, P. Loyalka. _Heart Failure, University of Texas, Houston, TX

 

[*(904) *]North American Experience with Biventricular HVAD Total Artificial Heart as a Successful Bridge to Orthotopic Heart Transplantation; _]M. S. Mulvihill^1^, M. A. Daneshmand1, C. B. Patel2, C. A. Milano1, J. N. Schroder1. [^1^]_]Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC, 2Department of Medicine, Duke University, Durham, NC

 

[*(905) *]Outcomes Following Minimally Invasive Implantation of a Centrifugal Continuous-Flow Left Ventricular Assist Device; _]M. A. Psotka^1^, D. Lowe2, J. C. Cox2, R. G. Kiel1, M. Janmohamed1, V. N. Selby1, T. De Marco1, L. Klein1, G. M. Wieselthaler2. [^1^]_]Cardiology, University of California San Francisco, San Francisco, CA, 2Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA

 

[*(906) *]Minimally-Invasive Access and Off-Pump LVAD Implantation – Strategies to Improve Outcomes; _]U. A. Stock1, A. Kornberger^1^, C. Reyher2, F. Jäger2, B. Assmus3, A. Moritz1, A. Beiras-Fernandez1. [^1^]_]Thoracic, Cardiac and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany, 2Anaesthesia and Intensive Care, University Hospital Frankfurt, Frankfurt, Germany, 3Cardiology, University Hospital Frankfurt, Frankfurt, Germany

 

[*(907) *]Safety of Trans Esophageal Echocardiogram Guided Percutaneous Insertion of Bi-Caval Dual Lumen Cannula (AVALON ELITE®) for Veno-Venous Extracorporeal Membrane Oxygenation; _]S. Bressler, C. Brehm, A. Ghodsizad, M. Pfeiffer. [_Heart & Vascular Intensive Care, PennState Hershey Medical Center, Hershey, PA

 

[*(908) *][A Mock Circulatory System to Research the HeartWare Pump Flow Waveform; _]G. M. Christensen, B. D. King, B. B. Reid, S. Stoker, R. Alharethi, K. T. Bjerregaard, D. M. Allen, A. K. Johnson, W. T. Caine, B. Y. Rasmusson, A. G. Kfoury. _Artificial Heart Program, Intermountain Medical Center, Murray, UT

 

[*(909) *]WITHDRAWN

 

[*(910) *]A Novel Cardiac Coordinate Modeling System for Three Dimensional Quantification of Inflow Cannula Malposition in HeartMate II Left Ventricular Assist Device Implantation; _]B. Lima^1^, O. Dur2, J. Chuang2, T. Chamogeorgakis1, D. Farrar2, K. Sundareswaran2, S. Hall1, G. Gonzalez-Stawinski1. [^1^]_]Baylor University Medical Center, Dallas, TX, 2Thoratec, Pleasanton, CA

 

[*(911) *]Advanced Ventricular Assist Device with Pulse Augmentation and Automatic Regurgitant Flow Shutoff; _]K. Fukamachi^1^, D. J. Horvath1, N. Byram1, G. Sunagawa1, J. H. Karimov1, B. D. Kuban1, R. Dessoffy1, N. Moazami2. [^1^]_]Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH, 2Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH

 

[*(912) *]Digitizing Medication Adherence Monitoring with a Novel Ingestible Nanosensor – First in Man Application Among Recipients of Continuous Flow Left Ventricular Assist Devices; _]S. P. Bhavnani^1^, A. Srivastava2, D. Meyer3, R. Kuo4, J. Nowaczyk5, L. Wolman5, S. Baradarian3, T. Heywood2. [^1^]_]Cardiology, Scripps Clinic and Research Institute, San Diego, CA, 2Heart Failure Research and Recovery Program, Scripps Clinic and Research Institute, San Diego, CA, 3Cardiothoracic Surgery, Scripps Clinic and Research Institute, San Diego, CA, 4Pharmacy, Scripps Clinic and Research Institute, San Diego, CA, 5Left Ventricular Assist Device Program, Scripps Clinic and Research Institute, San Diego, CA

 

[*(913) *][_ Myocardial and End-Organ Response after Long-Term Mechanical Unloading with Continuous-Flow Left Ventricular Assist Device: Axial- Versus Centrifugal-Flow; ]M. Al-Sarie, A. Rauf, J. Wever-Pinzon, A. Catino, J. Stehlik, A. Kfouri, S. H. McKellar, O. Wever-Pinzon, A. Kelkhoff, R. Alharethi, B. Reid, J. Fang, C. Selzman, S. G. Drakos. [_UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT]

 

[*(914) *][Expanded Experience with Percutaneous Placement of Axillary-Subclavian Intra-Aortic Balloon Pump that Permits Sitting Upright and Ambulation in Patients with Advanced Heart Failure; _]J. Amione-Guerra, A. M. Cordero-Reyes, A. S. Cruz-Solbes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, C. H. Lin, B. Bruckner, E. E. Suarez, G. Torre-Amione, M. H. Park, J. D. Estep. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*(915) *][Contemporary Outcomes of Mechanical Circulatory Support for Cardiogenic Shock: Single Center Experience of over 300 Patients; _]S. Fukuhara, Y. Naka, K. Takeda, M. Yuzefpolskaya, B. Li, S. Sreekanth, P. C. Colombo, V. K. Topkara, A. R. Garan, P. Kurlansky, H. Takayama. _Columbia University Medical Center, New York, NY

 

[*(916) *]Very-Low Threshold for Indication of Temporary RVAD Support in LVAD Recipients: Towards a Monoventricular Philosophy? A Multicentre Experience; _]M. Pozzi^1^, J. Robin1, D. Grinberg1, L. Sebbag2, P. Boissonnat2, T. Bochaton2, I. Sanchez2, C. Flamens3, S. Paulus3, R. Giraud4, K. Bendjelid4, P. Meyer5, M. Licker6, C. Banfi7, J. Obadia1, M. Kirsch8. [^1^]_]Department of Cardiac Surgery, “Louis Pradel” Cardiologic Hospital, Lyon, France, 2Department of Cardiology, “Louis Pradel” Cardiologic Hospital, Lyon, France, 3Department of Anesthesia and ICU, “Louis Pradel” Cardiologic Hospital, Lyon, France, 4Intensive Care Service, Geneva University Hospitals, Geneva, Switzerland, 5Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland, 6Division of Anesthesiology, Geneva University Hospitals, Geneva, Switzerland, 7Division of Cardiovascular Surgery, Geneva University Hospitals, Geneva, Switzerland, 8Department of Cardiac Surgery, University Hospital of Lausanne, Lausanne, Switzerland

 

[*(917) *]Mid Term Results of Mechanical Circulatory Support in the Netherlands, a Single Centre Experience from the University Medical Centre Utrecht (UMCU); _]S. E. Felix^1^, F. Z. Ramjankhan2, F. de Heer2, N. de Jonge1, M. P. Buijsrogge2, W. J. Suyker2. [^1^]_]Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands, 2Cardiothoracic Surgery, University Medical Centre Utrecht, Utrecht, Netherlands

 

[*(918) *]Persistent Hyponatremia Early after LVAD Implantation Does Not Result in Poor Long-Term Outcomes; _]D. C. Rodriguez^1^, M. Algodi2, C. Berardi1, M. Makkiya1, N. Cyrille2, O. Saeed2, J. J. Shin2, S. R. Patel2, D. J. Goldstein3, U. P. Jorde2, D. B. Sims2. [^1^]_]Medicine, Montefiore Medical Center, Bronx, NY, 2Cardiology, Montefiore Medical Center, Bronx, NY, 3Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

 

[*(919) *]Single Center Experience with Successful Left Ventricular Assist Device Explantation Following Myocardial Recovery; _]A. Mirza^1^, F. Raza2, A. Shiose3, D. Schwartz2, Y. Toyoda3, R. Alvarez2, E. Hamad2. [^1^]_]Internal Medicine, Temple University Hospital, Philadelphia, PA, 2Cardiology, Temple University Hospital, Philadelphia, PA, 3Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA

 

[*(920) *][1040 Consecutive Adult Patients Treated with Extracorporeal Membrane Oxygenation for Refractory Postcardiotomy Cardiogenic Shock, Longterm Follow-Up; _]S. Lehmann, F. Emrich, C. D. Etz, A. Meyer, A. K. Funkat, A. Oberbach, M. Misfeld, J. Garbade, F. W. Mohr. _Heartcenter Leipzig, Leipzig, Germany

 

[*(921) *][How Does the Effect of Opening the Pericardium on Right Ventricular Failure after LVAD Implantation; _]U. Kervan, S. S. Kocabeyoglu, D. E. Sert, E. U. Unal, E. Aygun, M. Karahan, M. Pac. _Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

 

[*(922) *]Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS) – Non-Pulsatile Implantable LVAS vs. Extracorporeal LVAD as Bridge to Transplantation; _]T. Nakatani^1^, K. Sase2, H. Oshiyama3, M. Akiyama4, M. Horie5, K. Nawata6, T. Nishinaka7, Y. Tanoue8, K. Toda9, M. Tozawa10, M. Yanase1, S. Yamazaki11, M. Ishida12, A. Hiramatsu12, S. Kitamura13. [^1^]_]Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Juntendo University, Tokyo, Japan, 3Medical Technology Association of Japan, Tokyo, Japan, 4Tohoku University, Sendai, Japan, 5Nipro Corp, Osaka, Japan, 6The University of Tokyo, Tokyo, Japan, 7Tokyo Women’s Medical University, Tokyo, Japan, 8Kyushu University, Fukuoka, Japan, 9Osaka University, Osaka, Japan, 10Century Medical, Inc., Tokyo, Japan, 11Sun Medical Technology Research Corp., Suwa, Japan, 12Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 13National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*(923) *]Differences in Heat Generation Between Axial and Centrifugal Continuous Flow Left Ventricular Assist Devices; _]R. Y. Loyaga-Rendon^1^, S. V. Pamboukian1, D. Acharya1, J. Tallaj1, F. Siric2, C. Hoopes2, W. Holman2, J. Kirklin2, D. L. Smith3. [^1^]_]Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, 2Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, 3Department of Nutritional Sciences, University of Alabama at Birmingham, Birmingham, AL

 

[*(924) *]Evaluation of Functional Capacity Scores After Left Ventricular Assist Device Implantation in Cases with End Stage Heart Failure; _]P. Ozturk^1^, S. Ertugay1, S. Nalbantgil2, H. Karapolat3, C. Engin4, T. Yagdi4, M. Ozbaran1. [^1^]_]Ege Unv. Hospital, Izmir, Turkey, 2Cardiology, Ege Unv. Hospital, Izmir, Turkey, 3Physical Therapy and Rehabilitation (Cardiac Rehabilitation), Ege Unv. Hospital, Izmir, Turkey, 4Cardiovascular Surgery, Ege Unv. Hospital, Izmir, Turkey

 

[*(925) *][Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management; _]E. A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr, B. Cramer-Manchin, J. Merkel, L. Ciniglia, D. Dougherty, J. Wilson, R. Alvarez. _Dept of Medicine, Temple Univ Hosp, Philadelphia, PA

 

[*(926) *][Readmission Rates in Patients with Left Ventricular Assist Devices; _]J. Nativi-Nicolau, A. Healy, S. Abdelrahman, J. Jaramillo, A. Elmer, S. Tagge, S. McKellar, J. Stehlik, S. Drakos, J. Fang, E. M. Gilbert, O. Wever-Pinzon, K. Kawamoto, C. Selzman. _University of Utah Division of Cardiology, Salt Lake City, UT

 

[*(927) *][Clinical Outcomes and Survival after Continuous-Flow Left Ventricular Assist Device Therapy in United States Veterans: A Single Center Experience; _]E. Lushaj, L. Lozonschi, T. Kohmoto, S. Akhter, M. Murray, D. Murray, S. Osaki. _University of Wisconsin, Madison, WI

 

[*(928) *]Application of Extracorporeal Membrane Oxygenator (ECMO) Support in Adult Patients with Cardiogenic Shock as a Bridge to Implantable Left Ventricular Assist Device (LVAD); _]B. Soleimani^1^, C. Brehm2, E. Stephenson1, W. Pae1. [^1^]_]Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA, 2Heart & Vascular Institute, Penn State Hershey Medical Center, Hershey, PA

 

[*(929) *][The Value of N-Terminal Pro-Brain Natriuretic Peptide After LVAD Implantation; _]G. Lolay, M. Guglin, B. George, K. Kido, R. Charingo. _Cardiology, University of Kentucky Medical Center, Lexington, KY

 

[*(930) *][Hospital Readmission and Survival Rates One Year Post-ECMO Discharge; _]S. M. Evrard, K. Milley, J. Camuso, K. E. Perkins. _Cardiac Surgery, Massachusetts General Hospital, Boston, MA

 

[*(931) *]The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection; _]A. Iyengar, O. Kwon, M. Tamrat, N. Satou, C. Gomez, R. J. Shemin, M. Kwon. [_University of California – Los Angeles, Los Angeles, CA

 

[*(932) *]Improved Medical Resource Use by Deploying a Novel Multidisciplinary Team-Based In-Hospital MCS Unit; _]E. N. Lyons, K. A. Frankel, L. Coakley, M. Hickey, F. Melanson, E. G. Olanda, S. E. Shaughnessy, D. S. Medina, M. M. Givertz, G. S. Couper, M. R. Mehra, G. C. Stewart. [_Brigham & Women’s Hospital, Boston, MA

 

[*(933) *]PCI in Patients Supported with CF-LVADs: Indications, Safety, and Outcomes; _]E. C. Anyanwu^1^, S. Atman2, S. Nathan2, G. Sayer3, S. Adatya3, N. Sarswat3, T. Ota4, V. Jeevanandum4, N. Uriel3. [^1^]_]Internal Medicine, University of Chicago, Chicago, IL, 2Interventional Cardiology, University of Chicago, Chicago, IL, 3Advanced Heart Failure, University of Chicago, Chicago, IL, 4Cardiac Surgery, University of Chicago, Chicago, IL

 

[*(934) *]Changes in Lipid Profile Subfractions on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Therapy; _]V. K. Topkara^1^, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, J. A. Fried1, K. Wong1, D. Jennings1, R. Te-Frey2, J. Haythe1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*(935) *]Palliative Care Integration for Patients Receiving Left Ventricular Assist Device as Destination Therapy; _]H. Groninger^1^, M. Aggarwal2, K. A. Walker3, J. T. Panke1, A. M. Kelemen1, R. M. Holder1, G. Ruiz4. [^1^]_]Medicine, MedStar Washington Hospital Center, Washington, DC, 2Medicine, MedStar Georgetown University Hospital, Washington, DC, 3Palliative Care, MedStar Health, Columbia, MD, 4Advanced Heart Failure, MedStar Heart and Vascular Institute, Washington, DC

 

[*(936) *]Greater Reduction in NT Pro-BNP Levels Post LVAD Is Associated with a Greater Improvement in Diabetes Control; _]S. Madan, P. Vlismas, O. Saeed, S. R. Patel, J. Shin, S. Murthy, D. Sims, U. Jorde. [_Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, bronx, NY

 

[*(937) *][Prealbumin as a Predictor of Mortality After LVAD Implantation; _]M. E. Rodrigo, D. T. Majure, F. H. Sheikh, C. Bither, M. Hofmeyer, N. Shah, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC

 

[*(938) *]Sodium Nadir during Left Ventricular Assist Device Implantation Is Not Associated with Increased Mortality; _]S. Gupta^1^, S. Roy2, R. John3, R. Cogswell2. [^1^]_]Medicine, University of Minnesota Health, Minneapolis, MN, 2Cardiology, University of Minnesota Health, Minneapolis, MN, 3Cardiothoracic Surgery, University of Minnesota Health, Minneapolis, MN

 

[*(939) *]Measuring Blood Pressure in Patients with Continuous-Flow Left Ventricular Assist Devices; _]K. L. Kerk^1^, T. H. Truong2, C. H. Lim1, T. E. Tan1, D. Sim3, C. P. Lim3, C. Sivathasan1. [^1^]_]Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore, 2SingHealth Transplant, Singapore Health Services, Singapore, Singapore, 3Cardiology, National Heart Centre Singapore, Singapore, Singapore

 

[*(940) *]The Nutritional Risk Index as a Marker for Outcomes Following Left Ventricular Assist Device Implantation; _]G. Yost1, G. Bhat^2^. [^1^]_]Heart Transplant, Advocate Christ Medical Center, Oak Lawn, IL, 2Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL

 

[*(941) *]Integration of Palliative Care in End of Life Care for Patients on Durable Mechanical Circulatory Support; _]H. J. Halazun^1^, S. Pinney1, N. Goldstein2, L. Gelfman2, K. Ashley1, A. Anyanwu1, A. Lala1. [^1^]_]Cardiology, Mount Sinai Heart, New York, NY, 2Palliative Care, Mount Sinai, New York, NY

 

[*(942) *][Hospital Readmissions After Left Ventricular Assist Device Implantation; _]C. Heim, N. Mekkhala, M. Kondruweit, M. Weyand, R. Tandler. _Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany

 

[*(943) *]Quality of Life among LVAD Recipients: A Comparison of Bridge-to Transplant vs. Destination Therapy Patients; _]K. D. Milley^1^, S. M. Evrard1, G. Lewis2, D. A. D’Alessandro3, T. E. MacGillivray3, S. C. Wiafe4, J. M. Camuso1, K. E. Perkins3. [^1^]_]Cardiac Surgery Research, Massachusetts General Hospital, Boston, MA, 2Heart Failure/Cardiology, Massachusetts General Hospital, Boston, MA, 3Cardiac Surgery, Massachusetts General Hospital, Boston, MA, 4Cardiac Surgery/VAD Coordinator, Massachusetts General Hospital, Boston, MA

 

[*(944) *]The Real World: Self-Reported Dressing Practices in LVAD Outpatients; _]A. Kaan1, D. Christensen^2^, M. Mackay3. [^1^]_]Acute Heart Failure Program, St. Paul’s Hospital, Vancouver, BC, Canada, 2MyLVAD.com, Washington, DC, 3St Paul’s Hospital & University of British Columbia, Vancouver, BC, Canada

 

[*(945) *]A Single Center U.S. Experience with the Implementation of Mandatory Patient and Caregiver Pre-Ventricular Assist Device Implantation Education; _]M. L. Safiran, E. Boyes, B. Duebner, E. Coglianese. [_Heart Failure / Cardiac Transplant, Loyola University Medical Center, Maywood, IL

 

[+NURSING, HEALTH SCIENCES, ALLIED HEALTH +]

 

[+Target Audience: +]

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM

Poster Discussants:

Bryan Boling, Pamela Combs, Jennifer Franzwa, Bronwyn Levvey, Lauren Schneider, Diana Shellmer

[*(946) *]Is Functional Status a Mediator of the Effect of the Sickness Behavior & Discomforts Symptom Clusters on Quality of Life in Heart Failure Patients?; _]J. Salyer^1^, M. P. Flattery2. [^1^]_]Adult Health, VCU Health System, Richmond, VA, 2Nursing, Pauley Heart Center, VCU Health System, Richmond, VA

 

[*(947) *][High Rates of Post-Transplant Depressive Symptoms Identified Using the CES-D; _]T. Holland, R. Byrd, R. Crouch, M. G. Hartwig, K. Holleman, A. Pastva, J. Reynolds, P. Smith, L. D. Snyder. _Duke University Med Ctr, Durham, NC

 

[*(948) *][The Positive Outcomes for Patients Receiving Animal Assisted Therapy after Lung Transplantation; _]K. Holleman, T. Holland, L. West, L. D. Snyder. _Duke University Med Ctr, Durham, NC

 

[*(949) *]Pre Lung Transplant Patients’ Ability to Predict Post Lung Transplant Quality of Life with and without CLAD; _]M. Aversa^1^, N. A. Chowdhury2, G. Tomlinson1, L. G. Singer1. [^1^]_]Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

 

[*(950) *]Relationship of Depression Symptoms with Sense of Coherence Among Japanese Patients After Implantation of Left Ventricular Assist Device; _]N. P. Kato^1^, I. Okada2, D. Nitta3, T. Imamura2, Y. Yamashita2, Y. Kagami4, M. Endo4, M. Hatano3, M. Ono5, T. Jaarsma1, K. Kinugawa6. [^1^]_]Social and Welfare Studies, Linköping University, Linköping, Sweden, 2Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan, 3Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan, 4Organ Transplantation, The University of Tokyo, Tokyo, Japan, 5Cardiovascular Surgery, The University of Tokyo, Tokyo, Japan, 6The 2nd Department of Internal Medicine, University of Toyama, Toyama, Japan

 

[*(951) *]Associations and Differences in Behavioral and Emotional Symptoms Among Parents, Teachers, and School-Aged Youth: The School Experience After Pediatric Heart Transplantation (HT); _]C. White-Williams^1^, P. Fazeli-Wheeler1, A. Crosswy1, M. Hubbard2, J. Kirklin1. [^1^]_]University of Alabama, Birmingham, AL, 2Children’s Hospital of Alabama, Birmingham, AL

 

[*(952) *]Implant Strategy Is Related to Health-Related Quality of Life at 2 Years After LVAD Implantation: An INTERMACS Analysis; _]K. L. Grady^1^, P. L. Fazeli2, C. White-Williams3, S. L. Myers4, S. V. Pamboukian5, D. C. Naftel4, J. K. Kirklin4. [^1^]_]Surgery, Northwestern Mem Hosp, Chicago, IL, 2Psychology, University of Alabama at Birmingham, Birmingham, AL, 3Nursing, University of Alabama Medical Center, Birmingham, AL, 4Surgery, University of Alabama at Birmingham, Birmingham, AL, 5Medicine, University of Alabama at Birmingham, Birmingham, AL

 

[*(953) *]Patients Previously Supported by Veno-Arterial Extra Corporeal Membrane Oxygenation Have Good Long Term Quality of Life; _]K. Hryniewicz^1^, K. Wilson2, A. Pai2, R. Garberich3. [^1^]_]Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, 2Minneapolis Heart Institute Foundation, Minneapolis, MN, 3Minneapolis Heart Institute Foundation, Minneapolis Heart Institute Foundation, Minneapolis, MN

 

[*(954) *]Cognitive Function and Self-Care in Patients with Left Ventricular Assist Devices (LVADs); _]J. Casida^1^, F. D. Pagani2, H. Yarandi3, C. Williams4, M. Lefebvre2, S. Fox2, P. Lichtenberg5. [^1^]_]School of Nursing, University of Michigan, Ann Arbor, MI, 2Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, 3College of Nursing, Wayne State University, Detroit, MI, 4Advanced Heart Failure & Transplant, Henry Ford Hospital, Detroit, MI, 5Institute of Gerontology, Wayne State University, Deteroit, MI

 

[*(955) *]Does Age Affect Exercise Outcomes for Adult Cystic Fibrosis Lung Transplant Recipients?; _]L. M. Fuller^1^, G. Snell2, A. E. Holland1, M. Paraskeva2. [^1^]_]Physiotherapy Department, The Alfred, Melbourne, Australia, 2Lung Transplant Services, The Alfred, Melbourne, Australia

 

[*(956) *][The Challenges Associated with the Ongoing Management of Heart Transplantation in Young Adults, Including Transitioning from Paediatric to Adult Care; _]G. Minio. _Transplant Services, Alfred Hospital, Melbourne, Australia

 

[*(957) *][Use of In-Situ Simulation Technique to Implement a Mechanical Circulatory Support Emergency Response System in the Pediatric Setting; _]A. Schubert, C. Villa, A. Gardner, D. Morales, A. Lorts. _Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*(958) *]Lung Transplant Patients and Carers Report Unmet Palliative Care Needs; _]C. Li^1^, A. Collins2, M. Gold1, J. Philip2, G. Snell1. [^1^]_]Alfred Health, Melbourne, Australia, 2Centre for Palliative Care, St Vincent’s Hospital, Melbourne, Australia

 

[*(959) *]A 7 Center Review of Left Ventricular Assist Device (LVAD) Caregiver Perceptions; _]S. Schettle^1^, L. Staley2, S. Schroeder3, A. Luckhardt1, S. Chillcott4, M. Kasper5, J. Bjelkengren6, C. Marchand7, J. Stulak1, S. Dunlay8. [^1^]_]Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN, 2Cardiovascular Surgery, Mayo Clinic Arizona, Phoenix, AZ, 3Cardiovascular Surgery, Bryan Heart, Lincoln, NE, 4Cardiovascular Surgery, Sharp Memorial Hospital, San Diego, CA, 5Cardiovascular Surgery, University Hospitals of Cleveland, Cleveland, OH, 6Cardiovascular Surgery, Providence Sacred Heart Medical Center, Spokane, WA, 7Cardiovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, 8Cardiology, Mayo Clinic Rochester, Rochester, MN

 

[*(960) *][Tales of Roller Coaster Rides and Resilience: Lung Transplant Caregivers in Their Own Words; _]A. J. Haines. _Acute and Tertiary Care, Univ Pittsburgh Sch Nursing, Monroeville, PA

 

[*(961) *]Getting a New Life: Women Living with a Left Ventricular Assist Device; _]A. D. Pal^1^, A. E. Berndt1, C. J. Braden1, J. H. Calhoon1, J. D. Pal2, S. L. Gill1. [^1^]_]University of Texas Health Science Center, San Antonio, TX, 2Univ of Washington, Seattle, WA

 

[*(962) *][Non-Adherence to Medical Advice Does Not Impact Survival in a Bridge to Transplant (BTT) Left Ventricular Assist Device (LVAD) Program; _]A. Kaan, E. Johansson, W. Chiu, Q. Young, C. Cannon, S. Prytula, A. Cheung, M. Toma. _St. Paul’s Hospital, Vancouver, BC, Canada

 

[*(963) *][A Review of Warfarin Management in Patients Supported with a Heartware HVAD Using Home INR Testing; _]A. Woods, G. MacGowan, S. Schueler, N. Robinson Smith, N. Wrightson. _Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom

 

[*(964) *][Implementing a Change Package to Improve the Anti-Coagulation Management of Pediatric Patients on Ventricular Assist Devices; _]A. Schubert, C. Villa, J. Brown, D. Morales, J. Sawyer, A. Gardner, A. Lorts. _Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*(965) *]Validating the Effectiveness of Ventricular Assist Device-Specific Education during the Pre-Discharge Phase; _]L. Coakley, D. S. Medina, M. Hickey, F. Melanson, E. G. Olanda, S. E. Shaughnessy, J. A. Smallwood, G. S. Couper, M. M. Givertz. [_Brigham & Women’s Hospital, Boston, MA

 

[*(966) *]Slow-Paced Respiration Therapy to Treat Sleep Disturbance and Symptoms in Pulmonary Arterial Hypertension; _]L. Matura^1^, J. Fargo2, J. S. Fritz1, K. A. Smith1, A. Vaidya1, D. Pinder1, C. Archer-Chicko1, D. Dubow1, H. I. Palevsky1, A. I. Pack1, M. S. Sommers1, S. M. Kawut1. [^1^]_]University of Pennsylvania, Philadelphia, PA, 2Utah State University, Logan, UT

 

[*(967) *][Opportunities and Restrictions in Digitizing VAD Care; _]K. Vandersmissen, J. Driesen, H. Bollen, K. Van den Bossche, J. Cloetens, W. Droogne, F. Rega, B. Meyns. _Cardiac Surgery, UZ Leuven, Leuven, Belgium

 

[+PEDIATRICS +]

 

[+Target Audience: +]

PEDS, HTX, ID, LTX, PHARM

Poster Discussants:

Jennifer Conway, George Mallory, Ernestina Melicoff-Portillo, Martin Schweiger, Melinda Solomon, Stuart Sweet, Josef Thul, Gary Visner

[*(968) *]Impact of Infant Nutritional Status on Outcomes in Lung Transplant; _]S. Das^1^, S. Culhane2. [^1^]_]Baylor College of Medicine, Houston, TX, 2Texas Children’s Hospital, Houston, TX

 

[*(969) *]Evaluation of Epstein-Barr Viral Loads as a Predictor of Development of Post-Transplant Lymphoproliferative Disorder; _]A. Parrish^1^, M. Fenchel1, G. Storch2, R. Buller2, S. Mason2, S. Mason2, N. Williams3, D. Ikle4, S. Sweet2, L. Danziger-Isakov1. [^1^]_]Cincinnati Children’s Hosp Med Ctr, Cincinnati, OH, 2Washington University, St. Louis, MO, 3National Institutes of Health, Bethesda, MD, 4Rho, Inc., Chapel Hill, NC

 

[*(970) *][Prevalence of Malnutrition and Growth in Children after Lung Transplantation; _]M. C. Gazzaneo, G. Mackey, U. Kyle, S. Culhane, E. Melicoff-Portillo, S. Das, N. Crews, G. Mallory, L. Shekerdemian, J. Cossbu. _Pediatrics, Texas Children’s Hospital, Houston, TX

 

[*(971) *][Improving Health Management: The Development of an Adolescent Specific Education Program; _]M. Paraskeva, R. Martin, K. Attard, B. Levvey, J. Marshall, B. Tarrant, S. Ivulich, G. P. Westall. _Lung Transplant Service, Alfred Hospital, Melbourne, Australia

 

[*(972) *]Pediatric Extracorporeal Membrane Oxygenation Support as Treatment for Refractory Cardiogenic Shock; _]A. Loforte^1^, G. Murana1, M. Sposito1, L. Careddu2, F. Petridis2, E. Angeli2, L. Ragni3, G. Frascaroli4, G. Gargiulo2. [^1^]_]Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 2Pediatric Cardiac Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 3Pediatric Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, 4Anesthesiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy

 

[*(973) *]Cannula Site Management Strategies in Pediatric Ventricular Assist Device (VAD) Patients; _]M. V. Horn^1^, P. Shah2, J. Menteer1, C. Herrington1, D. Guadiz1, D. Dechant1, J. Szmuszkovicz1. [^1^]_]Heart Institute, Children’s Hospital Los Angeles, Los Angeles, CA, 2Hematology Oncology, Children’s Hospital Los Angeles, Los Angeles, CA

 

[*(974) *]Incidence of Thrombo-Embolic Events of Intra-Corporeal Ventricular Assist Devices in Pediatrics – EUROMACS Analyses; _]M. Schweiger^1^, M. Hübler1, F. Berger2, O. Miera2, A. Loforte3, G. Gargiulo3, T. M. de By4, J. Gummert5, O. behalf of all EUROMACS Members6, P. Mohacsi7. [^1^]_]Children’s Hospital, Zurich, Switzerland, 2Klinik für Angeborene Herzfehler/Kinderkardiologie, Deutsches Herzzentrum, Berlin, Germany, 3Dipartimento di Chirurgia Cardio-Toraco-Vascolare e Trapianti, Policlinico S. Orsola-Malpighi, Università di Bologna, Bologna, Italy, 4Euromacs e.V., c/o Deutsches Herzzentrum Berlin, Germany, 5[_ Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Switzerland, 6_]Euromacs e.V. c/o, Deutsches Herzzentrum, Berlin, Germany, 7Department of Cardiology, Swiss Cardiovascular Center, University Hospital (Inselspital), Bern, Switzerland

 

[*(975) *]ECMO Support in Infant Less Than 3 kg: Indications, Complications and Outcomes; _]S. R. Deshpande^1^, G. Kasniya2, J. Davis3, M. Paden3, A. J. Piazza4. [^1^]_]Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA, 2Children’s Healthcare of Atlanta, Atlanta, GA, 3Emory University Children’s Healthcare of Atlanta, Atlanta, GA, 4Division of Neonatal-Perinatal Medicine, Emory University Children’s Healthcare of Atlanta, Atlanta, GA

 

[*(976) *][Bridging Children to Transplant with Short Term VADs Does Not Affect Post-Transplant Mortality; _]C. Villa, R. Rizwan, F. Zafar, A. Lorts, D. Morales. _Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

 

[*(977) *][Successful Treatment of VAD Pump Thrombosis in Four Pediatric Patients; _]D. Chetan, H. Buchholz, M. Bauman, V. Anand, P. Holinski, J. Conway. _Stollery Children’s Hospital, Edmonton, AB, Canada

 

[*(978) *]Sensitization across the Age Spectrum Post VAD: Can We Detect Differences between Adults and Children?; _]A. Halpin^1^, B. Martin2, S. Urschel3, D. Kim1, L. West1, P. Campbell4, H. Buchholz5, J. Conway3. [^1^]_]Department of Medicine, Pediatrics, University of Alberta, Edmonton, AB, Canada, 2Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, 3Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada, 4Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, 5Stollery Children’s Hospital and Mazankowski Heart Institute, University of Alberta, Edmonton, AB, Canada

 

[*(979) *]WITHDRAWN

 

[*(980) *]Worldwide Use of SynCardia Total Artificial Heart in Pediatric Population: A 30 Year Experience; _]A. Lorts^1^, R. Rizwan2, F. Zafar2, J. L. Jefferies1, J. S. Tweddell2, F. A. Arabia3, D. L. Morales2. [^1^]_]Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA

 

[*(981) *]Pediatric Implantable Left Ventricular Assist Device Experience; _]S. Kocabeyoglu^1^, U. Kervan1, E. Unal1, D. Sert1, S. Koca2, K. Kavasoglu1, D. Bagrul2, F. Pac2, M. Pac1. [^1^]_]Cardiovascular Surgery, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey, 2Pediatric Cardiology, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

 

[*(982) *]Cost Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy; _]D. A. Magnetta^1^, J. Kang2, P. D. Wearden3, K. J. Smith4, B. Feingold1. [^1^]_]Pediatric Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2School of Nursing, University of Pittsburgh, Pittsburgh, PA, 3Cardiothoracic Surgery, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 4Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*(983) *]Jarvik 2000 in Pediatrics as a Bridge to Trasplantation or as Destination Therapy: Perioperative Management; _]F. Iodice^1^, G. Testa1, S. Morelli1, F. Gandolfo2, A. Amodeo2. [^1^]_]Pediatric Intesive Cardiac Unit, Bambino Gesù Children’s Hospital, Rome, Italy, 2Pediatric Cardiac Surgery, Bambino Gesù Children’s Hospital, Rome, Italy

 

[+PULMONARY HYPERTENSION +]

 

[+Target Audience: +]

PH, BSI, HF

Poster Discussants:

Eric Adler, Jose Cifrian, Rebecca Cogswell, Rachel Crackett, Mardi Gomberg-Maitland, Dana McGlothlin, Ioana Preston, Oksana Shlobin, Marc Simon, Dario Vizza

 

[*(984) *]WITHDRAWN

 

(985) WITHDRAWN

 

(986) MOVED TO MINI ORAL SESSION 12

 

[*(987) *]Clinical and Pathologic Features in Lung or Heart and Lung Transplanted Patients with a Diagnosis of Pulmonary Sarcoidosis; _]P. Ausin1, J. Le Pavec^1^, S. Feuillet1, P. Dorfmuller1, S. Mussot1, L. Savale2, O. Mercier1, H. Nunes3, D. Valeyre3, E. Fadel1. [^1^]_]Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, 2Service de Pneumologie, Hôpital Kremlin Bicètre, Paris, France, 3Service de Pneumologie, Hôpital Avicenne, Bobigny, France

 

[*(988) *][An Analysis of Mechanism of Hypoxia in Chronic Thromboembolic Pulmonary Hypertension; _]S. Minatsuki, H. Maki, M. Hatano, I. Komuro. _Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan

 

[*(989) *][Exercise CMR Can Evaluate RV Function and Hemodynamics in Patients with Pulmonary Arterial Hypertension: A Pilot Study; _]E. W. Pollock, S. Raman, V. Franco. _The Ohio State University, Columbus, OH

 

[*(990) *]Parenchymal Lung Disease in PAH Patients Managed with Prostacyclin Agonists; _]N. A. Weir, O. A. Shlobin, D. Brown, S. D. Nathan, S. Ahmad, C. King, A. Brown. [_Inova Advanced Lung Disease & Transplant, Fairfax, VA

 

[*(991) *][Phenotypic Differences in Pulmonary Hypertension Due to Left Heart Disease (PHLHD) and Reversibility with Left Ventricular Assist Devices (LVAD); _]S. Lim, N. Howell, A. Ranasinghe, J. Mascaro. _University Hospital Birmingham, Birmingham, United Kingdom

 

[*(992) *][Tricuspid Regurgitation Is Associated with Pulmonary Hemodynamics and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension But Does Not Alter the Geometry of Right Ventricular Contraction; _]J. Po, T. Meeran, R. Davey, R. Benza, A. Raina. _Allegheny General Hospital, Pittsburgh, PA

 

[*(993) *]A Coding Polymorphism in PFAS (The Gene Encoding Phosphoribosylformylglycinamidine Synthase) Is a Determinant of Prostacyclin Dose; _]V. Thomeas^1^, M. L. Maitland1, R. L. Benza2, M. Tamari3, E. R. Gamazon4, A. Konkashbaev4, H. Wheeler5, T. Hirota3, M. Kubo3, N. J. Cox4, M. Gomberg-Maitland1. [^1^]_]University of Chicago, Chicago, IL, 2Allegheny General Hospital, Pittsburgh, PA, 3Institute of Physical and Chemical Research (RIKEN), Center for Integrative Medical Sciences, Yokohama, Japan, 4Vanderbilt University, Nashville, TN, 5Loyola Unviersity, Chicago, IL

 

[*(994) *]Left Ventricular Failure after Surgery to Correct Right Ventricular Pressure Overload in Pulmonary Hypertension Patients; _]T. Verbelen^1^, A. Van De Bruaene2, D. Van Raemdonck3, M. Delcroix4, F. Rega1, B. Meyns1. [^1^]_]Cardiac Surgery, UZ Leuven, Leuven, Belgium, 2Cardiology, UZ Leuven, Leuven, Belgium, 3Thoracic Surgery, UZ Leuven, Leuven, Belgium, 4Pneumology, UZ Leuven, Leuven, Belgium

 

[*(995) *][Pulmonary Pulse-Wave Transit Time Is a Noninvasive Marker of Intrinsic Pulmonary Vascular Disease; _]K. W. Prins, E. K. Weir, J. Markowitz, M. Pritzker, R. Madlon-Kay, T. Thenappan. _Cardiovascular Division, University of Minnesota, Minneapolis, MN

 

[*(996) *]The Nuclear Orphan Receptors NR4A as Therapeutic Target in Pulmonary Arterial Hypertension Therapy; _]X. Nie, W. Mao, Y. Dai, J. Tan, J. Chen. [_Department of Lung Transplant Center, Key Laboratory of Human Organ Transplant in Jiangsu Province, Nanjing Medical University affiliated Wuxi People’s Hospital, Wuxi, China

 

[*(997) *]Right Atrial Pressure to Stroke Volume Ratio Predicts Mortality in Pulmonary Arterial Hypertension; _]S. Mazimba1, J. L. Kennedy1, K. C. Bilchick1, J. A. Wynter^2^, A. D. Mihalek1, J. A. Tallaj3. [^1^]_]Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, 2Department of Medicine, University of Virginia Health System, Charlottesville, VA, 3Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL

 

[*(998) *]The Long Noncoding RNA MEG3 Is an Emerging Factor in Hypoxia-Induced Pulmonary Hypertension; _]M. Brock1, C. Schuoler1, S. Ulrich1, R. Speich1, M. Gassmann2, M. Kohler1, L. C. Huber^1^. [^1^]_]University Hospital, Zurich, Switzerland, 2University Zurich, Institute of Veterinary Physiology, Zurich, Switzerland

 

[*(999) *]Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2; _]J. Granton^1^, E. Bergot2, A. Boonstra3, P. E. Subias4, N. Galiè^5^, D. Langleben6, J. C. Lemarié^7^, T. Pfister8, G. Simonneau9, O. Sitbon9, M. Delcroix10. [^1^]_]University of Toronto, Toronto, ON, Canada, 2Hôpital Côte de Nacre-CHU, Caen, France, 3VU University Medical Center, Amsterdam, Netherlands, 4Hospital Universitario 12 de Octubre, Madrid, Spain, 5University of Bologna, Bologna, Italy, 6McGill University, Montreal, QC, Canada, 7Effi-Stat, Paris, France, 8Actelion Pharmaceuticals ltd, Allschwil, Switzerland, 9Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France, 10Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium

 

[*(1000) *]Fasudil Prevents Pulmonary Vascular Remodeling in a Rat Model of Pulmonary Hypertension with Left Heart; _]X. Zhou^1^, J. Wu2, F. Lin1, Q. Meng1, J. Liu1, H. Fan1, Z. Liu1. [^1^]_]Tongji University School of Medicine, Shanghai East Hospital, Shanghai, China, 2Zhengzhou University, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China

 

[*(1001) *][Riociguat Significantly Improved SpO2 during Exercise in Patients with CTEPH; _]M. Hatano, H. Maki, T. Inaba, S. Minatsuki, I. Komuro. _Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan

 

[*(1002) *]Multi-Disciplinary Care Impacts Mortality in Children with Idiopathic Pulmonary Arterial Hypertension – Results from a Bi-National Population Based Study; _]P. M. Alexander^1^, M. Rose2, C. O’Donnell3, S. Vidmar4, R. Justo5, M. Richardson6, J. Ramsay7, S. Hope8, G. Sholler9, D. J. Penny10, I. King11, R. J. Weintraub2. [^1^]_]Cardiology, Boston Children’s Hospital, Boston, MA, 2Cardiology, The Royal Children’s Hospital, Melbourne, Australia, 3Cardiology, Starship Children’s Hospital, Auckland, New Zealand, 4Clinical Epidemiology and Biostatistics Unit, Murdoch Children’s Research Institute, Melbourne, Australia, 5Cardiology, Lady Client Children’s Hospital, Brisbane, Australia, 6Cardiology, Women’s and Children’s Hospital, Adelaide, Australia, 7Cardiology, Princess Margaret Hospital for Children, Perth, Australia, 8Cardiology, Monash Medical Centre, Melbourne, Australia, 9Cardiology, The Children’s Hospital at Westmead, Sydney, Australia, 10Cardiology, Texas Children’s Hospital, Houston, TX, 11Cardiology, Murdoch Children’s Research Institute, Melbourne, Australia

 

[*(1003) *]Serum Cytokine Profiling in Pulmonary Arterial Hypertension; _]A. H. Siddiqui1, N. A. Weir2, M. Lemma WoldeHanna2, A. J. Mazer1, A. Biancotto3, R. Cai1, G. Graninger1, B. Harper1, J. Sun1, S. D. Nathan2, R. L. Danner1, M. A. Solomon4, J. M. Elinoff^1^. [^1^]_]Critical Care Medicine Department, National Institutes of Health, Bethesda, MD, 2Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, 3Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bethesda, MD, 4Critical Care Medicine Department and Cardiovascular and Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, MD

 

[*(1004) *]PVR Predicts Cardiac Hospitalizations in Pulmonary Hypertension Associated with HFpEF and HFrEF; _]R. R. Vanderpool^1^, M. Saul2, S. Nouraie3, M. T. Gladwin1, M. A. Simon1. [^1^]_]Heart, Blood, Lung and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Howard University, Washington DC, DC

 

[*(1005) *][Right Ventricular Performance with Exercise Declines Predictably in Patients with Idiopathic PAH; _]P. Jain, A. Jabbour, E. Kotlyar, C. Hayward, P. Macdonald, A. Keogh. _Cardiology, St Vincent’s Hospital, Sydney, Australia

 

[*(1006) *][Change in PH Therapy from PDE5i to Riociguat Is Associated with Significant Incremental Increase in Cardiac Index, Decrease in Pulmonary Vascular Resistance and Mean Arterial Pressure; _]R. A. Davey, A. Raina, G. Sokos, M. Kanwar, M. Patarroyo Aponte, R. Agarwal, R. L. Benza. _Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

 

[*(1007) *]Survival of the PAH and CTEPH Patients in the Swedish Pulmonary Arterial Hypertension Register 2000-2014; _]G. Rådegran^1^, B. Kjellström2, B. Ekmehag3, R. Hesselstrand4, B. Kornhall1, F. Larsen5, M. Nissel6, B. Rundkvist7, B. Ullman8, K. Wall9, G. Wikström10, M. Willehadson10, K. Jansson11, S. Söderberg12. [^1^]_]Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, 2Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 3Department of Public Health and Caring Science, Uppsala University, Uppsala, Sweden, 4Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, 5Department of Molecular Medicine and Surgery, Section of Clinical Physiology, Karolinska Institute, Stockholm, Sweden, 6Department of Medicine, Karolinska Institute, Stockholm, Sweden, 7Department of Cardiology, The Sahlgenska Academy, Gothenburg University, Gothenburg, Sweden, 8Department of Cardiology, Karolinska Institute, Stockholm, Sweden, 9Department of Clinical Physiology, Örebro University, Örebro, Sweden, 10Department of Medical Sciences Cardiology, Uppsala University, Uppsala, Sweden, 11Departments of Cardiology and Clinical Physiology, Institution of Medicine and Health Sciences, Linköping University, Linköping, Sweden, 12Department of Public Health and Clinical Medicine, Cardiology and the Heart Centre, Umeå University, Umeå, Sweden

 

[*(1008) *]Autologous Transfusion of Stored Red Blood Cells Impairs Endothelium-Dependent Vasodilatation in Experimental Pulmonary Arterial Hypertension. This Effect Is Reversed by Inhaled Nitric Oxide; _]A. Rungatscher^1^, L. Daniele1, L. San Biagio1, S. Bombieri1, S. Hallström2, G. Luciani1, G. Faggian1. [^1^]_]University f Verona, Verona, Italy, 2Institute of Physiological Chemistry, University of Graz Medical School, Graz, Austria

 

[* *]

POSTER SESSION 3

FRIDAY, APRIL 29, 2016

6:00 PM – 7:00 PM

Exhibit Hall B & C

[+INFECTIOUS DISEASES +]

 

[+Target Audience: +]

ID, HTX, LTX, MCS, NHSAH, PHARM

Poster Discussants:

Lara Danziger-Isakov, Martha Mooney, Orla Morrissey, Joanna Schaenman

[*(1009) *]WITHDRAWN

 

[*(1010) *][_ Antimicrobial Activity of Cysteamine Against Antibiotic Resistant Pathogens Isolated from Cystic Fibrosis and Non- CF Patients Including Mycobacterium abscessus Complex from Lung Transplant Recipients; ]A. Perry, J. D. Perry, C. Preece, D. Tierney, S. Peart, F. K. Gould. _Microbiology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

[*(1011) *]Posaconazole Tablets Exposure in the Real-Life of Lung Transplantation; _]B. Douvry1, B. Toussaint2, A. Roux^1^, L. Lecuyer3, E. Rivaud1, L. Couderc1, V. Boussaud3, D. Grenet1, R. Guillemain3, E. M. Billaud2. [^1^]_]Pneumology, Hosp Foch, Suresnes, France, 2Pharmacology, Hosp Georges Pompidou, Paris Cedex 15, France, 3Thoracic Transplantation, Hosp Georges Pompidou, Paris Cedex 15, France

 

[*(1012) *]Successful Heart Transplantation in Patients with Total Artificial Heart Infections; _]S. Taimur^1^, T. Sullivan1, M. Rana1, G. Patel1, K. Ashley2, J. Roldan2, B. Griffin2, S. Pinney3, A. Anyanwu4, S. Huprikar1. [^1^]_]Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 2Mount Sinai Hospital, New York, NY, 3Department of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, 4Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY

 

[*(1013) *][Stopping Conventional Showering Decreases Pseudomonas Exit Site Infections in Left Ventricular Assist Device Patients; _]N. Aburjania, S. Sherazi, V. Tchantchaleishvili, J. Alexis, C. Hay. _Infectious Diseases, University of Rochester, Rochester, NY

 

[*(1014) *]The Impact of the Exit Site Left Ventricle Assist Device Power Supply on Infection Incidence: A Single Center Experience; _]F. Toto, J. Bejko, M. Carrozzini, M. Comisso, G. Bortolussi, M. Gallo, D. Gregori, V. Tarzia, G. Gerosa, T. Bottio. [_Department of Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy

 

[*(1015) *]Bacteremia Is Associated with Increased LVAD Mortality; _]M. Naidu^1^, M. R. Bochan2, M. Walsh3, T. P. Schleeter3, S. Moainie4, C. T. Salerno4, J. A. Cowger3. [^1^]_]Internal Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, 2Infectious Disease, St. Vincent Heart Center of Indiana, Indianapolis, IN, 3Cardiology, St. Vincent Heart Center of Indiana, Indianapolis, IN, 4Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN

 

[*(1016) *]Successful Heart Transplantation in Patients with Active Staphylococcus Bloodstream Infection and Suspected Mechanical Circulatory Support Device Infection; _]T. Sullivan1, S. Taimur^1^, M. Rana1, G. Patel1, S. Pinney2, A. Anyanwu3, S. Huprikar1. [^1^]_]Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 2Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY

 

[+LUNG TRANSPLANTATION +]

 

[+Target Audience: +]

LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Amir Emtiazjoo, Allan Glanville, Matthew Hartwig, Michael Trotter, Gregor Warnecke, Glen Westall, Christopher Wigfield

[*(1017) *]Transplantation of Lungs Recovered from Donors After Euthanasia Results in Excellent Long-Term Outcome; _]D. Van Raemdonck^1^, A. Neyrinck2, S. Van Cromphaut3, S. Verleden4, B. Vanaudenaerde4, D. Claes5, K. Degezelle5, B. Desschans5, R. Vos6, L. Dupont6, W. Coosemans1, H. Decaluwé^1^, L. Depypere1, P. Nafteux1, H. Van Veer1, P. De Leyn1, G. M. Verleden6. [^1^]_]Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, 2Anesthesiology, University Hospitals Leuven, Leuven, Belgium, 3Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium, 4Department of Clinical and Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, 5Transplant Coordination, University Hospitals Leuven, Leuven, Belgium, 6Pneumology, University Hospitals Leuven, Leuven, Belgium

 

[*(1018) *][Bile Acid in Donor Bronchial Wash as a Biomarker of Gastric Acid Aspiration to Determine Suitability of Donor Lungs for Transplantation; _]D. Nakajima, M. Cypel, T. Martinu, T. Saito, S. Azad, W. Klement, M. Chen, T. K. Waddell, M. Liu, S. Keshavjee. _Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

 

[*(1019) *][Cadaveric Lobar Lung Transplantation Based on the Experiences of Living-Donor Lobar Lung Transplantation; _]M. Irie, S. Sugimoto, T. Kurosaki, K. Miyoshi, S. Otani, M. Yamane, T. Oto, S. Miyoshi. _Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Hospital, Okayama, Japan

 

[*(1020) *]Regional Variation in Lung Transplantation in the Era of the Lung Allocation Score; _]V. Ambur^1^, S. Taghavi2, S. Jayarajan2, S. Kadakia1, H. Zhao1, J. Gomez-Abraham1, E. Leotta1, A. Shiose1, Y. Toyoda1. [^1^]_]Temple University Hospital, Philadelphia, PA, 2Barnes-Jewish Hospital/Washington University in St. Louis, St. Louis, MO

 

[*(1021) *][Strategies of Donor Lung Preservation after Cessation of Circulation in Controlled DCDs; _]Y. Watanabe, D. Nakajima, M. Pipkin, M. Chen, J. Zhu, S. Eilert, C. Jaynes, A. Osumi, P. Pierre-Benoit, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

 

[*(1022) *]A Survival Benefit in More Recent Eras for Lung Transplant Recipients with a LAS in the Upper Quartile; _]T. C. Crawford^1^, J. C. Grimm1, J. Magruder1, C. M. Sciortino1, B. S. Kim1, E. L. Bush1, J. V. Conte1, R. S. Higgins1, A. S. Shah2, C. A. Merlo3. [^1^]_]Cardiac Surgery, Johns Hopkins University, Baltimore, MD, 2Cardiac Surgery, Vanderbilt University, Nashville, TN, 3Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD

 

[*(1023) *]Preformed HLA Specific Antibodies in Adult Cardiothoracic Transplantation – Does the Presence of Low Levels Matter?; _]K. L. Booth^1^, V. Carter2, S. Clark1, G. Parry1. [^1^]_]Cardiothoracic Transplantation, Freeman Hospital, Newcastle, United Kingdom, 2Cardiothoracic Transplantation, NHSBT, Newcastle, United Kingdom

 

[*(1024) *]OTO Score and Medium-Term Survival in Lung Transplantation; _]V. Rossetti1, L. Morlacchi1, A. D’Adda1, M. Pappalettera1, D. Tosi2, A. Palleschi2, P. Tarsia^1^, M. Nosotti2, F. Blasi1. [^1^]_]U.O. Broncopneumologia, Dipartimento di Fisiopatologia e dei Trapianti, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano., Milano, Italy, 2U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano., Milano, Italy

 

[*(1025) *]Management and Outcomes of Incidental Donor Derived Pulmonary Embolism; _]G. R. Dincheva^1^, A. S. Bratt1, B. C. Hamilton1, K. Rajalingam1, E. L. Bush1, P. Brandenhoff1, L. E. Leard2, R. J. Shah2, M. E. Kleinhenz2, M. Brzezinski3, J. A. Golden2, S. R. Hays2, J. P. Singer2, J. Kukreja1. [^1^]_]Surgery; Division of Cardiothoracic Surgery, Univ of California, San Francisco, CA, 2Medicine, Univ of California, San Francisco, CA, 3Anesthesia, Univ of California, San Francisco, CA

 

[*(1026) *]The Paradoxical Impact of Warm Ischemia on Lung Allograft Survival; _]D. D. Odell^1^, E. Chan1, N. Shigemura1, M. R. Morrell2, M. M. Crespo2, J. M. Pilewski2, J. D. Luketich1, J. D’Cunha1. [^1^]_]Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*(1027) *]Does Hanging Donors Be Really Marginal for Lung Transplantation?; _]R. Renard^1^, T. Le Houerou1, P. Puyo1, P. Bonnette1, M. Glorion1, S. Abou Taam1, A. Roux2, M. Leguen3, F. Parquin1, A. Chapelier1, E. Sage1. [^1^]_]Thoracic Surgery and Lung Transplant Department, Hôpital Foch, Suresnes, France, 2Pneumology and Lung Transplant Department, Hôpital Foch, Suresnes, France, 3Anaesthesiology Department, Hôpital Foch, Suresnes, France

 

[*(1028) *]ABO Compatibility in Lung Transplantation; _]D. Demos^1^, G. Divine2, G. Paone1, J. Borgi1, J. Morgan1, L. Allenspach3, L. Stagner3, H. Nemeh1. [^1^]_]Cardiothoracic Surgery, Henry Ford Hospital, Detroit, MI, 2Public Health Sciences, Henry Ford Hospital, Detroit, MI, 3Pulmonary Medicine, Henry Ford Hospital, Detroit, MI

 

[*(1029) *]Correlation New UNOS LAS and ET LAS; _]G. D. Nossent^1^, J. Smits2, J. Gottlieb3. [^1^]_]Lung Transplantation, UMCG, Groningen, Netherlands, 2Eurotransplant International Foundation, Leiden, Netherlands, 3Department of Pulmonary Medicine, Hannover Medical School, Hannover, Germany

 

[*(1030) *]How Big Is the Pool of Rejected Donor Lungs That Potentially Could Become Transplantable with EVLP? A Single Center Analysis of Registered Donor Data; _]A. Martens^1^, K. Degezelle2, B. Desschans2, D. E. Van Raemdonck3, B. M. Vanaudenaerde4, G. M. Verleden4, R. Vos4, S. E. Verleden4, A. P. Neyrinck1. [^1^]_]Cardiovascular Sciences – Anesthesiology and Algology, KU Leuven, Leuven, Belgium, 2Transplant Coordination, UZ Leuven, Leuven, Belgium, 3Department of Clinical and Experimental Medicine – Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium, 4Department of Clinical and Experimental Medicine – Pneumology, KU Leuven, Leuven, Belgium

 

[*(1031) *][Refinement of Lung Donor Scoring System with Consideration for Negative Impact of Prolonged Donor Intubation Time; _]S. Tanaka, K. Miyoshi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. _Okayama University Hospital, Okayama, Japan

 

[*(1032) *][Clinical Outcomes of Lung Transplantation from Extended Criteria Donor Lungs; _]H. Jung, H. Paik, J. Lee, S. Haam, C. Lee, Y. Do, K. Nam. _Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of

 

[*(1033) *][Massive Donor Transfusion Increases Recipient Early Mortality after Lung Transplantation; _]C. Borders, Y. Suzuki, C. Schaufler, J. Lasky, D. Mallem, J. Lee, K. Carney, C. Bermudez, J. Diamond, J. Christie, E. Cantu. _Hosp U. Pennsylvania, Philadelphia, PA

 

[*(1034) *]Lung Transplantation from Uncontrolled Circulatory Death Donors: Potential Benefits and Barriers; _]N. N. Niles^1^, M. Connellan1, A. R. Glanville2, G. W. Fulde3, E. K. Granger1. [^1^]_]Department of Cardiothoracic Surgery, St. Vincent’s Hospital, Sydney, Australia, 2Department of Thoracic Medicine, St. Vincent’s Hospital, Sydney, Australia, 3Deparment of Emergency Medicine, St. Vincent’s Hospital, Sydney, Australia

 

[*(1035) *][HLA-DQB-Matching Is Feasible and Does Not Prolong Wait Times for Lung Transplant Recipients; _]J. M. Tikkanen, A. Hirji, R. Zamel, H. Zhao, L. G. Singer, S. Keshavjee, K. Tinckam. _Toronto General Hospital, Toronto, ON, Canada

 

[*(1036) *]The Association between Donor-Recipient Race Matching and Survival Following Lung Transplantation Differs Based on Recipient Race; _]C. F. Evans^1^, P. G. Sanchez1, Z. N. Kon1, X. Wang1, H. Valantine2, S. Agbor-Enoh2, A. T. Iacono3, B. P. Griffith1, S. M. Pham1. [^1^]_]Surgery, Univ of Maryland School of Medicine, Baltimore, MD, 2Genomic Research Alliance for Organ Transplantation, National Heart, Lung and Blood Institute, Bethesda, MD, 3Pulmonary and Transplant Medicine, R Adams Cowley Shock Trauma Center, Baltimore, MD

 

[*(1037) *]Veno-Arterial Extracorporeal Life Support (ECLS) After Bilateral Lung and Heart-Lung Transplantations for Pulmonary Hypertension; _]T. Kortchinsky1, S. Mussot2, S. Rezaiguia-Delclaux1, M. Artiguenave1, E. Fadel2, F. Stephan^1^. [^1^]_]Reanimation Adulte, Hopital Marie Lannelongue, Le Plessis Robinson, France, 2Pole Thoracique et Vasculaire-Transplantation Pulmonaire, Hopital Marie Lannelongue, Le Plessis Robinson, France

 

[*(1038) *]Interim Results of a Phase II Clinical Trial Comparing Outcomes of Recipients of Lungs Recovered from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) Assessed by Ex-Vivo Lung Perfusion (EVLP) and CT Scan to Outcomes of Recipients of Lungs from Brain-Dead Donors (BDDs); _]T. M. Egan^1^, B. Haithcock1, J. Long1, K. Birchard2, J. Lobo3, P. Stewart4, J. Blackwell1, D. Yuan1, C. Thys5, D. Karb6, S. Miller6, M. Hartwig7. [^1^]_]Surgery, U. North Carolina Sch Med, Chapel Hill, NC, 2Radiology, U. North Carolina Sch Med, Chapel Hill, NC, 3Medicine, U. North Carolina Sch Med, Chapel Hill, NC, 4Biostatistics, U. North Carolina Sch Med Gillings School of Public Health, Chapel Hill, NC, 5Carolina Donor Serices, Durham, NC, 6U. North Carolina Sch Med, Chapel Hill, NC, 7Surgery, Duke University School of Medicine, Durham, NC

 

[+MECHANICAL CIRCULATORY SUPPORT +]

 

[+Target Audience: +]

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Andrew Boyle, Jennifer Cowger, Stavros Drakos, Jerry Estep, Christopher Hayward, Ulrich Jorde, Susan Joseph, Anna Meyer, Sean Pinney, Evgenij Potapov, Victor Rossel, Jan Schmitto, Andre Simon, Mark Slaughter, Martin Strueber, Nir Uriel

[*(1039) *]Successfully Weaned Patients after VA ECMO Due to Cardiogenic Shock: Etiology and 1-Year Survival; _]D. Pabst^1^, A. Ghodsizad1, A. El-Banayosy2, B. Soleimani1, C. Brehm1. [^1^]_]Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA, 2INTEGRIS Baptist Medical Center, Oklahoma City, OK

 

[*(1040) *][Left Ventricular Assist Device Placement with Concomitant Ventricular Reconstruction for Aneurysmal Disease; _]J. W. Smith, J. D. Pal, D. Walters, C. M. Mahr, N. A. Mokadam. _Univ of Washington, Seattle, WA

 

[*(1041) *]Left Ventricle Mechanical Circulatory Support Implantation as Successful Bridge to Transplantation for Patients with Cardiac Cachexia; _]M. Hegarova^1^, I. Malek1, V. Melenovsky1, Z. Dorazilova1, J. Kettner1, J. Maly2, I. Netuka2, J. Pirk2. [^1^]_]Department of Cardiology, IKEM, Prague, Czech Republic, 2Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic

 

[*(1042) *]A Novel Combined Endpoint Integrating Quality of Life Can Inform Decisions about VAD in Ambulatory Advanced Heart Failure; _]G. C. Stewart^1^, A. V. Ambardekar2, M. M. Kittleson3, M. Palardy4, A. DeVore5, J. T. Thibodeau6, J. J. Teuteberg7, L. M. Cadaret8, R. C. Forde-McLean9, M. M. Mountis10, S. V. Pamboukian11, R. Cantor11, R. Xie11, L. W. Stevenson1. [^1^]_]Brigham & Women’s Hospital, Boston, MA, 2University of Colorado Hospitals, Denver, CO, 3Cedars-Sinai Heart Institute, Los Angeles, CA, 4University of Michigan, Ann Arbor, MI, 5Duke University Medical Center, Durham, NC, 6University of Texas Southwestern, Dallas, TX, 7University of Pittsburgh Medical Center, Pittsburgh, PA, 8University of Iowa, Iowa City, IA, 9University of Pennsylvania, Philadelphia, PA, 10Cleveland Clinic, Cleveland, OH, 11University of Alabama Birmingham, Birmingham, AL

 

[*(1043) *][Myocarditis Treated with VA-ECMO: A Single Centers Experience; _]A. Burdorf, S. Varnado, J. L. Balk, T. Ryan, E. Raichlin, H. Vongooru, B. Lowes, R. Zolty, J. Um, H. Merritt-Genore, M. Moulton, A. Siddique. _Nebraska Medicine, Omaha, NE

 

[*(1044) *][Implantation of Continuous Flow-Left Ventricular Assist Devices (CF-LVAD) in the Extremely Obese (BMI ≥40 kg/m2): A Single Center Experience; _]J. Amione-Guerra, A. Bhimaraj, G. Ashrith, B. Bruckner, E. E. Suarez, M. H. Park, J. D. Estep, B. H. Trachtenberg. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*(1045) *]Cardiopulmonary Resuscitation – Is Veno-Arterial Extracorporeal Membrane Oxygenation an Option?; _]S. Zipfel^1^, S. Pecha2, S. Braune3, S. Kluge3, A. Bernhardt2, B. Sill1, S. Hakmi1, M. Kubik1, H. Reichenspurner1, T. Deuse1. [^1^]_]Hamburg Heart Center, Hamburg, Germany, 2Heart an Vascular Surgery, Hamburg Heart Center, Hamburg, Germany, 3Intensive Care Medicine, Universital Hospital of Hamburg, Hamburg, Germany

 

[*(1046) *]Is “Cardiopulmonary Exercise Testing” Essential to Indicate Ventricular Assist Device in Patients with INTERMACS Profile 4-7?; _]T. Imamura^1^, K. Kinugawa1, D. Nitta2, M. Hatano2, Y. Itoda3, M. Kimura3, O. Kinoshita3, K. Nawata3, M. Ono3. [^1^]_]Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

 

[*(1047) *]Clinical and Hemodynamic Profile of Bridge to Recovery Patients Implanted with a Continuous Flow LVAD; _]O. Gerami^1^, H. Nazzari1, J. Bashir2, A. Kaan1, E. Johansson1, S. Virani1, M. Davis1, B. Munt1, A. Ignaszewski1, A. Cheung2, M. Toma1. [^1^]_]Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, 2Division of Cardiovascular Surgery, University of British Columbia, Vancouver, BC, Canada

 

[*(1048) *]Impact of Venous-Arterial Extracorporeal Membrane Oxygenation Standardized Guidelines: Worth the Effort?; _]A. C. Miller^1^, A. K. Rauf1, A. K. Johnson1, H. Choi1, R. Alharethi1, K. Afshar1, D. Budge1, J. Revenaugh1, S. Froebe2, B. Rasmusson1, S. Stoker1, W. Caine1, B. B. Reid1, A. G. Kfoury1. [^1^]_]Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, UT, 2Perfusion, Intermountain Medical Center, Salt Lake City, UT

 

[*(1049) *]Patient Selection for Ventricular Assist Devices: What Happens in Real Practice?; _]Q. Yang^1^, M. Kanwar2, J. F. Antaki3, L. Carey3, J. Zimmerman1. [^1^]_]School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, 2Allegheny General Hospital, Pittsburgh, PA, 3Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA

 

[*(1050) *]Does INTERMACS Classification Predict Outcomes after LVAD Implantation?; _]S. Maltais^1^, N. A. Haglund2, M. E. Davis2, J. Cowger3, P. Shah4, P. Shah4, F. D. Pagani5, K. D. Aaronson5, S. M. Dunlay6, J. M. Stulak1. [^1^]_]Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Vanderbilt, Nashville, TN, 3St-Vincent Hospital, Rochester, MN, 4Inova Fairfax, Virginia, VA, 5Michigan, Michigan, MI, 6Mayo Clinic, Rochester, MN

 

[*(1051) *]Performance of Continuous Flow Left Ventricular Assist Devices for the Smaller Size Patient Population; _]T. Fujita^1^, H. Hata1, Y. Matsumoto1, Y. Shimahara1, O. Seguchi2, M. Yanase2, T. Nakatani2, N. Fukushima2, J. Kobayashi1. [^1^]_]Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, 2Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan

 

[*(1052) *]Combined Renal Risk Score Predicts Post-Implant Renal Failure in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients; _]V. Topkara^1^, E. Coromilas1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Li1, M. Tiburcio2, K. Ross2, R. N. Sladen3, D. M. Mancini1, Y. Naka2, J. Radhakrishnan1, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY, 3Anesthesiology, Columbia University, New York, NY

 

[*(1053) *]No Distance Is Too Great: A Patient’s Commute to Their Implantation Center Is Not Associated with Worse Outcomes Following Placement of a Left Ventricular Assist Device; _]M. Andrews^1^, S. Wesner1, R. Watkins1, J. N. Katz2. [^1^]_]Transplantion, Univ of North Carolina, Chapel Hill, NC, 2Cardiology, Univ of North Carolina, Chapel Hill, NC

 

[*(1054) *]Impact of Preoperative Glycemic Control on Long-Term Mechanical Circulatory Support Device Implantation; _]E. A. Downs^1^, L. E. Johnston1, D. J. LaPar1, L. T. Yarboro1, J. A. Kern1, J. L. Kirby2, S. Mazimba2, A. M. Speir3, J. B. Rich4, M. A. Quader5, G. Ailawadi1, J. L. Kennedy2. [^1^]_]Surgery, University of Virginia, Charlottesville, VA, 2Medicine, University of Virginia, Charlottesville, VA, 3Cardiovascular and Thoracic Associates, Inova Heart and Vascular Institute, Falls Church, VA, 4Virginia Cardiac Surgery Quality Initiative, Charlottesville, VA, 5Virginia Commonwealth University, Richmond, VA

 

[*(1055) *]Role of ECMO in Acute Myocardial Infarction Complicating Cardiogenic Shock; _]H. Lee^1^, S. Song2, S. Kim2, S. Oh1, N. Kim1, J. Kim1, S. Lee1, J. Park1, J. Oh1, J. Choi1, H. Lee1, K. Cha1, T. Hong1. [^1^]_]Department of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of, 2Department of Thoracic Surgery, Pusan National University Hospital, Busan, Korea, Republic of

 

[*(1056) *]Characteristics of Non-Compliant (NC) LVAD Patients; _]J. Larsen^1^, E. M. Dunn2, N. M. Kunz2, K. L. Lockard2, J. J. Teuteberg2, L. Lagazzi2, A. D. Althouse2, R. L. Kormos2. [^1^]_]University of Pittsburgh School of Medicine, Pittsburgh, PA, 2The Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA

 

[*(1057) *]Arrhythmia History Predicts Morbidity and Mortality Following LVAD Implantation; _]A. R. Garan^1^, V. K. Topkara1, X. Mai1, B. C. Varr1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, M. Tiburcio3, M. Flannery3, D. L. Jennings1, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, W. Whang1, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*(1058) *]QRS Duration Predicts Outcomes Following Implantation of a Left Ventricular Assist Device; _]A. R. Garan^1^, X. Mai1, V. K. Topkara1, K. J. Clerkin1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, D. L. Jennings1, M. F. Torres3, B. Cagliostro3, G. Parkis3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, J. M. Dizon1, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Epidemiology, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY

 

[*(1059) *][LVAD Implantation in Cardiogenic Shock: Improved Outcome by Less Invasive Surgery; _]S. V. Rojas, M. Avsar, M. Hillert, J. S. Hanke, A. Uribarri, K. Tuemler, C. Kuehn, A. Haverich, J. D. Schmitto. [ Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany _]

 

[*(1060) *]Impact of Preoperative Variables on Hospital Length of Stay in Patients Undergoing Continuous Flow LVAD Implantation; _]D. Plack1, S. S. Roy2, R. Cogswell2, J. Spratt^1^, K. Liao1, R. John1. [^1^]_]Department of Cardiothoracic Surgery, University of Minnesota Medical School, Minneapolis, MN, 2Department of Cardiology, University of Minnesota Medical School, Minneapolis, MN

 

[*(1061) *]Understanding Perceived Racial and Gender Differences in LVAD Use on the Transplant Waitlist; _]A. R. Alejos^1^, D. Schaubel2, J. Magee3, M. Colvin3, R. Sung3. [^1^]_]University of Michigan Medical School, Ann Arbor, MI, 2University of Michigan School of Public Health, Ann Arbor, MI, 3University of Michigan Health System, Ann Arbor, MI

 

[*(1062) *]WITHDRAWN

 

[*(1063) *]How Can We Predict Bi-Ventricular Assist Device Requirement?; _]T. Imamura^1^, K. Kinugawa1, D. Nitta2, M. Hatano2, O. Kinoshita3, K. Nawata3, M. Ono3. [^1^]_]Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

 

[*(1064) *]Pre-Extra Corporeal Membrane Oxygenation (ECMO) MELD Score May Predict Meaningful Survival; _]M. Byku^1^, R. Piotrowski1, A. Itoh2, S. J. Larue1, J. M. Vader1, C. L. Holley1, G. A. Ewald1. [^1^]_]Cardiology, Washington University in St. Louis, Saint Louis, MO, 2Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO

 

[*(1065) *]Mean Arterial Pressure to Central Venous Pressure Ratio – A Novel Marker for Right Ventricular Failure after Left Ventricular Assist Device Placement; _]B. Mohamedali1, G. Yost2, R. Doukky1, G. Bhat^2^. [^1^]_]Cardiology, Rush University Medical Center, Chicago, IL, 2Heart Institute, Advocate Christ Med Center, Oak Lawn, IL

 

[*(1066) *]MOVED TO MINI ORAL SESSION 08

 

[*(1067) *][Changes in Left Ventricular Pacing Lead Impedance Correlate with Changes in Pulmonary Capillary Wedge Pressure during Hemodynamic Ramp Tests; _]J. D. Moss, E. E. Flatley, A. Oesterle, N. Sarswat, S. Adatya, G. H. Kim, G. Sayer, N. Uriel. _University of Chicago, Chicago, IL

 

[*(1068) *]Assessment of Ventricular Remodeling Post-LVAD with 3D Echocardiography and Surface Analysis; _]G. Sayer^1^, D. Medvedofsky1, S. Adatya1, N. Sarswat1, G. H. Kim1, K. Addetia1, E. Kruse1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. [^1^]_]Division of Cardiology, University of Chicago, Chicago, IL, 2Cardiothoracic Surgery, University of Chicago, Chicago, IL

 

[*(1069) *][A Retrospective Cohort Analysis of Chimney Graft Versus Percutaneous PerfusionTechniques for Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Refractory Cardiogenic Shock; _]M. Cakici, E. Ozcinar, B. M. Inan, S. M. Durdu, C. M. Sarıcaoglu, A. Aral, M. Sirlak, R. A. Akar. _Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey

 

[*(1070) *][Blood Product Utilization in Continuous Flow Left Ventricular Assist Devices: Single Institution Trends; _]P. B. Harrington, D. Nguyen, A. Pekarek, J. Binongo, Y. Lasajanak, J. D. Vega. _Cardiothoracic Surgery, Emory University, Atlanta, GA

 

[*(1071) *]Considering LV Dimension Is Important in Assessing the Risk of Right Ventricular Failure after Left Ventricular Assist Device Implantation; _]K. Nakamoto^1^, T. Ohtani1, H. Kioka1, Y. Tsukamoto1, D. Yoshioka2, S. Saito2, K. Toda2, Y. Sawa2, Y. Sakata1. [^1^]_]Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 2Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

 

[*(1072) *]Incidence and Predictors of Left Ventricular Functional Recovery on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support; _]V. K. Topkara^1^, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, J. A. Fried1, B. Toennes1, F. Castagna1, A. M. Clemons1, J. Eadie2, B. Cagliostro1, S. Restaino1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*(1073) *]Can Patients with Restrictive Physiology Be Successfully Bridged to Transplant with Left Ventricular Support Alone Versus Biventricular Support?; _]C. Runyan, H. Henry, N. Huie, J. Moriguchi, M. Kittleson, L. Czer, D. Chang, E. Passano, T. Aintablian, J. A. Kobashigawa, F. Esmailian, F. Arabia. [_Cedars-Sinai Heart Institute, Los Angeles, CA

 

[*(1074) *][Invasive and Noninvasive Hemodynamic Measures Correlate in Patients with Continuous Flow Left Ventricular Assist Devices; _]H. Fan, C. T. Sparrow, D. S. Raymer, M. E. Nassif, J. M. Vader, S. J. LaRue. _Washington Univ St. Louis, Saint Louis, MO

 

[*(1075) *][Effect of Biventricular Support on Exercise Capacity Compared to Left Ventricular Support Alone: Is This the Right Time for Endurance Testing?; _]J. Silva Enciso, K. Alqahtani, H. Tran, T. Upham, E. Adler, V. Pretorius. _University of California San Diego, San Diego, CA

 

[*(1076) *]Individual Optimal Blood Pressure Determined by Cerebral Autoregulation Monitoring During and After Continuous-Flow Left Ventricular Assist Device Implantation; _]M. Ono^1^, S. K. Singh2, K. K. Kibler3, R. Easley3, K. M. Brady3. [^1^]_]Texas Heart Institute, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Texas Children’s Hospital, Houston, TX

 

[*(1077) *]Impact of Aortic Insufficiency on Unloading Properties of Continuous-Flow Left Ventricular Assist Devices; _]G. Sayer^1^, E. Kruse1, K. Addetia1, J. Grinstein1, S. Adatya1, N. Sarswat1, G. H. Kim1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. [^1^]_]Cardiology, University of Chicago, Chicago, IL, 2Cardiothoracic Surgery, University of Chicago, Chicago, IL

 

[*(1078) *]Implications of Exercise Oscillatory Ventilation Post Ventricular Assist Device Implantation; _]L. Elbaum^1^, S. Pinney2, A. Anyanwu3, A. Lala2. [^1^]_]Medicine, Mount Sinai School of Medicine, New York, NY, 2Cardiology, The Mount Sinai Hospital, New York, NY, 3Cardiothoracic Surgery, The Mount Sinai Hospital, New York, NY

 

[*(1079) *][The Role of Inertgas-Rebreathing Method During Exercise Testing in LVAD Patients; _]N. Reiss, T. Schmidt, S. Mommertz, M. Altesellmeier, D. Willemsen, S. Schulte-Eistrup. _Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany

 

[*(1080) *]Correlation of Non-Invasive Flow Estimation of the Axial-Flow Left Ventricular Assist Device with Fick and Thermal Cardiac Output; _]V. Raje^1^, A. K. Mankad2. [^1^]_]Cardiovascular Disease, Virginia Commonwealth University, Richmond, VA, 2Cardiovascular Disease, McGuire Veterans Medical Center, Richmond, VA

 

[*(1081) *]To Compress or Not to Compress: Revisiting the Use of Chest Compressions in LVAD Patients; _]J. Johannesen^1^, J. Whittier2, S. Kunnirickal2, S. Feitell3, T. Rowe4, W. Fischer5, S. R. Hankins2, H. J. Eisen2. [^1^]_]Medicine, Drexel University, Philadelphia, PA, 2Cardiology/Medicine, Drexel University, Philadelphia, PA, 3Cardiology/Medicine, Cleveland Clinic Foundation, Cleveland, OH, 4Center for Advanced Heart Failure Care, Drexel University, Philadelphia, PA, 5Cardiothoracic Surgery, Drexel University, Philadelphia, PA

 

[*(1082) *][Routine Postoperative Cardiac Monitoring with Hemodynamic Transesophageal Echocardiography (hTEE) for Patients with Left Ventricular Assist Device (LVAD); _]N. Bahatyrevich, Q. Yang, H. Hirose, N. C. Cavarocchi. _Department of Surgery, Thomas Jefferson University, Philadelphia, PA

 

[*(1083) *]No Pulse, No Problem! Measuring Blood Pressure and Estimating Pulse Pressure in Centrifugal Flow Left Ventricular Assist Devices; _]J. E. Holtz^1^, A. N. Potter2, B. C. Lampert3, L. Lagazzi1, R. L. Kormos1, J. J. Teuteberg1. [^1^]_]University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3The Ohio State University, Columbus, OH

 

[*(1084) *]Changes in Lipid Profile Following Durable Mechanical Circulatory Support: Confirming the “Lipid Paradox” in Heart Failure; _]K. S. Telukuntla^1^, T. C. Hanff1, E. W. Grandin2, J. A. Mazurek2, J. L. Howard3, J. W. Wald2, L. R. Goldberg2, M. L. Jessup2, M. A. Acker3, K. B. Margulies2, P. Atluri3, J. E. Rame2, E. Y. Birati2. [^1^]_]Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3Division of Cardiovascular Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

 

[*(1085) *]Standardized Telephone Intervention Algorithm for Improved Ventricular Assist Device Outpatient Management; _]T. Schlöglhofer^1^, J. Horvat2, Z. Hartner2, J. Riebandt2, T. Haberl2, D. Wiedemann2, K. Dimitrov2, F. Moscato3, D. Zimpfer1, H. Schima1. [^1^]_]Cardiac Surgery, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria, 2Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 3Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria

 

[*(1086) *]VAD Weaning Protocol: A Guideline for Explantation; _]C. E. Weaver^1^, M. K. Bennett2, K. M. Hryniewicz2, M. A. Samara2, B. Sun3. [^1^]_]Transplant & VAD Department, Abbott Northwestern Hospital, Minneapolis, MN, 2Advanced Heart Failure/VAD/Transplant, Minneapolis Heart Institute, Minneapolis, MN, 3Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN

 

[*(1087) *][Oxydative Stress in Heart Failure Patients after Implantation of Continuous Flow Left Ventricular Assist Devices; _]M. Hyden, R. Zolty, M. C. Zimmerman, E. Raichlin, H. Vongooru, A. Burdorf, S. Varnado, B. D. Lowes. _Cardiology, UNMC, Omaha, NE

 

[*(1088) *]Feasibility of 24-Hour Advanced Ambulatory Blood Pressure and Hemodynamic Monitoring in Patients with Continuous-Flow Left Ventricular Assist Device; _]F. Castagna^1^, B. J. McDonnell2, V. K. Topkara1, M. Yuzefpolskaya1, A. R. Garan1, K. Wong1, G. Parkis1, M. R. Torres3, M. Maurer1, K. Ross3, D. M. Mancini1, H. Takayama3, K. Takeda3, Y. Naka3, J. R. Cockcroft2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Cardiology, Cardiff Metropolitan University, Cardiff, United Kingdom, 3Surgery, Columbia University, New York, NY

 

[*(1089) *]Lessons from a 7-Year Experience Using a Rescue-to-Bridge Strategy with TandemHeart to HeartMate II for Severe Refractory Cardiogenic Shock; _]K. W. Yount^1^, J. L. Kennedy2, J. D. Bergin2, M. Ragosta2, D. S. Lim2, A. Taylor2, J. A. Kern1, L. T. Yarboro1. [^1^]_]Division of Thoracic & Cardiovascular Surgery, University of Virginia, Charlottesville, VA, 2Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA

 

[*(1090) *][Outcomes with Implementation of Algorithmic Hemodynamic Ramps in Patients with Continuous Flow LVADs; _]N. Sarswat, S. Adatya, G. Sayer, G. Kim, T. Ota, V. Jeevandandam, N. Uriel. _University of Chicago, Chicago, IL

 

[*(1091) *][Specialized Heart Clinic Versus Standard Anticoagulation Clinic Warfarin Management in Patients with Left Ventricular Assist Devices; _]A. McCarty, S. Lee, P. de Voest, J. McDermott. _Spectrum Health, Grand Rapids, MI

 

[*(1092) *][Invasive Hemodynamic Testing in Ambulatory Left Ventricular Assist Device Patients; _]N. Badoe, K. Abdullah, S. Phillips, J. Nabut, A. J. Rongione, S. S. Desai, P. Shah. _Inova Heart and Vascular Institute, Falls Church, VA

 

[*(1093) *]Inpatient Rehabilitation of Biventricular Support Patients – A Special Challenge; _]N. Reiss^1^, E. Deniz2, S. Jan2, D. Willemsen1. [^1^]_]Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, 2Medical School Hannover, Hannover, Germany

 

[*(1094) *]3D Surface Analysis of RV and LV Shapes as Predictors of Post-LVAD RV Failure; _]G. Sayer^1^, D. Medvedofsky1, S. Adatya1, N. Sarswat1, G. Kim1, K. Addetia1, E. Kruse1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. [^1^]_]Division of Cardiology, University of Chicago, Chicago, IL, 2Cardiothoracic Surgery, University of Chicago, Chicago, IL

 

[*(1095) *][Vascular Reactivity Analysis in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVADs) – The Role of Endothelial Function in Continuous Flow Physiology; _]A. S. Cruz-Solbes, C. Uribe, K. A. Youker, B. H. Trachtenberg, G. Ashrith, J. D. Estep, G. Torre-Amione, B. A. Bruckner, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

 

[*(1096) *]Pump Speed Increase Improves Submaximal Exercise Tolerance in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients-A Double Blind Randomized Trial; _]M. H. Jung^1^, B. Houston2, S. D. Russell2, F. Gustafsson1. [^1^]_]Department of Cardiology, University Hospital Rigshospitalet., Copenhagen, Denmark, 2Department of Cardiology, Johns Hopkins Hospital, Baltimore, MD

 

[*(1097) *][Coagulation and Inflammation Profiles with Axial and Centrifugal Flow LVADs; _]V. Tarzia, G. Bortolussi, J. Bejko, M. Gallo, M. Comisso, M. Carrozzini, M. Nadali, R. Bianco, T. Bottio, G. Gerosa. _Cardiac Surgery, University of Padova, Padova, Italy

 

[*(1098) *]Advanced Heart Failure Therapies in a High Risk Urban Population; _]B. A. Smith^1^, N. Uriel1, S. Adatya1, G. Sayer1, N. Sarswat1, S. Kalantari Tannenbaum1, J. Grinstein1, K. Marinescu1, V. Kagan2, C. Juricek2, H. Ruedlinger2, V. Jeevanandam2, T. Ota2, G. Kim1. [^1^]_]Division of Cardiology, University of Chicago, Chicago, IL, 2Cardiothoracic Surgery, University of Chicago, Chicago, IL

 

[*(1099) *]Clinical Experience with Long-Distance Transportation of Patients on Acute Mechanical Circulatory Support Devices; _]T. Kang1, B. Ko2, S. G. Drakos2, J. Stehlik2, E. M. Gilbert2, J. Nativi-Nicolau2, O. Wever-Pinzon2, J. C. Fang2, A. Koliopoulou1, S. I. Bott3, J. E. Tonna4, C. H. Selzman1, S. H. McKellar1. [^1^]_]Cardiothoracic Surgery, Utah University Hospital, Salt Lake City, UT, 2Cardiovascular Medicine, Utah University Hospital, Salt Lake City, UT, 3Anesthesiology, Utah University Hospital, Salt Lake City, UT, 4Emergency Medicine, Utah University Hospital, Salt Lake City, UT

 

[*(1100) *]Lactate Dehydrogenase Isoenzyme Monitoring in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs); _]V. K. Topkara^1^, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, B. Cagliostro1, L. Effner2, F. Castagna1, S. Singh1, J. A. Fried1, J. Haythe1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. [^1^]_]Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

 

[*(1101) *][Patients with Continuous-Flow Left Ventricular Assist Devices Have a Reduced Baroreceptor Sensitivity Compared to Healthy Controls; _]W. K. Cornwell, T. Tarumi, Q. fu, M. Drazner, B. Levine. _Cardiology, Univ of Texas SW, Coppell, TX

 

[*(1102) *]WITHDRAWN

 

(1103) *][Investigating a Novel Synergy Applying Remote [+I+]*]schemic Conditioning to Modulate the Altered Physiology of ContinUous Flow Left Ventricular Assist Devices, to Reduce Stroke and Other Adverse Effects: The *IMPULSE *Trial Pilot Results; _]D. Pujara, H. R. Mallidi, W. E. Cohn, J. Anand, O. H. Frazier, S. K. Singh. _Surgery, Baylor College of Medicine, Houston, TX

 

[*(1104) *]Plasma Proteomics in Left Ventricular Assist Device Recipients: A Pilot Study; _]C. L. Aquilante^1^, A. Brieke2, K. S. Fritz1, L. M. Saba1, D. L. Bain1, L. M. Wolfe3, R. L. Page II1, J. Lindenfeld4. [^1^]_]Pharmaceutical Sciences, University of Colorado, Aurora, CO, 2Division of Cardiology, University of Colorado, Aurora, CO, 3Colorado State University, Fort Collins, CO, 4Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN

 

[*(1105) *][Does Right Ventricular-Arterial Coupling Predict Early Right Heart Failure in LVAD Recipients?; _]S. Airhart, R. Cheng, T. Dardas, J. Kirkpatrick, J. Pal, J. Smith, N. Mokadam, C. Mahr, C. Masri. _Cardiology, University of Washington, Seattle, WA

 

[*(1106) *]The Effect of Cardiac Rehabilitation on Functional Capacity, Psychological Symptoms and Quality of Life in Patiens with a Left Ventricular Assist Device; _]H. Karapolat1, E. Cinar^1^, K. Capaci1, C. Engin2, T. Yagdi2, M. Ozbaran2, S. Nalbantgil3, M. Zoghi3. [^1^]_]Department of Physical Medicine and Rehabilitation, Ege University School of Medicine, Izmir, Turkey, 2Department of Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey, 3Department of Cardiology, Ege University School of Medicine, Izmir, Turkey

 

[*(1107) *]Outcomes of Ventricular Assist Device Therapy for Patients at an INTERMACS Profile 1: Single Center Experience; _]O. Seguchi^1^, T. Fujita2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, J. Kobayashi2, N. Fukushima1, T. Nakatani1. [^1^]_]Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Adult Cadiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[*(1108) *]Agreeing to Disagree: A Comparison of Antiplatelet and Anticoagulant Management Strategies at US versus International HVAD Implanting Centers; _]J. J. Teuteberg^1^, K. D. Aaronson2, C. Mahr3, H. Reichenspurner4, T. Krabatsch5, C. B. Patel6, M. Strueber7, M. S. Kiernan8, D. Zimpfer9, M. V. Jacoski10, S. Schueler11. [^1^]_]University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Michigan, Ann Arbor, IL, 3University of Washington, Seattle, WA, 4University Hospital Eppendorf, Hamburg, Germany, 5Deutsches Herzzentrum Berlin, Berlin, Germany, 6Duke University School of Medicine, Durham, NC, 7Spectrum Health, Grand Rapids, MO, 8Tufts Medical Center, Boston, MA, 9Medical University of Vienna, Vienna, Austria, 10Medical Affairs, HeartWare Inc., Framingham, MA, 11Newcastle upon Tyne Freeman Hospital, Newcastle upon Tyne, United Kingdom

 

[*(1109) *][The Role of Neurohormonal Therapy in Patients with Left Ventricular Assist Devices; _]R. Ghashghaei, R. Yousefzai, F. Liwinski, H. Tran, E. D. Adler. _Cardiology, University of California San Diego, San Diego, CA

 

[*(1110) *][Evaluation of Systemic Heparin vs. Bivalrudin Anticoagulation in Patients Supported by Extracorporeal Membrane Oxygenation; _]T. J. Berei, M. P. Lillyblad, K. M. Hryniewicz, K. Wilson, R. Garberich. _Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN

 

[*(1111) *]Evaluating the Safety and Efficacy of Enoxaparin in Bridging Mechanical Circulatory Support (MCS) Patients from Subtherapeutic to Therapeutic INR in an Outpatient Setting; _]L. D. Lam^1^, U. Duong2, L. Luu2, K. Del Rosario2, M. Fan2, P. Ambrose2, J. Moriguchi1, A. Francisco1. [^1^]_]Cedars Sinai Medical Center, Los Angeles, CA, 2UCSF School of Pharmacy, San Francisco, CA

 

[*(1112) *]The Role of Biventricular Assist Device on Patients with Multiorgan Failure Due to Fulminant Myocarditis: Single-Center Experience; _]S. Nakajima^1^, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, T. Sato1, O. Seguchi1, M. Yanase1, H. Hata2, T. Fujita2, N. Fukushima1, J. Kobayashi2, T. Nakatani1. [^1^]_]Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

 

[+PEDIATRICS +]

 

[+Target Audience: +]

PEDS, HTX, ID, PHARM

Poster Discussants:

Juan Alejos, Estela Azeka, Ryan Butts, Michael Carboni, Michiel Dalinghaus, Susan Denfield, R. Erik Edens, Ranny Goldwasser, Stephan Schubert, Kurt Schumacher, Rakesh Singh, Tajinder Singh, Simon Urschel, Shawn West, Steven Zangwill

[*(1113) *]Utility of a Novel Biomarker, Symmetric Dimethylarginine, to Assess Renal Function in Pediatric Heart Transplant Recipients; _]P. T. Thrush^1^, M. J. Bock2, S. Haymond3, C. L. Backer4, E. Pahl1. [^1^]_]Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 2Pediatrics, Loma Linda University, Loma Linda University Children’s Hospital, Loma Linda, CA, 3Pathology, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 4Surgery, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

 

[*(1114) *]Risk of Death Due to Cardiac Arrest in Pediatric Heart Transplantation: Query of the UNOS Database; _]R. W. Loar^1^, S. W. Denfield1, H. Tunuguntla1, A. G. Cabrera1, J. F. Price1, W. Zhang2, K. Hosek2, J. J. Kim1, W. J. Dreyer1, A. Jeewa1. [^1^]_]Pediatric Cardiology, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX, 2Outcomes and Impact Service, Texas Children’s Hospital, Houston, TX

 

[*(1115) *]Heart Failure Related Hospitalizations in Children with Single Ventricle Heart Disease: Prevalence, Risk Factors for Mortality, and Economic Burden; _]A. Misfeldt^1^, D. J. Goldberg1, M. J. O’Conner1, P. Shamszad1, C. S. Almond2, C. E. Mascio3, K. Y. Lin1, X. Zhang1, J. Rychik1, R. E. Shaddy1, J. W. Rossano1. [^1^]_]Dept of Pediatrics, The Cardiac Center, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Dept of Pediatrics, Div. of Cardiology, Lucile Packard Children’s Hospital Stanford University, Palo Alto, CA, 3Dept of Surgery, The Cardiac Center, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

 

[*(1116) *]Correlation between Solid Phase Assays and Positive CDC Crossmatches in a Surrogate Transplant Model; _]C. Chin^1^, E. Portwood2, P. Brailey2, B. Mantell1, A. Tica3, A. Girnita4. [^1^]_]Cincinnati Children’s Hospital, Cincinnati, OH, 2Hoxworth Blood Center, Cincinnati, OH, 3University of Medicine and Pharmacy, Craiova, Dolj, Romania, 4University of Cincinnati, Cincinnati, OH

 

[*(1117) *]Developmental Delay Is Not a Risk Factor for Poor Outcome in Pediatric Heart Transplantation; _]A. N. Goel^1^, A. Iyengar1, K. O. Schowengerdt2, A. Fiore2, C. Huddleston2. [^1^]_]David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA, 2Saint Louis University School of Medicine, Saint Louis, MO

 

[*(1118) *][Functional Status of Children Supported on LVADs at Transplant: How Does It Compare to Children on Inotropic Support?; _]A. Bulic, K. Maeda, S. Chen, D. Rosenthal, J. Murray, P. Shuttleworth, C. Almond. _Division of Pediatric Cardiology, Stanford University, Palo Alto, CA

 

[*(1119) *][Platelet Activation, Receptor Shedding and Aggregation in Pediatric Patients with Congenital Heart Disease Undergoing Cardiopulmonary Bypass; _]N. K. Mondal, G. M. Pantalos, Z. Chen, J. Ding, M. Sobieski, S. C. Koenig, M. S. Slaughter, Z. J. Wu. _Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville, KY

 

[*(1120) *]Emergency Department Utilization by Pediatric Heart Transplant Recipients; _]C. A. Wittlieb-Weber^1^, J. W. Rossano2, D. R. Weber1, K. Y. Lin2, C. Ravishankar2, C. E. Mascio2, R. E. Shaddy2, M. J. O’Connor2. [^1^]_]University of Rochester Medical Center, Rochester, NY, 2The Children’s Hospital of Philadelphia, Philadelphia, PA

 

[*(1121) *]Impact of Pediatric Obesity on Heart Transplantation; _]E. Adams^1^, R. Biniwale2. [^1^]_]David Geffen School of Medicine, UCLA, Los Angeles, CA, 2Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

 

[*(1122) *]Near Infra-Red Spectroscopy in Pediatric Heart Failure: A Novel Application of a Promising Technology; _]D. Gupta^1^, R. S. Samraj2, D. Lopez-Colon1, B. A. Pietra1, M. S. Bleiweis1, F. J. Fricker1. [^1^]_]Congenital Heart Center, University of Florida, Gainesville, FL, 2Pediatric Critical Care, University of Florida, Gainesville, FL

 

[*(1123) *]Insights into Mixed Cellular and Antibody-Mediated Rejection (MR) in Pediatric Heart Transplant Recipients; _]H. S. Magdo^1^, D. V. Miller2, G. Snow3, K. M. Molina1, L. May1, H. E. Hammond2, J. Stehlik4, A. K. Lal1, D. Budge4, P. Revelo2, P. Burch5, A. Eckhauser5, A. G. Kfoury4. [^1^]_]